0001437749-21-005096.txt : 20210305 0001437749-21-005096.hdr.sgml : 20210305 20210305132227 ACCESSION NUMBER: 0001437749-21-005096 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210305 DATE AS OF CHANGE: 20210305 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATIONAL RESEARCH CORP CENTRAL INDEX KEY: 0000070487 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 470634000 STATE OF INCORPORATION: WI FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35929 FILM NUMBER: 21717664 BUSINESS ADDRESS: STREET 1: 1245 Q STREET CITY: LINCOLN STATE: NE ZIP: 68508 BUSINESS PHONE: 4024752525 MAIL ADDRESS: STREET 1: 1245 Q STREET CITY: LINCOLN STATE: NE ZIP: 68508 10-K 1 nrc20201231_10k.htm FORM 10-K nrc20201231_10k.htm
0000070487 National Research Corporation false --12-31 FY 2020 120 144 0.01 0.01 2,000,000 2,000,000 0 0 0.001 0.001 60,000,000 60,000,000 30,775,154 30,151,574 25,390,968 24,947,500 5,384,186 5,204,074 218,344 3,677 468,318 9,296 3,496 3,271 90,369 3,527,246 69,099 3,527,246 4,328,552 1.13 0.60 87,203 227,902 6,005 0.78 180,112 630,373 6,793 0.21 3 5 3 10 3 5 1 5 7 40 0 0 0 0 0 0 1 1 1 0 0 0 21 21 0 1.10 3.00 1 5 5 10 100,000 100,000 1 10 3 5 10 0 0 0 5 1 6 1 00000704872020-01-012020-12-31 iso4217:USD 00000704872020-06-30 xbrli:shares 00000704872021-02-26 thunderdome:item 00000704872020-12-31 00000704872019-12-31 iso4217:USDxbrli:shares 00000704872019-01-012019-12-31 00000704872018-01-012018-12-31 0000070487us-gaap:CommonClassAMember2020-01-012020-12-31 0000070487us-gaap:CommonClassAMember2019-01-012019-12-31 0000070487us-gaap:CommonClassAMember2018-01-012018-12-31 0000070487us-gaap:CommonClassBMember2018-01-012018-12-31 0000070487us-gaap:CommonClassAMemberus-gaap:CommonStockMember2017-12-31 0000070487us-gaap:CommonClassBMemberus-gaap:CommonStockMember2017-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2017-12-31 0000070487us-gaap:RetainedEarningsMember2017-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-31 0000070487us-gaap:TreasuryStockMember2017-12-31 00000704872017-12-31 0000070487us-gaap:TreasuryStockMember2018-01-012018-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-31 0000070487us-gaap:CommonClassAMemberus-gaap:CommonStockMember2018-01-012018-12-31 0000070487us-gaap:CommonClassBMemberus-gaap:CommonStockMember2018-01-012018-12-31 0000070487us-gaap:RetainedEarningsMember2018-01-012018-12-31 0000070487srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2018-12-31 0000070487srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-31 0000070487us-gaap:CommonClassAMemberus-gaap:CommonStockMember2018-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2018-12-31 0000070487us-gaap:RetainedEarningsMember2018-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-31 0000070487us-gaap:TreasuryStockMember2018-12-31 00000704872018-12-31 0000070487us-gaap:TreasuryStockMember2019-01-012019-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-31 0000070487us-gaap:RetainedEarningsMember2019-01-012019-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-31 0000070487us-gaap:CommonClassAMemberus-gaap:CommonStockMember2019-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2019-12-31 0000070487us-gaap:RetainedEarningsMember2019-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31 0000070487us-gaap:TreasuryStockMember2019-12-31 0000070487us-gaap:TreasuryStockMember2020-01-012020-12-31 0000070487us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-01-012020-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0000070487us-gaap:RetainedEarningsMember2020-01-012020-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-31 0000070487us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2020-12-31 0000070487us-gaap:RetainedEarningsMember2020-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 0000070487us-gaap:TreasuryStockMember2020-12-31 0000070487nrc:RevenueRecognitionMemberus-gaap:AccountingStandardsUpdate201409Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-01-01 0000070487nrc:IncomeTaxRelatedToRevenueAdjustmentMemberus-gaap:AccountingStandardsUpdate201409Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-01-01 utr:Y 0000070487srt:MinimumMember2020-12-31 0000070487srt:MaximumMember2020-12-31 0000070487nrc:ChangesRelatedToContractCostsMemberus-gaap:AccountingStandardsUpdate201409Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-01-01 0000070487nrc:ChangesRelatedToContractCostsIncomeTaxEffectMemberus-gaap:AccountingStandardsUpdate201409Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-01-01 0000070487nrc:ChangesRelatedToContractCostsMemberus-gaap:AccountingStandardsUpdate201409Member2018-01-01 0000070487nrc:DirectExpensesMember2020-01-012020-12-31 0000070487nrc:DirectExpensesMember2019-01-012019-12-31 0000070487nrc:DirectExpensesMember2018-01-012018-12-31 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-31 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-31 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-01-012018-12-31 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-31 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-31 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-01-012018-12-31 0000070487us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2020-01-012020-12-31 0000070487us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2020-01-012020-12-31 0000070487us-gaap:ComputerEquipmentMembersrt:MinimumMember2020-01-012020-12-31 0000070487us-gaap:ComputerEquipmentMembersrt:MaximumMember2020-01-012020-12-31 0000070487us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MinimumMember2020-01-012020-12-31 0000070487us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MaximumMember2020-01-012020-12-31 0000070487us-gaap:BuildingAndBuildingImprovementsMembersrt:MinimumMember2020-01-012020-12-31 0000070487us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2020-01-012020-12-31 xbrli:pure 0000070487nrc:CanadianSubsidiaryMember2020-12-31 0000070487nrc:CanadianSubsidiaryMember2020-01-012020-12-31 0000070487nrc:CyberAttackMembernrc:RecoveriesReceivedDirectByTheCompanyMember2020-01-012020-12-31 0000070487nrc:CyberAttackMembernrc:RecoveriesPaidDirectlyByInsurerToOutsideVendorMember2020-01-012020-12-31 0000070487nrc:CyberAttackMembernrc:ReimbursementForLostRevenueMember2020-01-012020-12-31 0000070487us-gaap:OtherIncomeMembernrc:PropertyDamageExcludingCyberAttackMember2020-01-012020-12-31 00000704872019-01-01 0000070487nrc:OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember2019-01-01 0000070487us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-31 0000070487us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-31 0000070487us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-31 0000070487us-gaap:FairValueMeasurementsRecurringMember2020-12-31 0000070487us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-31 0000070487us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-31 0000070487us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-31 0000070487us-gaap:FairValueMeasurementsRecurringMember2019-12-31 0000070487stpr:WA2020-09-30 0000070487us-gaap:CommonStockMember2020-01-012020-12-31 0000070487us-gaap:CommonStockMember2019-01-012019-12-31 0000070487nrc:ConversionOfClassBCommonStockIntoClassACommonStockMember2018-04-162018-04-16 00000704872018-04-17 0000070487nrc:ConversionOfClassBCommonStockIntoClassACommonStockMember2018-04-172018-04-17 0000070487nrc:SubscriptionServicesMemberus-gaap:TransferredOverTimeMember2020-01-012020-12-31 0000070487nrc:SubscriptionServicesMemberus-gaap:TransferredOverTimeMember2019-01-012019-12-31 0000070487nrc:SubscriptionServicesMemberus-gaap:TransferredOverTimeMember2018-01-012018-12-31 0000070487us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2020-01-012020-12-31 0000070487us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2019-01-012019-12-31 0000070487us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2018-01-012018-12-31 0000070487nrc:FixedNonSubscriptionServicesMemberus-gaap:TransferredOverTimeMember2020-01-012020-12-31 0000070487nrc:FixedNonSubscriptionServicesMemberus-gaap:TransferredOverTimeMember2019-01-012019-12-31 0000070487nrc:FixedNonSubscriptionServicesMemberus-gaap:TransferredOverTimeMember2018-01-012018-12-31 0000070487nrc:UnitPriceServicesMemberus-gaap:TransferredOverTimeMember2020-01-012020-12-31 0000070487nrc:UnitPriceServicesMemberus-gaap:TransferredOverTimeMember2019-01-012019-12-31 0000070487nrc:UnitPriceServicesMemberus-gaap:TransferredOverTimeMember2018-01-012018-12-31 0000070487nrc:VoCPlatformMember2020-01-012020-12-31 0000070487nrc:VoCPlatformMember2019-01-012019-12-31 0000070487nrc:VoCPlatformMember2018-01-012018-12-31 0000070487us-gaap:OtherCurrentAssetsMember2020-12-31 0000070487us-gaap:OtherCurrentAssetsMember2019-12-31 0000070487us-gaap:LongTermContractWithCustomerMember2021-01-012020-12-31 0000070487nrc:PracticingExcellencecomMember2020-12-31 0000070487us-gaap:FurnitureAndFixturesMember2020-12-31 0000070487us-gaap:FurnitureAndFixturesMember2019-12-31 0000070487us-gaap:ComputerEquipmentMember2020-12-31 0000070487us-gaap:ComputerEquipmentMember2019-12-31 0000070487us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-12-31 0000070487us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2019-12-31 0000070487us-gaap:BuildingAndBuildingImprovementsMember2020-12-31 0000070487us-gaap:BuildingAndBuildingImprovementsMember2019-12-31 0000070487us-gaap:LeaseholdImprovementsMember2020-12-31 0000070487us-gaap:LeaseholdImprovementsMember2019-12-31 0000070487us-gaap:LandMember2020-12-31 0000070487us-gaap:LandMember2019-12-31 0000070487nrc:IncludingAssetsHeldUnderCapitalLeaseMember2020-01-012020-12-31 0000070487nrc:IncludingAssetsHeldUnderCapitalLeaseMember2019-01-012019-12-31 0000070487nrc:IncludingAssetsHeldUnderCapitalLeaseMember2018-01-012018-12-31 0000070487nrc:TradeNames1Member2020-12-31 0000070487us-gaap:CustomerRelationshipsMembersrt:MinimumMember2020-01-012020-12-31 0000070487us-gaap:CustomerRelationshipsMembersrt:MaximumMember2020-01-012020-12-31 0000070487us-gaap:CustomerRelationshipsMember2020-12-31 0000070487us-gaap:TechnologyBasedIntangibleAssetsMember2020-01-012020-12-31 0000070487us-gaap:TechnologyBasedIntangibleAssetsMember2020-12-31 0000070487us-gaap:TradeNamesMembersrt:MinimumMember2020-01-012020-12-31 0000070487us-gaap:TradeNamesMembersrt:MaximumMember2020-01-012020-12-31 0000070487us-gaap:TradeNamesMember2020-12-31 0000070487nrc:TradeNames1Member2019-12-31 0000070487us-gaap:CustomerRelationshipsMembersrt:MinimumMember2019-01-012019-12-31 0000070487us-gaap:CustomerRelationshipsMembersrt:MaximumMember2019-01-012019-12-31 0000070487us-gaap:CustomerRelationshipsMember2019-12-31 0000070487us-gaap:TechnologyBasedIntangibleAssetsMember2019-01-012019-12-31 0000070487us-gaap:TechnologyBasedIntangibleAssetsMember2019-12-31 0000070487us-gaap:TradeNamesMembersrt:MinimumMember2019-01-012019-12-31 0000070487us-gaap:TradeNamesMembersrt:MaximumMember2019-01-012019-12-31 0000070487us-gaap:TradeNamesMember2019-12-31 0000070487nrc:TermLoanMember2020-12-31 0000070487nrc:TermLoanMember2019-12-31 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:TermLoanMember2020-05-28 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:DelayedDrawTermLoanMember2020-05-28 0000070487us-gaap:RevolvingCreditFacilityMembernrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2020-06-30 0000070487us-gaap:RevolvingCreditFacilityMembernrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2020-12-31 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:TermLoanMember2020-01-012020-12-31 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:TermLoanMember2020-12-31 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-12-31 0000070487us-gaap:RevolvingCreditFacilityMembernrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2020-01-012020-12-31 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2020-01-012020-12-31 0000070487nrc:The2001EquityIncentivePlanMemberus-gaap:CommonStockMember2020-12-31 0000070487nrc:The2001EquityIncentivePlanMemberus-gaap:CommonClassBMember2020-12-31 0000070487us-gaap:EmployeeStockOptionMembernrc:The2001EquityIncentivePlanMembersrt:MinimumMember2020-01-012020-12-31 0000070487us-gaap:EmployeeStockOptionMembernrc:The2001EquityIncentivePlanMembersrt:MaximumMember2020-01-012020-12-31 0000070487nrc:The2001EquityIncentivePlanMember2015-12-31 0000070487nrc:DirectorPlan2004Memberus-gaap:CommonStockMember2020-12-31 0000070487nrc:DirectorPlan2004Memberus-gaap:CommonClassBMember2020-12-31 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:DirectorMember2018-01-012018-12-31 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:DirectorMember2019-01-012019-12-31 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:DirectorMember2020-01-012020-12-31 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:MaximumMembersrt:DirectorMember2020-01-012020-12-31 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:MinimumMembersrt:DirectorMember2020-01-012020-12-31 0000070487nrc:DirectorPlan2004Member2020-12-31 0000070487nrc:The2006EquityIncentivePlanMemberus-gaap:CommonStockMember2020-12-31 0000070487nrc:The2006EquityIncentivePlanMemberus-gaap:CommonClassBMember2020-12-31 0000070487nrc:The2006EquityIncentivePlanMembersrt:MinimumMember2020-01-012020-12-31 0000070487nrc:The2006EquityIncentivePlanMembersrt:MaximumMember2020-01-012020-12-31 0000070487nrc:The2006EquityIncentivePlanMember2020-12-31 0000070487nrc:CommonStockOptionsMember2020-01-012020-12-31 0000070487nrc:CommonStockOptionsMember2019-01-012019-12-31 0000070487nrc:CommonStockOptionsMember2018-01-012018-12-31 0000070487us-gaap:CommonStockMember2020-01-012020-12-31 0000070487us-gaap:CommonStockMember2019-01-012019-12-31 0000070487us-gaap:CommonStockMember2018-01-012018-12-31 0000070487nrc:CommonStockOptionsMember2019-12-31 0000070487nrc:CommonStockOptionsMemberus-gaap:CommonStockMember2020-01-012020-12-31 0000070487nrc:CommonStockOptionsMember2020-12-31 0000070487nrc:CommonStockOptionsMemberus-gaap:CommonStockMember2020-12-31 0000070487us-gaap:CommonStockMember2018-01-012018-12-31 0000070487us-gaap:EmployeeStockOptionMember2020-12-31 0000070487us-gaap:EmployeeStockOptionMember2020-01-012020-12-31 0000070487us-gaap:EmployeeStockOptionMembernrc:DirectSellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-31 0000070487us-gaap:EmployeeStockOptionMembernrc:DirectSellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-31 0000070487us-gaap:EmployeeStockOptionMembernrc:DirectSellingGeneralAndAdministrativeExpensesMember2018-01-012018-12-31 0000070487nrc:NonvestedMembernrc:The2006EquityIncentivePlanMember2019-01-012019-12-31 0000070487nrc:NonvestedMembernrc:The2006EquityIncentivePlanMember2018-01-012018-12-31 0000070487nrc:NonvestedMembernrc:The2006EquityIncentivePlanMember2020-01-012020-12-31 0000070487nrc:NonvestedMembernrc:The2006EquityIncentivePlanMember2020-12-31 0000070487nrc:NonvestedMember2020-01-012020-12-31 0000070487nrc:NonvestedMembernrc:DirectSellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-31 0000070487nrc:NonvestedMembernrc:DirectSellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-31 0000070487nrc:NonvestedMembernrc:DirectSellingGeneralAndAdministrativeExpensesMember2018-01-012018-12-31 0000070487us-gaap:RestrictedStockMember2020-01-012020-12-31 0000070487us-gaap:RestrictedStockMember2018-01-012018-12-31 0000070487us-gaap:RestrictedStockMember2019-01-012019-12-31 0000070487us-gaap:CommonStockMember2019-12-31 0000070487us-gaap:CommonStockMember2020-12-31 0000070487nrc:NonvestedMember2020-12-31 0000070487us-gaap:OtherCurrentLiabilitiesMember2020-12-31 0000070487us-gaap:OtherCurrentLiabilitiesMember2019-12-31 0000070487us-gaap:OtherNoncurrentLiabilitiesMember2020-12-31 0000070487us-gaap:OtherNoncurrentLiabilitiesMember2019-12-31 0000070487nrc:OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember2020-12-31 0000070487nrc:OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember2019-12-31 0000070487nrc:FurnitureAndEquipmentHeldUnderFinanceLeasesMember2020-12-31 0000070487nrc:FurnitureAndEquipmentHeldUnderFinanceLeasesMember2019-12-31 0000070487nrc:ComputerEquipmentHeldUnderFinanceLeasesMember2020-12-31 0000070487nrc:ComputerEquipmentHeldUnderFinanceLeasesMember2019-12-31 0000070487nrc:ComputerSoftwareHeldUnderFinanceLeasesMember2020-12-31 0000070487nrc:ComputerSoftwareHeldUnderFinanceLeasesMember2019-12-31 0000070487nrc:AssetsHeldUnderFinanceLeasesMember2020-12-31 0000070487nrc:AssetsHeldUnderFinanceLeasesMember2019-12-31 0000070487us-gaap:SubsequentEventMember2021-02-012021-02-28 0000070487nrc:AmeritasLifeInsuranceCorpMember2020-01-012020-12-31 0000070487nrc:AmeritasLifeInsuranceCorpMember2019-01-012019-12-31 0000070487nrc:AmeritasLifeInsuranceCorpMember2018-01-012018-12-31 0000070487nrc:PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMembernrc:IMAFinancialGroupMember2020-01-012020-12-31 0000070487nrc:PracticingExcellencecomMember2017-01-012017-12-31 0000070487nrc:PracticingExcellencecomMember2020-01-012020-12-31 0000070487nrc:PracticingExcellencecomMember2019-01-012019-12-31 0000070487nrc:PracticingExcellencecomMember2018-01-012018-12-31 0000070487country:US2020-01-012020-12-31 0000070487country:US2019-01-012019-12-31 0000070487country:US2018-01-012018-12-31 0000070487country:CA2020-01-012020-12-31 0000070487country:CA2019-01-012019-12-31 0000070487country:CA2018-01-012018-12-31 0000070487country:US2020-12-31 0000070487country:US2019-12-31 0000070487country:US2018-12-31 0000070487country:CA2020-12-31 0000070487country:CA2019-12-31 0000070487country:CA2018-12-31 0000070487nrc:PatientWisdomIncMemberus-gaap:SubsequentEventMember2021-01-042021-01-04
 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2020     

 or

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

  
 

For the transition period from ________ to ________

Commission File Number 001-35929

 

      National Research Corporation      

(Exact name of Registrant as specified in its charter)

 

Wisconsin

 

47-0634000

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)

 

 

1245 Q Street, Lincoln, Nebraska          68508

 
 

(Address of principal executive offices) (Zip Code)

 

 

 

(402) 475-2525

 
 

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.001 par value

NRC

The NASDAQ stock market

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☒  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

Accelerated filer     

☒

 

Non-accelerated filer

☐

Smaller reporting company

☐

 
  

Emerging growth company

☐

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.) Yes ☐    No  ☒ 

 

Aggregate market value of the common stock held by non-affiliates of the registrant at June 30, 2020: $653,540,609.

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

 

Common Stock, $.001 par value, outstanding as of February 26, 2021: 25,420,408

 

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Proxy Statement for the 2021 Annual Meeting of Shareholders are incorporated by reference into Part III.

 

 
Table of Contents

 

 

TABLE OF CONTENTS

 

   

Page

PART I
     

Item 1.

Business

1

Item 1A.

Risk Factors

7

Item 1B.

Unresolved Staff Comments

12

Item 2.

Properties

13

Item 3.

Legal Proceedings

13

Item 4.

Mine Safety Disclosures

13
     

PART II
     

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

14

Item 6.

Selected Financial Data

16

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 7A.

Quantitative and Qualitative Disclosure About Market Risk

25

Item 8.

Financial Statements and Supplementary Data

26

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

53

Item 9A.

Controls and Procedures

53

Item 9B.

Other Information

53
     

PART III
     

Item 10.

Directors, Executive Officers and Corporate Governance

54

Item 11.

Executive Compensation

54

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

54

Item 13.

Certain Relationships and Related Transactions, and Director Independence

55

Item 14.

Principal Accountant Fees and Services

55
     

PART IV
     

Item 15.

Exhibits

56

Item 16.

Form 10-K Summary

57

Signatures

59

 

i
Table of Contents

 

 

PART I

 

Item 1.

Business
 

Special Note Regarding Forward-Looking Statements

 

Certain matters discussed in this Annual Report on Form 10-K are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can generally be identified as such because the context of the statement includes phrases such as National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), “believes,” “expects,” “may,” “could,” “anticipates,” or the use of words such as “would,” “may,” “could,” or “should,” or other words of similar import. Similarly, statements that describe our future plans, objectives or goals are also forward-looking statements. In this Annual Report on Form 10-K, statements regarding the future impact of adopting new accounting standards, value and utility of, and market demand for, our service offerings, future opportunities for growth and respect to new and existing clients, our future ability to compete and the types of firms with which we will compete, future consolidation in the healthcare industry, future adequacy of our liquidity sources, future revenue sources, future capital expenditures and the sources of cash to fund such capital expenditures, the expected impact of pending claims and contingencies, the future outcome of uncertain tax positions, our future use of owned and leased real property, the source of funds for future payments of deferred purchase price obligations and other cash expenses, the future phase out of LIBOR and applicable replacement benchmark rates and the expected impact of the COVID-19 pandemic and related government mandates and recommendations, among others, are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties which could cause actual results or outcomes to differ materially from those currently anticipated. Factors that could affect actual results or outcomes include, without limitation, the following factors:

 

 

●

The likelihood that the COVID-19 pandemic will adversely affect our sales, earnings, financial condition and liquidity;

 

 

●

The possibility of non-renewal of our client service contracts and retention of key clients;

 

 

●

Our ability to compete in our markets, which are highly competitive with new market entrants, and the possibility of increased price pressure and expenses;

 

 

●

The effects of an economic downturn;

 

 

●

The impact of consolidation in the healthcare industry;

 

 

●

The impact of federal healthcare reform legislation or other regulatory changes;

 

 

●

Our ability to attract and retain key managers and other personnel;

 

 

●

The possibility that our intellectual property and other proprietary information technology could be copied or independently developed by our competitors;

 

 

●

The possibility for failures or deficiencies in our information technology platform;

 

 

●

The possibility that we could be subject to cyber-attacks, security breaches or computer viruses; and 

 

 

●

The factors set forth under the caption “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission.

 

Shareholders, potential investors and other readers are urged to consider these and other factors in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included are only made as of the date of this Annual Report on Form 10-K and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances, except as required by the federal securities laws.

 

General

 

Our purpose is to establish human understanding. Our solutions enable health care organizations to understand what matters most to each person they serve. We are a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations. Our heritage, proprietary methods, and holistic approach enable our partners to better understand the people they care for and design experiences that inspire loyalty and trust, while also facilitating regulatory compliance and the shift to population-based health management. Our ability to measure what matters most and systematically capture, analyze and deliver insights based on self-reported information from patients, families and consumers is critical in today’s healthcare market. We believe that access to and analysis of our extensive consumer-driven information is becoming more valuable as healthcare providers increasingly need to more deeply understand and engage the people they serve to build customer loyalty.

 

1
Table of Contents

 

Our expertise includes the efficient capture, transmittal, benchmarking, analysis and interpretation of critical data elements from millions of healthcare consumers. Using our digital Voice of the Customer platform, our clients gain insights into what people think and feel about their organizations in real-time, allowing them to build on their strengths and resolve service issues with greater speed and personalization. We also provide legacy experience-based solutions and shared intelligence from industry thought leaders and the nation’s largest member network focused on healthcare governance and strategy to member boards and executives.

 

Our portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management and brand loyalty. We partner with clients across the continuum of healthcare services. Our clients include integrated health systems, post-acute providers and payer organizations. We believe this cross-continuum positioning is a unique and an increasingly important capability as evolving payment models drive healthcare providers and payers towards a more collaborative and integrated service model.

 

We have achieved a market leadership position through our more than 39 years of industry innovation and experience, as well as our long-term, recurring revenue relationships (solutions that are used or required by a client each year) with many of the healthcare industry’s largest organizations. Since our founding in 1981, we have focused on meeting the evolving information needs of the healthcare industry through internal product development, as well as select acquisitions. We are a Wisconsin corporation headquartered in Lincoln, Nebraska.

 

Sales

 

Our portfolio of solutions represents a unique set of capabilities that individually and collectively provide value to our clients. The solutions are offered at an enterprise level through the Voice of the Customer platform, The Governance Institute, and legacy Experience solutions.

 

We partner with clients across the continuum of healthcare services. Our clients include integrated health systems, post-acute providers and payer organizations. Our ten largest clients collectively accounted for 14%, 16%, and 17% of our total revenue in 2020, 2019 and 2018, respectively. Approximately 2%, 3% and 4% of our revenue was derived from foreign customers in 2020, 2019, and 2018, respectively.

 

Voice of the Customer Platform Solutions

 

Our Voice of the Customer (“VoC”) platform represents a portfolio of solutions that collectively provide a comprehensive set of capabilities that enable healthcare providers to collect, measure and analyze data collected across the patient journey to understand the preferences, experiences and needs of the people they serve. The digital platform consists of three primary solution categories which can be implemented both collectively as an enterprise solution or individually to meet specific needs within the organization. The primary solution categories include Market Insights solutions, Transparency solutions, and certain Experience solutions. Our solutions within the digital VoC platform accounted for 73.3% of total revenue in 2020.

 

Market Insights Solutions – Our Market Insights solutions are subscription-based services that allow for improved tracking of awareness, perception, and consistency of healthcare brands; real-time assessment of competitive differentiators; and enhanced segmentation tools to evaluate the needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. Market Insights is the largest U.S. healthcare consumer database of its kind, measuring the opinions and behaviors of approximately 300,000 healthcare consumers across the contiguous United States annually. Our Market Insights is a syndicated survey that provides clients with an independent third-party source of information that is used to understand consumer perception and preferences and optimize marketing strategies. Our Market Insights solutions provide clients with on-demand tools to measure brand value and build brand equity in their markets, evaluate and optimize advertising efficacy and consumer recall, and tailor research to obtain the real time voice of customer feedback to support branding and loyalty initiatives. Our Market Insights solutions were historically marketed under the Healthcare Market Guide and Ticker brands.

 

2
Table of Contents

 

Experience Solutions – Our Experience solutions are provided on a subscription basis via a cross-continuum VoC platform that collects and measures data and then delivers business intelligence that our clients utilize to improve patient experience, engagement and loyalty. Patient experience data can also be collected on a periodic basis using CAHPS compliant mail and telephone survey methods for regulatory compliance purposes and to monitor and measure improvement in CAHPS survey scores. CAHPS survey data can be collected and measured as an integrated service within the VoC platform or independently as a legacy service offering. Our Experience solutions provide hospitals and healthcare providers the ability to receive and take action on customer and employee feedback across all care settings in real-time. Experience solutions include patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools, which are provided through the Experience, Transitions and National Research Canada Corporation operating segments. These solutions enable clients to comply with regulatory requirements and to improve their reimbursement under value-based purchasing models. More importantly, our Experience solutions provide quantitative and qualitative real-time feedback, improvement plans, and coaching tools to enable clients to improve the experiences of patients, residents, physicians and staff.   By illuminating the complete care journey in real time, our clients are able to ensure each individual receives the care, respect, and experience he or she deserves. Developing a longitudinal profile of what healthcare customers want and need allows for organizational improvement, increased clinician and staff engagement, loyal relationships and personal well-being. These solutions have previously been marketed under the NRC Picker, My InnerView (“MIV”), Customer-Connect LLC (“Connect”), and NRC Canada brands.

 

Our Health Risk Assessment solutions (formerly Payer solutions) enable our clients to understand the health risks associated with populations of patients, analyze and address readmission risks, and efficiently reach out to patients to impact their behaviors outside of the healthcare provider settings. These health risk assessment solutions enable clients to effectively segment populations and manage care for those who are most at-risk, engage individuals, increase preventative care and manage wellness programs to improve patient experience and outcomes.

 

Our Transitions solutions are provided to healthcare organizations on a subscription basis to drive effective communication between healthcare providers and patients in the critical 24-72 hours post discharge using a discharge call program. Through preference-based communications and real-time alerts, these solutions enable organizations to identify and manage high-risk patients to reduce readmissions, increase patient satisfaction and support safe care transitions. Tracking, trending and benchmarking tools isolate the key areas for process improvement allowing organizations to implement changes and reduce future readmissions. Our Transitions solutions were previously provided by Connect.

 

Transparency Solutions – Our Transparency solutions allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs better consumer decision-making. Our Star Ratings solution (formerly Reputation) enables clients to publish a five-star rating metric and verified patient feedback derived from actual patient survey data to complement their online physician information. Sharing this feedback not only results in better-informed consumer decision-making but also has the ability to drive new patient acquisition and grow online physician reputation. Our Reputation Monitoring solution alerts clients to ratings and reviews on third-party websites and provides workflows for response and service recovery. These solutions raise physician awareness of survey results and provide access to improvement resources and educational development opportunities designed to improve the way care is delivered.

 

The Governance Institute

 

Our Governance solutions, branded as The Governance Institute (“TGI”), serves not-for-profit hospital and health system boards of directors, executives, and physician leadership. TGI’s subscription-based, value-driven membership services are provided through national conferences, publications, advisory services, and an online portal designed to improve the effectiveness of hospital and healthcare systems by continually strengthening their board governance, strategic planning, medical leadership, management performance, and transparency positioning. TGI also conducts research studies and tracks industry trends showcasing emerging healthcare trends and best practice solutions of healthcare boards across the country. TGI thought leadership helps our client board members and executives inform and guide their organization’s strategic priorities in alignment with the rapidly changing healthcare market.

 

For additional information on our operating segments and our revenue and assets by geographic area, see Note 13, “Segment Information,” to our consolidated financial statements.

 

Markets

 

Growth Strategy

 

We believe that the value proposition of our current solutions, combined with the favorable alignment of our solutions with emerging market demand, positions us to benefit from multiple growth opportunities. We believe that we can accelerate our growth through (1) increasing scope of services and sales of our existing solutions to our existing clients (or cross-selling), (2) winning additional new clients through market share growth in existing market segments, (3) developing and introducing new solutions to new and existing clients, and (4) pursuing acquisitions of, or investments in, firms providing products, solutions or technologies which complement ours.

 

Increasing contract value with existing clients. Approximately 28% of our existing clients purchase more than one of our solutions. Our sales organization actively identifies and pursues cross-sell opportunities for clients to add additional solutions in order to accelerate our growth. Organic contract value growth is also realized by the increased scope of solution adoption as the size of client organizations increase from market expansion and consolidation.

 

3
Table of Contents

 

Adding new clients. We believe that there is an opportunity to add new clients across all existing market segments. Our sales organization is actively identifying and engaging new client prospects with a focus on demonstrating the economic value derived from adopting the portfolio of solutions in alignment with the prospect’s strategic objectives.

 

Adding new solutions. The need for effective solutions in the market segments that we serve is evolving to align with emerging healthcare consumerism trends. The evolving market creates an opportunity for us to introduce new solutions that leverage and extend our existing core competencies. We believe that there is an opportunity to drive sales growth with both existing and new clients, across all of the market segments that we serve, through the introduction of new solutions.

 

Pursue strategic acquisitions and investments. We have historically complemented our organic growth with strategic acquisitions, having completed seven such transactions over the past eighteen years. These transactions have added new capabilities and access to market segments that are adjacent and complementary to our existing solutions and market segments. We believe that additional strategic acquisition and/or investment opportunities will exist from time to time to complement our organic growth by further expanding our service capabilities, technology offerings and end markets.

 

We generate the majority of our revenue from the renewal of subscription-based client service agreements, supplemented by sales of additional solutions to existing clients and the addition of new clients. Our sales activities are carried out by a direct sales organization staffed with professional, trained sales associates.

 

We engage in marketing activities that enhance our brand visibility in the marketplace, generate demand for our solutions and engage existing clients. Strategic campaigns and programs focus on (1) ensuring coverage of prospective clients via targeted advertising and account-based campaigns, (2) elevating client value evidence and success stories to an executive level profile, (3) engaging key stakeholders with content, programming and events and (4) amplifying thought leadership through public and media relations programs that include earning placement in national media and trade publications, securing podium presentations at key industry events and winning awards on behalf of us and our executives.

 

Competition

 

The healthcare information and market research services industry is highly competitive. We have traditionally competed with healthcare organizations’ internal marketing, market research, and/or quality improvement departments which create their own performance measurement tools, and with relatively small specialty research firms which provide survey-based healthcare market research and/or performance assessment. Our primary competitors among such specialty firms include Press Ganey, which we believe has significantly higher annual revenue than us, and several other organizations that we believe have less annual revenue than us. We, to a certain degree, currently compete with, and anticipate that in the future we may increasingly compete with, (1) market research firms and technology solutions which provide survey-based, general market research or voice of the customer feedback capabilities and (2) firms that provide services or products that complement healthcare performance assessments such as healthcare software or information systems.

 

We believe the primary competitive factors within our market include quality of service, timeliness of delivery, unique service capabilities, credibility of provider, industry experience, and price. We believe that our industry leadership position, exclusive focus on the healthcare industry, cross-continuum presence, comprehensive portfolio of solutions and relationships with leading healthcare payers and providers position us to compete in this market.

 

Although only a few of these competitors have offered specific services that compete directly with our solutions, many of these competitors have substantially greater financial, information gathering, and marketing resources than us and could decide to increase their resource commitments to our market. There are relatively few barriers to entry into our market, and we expect increased competition in our market which could adversely affect our operating results through pricing pressure, increased marketing expenditures, and market share losses, among other factors. There can be no assurance that we will continue to compete successfully against existing or new competitors.

 

We believe that our competitive strengths include the following:

 

A leading provider of patient experience solutions for healthcare providers, payers and other healthcare organizations. Our history is based on capturing the voice of the consumer in healthcare markets. Our solutions build on the “Eight Dimensions of Patient-Centered Care,” a philosophy developed by noted patient advocate Harvey Picker, who believed patients’ experiences are integral to quality healthcare. This foundation has been enhanced through the digital VoC platform offering that provides the delivery of data and insights on a real time basis.

 

4
Table of Contents

 

Premier client portfolio across the care continuum. Our client portfolio encompasses leading healthcare organizations across the healthcare continuum, from acute care hospitals and post-acute providers to healthcare payers. Our client base is diverse, with our top ten clients collectively representing approximately 14% of total revenue for the year ended December 31, 2020, and no single client representing more than 4% of our revenue.

 

Highly scalable and visible revenue model. Our solutions are offered to healthcare providers, payers and other healthcare organizations primarily through subscription-based service agreements. The solutions we provide are also recurring in nature, which enables an ongoing relationship with our clients. This combination of subscription-based revenue, a base of ongoing client renewals and automated platforms creates a highly visible and scalable revenue model.

 

Comprehensive portfolio of solutions. We offer a portfolio of solutions that provide insights across the patient journey, which is unique in the healthcare industry, enabling our clients to initially establish an enterprise relationship utilizing the entire portfolio or begin with an individual solution and increase the scope of services over time, increasing overall contract value.

 

Exclusive focus on healthcare. We focus exclusively on healthcare and serving the unique needs of healthcare organizations across the continuum, which we believe gives us a distinct competitive advantage compared to other survey and analytics software providers. Our platform includes features and capabilities built specifically for healthcare providers, including a library of performance improvement content which can be tailored to the provider based on their specific customer feedback profile.

 

Experienced senior management team led by our founder. Our senior management team has extensive industry and leadership experience. Michael D. Hays, our Chief Executive Officer and President as of October 2, 2020, founded NRC Health in 1981. Prior to launching the Company, Mr. Hays served as Vice President and as a Director of SRI Research Center, Inc. (now known as the Gallup Organization). Our Chief Financial Officer, Kevin Karas, CPA, has extensive financial experience having served as CFO at two previous companies, along with healthcare experience at Rehab Designs of America, Inc. and NovaCare, Inc. Steven D. Jackson, our President through October 1, 2020, served as Chief Strategy Officer for Vocera Communications. Jona Raasch has served as our Chief Operating Officer for most of the last 30 years and as Chief Executive Officer of the Governance Institute for nearly 15 years.  Helen Hrdy was appointed as our Chief Growth Officer in 2020.  Prior to this position Ms. Hrdy served as our Senior Vice President, Customer Success, for eight years.

 

Resources

 

Our success depends in part upon our data collection processes, research methods, data analysis techniques and internal systems, and procedures that we have developed specifically to serve clients in the healthcare industry. We have no patents for most of our intellectual property. Consequently, we rely on a combination of copyright and trade secret laws and associate nondisclosure agreements to protect our systems, survey instruments and procedures. There can be no assurance that the steps we have taken to protect our rights will be adequate to prevent misappropriation of such rights or that third parties will not independently develop functionally equivalent or superior systems or procedures. We believe that our systems and procedures and other proprietary rights do not infringe upon the proprietary rights of third parties. There can be no assurance, however, that third parties will not assert infringement claims against us in the future or that any such claims will not result in protracted and costly litigation, regardless of the merits of such claims or whether we are ultimately successful in defending against such claims.

 

Government Regulation

 

According to the Centers for Medicare and Medicaid Services (“CMS”), health expenditures in the United States were approximately $3.8 trillion in 2019, or $11,582 per person. In total, health spending accounted for 17.7% of the nation’s Gross Domestic Product in 2019. Addressing this growing expenditure burden continues to be a major policy priority at both federal and state levels. In addition, increased co-pays and deductibles in healthcare plans have focused even more consumer attention on health spending and affordability. In the public sector, Medicare provides health coverage for individuals aged 65 and older, while Medicaid provides coverage for low-income families and other individuals in need. Both programs are administered by the CMS. With the aging of the U.S. population, Medicare enrollment has increased significantly.  In addition, longer life spans and greater prevalence of chronic illnesses among both the Medicare and Medicaid populations have placed tremendous demands on the health care system.

 

An increasing percentage of Medicare reimbursement and reimbursement from commercial payers has been determined under value payment models, based on factors such as patient readmission rates and provider adherence to certain quality-related protocols. At the same time, many hospitals and other providers are creating new models of care delivery to improve patient experience, reduce cost and provide better clinical outcomes. These new models are based on sharing financial risk and managing the health and behaviors of large populations of patients and consumers. This transformation towards value-based payment models and increased engagement of healthcare consumers is resulting in a greater need for existing healthcare providers to deliver more customer-centric healthcare. At the same time, organizations that have successfully developed effective customer service models and brand loyalty in other industry verticals are entering the healthcare services market.

 

5
Table of Contents

 

We believe that our current portfolio of solutions is uniquely aligned to address these healthcare market trends and related business opportunity. We provide tools and solutions to capture, interpret and improve the Consumer Assessment of Healthcare Providers and Systems ("CAHPS") data required by CMS as well as real time feedback that enables clients to better understand what matters most to people at key moments in their relationship with a health organization. Our solutions enable our clients to both satisfy patient survey compliance requirements and design experiences to build loyalty and improve the wellbeing of the people and communities they care for.

 

Human Capital

 

As of December 31, 2020, we employed a total of 485 associates, 13 of those were employed in Canada. None of our associates are represented by a collective bargaining unit. As a result of the COVID-19 pandemic, the majority of our associates are working remotely with very successful results. We attract a passionate team of associates who care deeply about making a difference in advancing “Human Understanding” in healthcare. We consider our relationships with our associates to be good.

 

Available Information

 

More information regarding NRC Health is available on our website at www.nrchealth.com. We are not including the information contained on or available through our website as part of, or incorporating such information by reference into, this Annual Report on Form 10-K. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports are made available to the public at no charge through a link appearing on our website. We provide access to such materials through our website as soon as reasonably practicable after electronically filing such material with, or furnishing it to, the Securities and Exchange Commission. Reports and amendments posted on our website do not include access to exhibits and supplemental schedules electronically filed with the reports or amendments.

 

6
Table of Contents

 

Item 1A.

Risk Factors

 

You should carefully consider each of the risks described below, together with all of the other information contained in this Annual Report on Form 10-K, before making an investment decision with respect to our securities. If any of the following risks develop into actual events, our business, financial condition or results of operations could be materially and adversely affected and you may lose all or part of your investment.

 

Risks Related to our Business

 

We could be negatively impacted by the recent Coronavirus or “COVID-19” outbreak or other similar outbreaks.

 

The outbreak of COVID-19 has been recognized as a global pandemic by the World Health Organization. Federal, state, local and foreign governments have restricted travel and business operations and recommended or imposed social distancing and isolation mandates. These measures have severely restricted economic activity around the world. These events have had and may continue to have adverse effects on our business in a number of respects.

 

The outbreak of COVID-19 has significantly increased economic and demand uncertainty.  The current outbreak and continued spread of COVID-19 and associated government mandates and recommendations have resulted in an economic slowdown and a global recession.  Although the impact on our healthcare clients has varied, the restrictions on movement outside of individuals’ homes has resulted in significantly decreased demand for elective healthcare services, which are a large source of revenue for healthcare providers. These circumstances have resulted in many of our clients experiencing decreased revenues, contracting margins, and cash losses.  Some clients’ cost reducing measures have included and could continue to include reducing or eliminating the services they purchase from us. While these circumstances did not significantly impact our financial position or results of operations in 2020, the negative impact could continue to increase. 

 

We rely on third-party service providers and business partners, for services or supplies that are critical to providing our clients’ services. These include activities such as internet, cloud data storage, information technology services, and survey related services. These third parties are also subject to risks and uncertainties related to the COVID-19 pandemic, which may interfere with their ability to provide their services in a timely manner and in accordance with the agreed-upon terms or our agreements, which could interfere with our ability to operate our business.

 

The COVID-19 pandemic may also have legal or regulatory impacts that have an impact on our business and operations. Historically CMS required certain healthcare organizations to periodically assess, through surveys or related methodologies, the performance of the care they provide. Many of these organizations use our services to comply with this regulatory requirement. However, as a result of the COVID-19 pandemic CMS has suspended the requirement for healthcare organizations to perform these assessments, and some clients have suspended or reduced these services, and others may do so.

 

In addition, the vast majority of our workforce has been working remotely since March 2020. Historically we have relied on national travel as part of our sales efforts, but as a result of the pandemic we have placed an indefinite hold on all company related travel. To date, we are still capable of providing our services without interruption and without significant changes to our internal control over financial reporting. However, an extended period of associates working remotely and restrictions on travel may interfere with our ability to conduct business, including our ability to sell our products or develop new products.

 

Furthermore, COVID-19 has negatively impacted the proper functioning of financial and capital markets, foreign currency exchange rates, and interest rates. In particular, the continued spread of COVID-19 has led to disruption and volatility in the global capital markets which increases the cost of capital and adversely impacts access to capital. If we need to seek additional liquidity in response to some of the economic and business impacts of COVID-19, these circumstances could increase our cost of capital or limit the extent to which capital is available to us.

 

The impact of the COVID-19 pandemic (or any future pandemic or similar event) on our business will depend on a variety of factors, including the duration and spread of the outbreak in the United States and Canada, the associated government and industry mandates and practices, the economic and regulatory impacts on our clients and the markets in which we operate, the policies we implement, and the response of our associates and clients to these factors, all of  which are difficult to predict. We may need to develop or adapt to new ways of doing business that challenge our leadership, our associate training, our human resources, and our business practices, and we cannot assure you that we will be successful in doing so. The short and long-term costs associated with these potential changes are difficult to quantify.  For these and other reasons, the outbreak and associated responses have negatively affected and are expected to continue to affect our business, and the impact could be material.

 

7
Table of Contents

 

We depend on contract renewals, including retention of key clients, for a large share of our revenue and our operating results could be adversely affected.

 

We expect that a substantial portion of our revenue for the foreseeable future will continue to be derived from renewable service contracts. Substantially all contracts are renewable annually at the option of our clients, although contracts with clients under unit-based arrangements generally have no minimum purchase commitments. Client contracts are generally cancelable on short notice without penalty, however we are entitled to payment for services through the cancellation date. To the extent that clients fail to renew or defer their renewals, we anticipate our results may be materially adversely affected. We rely on a limited number of key clients for a substantial portion of our revenue. Our ten largest clients collectively accounted for 14%, 16%, and 17% of our total revenue in 2020, 2019, and 2018, respectively. Our ability to secure renewals depends on, among other things, our ability to gather and analyze performance data in a consistent, high-quality, and timely fashion. In addition, the service needs of our clients are affected by accreditation requirements, enrollment in managed care plans, the level of use of satisfaction measures in healthcare organizations’ overall management and compensation programs, the size of operating budgets, clients’ operating performance, industry and economic conditions, and changes in management or ownership. As these factors are beyond our control, we cannot ensure that we will be able to maintain our renewal rates. Any material decline in renewal rates from existing levels would have an adverse effect on our revenue and a corresponding effect on our operating and net income.

 

We operate in a highly competitive market and could experience increased price pressure and expenses as a result.

 

The healthcare information and market research services industry is highly competitive. We have traditionally competed with healthcare organizations’ internal marketing, market research and/or quality improvement departments that create their own performance measurement tools, and with relatively small specialty research firms that provide survey-based healthcare market research and/or performance assessment. Our primary competitors among such specialty firms include Press Ganey, which we believe has significantly higher annual revenue than us, and three or four other firms that we believe have lower annual revenue than us. To a certain degree, we currently compete with, and anticipate that in the future we may increasingly compete with, (1) market research firms and technology solutions which provide survey-based, general market research or Voice of the Customer Feedback capabilities and (2) firms that provide services or products that complement healthcare performance assessments, such as healthcare software or information systems. Although only a few of these competitors have offered specific services that compete directly with our services, many of these competitors have substantially greater financial, information gathering, and marketing resources than us and could decide to increase their resource commitments to our market. There are relatively few barriers to entry into our market, and we expect increased competition in our market which could adversely affect our operating results through pricing pressure, increased marketing expenditures, and market share losses, among other factors. There can be no assurance that we will continue to compete successfully against existing or new competitors.

 

Because our clients are concentrated in the healthcare industry, our revenue and operating results may be adversely affected by changes in regulations, a business downturn or consolidation with respect to the healthcare industry.

 

Substantially all of our revenue is derived from clients in the healthcare industry. As a result, our business, financial condition and results of operations are influenced by conditions affecting this industry, including changing political, economic, competitive and regulatory influences that may affect the procurement practices and operation of healthcare providers and payers. Future legislative changes, including additional provisions to control healthcare costs, improve healthcare quality and expand access to health insurance, could result in lower reimbursement rates and otherwise change the environment in which providers and payers operate. In addition, large private purchasers of healthcare services are placing increasing cost pressure on providers. Healthcare providers may react to these cost pressures and other uncertainties by curtailing or deferring purchases, including purchases of our services.

 

Moreover, there has been consolidation of companies in the healthcare industry, a trend which we believe will continue to grow. Consolidation in this industry, including the potential acquisition of certain of our clients, could adversely affect aggregate client budgets for our services, could result in clients performing more marketing, market research and/or quality improvement functions internally or could result in the termination of a client’s relationship with us. The impact of these developments on the healthcare industry is difficult to predict and could have an adverse effect on our revenue and a corresponding effect on our operating and net income.

 

We rely on third parties for data collection and other services whose actions could have a material adverse effect on our business.

 

We outsource certain operations and engage third parties to perform work needed to fulfill our client services. For example, we use vendors to perform certain printing, mailing, information transmittal and other services related to our survey operations. If any of these vendors cease to operate or fail to adequately perform the contracted services and alternative resources and processes are not utilized in a timely manner, our business could be adversely affected. The loss of any of our key vendors could impair our ability to perform our client services and result in lower revenues and income. It would also be time-consuming and expensive to replace, either directly or through other vendors, the services performed by these vendors, which could adversely impact revenues, expenses and net income. Furthermore, our ability to monitor and direct our vendors’ activities is limited. If their actions and business practices violate policies, regulations or procedures otherwise considered illegal, we could be subject to reputational damage or litigation which would adversely affect our business.

 

8
Table of Contents

 

We face several risks relating to our ability to collect the data on which our business relies.

 

Our ability to provide timely and accurate performance measurement and improvement services to our clients depends on our ability to collect large quantities of high-quality data through surveys and interviews. If our mail survey operations are disrupted and we are unable to mail our surveys in a timely manner, then our revenue and net income could be negatively impacted. If receptivity to our survey and interview methods by respondents declines, or, for some other reason, their willingness to complete and return surveys declines, or if we, for any reason, cannot rely on the integrity of the data we receive, then our revenue could be adversely affected with a corresponding effect on our operating and net income. We also rely on third-party panels of pre-recruited consumer households to produce our Market Insights in a timely manner. If we are not able to continue to use these panels, or the time period in which we use these panels is altered and we cannot find alternative panels on a timely, cost-competitive basis, we could face an increase in our costs or an inability to effectively produce our Market Insights. In either case, our operating and net income could be negatively affected.

 

If intellectual property and other proprietary information technology were copied or independently developed by our competitors, our operating results could be negatively affected.

 

Our success depends in part upon our data collection process, research methods, data analysis techniques, and internal systems and procedures that we have developed specifically to serve clients in the healthcare industry. We have no patents for most of our intellectual property. Consequently, we rely on a combination of copyright, trade secret laws and associate nondisclosure agreements to protect our systems, survey instruments and procedures. We cannot assure you that the steps we have taken to protect our rights will be adequate to prevent misappropriation of such rights, or that third parties will not independently develop functionally equivalent or superior systems or procedures. We believe that our systems and procedures and other proprietary rights do not infringe upon the proprietary rights of third parties. We cannot assure you, however, that third parties will not assert infringement claims against us in the future, or that any such claims will not result in protracted and costly litigation, regardless of the merits of such claims, or whether we are ultimately successful in defending against such claims.

 

Failures or deficiencies in our information technology platform could negatively impact our operating results.

 

Our ability to provide client service is dependent, to a significant extent, upon the technology that we develop internally. Investment in the enhancement of existing and development of new information technology processes is costly and affects our ability to successfully serve our clients. The failure or deficiency of the technology we develop could negatively impact the willingness or ability for our clients to use our services and our ability to perform our services. Our failure to anticipate clients’ expectation and needs, adapt to emerging technological trends, or design efficient and effective information technology platforms, could result in lower utilization, loss of customers, damage to customer relationships, reduced revenue and profits, refunds to customers and damage to our reputation. Although we have procedures to monitor the efficacy of our information technology platforms, the procedures may not prevent failures or deficiencies in the information technology platforms we develop, we may not adapt quickly enough and may incur significant costs and delays that could harm our business. Additional costs could be incurred to further develop and improve our information technology platforms.

 

Our business and operating results could be adversely affected if we experience business interruptions or failure of our information technology and communication systems.

 

Our ability to provide timely and accurate performance measurement and improvement services to our clients depends on the efficient and uninterrupted operation of our information technology and communication systems, and those of our external service providers. Our systems and those of our external service providers could be exposed to damage or interruption from fire, natural disasters, energy loss, telecommunication failure, security breach and computer viruses. An operational failure or outage in our information technology and communication systems or those of our external service providers, could result in loss of customers, damage to customer relationships, reduced revenue and profits, refunds of customer charges and damage to our reputation and may result in additional expense to repair or replace damaged equipment and recover data loss resulting from the interruption. Although we have taken steps to prevent system failures and have back-up systems and procedures to prevent or reduce disruptions, such steps may not prevent an interruption of services and our disaster recovery planning may not account for all contingencies. Additionally, our insurance may not adequately compensate us for all losses or failures that may occur. Any one of the above situations could have a material adverse effect on our business, financial condition, results of operations and reputation.

 

9
Table of Contents

 

If we sustain cyber-attacks or other privacy or data security incidents that result in security breaches that disrupt our operations or result in the unintended dissemination of protected personal information or proprietary or confidential information, we could suffer a loss of revenue and increased costs, exposure to significant liability, reputational harm and other serious negative consequences. 

 

In connection with our client services, we receive, process, store and transmit sensitive business information and, in certain circumstances, personal medical information of our clients’ patients, electronically over the internet. We may become the target of attempted cyber-attacks and other security threats and may be subject to breaches of the information technology systems we use. Experienced computer programmers and hackers may be able to penetrate our security controls and access, misappropriate or otherwise compromise protected personal information or proprietary or confidential information or that of third-parties, create system disruptions or cause system shutdowns that could negatively affect our operations. They also may be able to develop and deploy viruses, worms, ransomware, and other malicious software programs that attack our systems or otherwise exploit any security vulnerabilities.

 

We were the target of an external cyber-attack in February 2020 (the “February incident”) which resulted in a temporary suspension of our services to clients.  We will likely continue to be the target of other attempted cyber-attacks and security threats. Such cyber-attacks may subject us to litigation and regulatory risk, civil and criminal penalties, additional costs and diversion of management attention due to investigation, remediation efforts and engagement of third party consultants and legal counsel in connection with such incidents, payment of “ransoms” to regain access to our systems and information, loss of clients, damage to client relationships, reduced revenue and profits, refunds of client charges and damage to our reputation, any of which could have a material adverse effect on our business, cash flows, financial condition and results of operations. While we have contingency plans and insurance coverage for potential liabilities of this nature, they may not be sufficient to cover all claims and liabilities and in some cases are subject to deductibles and layers of self-insured retention.

 

We cannot ensure that we will be able to identify, prevent or contain the effects of cyber-attacks or other cybersecurity risks that bypass our security measures or disrupt our information technology systems or business. We have security technologies, processes and procedures in place to protect against cybersecurity risks and security breaches. However, hardware, software or applications we develop or procure from third parties may contain defects in design, manufacturer defects or other problems that could unexpectedly compromise information security. In addition, because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently, are becoming increasingly sophisticated, and may not immediately produce signs of intrusion, we may be unable to anticipate these techniques, timely discover or counter them or implement adequate preventative measures.

 

In addition, we use third-party technology, systems and services for a variety of reasons, including, without limitation, encryption and authentication technology, employee email, content delivery to clients, back-office support, and other functions that in some cases involve processing, storing and transmitting large amounts of data for our business. These third-party providers may also experience security breaches or interruptions to their information technology hardware and software infrastructure and communications systems that could adversely impact us.

 

Under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, implementing regulations promulgated by the U.S. Department of Health and Human Services, or “HHS,” including what are referred to as the “Privacy Rule” and the “Security Rule” (collectively, “HIPAA”), we face potential liability related to the privacy of health information we obtain.  We are required through our contracts with our clients and by HIPAA to protect the privacy and security of certain health information and to make certain disclosures to our clients or to the public if this information is unlawfully accessed. 

 

Changes in privacy and information security laws and standards may require we incur significant expense to ensure compliance due to increased technology investment and operational procedures. Noncompliance with any privacy or security laws and regulations, including, without limitation, HIPPA, or any security breach, cyber-attack or cybersecurity breach, and any incident involving the misappropriation, loss or other unauthorized disclosure or use of, or access to, sensitive or confidential information, whether by us or by one of our third-party service providers, could require us to expend significant resources to continue to modify or enhance our protective measures and to remediate any damage. In addition, this could negatively affect our operations, cause system disruptions, damage our reputation, cause client losses and contract breaches, and could also result in regulatory enforcement actions, material fines and penalties, litigation or other actions that could have a material adverse effect on our business, cash flows, financial condition and results of operations.  Even if cyber-attacks or other cybersecurity breaches do not result in noncompliance with privacy or security laws, the perception that such noncompliance may have occurred by our clients or in the news media may have an adverse impact on our stock price and could result in damage to our reputation or loss of clients, which could have a material adverse effect on our business, cash flows, financial condition and results of operations.

 

10
Table of Contents

 

Reputational harm could have a material adverse effect on our business, financial condition and results of operations.

 

Our ability to maintain a good reputation is critical to selling our services. Our reputation could be adversely impacted by any of the following (whether or not valid): the failure to maintain high ethical and social standards; the failure to perform our client services in a timely manner; violations of laws and regulations; failure to adequately preserve information security; and the failure to maintain an effective system of internal controls or to provide accurate and timely financial information. Damage to our reputation or loss of our clients’ confidence in our services for any of these, or any other reasons, could adversely impact our business, revenues, financial condition, and results of operations, as well as require additional resources to rebuild our reputation.

 

Our operations are subject to laws and regulations that impose significant compliance costs and create reputational and legal risk.

 

Due to the nature of the services we offer, we are subject to significant commercial, trade and privacy regulations. We cannot predict the nature, scope or effect of future regulatory requirements to which our operations might be subject or the manner in which existing laws might be administered or interpreted, which could have a material and negative impact on our business and our results of operation. For example, recent years have seen an increase in the development or enforcement of legislation related to healthcare reform, privacy, trade compliance and anti-corruption. Additionally, some of the services we provide include information our clients need to fulfill regulatory reporting requirements. If our services result in errors or omissions in our clients’ regulatory reporting, we may be subject to loss of clients, reputational harm or litigation, each potentially adversely impacting our business. Furthermore, although we maintain a variety of internal policies and controls designed to educate, discourage, prevent and detect violations of such laws, we cannot guarantee that such actions will be effective or sufficient or that individual employees will not engage in inappropriate behavior in breach of our policies. Such conduct, or even an allegation of misbehavior, could result in material adverse reputational harm, costly investigations, severe criminal or civil sanctions, or could disrupt our business, and could negatively affect our results of operations or financial condition.

 

Our growth strategy includes future acquisitions and/or investments which involve inherent risk.

 

In order to expand services or technologies to existing clients and increase our client base, we have historically, and may in the future, make strategic business acquisitions and/or investments that we believe complement our business. Acquisitions have inherent risks which may have material adverse effects on our business, financial condition, or results of operations, including, among other things: (1) failure to successfully integrate the purchased operations, technologies, products or services and maintain uniform standard controls, policies and procedures; (2) substantial unanticipated integration costs; (3) loss of key associates including those of the acquired business; (4) diversion of management’s attention from other operations; (5) failure to retain the customers of the acquired business; (6) failure to achieve any projected synergies and performance targets; (7) additional debt and/or assumption of known or unknown liabilities; (8) dilutive issuances of equity securities; and (9) a write-off of goodwill, software development costs, client lists, other intangibles and amortization of expenses. If we fail to successfully complete acquisitions or integrate acquired businesses, we may not achieve projected results and there may be a material adverse effect on our business, financial condition and results of operations.

 

Risks Related to our Common Stock

 

Our principal shareholders effectively control the Company.

 

A majority of our common stock and voting power was historically owned and/or held by Michael D. Hays, our Chief Executive Officer and President. However, over the years Mr. Hays, for estate planning purposes, gifted and/or transferred almost all of his directly owned shares to two trusts for the benefit of his family, The K/I/E Trust under agreement dated October 24, 2018 and the Amandla MK Trust (collectively the “Trusts”).

 

As of February 26, 2021, approximately 44.0% of our outstanding common stock was owned by the Trusts and approximately 54.0% of our outstanding common stock was held by the Trusts and other entities owned or controlled by members of Mr. Hays’ family. As a result, the Trusts and these other entities have the power to indirectly control decisions such as whether to issue additional shares or declare and pay dividends and can control matters requiring shareholder approval, including the election of directors and the approval of significant corporate matters such as change of control transactions. The effects of such influence could be to delay or prevent a change of control of the Company unless the terms are approved by the Trusts and these other entities.

 

11
Table of Contents

 

The market price of our common stock may be volatile and shareholders may be unable to resell shares at or above the price at which the shares were acquired.

 

The market price and trading volume of our common stock has historically been and may continue to be highly volatile, and investors in our common stock may experience a decrease in the value of their shares, including decreases that are in response to factors beyond our control, including, but not limited to:

 

 

●

Variations in our financial performance and that of similar companies;
 

●

Regulatory and other developments that may impact the demand for our services;
 

●

Reaction to our press releases, public announcements and filings with the Securities and Exchange Commission;
 

●

Client, market and industry perception of our services and performance;
 

●

Actions of our competitors;
 

●

Changes in earnings estimates or recommendations by analysts who follow our stock;
 

●

Loss of key personnel;
 

●

Investor, management team or large stockholder sales of our stock;
 

●

Changes in accounting principles; and
 

●

Variations in general market, economic and political conditions or financial markets.

 

Any of these factors, among others, may result in changes in the trading volume and/or market price of our common stock. Following periods of volatility in the market price of our securities, shareholders have often filed securities class-action lawsuits.

Our involvement in a class-action lawsuit would result in substantial legal fees and divert our senior management’s attention from operating our business, which could harm our business and net income.

 

General Risk Factors

 

Our operating results may fluctuate and this may cause our stock price to decline.

 

Our overall operating results may fluctuate as a result of a variety of factors, including the size and timing of orders from clients, client demand for our services (which, in turn, is affected by factors such as accreditation requirements, enrollment in managed care plans, operating budgets and clients’ operating performance), the hiring and training of additional staff, expense increases, and industry and general economic conditions. Because a significant portion of our overhead is fixed in the short-term, particularly some costs associated with owning and occupying our building and full-time personnel expenses, our results of operations may be materially adversely affected in any particular period if revenue falls below our expectations. These factors, among others, make it possible that in some future period our operating results may be below the expectations of securities analysts and investors which would have a material adverse effect on the market price of our common stock.

 

Our business and operating results could be adversely affected if we are unable to attract or retain key managers and other personnel.

 

Our future performance may depend, to a significant extent, upon the efforts and ability of our key personnel who have expertise in gathering, interpreting and marketing survey-based performance information for healthcare markets. Although client relationships are managed at many levels within our company, the loss of the services of Michael D. Hays, our Chief Executive Officer and President, or one or more of our other senior managers, could have a material adverse effect, at least in the short to medium term, on most significant aspects of our business, including strategic planning, product development, and sales and customer relations. Our success will also depend on our ability to hire, train and retain skilled personnel in all areas of our business. Competition for qualified personnel in our industry is intense, and many of the companies that compete with us for qualified personnel have substantially greater financial and other resources than us. Furthermore, we expect competition for qualified personnel to become more intense as competition in our industry increases. We cannot assure you that we will be able to recruit, retain and motivate a sufficient number of qualified personnel to compete successfully.

 

Failure to comply with public company regulations could adversely impact our profitability.

 

As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Act Wall Street Reform and Consumer Protection Act, the listing requirements of NASDAQ and other applicable securities rules and regulations. Additionally, laws, regulations and standards relating to corporate governance and public disclosure are subject to varying interpretations and continue to develop and change. If we misinterpret or fail to comply with these rules and regulations, our legal and financial compliance costs and net income may be adversely affected.

 

Item 1B.

Unresolved Staff Comments

 

We have no unresolved staff comments to report pursuant to this item.

 

12
Table of Contents

 

Item 2.

Properties

 

Our headquarters is located in an owned office building in Lincoln, Nebraska, of which 62,000 square feet are used for our operations. This facility houses all the capabilities necessary for our survey programming, printing and distribution, data processing, analysis and report generation, marketing, and corporate administration. Our credit facilities are secured by this property and our other assets.

 

We are leasing 4,000 square feet of office space in Markham, Ontario, 4,300 square feet of office space in Seattle, Washington, 6,200 square feet of office space in Atlanta, Georgia and 200 square feet of office space in Nashville, Tennessee.  Due to our transition to a primarily remote workforce we do not anticipate renewing these office leases at expiration, other than Nashville, Tennessee, which is a month-to-month lease.  In February 2021 we began leasing 19,300 square feet of space in Lincoln, Nebraska for our survey programming, printing and distribution previously housed at our headquarters.

 

Item 3.

Legal Proceedings

 

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. For additional information, see Note 1, under the heading “Commitments and Contingencies,” to our consolidated financial statements. Regardless of the final outcome, any legal proceedings, claims, inquiries and investigations, however, can impose a significant burden on management and employees, may include costly defense and settlement costs, and could cause harm to our reputation and brand, and other factors.

 

Item 4.

Mine Safety Disclosures

 

Not applicable.

 

13
Table of Contents

 

PART II

 

Item 5.

Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

In May 2013, we consummated a recapitalization pursuant to which we established two classes of common stock (class A common stock and class B common stock), issued a dividend of three shares of class A common stock for each share of our then existing common stock and reclassified each then existing share of common stock as one-half of one share of class B common stock. Following the May 2013 recapitalization, our class A common stock and our class B common stock were traded on the NASDAQ Global Market under the symbols “NRCIA” and “NRCIB,” respectively.

 

On April 16, 2018, our shareholders approved, among other things, an amendment to our Amended and Restated Articles of Incorporation (the “Articles”) to effect a recapitalization (the “Recapitalization”) pursuant to which each share of our then-existing class B common stock was exchanged for one share of the our then-existing Class A common stock plus $19.59 in cash, without interest. On April 17, 2018, we filed an amendment to our Articles effecting the Recapitalization, followed by an amendment and restatement of our Articles, which resulted in the elimination of our class B common stock and the reclassification of our class A common stock as a share of Common Stock, par value $0.001 per share (“Common Stock”). We issued 3,617,615 shares of Common Stock and paid $72.4 million in exchange for all class B shares outstanding and to settle outstanding share-based awards for class B common stock. The Common Stock continues to trade on the NASDAQ Global Market under the revised symbol “NRC.”

 

Cash dividends in the aggregate amount of $5.3 million were declared and paid in 2020. Cash dividends in the aggregate amount of $19.4 million were declared in 2019 with $14.2 million paid in 2019 and the remaining $5.2 million paid in January 2020. Cash dividends in the aggregate amount of $29.7 million were declared in 2018 with $12.6 million paid in 2018 and the remaining $17.1 million paid in January 2019. The payment and amount of future dividends, if any, is at the discretion of our Board of Directors and will depend on our future earnings, financial condition, general business conditions, alternative uses of our earnings and cash and other factors.

 

On February 16, 2021, there were approximately 12 shareholders of record and approximately 7,479 beneficial owners of common stock.

 

In February 2006 and subsequently amended in May 2013, our Board of Directors authorized the repurchase of 2,250,000 shares of class A common stock and 375,000 shares of class B common stock in the open market or in privately negotiated transactions. In connection with the Recapitalization in April 2018, our Board of Directors further amended the stock repurchase program to eliminate the repurchase of the former class B common stock. Unless terminated earlier by resolution of our Board of Directors, the repurchase program will expire when we have repurchased all shares authorized for repurchase thereunder. No Common Stock was repurchased during the three-month period ended December 31, 2020. The remaining shares of Common Stock that may be purchased under that authorization are 280,491.

 

See Item 12 in Part III of this Annual Report on Form 10-K for certain information concerning shares of our Common Stock authorized for issuance under our equity compensation plans.

 

14
Table of Contents

 

The following graph compares the cumulative 5-year total return provided shareholders on our common stock relative to the cumulative total returns of the NASDAQ Composite Index and the Russell 2000 Index. An investment of $100 (with reinvestment of all dividends) is assumed to have been made in our common stock and in each of the indexes on December 31, 2015, and our relative performance is tracked through December 31, 2020. 

 

picture1copy2.gif

The stock price performance included in this graph is not necessarily indicative of future stock price performance.

   

12/15

    

12/16

    

12/17

    

12/18

    

12/19

    

12/20

  
                                                 

National Research Corporation – Formerly Class B

     100.00       123.06       173.87       --       --       --  
                                                 

National Research Corporation Common Stock - Formerly Class A

     100.00       121.06       241.04       253.96       445.62       290.26  
                                                 

NASDAQ Composite

     100.00       108.87       141.13       137.12       187.44       271.64  
                                                 

Russell 2000

     100.00       121.31       139.08       123.76       155.35       186.36  

 

15
Table of Contents

 

Item 6.

Selected Financial Data

 

The selected statement of income data for the years ended December 31, 2020, 2019 and 2018, and the selected balance sheet data as of December 31, 2020 and 2019, are derived from, and are qualified by reference to, our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. The selected statement of income data for the years ended December 31, 2017 and 2016, and the balance sheet data as of December 31, 2018, 2017 and 2016, are derived from audited consolidated financial statements not included herein. The information set forth below should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and notes thereto included in Items 7 and 8, respectively, of this Annual Report on Form 10-K.

 

   

Year Ended December 31,

 
   

2020

      2019 (2)(3)      2018 (1)(2)      2017      2016  

 

  

(In thousands, except per share data)

  
Statement of Income Data:      

Revenue

   $ 133,277     $ 127,982     $ 119,686     $ 117,559     $ 109,384  

Insurance recoveries

     533       --       --       --       --  

Operating expenses:

                                        

Direct

     49,187       46,435       47,577       49,068       45,577  

Selling, general and administrative

     34,441       32,973       31,371       29,686       28,385  

Depreciation, amortization and impairment

     7,505       5,539       5,463       4,586       4,225  

Total operating expenses

     91,133       84,947       84,411       83,340       78,187  

Operating income

     42,677       43,035       35,275       34,219       31,197  

Other income (expense)

     (1,210

)

     (2,516

)

     (566

)

     64       159  

Income before income taxes

     41,467       40,519       34,709       34,283       31,356  

Provision for income taxes

     4,207       8,113       4,662       11,340       10,838  

Net income

   $ 37,260     $ 32,406     $ 30,047     $ 22,943     $ 20,518  

Earnings per share common stock:

                                        
Basic Earnings per share:                                        

Common Stock (formerly Class A)

   $ 1.48     $ 1.30     $ 1.08     $ 0.54     $ 0.49  

Class B

   $ --     $ --     $ 1.31     $ 3.26     $ 2.93  

Diluted Earnings per share:

                                        

Common Stock (formerly Class A)

   $ 1.45     $ 1.26     $ 1.04     $ 0.52     $ 0.48  

Class B

   $ --     $ --     $ 1.27     $ 3.18     $ 2.88  

Weighted average share and share equivalents outstanding:

                                        

Common Stock (formerly Class A) – basic

     25,170       24,809       23,562       20,770       20,713  

Class B – basic

     --       --       3,527       3,514       3,505  

Common Stock (formerly Class A) – diluted

     25,696       25,653       24,448       21,627       21,037  

Class B – diluted

     --       --       3,628       3,603       3,560  

 

   

2020

      2019 (2)(3)      2018 (1)(2)      2017      2016  

 

  

(In thousands, except per share data)

  
Balance Sheet Data:      

Working capital surplus (deficiency)

   $ 22,431     $ (8,998

)

   $ (18,699

)

   $ 19,949     $ 15,551  

Total assets

     133,423       110,685       108,032       127,316       120,624  

Total debt and finance lease obligations, net of unamortized debt issuance costs

     31,878       34,959       38,723       1,225       3,732  

Total shareholders’ equity

     64,315       32,892       19,083       90,041       82,806  

Cash dividends declared per share:

                                        

Common Stock (formerly class A)

     0.21       0.78       1.13       .40       .34  

Class B common stock

   $ --     $ --     $ .60     $ 2.40     $ 2.04  

 

 

(1)

On January 1, 2018, we adopted Accounting Standards Update 2014-09, Revenue- Revenue from Contracts with Customers and all related amendments using the modified retrospective method for all incomplete contracts as of the date of adoption. See Notes 1 and 3 to our consolidated financial statements.
 

(2)

As described in Note 2 to our consolidated financial statements, we completed the Recapitalization in April 2018 which settled all then-existing outstanding class B share-based awards, resulting in the elimination of the class B common stock and reclassified class A common stock to Common Stock.
 

(3)

On January 1, 2019, we adopted Accounting Standards Update 2016-02, Leases, and all related amendments using the modified retrospective method for all incomplete contracts as of the date of adoption. See Notes 1 and 10 to our consolidated financial statements.

 

16
Table of Contents

 

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations 

 

Overview

 

Our purpose is to establish human understanding. Our solutions enable health care organizations to understand what matters most to each person they serve. We are a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations. Our heritage, proprietary methods, and holistic approach enable our partners to better understand the people they care for and design experiences that inspire loyalty and trust, while also facilitating regulatory compliance and the shift to population-based health management. Our ability to measure what matters most and systematically capture, analyze and deliver insights based on self-reported information from patients, families and consumers is critical in today’s healthcare market. We believe that access to and analysis of our extensive consumer-driven information is becoming more valuable as healthcare providers increasingly need to more deeply understand and engage the people they serve to build customer loyalty.

 

Our portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. We partner with clients across the continuum of healthcare services. Our clients include integrated health systems, post-acute providers and payer organizations. We believe this cross-continuum positioning is a unique and an increasingly important capability as evolving payment models drive healthcare providers and payers towards a more collaborative and integrated service model.

 

The outbreak of COVID-19, and the associated responses, have impacted our business in a variety of ways.  Governments have implemented business and travel restrictions, recommended social distancing and other guidelines, and temporarily suspended the requirement for certain healthcare organizations to periodically assess the performance of the care they provide (although many providers continue to do so). Many businesses, including many of our clients, have de-emphasized external business opportunities and restricted in-person meetings while shifting their attention toward addressing COVID-19 planning, business disruptions, higher costs, and revenue shortfalls. At NRC Health, our workforce remains intact and highly engaged.  The vast majority of our associates are working remotely, and to date we have been capable of providing our services without significant disruption. Historically, we have relied on national travel as part of our sales efforts, but as a result of the pandemic we have placed an indefinite hold on all company related travel. The duration and severity of the COVID-19 pandemic and associated responses on our business, including the impact on our revenue, expenses, and cash flows, cannot be predicted at this time.  Some clients cost reducing measures have included and could continue to include reducing or eliminating the services they purchase from us. Based on the foregoing, we do not expect our recent revenue and earnings growth to be indicative of future expectations.  We do, however, expect to have adequate sources of liquidity to meet our current and expected needs for the foreseeable future.

 

Our operating income in 2020 was impacted by a significant increase in depreciation and amortization, as well as an impairment adjustment. Depreciation and amortization increased by $1.1 million compared to 2019 due to the change in the estimated lives of certain assets related to our transformation to a distributed workforce environment, which includes building renovations in our headquarters, as well as shortening the useful lives of certain assets associated with our Atlanta, Georgia and Markham, Ontario offices based on the expectation that we will vacate the office space before the end of the lease term. In addition, we recognized a goodwill impairment adjustment for our Canadian reporting unit of $714,000, as described in more detail under “Critical Accounting Policies and Estimates”.

 

Critical Accounting Policies and Estimates

 

The preparation of financial statements requires management to make estimates and assumptions that affect amounts reported therein. The following areas are considered critical accounting estimates because they involve significant judgments or assumptions, involve complex or uncertain matters or they are susceptible to change and the impact could be material to our financial condition or operating results:

 

 

●

Revenue recognition; and
 

●

Valuation of goodwill and identifiable intangible assets.

 

Revenue Recognition

 

We derive a majority of our revenue from annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or no notice without penalty. See Notes 1 and 3 to our consolidated financial statements for a description of our revenue recognition policies.

 

17
Table of Contents

 

Our revenue arrangements with a client may include combinations of more than one service offering which may be executed at the same time, or within close proximity of one another. We combine contracts with the same customer into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated as a single performance obligation. For contracts that contain more than one separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable customers, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement.

 

Our fixed, non-subscription arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch up adjustment which could impact the amount and timing of revenue for any period.

 

If management made different judgments and estimates, then the amount and timing of revenue for any period could differ from the reported revenue. 

 

Valuation of Goodwill and Identifiable Intangible Assets

 

Intangible assets include customer relationships, trade names, technology, and goodwill. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment with other long-lived assets in the related asset group whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review intangible assets with indefinite lives for impairment annually as of October 1 and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.

 

When performing the impairment assessment, we will first assess qualitative factors to determine whether it is necessary to recalculate the fair value of the intangible assets with indefinite lives. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of the indefinite-lived intangibles is less than their carrying amount, we determine the fair value using a market or income approach. If the carrying value of intangible assets with indefinite lives exceeds their fair value, then the intangible assets are written-down to their fair values. We did not recognize any impairments related to indefinite-lived intangibles during 2020, 2019 or 2018.

 

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. All of our goodwill is allocated to our reporting units, which are the same as our six operating segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Transitions. Goodwill is reviewed for impairment at least annually, as of October 1, and whenever events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable.

 

We review goodwill for impairment by first assessing qualitative factors to determine whether any impairment may exist. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative analysis will be performed, and the fair value of the reporting unit is compared with its carrying value (including goodwill). If the carrying value of the reporting unit exceeds the fair value, then goodwill is written down by this difference. We performed a qualitative analysis as of October 1, 2020 and determined the fair value of each reporting unit likely exceeded the carrying value. No impairments were recorded during the years ended December 31, 2019 or 2018. A substantial portion of the revenue earned by our Canadian subsidiary is concentrated with one customer. While the customer has exercised its option to extend its existing contract to September 2022, during December 2020 we chose not to enter into a new contract with this customer or otherwise extend the term of the contract beyond September 2022. We subsequently announced that we would close the Canada office at the end of the contract.  As a result, we tested for impairment of the Canada reporting unit’s goodwill at December 31, 2020. We recognized an impairment of $714,000 for the excess of the Canada reporting unit’s carrying value over the fair value, using discounted cash flows. The remaining balance of goodwill of our Canada reporting unit at December 31, 2020 was $1.6 million. Changes in the actual amount or timing of cash flows or other assumption used to discount cash flows to estimate fair value of the Canada reporting unit could result in additional impairment.

 

18
Table of Contents

 

Results of Operations

 

The following table and graphs set forth, for the periods indicated, selected financial information derived from our consolidated financial statements, including amounts expressed as a percentage of total revenue and the percentage change in such items versus the prior comparable period (please note that all columns may not add up to 100% due to rounding). The trends illustrated in the following table and graphs may not necessarily be indicative of future results. The discussion that follows the information should be read in conjunction with our consolidated financial statements.

 

   

Percentage of Total Revenue
Year Ended December 31,

    

Percentage

Increase (Decrease)

  
   

2020

    

2019

    

2018

    

2020 over

2019

    

2019 over

2018

  
                                         

Revenue

     100.0

%

     100.0

%

     100.0

%

     4.1

%

     6.9

%

Insurance recoveries

     0.4       --       --       100.0       --  

Operating expenses:

                                        

Direct

     36.9       36.3       39.7       5.9       (2.4

)

Selling, general and administrative

     25.9       25.8       26.2       4.5       5.1  

Depreciation, amortization and impairment

     5.6       4.3       4.6       35.5       1.4  

Total operating expenses

     68.4       66.4       70.5       7.3       0.6  

Operating income

     32.0

%

     33.6

%

     29.5

%

     (0.8

)%

     22.0

%

 

picture2copy6.jpg

 

Year Ended December 31, 2020, Compared to Year Ended December 31, 2019

 

Revenue. Revenue in 2020 increased 4.1% to $133.3 million, compared to $128.0 million in 2019, which was driven primarily due to both new client sales and growth in contract value from existing clients. Revenue growth was partially offset by revenue reductions due to COVID-19, as some clients have reduced or eliminated the services they purchase from us as cost reducing measures. Our solutions within the VoC platform in 2020 accounted for 73.3% of total revenue compared to 62.7% in 2019. The remaining revenue consists of legacy Experience and Governance Solutions.

 

Direct expenses. Direct expenses increased 5.9% to $49.2 million in 2020, compared to $46.4 million in 2019. This was due to an increase in fixed expenses of $5.4 million, partially offset by a decrease in variable expenses of $2.6 million. Fixed expenses increased primarily as a result of increased salary and benefits and contracted services costs in the customer service and information technology areas and less sales tax incentives compared to the same period in 2019. These were partially offset by decreased travel and meal costs due to restricted travel from COVID-19. Variable expenses decreased mainly due to less postage, printing and paper costs primarily resulting from increased use of digital survey methodologies and decreased conference expenses due to rescheduling and virtually hosting the conferences on account of COVID-19. Direct expenses increased as a percentage of revenue to 36.9% in 2020, from 36.3% in 2019, as expenses increased by 5.9% while revenue for the same period increased by 4.1%.

 

Selling, general and administrative expenses. Selling, general and administrative expenses increased 4.5% to $34.4 million in 2020 compared to $33.0 million in 2019, primarily due to an increase in software license fees and platform hosting expenses of $1.5 million, an increase in contracted services of $1.4 million, additional salary and benefits costs of $864,000 and less sales tax incentives of $362,000 compared to the same period in 2019. These increases were partially offset by a decrease in travel and meals expense of $1.6 million due to restricted travel associated with COVID-19 and decreases in other taxes and licenses of $948,000 primarily due to less sales taxes. Selling, general, and administrative expenses as a percentage of revenue was 25.9% in 2020 and 25.8% in 2019.

 

19
Table of Contents

 

Depreciation, amortization and impairment. Depreciation, amortization and impairment expenses increased to $7.5 million for the twelve-month period ended December 31, 2020 compared to $5.5 million in 2019. This was primarily due $1.1 million in additional depreciation resulting from the change in useful lives of certain assets due to our transformation to a distributed workforce environment, which includes building renovations in our headquarters, as well as shortening the useful lives of certain assets associated with our Atlanta, Georgia and Markham, Ontario offices based on the expectation that we will vacate the office space before the end of the lease term. Additionally, we recognized a $714,000 goodwill impairment adjustment for our Canadian reporting unit due to our decision to not enter into a new agreement with an existing client, which accounted for the majority of revenue in Canada. Depreciation, amortization and impairment expenses increased as a percentage of revenue to 5.6% in 2020, from 4.3% in 2019 as depreciation, amortization and impairment expenses increased by 35.5% while revenue increased by 4.1% during the same period.

 

Other income (expense). Other expense, net was $1.2 million for the twelve-month period ended December 31, 2020, compared to $2.5 million for the same period in 2019. Interest expense decreased to $1.8 million in the 2020 period from $2.1 million for the same period in 2019 due to the declining balance on our term loan and no borrowings on our Line of Credit during the 2020 period. Other non-interest expense changed to other income of $585,000 for the twelve-month period ended December 31, 2020, compared to other expense of $462,000 for the same period in 2019, primarily due to gain on insurance recoveries for property damage of $260,000 and the revaluation of intercompany transactions for changes in the foreign exchange rates.

 

Provision for income taxes. Provision for income taxes was $4.2 million (10.1% effective tax rate) in 2020, compared to $8.1 million (20.0% effective tax rate) in 2019. The effective tax rate for the twelve-month period ended December 31, 2020, was lower primarily due to increased tax benefits of $4.8 million from the exercise and vesting of share-based compensation awards, partially offset by a non-deductible goodwill impairment adjustment and higher state income taxes. 

 

Year Ended December 31, 2019, Compared to Year Ended December 31, 2018

 

Revenue. Revenue in 2019 increased 6.9% to $128.0 million, compared to $119.7 million in 2018, which was driven primarily due to new customer sales, as well as increases in sales to the existing client base. Our solutions within the VoC platform in 2019 accounted for 62.7% of total revenue compared to 49.6% in 2018. The remaining revenue consists of legacy Experience and Governance Solutions. Clients with agreements for multiple solutions represented 27% of our client base at the end of 2019, up from 24% at the end of 2018.

 

Direct expenses. Direct expenses decreased 2.4% to $46.4 million in 2019, compared to $47.6 million in 2018. This was due to a decrease in variable expenses of $2.6 million, partially offset by an increase in fixed expenses of $1.4 million. Variable expenses decreased mainly due to less postage, printing and paper costs due to lower volumes and changes in survey methodologies. Fixed expenses increased primarily as a result of increased salary and benefit costs in the customer service and information technology areas partially offset by $730,000 of state payroll and sales tax incentives and lower contracted services. Direct expenses decreased as a percentage of revenue to 36.3% in 2019, from 39.7% in 2018, as expenses decreased by 2.4% while revenue for the same period increased by 6.9%.

 

Selling, general and administrative expenses. Selling, general and administrative expenses increased 5.1% to $33.0 million in 2019 compared to $31.4 million in 2018, primarily due to increased software license fees and platform hosting expenses of $790,000, sales tax expense of $775,000 as a result of a recent sales tax analysis, higher salary and benefit costs of $690,000, additional insurance costs of $285,000, increased travel costs of $196,000, higher marketing program expenses of $89,000 and additional company incentive event costs of $81,000. These were partially offset by decreased contract services of $529,000, a reduction in legal and accounting costs of $469,000 mainly associated with the Recapitalization, the Tax Cut and Jobs Act and adoption of ASC 606 in 2018 and state payroll and sales tax incentives of $917,000. Selling, general, and administrative expenses decreased as a percentage of revenue to 25.8% in 2019, from 26.2% in 2018 as expenses increased by 5.1% while revenue increased by 6.9% during the same period.

 

Depreciation and amortization. Depreciation and amortization expenses remained at $5.5 million for the twelve-month period ended December 31, 2019 and 2018, however, there was increased amortization from additional computer software investments primarily offset by an intangible asset that has been fully amortized. Depreciation and amortization expenses decreased as a percentage of revenue to 4.3% in 2019, from 4.6% in 2018 as depreciation and amortization expenses increased by 1.4% while revenue increased by 6.9% during the same period.

 

Other income (expense). Other expense, net was $2.5 million for the twelve-month period ended December 31, 2019, compared to $566,000 for the same period in 2018.  Interest expense increased $578,000 due to additional interest related to the term loan originated in April 2018 and borrowings on the line of credit. Other expense, net increased $1.3 million primarily due to revaluation of intercompany transactions for changes in the foreign exchange rates.

 

20
Table of Contents

 

Provision for income taxes. Provision for income taxes was $8.1 million (20.0% effective tax rate) in 2019, compared to $4.7 million (13.4% effective tax rate) in 2018. The effective tax rate for the twelve-month period ended December 31, 2019, was higher mainly due to lower income tax benefits from the exercise of share-based compensation awards and higher state income taxes due to requirements to file in more states.

 

Inflation and Changing Prices

 

Inflation and changing prices have not had a material impact on revenue or net income in the last three years.

 

Liquidity and Capital Resources

 

We believe that our existing sources of liquidity, including cash and cash equivalents, borrowing availability, and operating cash flows will be sufficient to meet our projected capital and debt maturity needs for the foreseeable future. Cash dividends in the aggregate amount of $5.3 million were declared and paid in 2020. An additional $5.2 million was paid in January 2020 from dividends declared in 2019. The dividends were paid from cash on hand.

 

As of December 31, 2020, our principal sources of liquidity included $34.7 million of cash and cash equivalents, up to $30 million of unused borrowings under our line of credit and up to $15 million on our delayed draw term note. Of this cash, $5.4 million was held in Canada. The delayed draw term note can only be used to fund permitted future business acquisitions or repurchasing our Common Stock.

 

Working Capital

 

We had a working capital surplus of $22.4 million and deficiency of $9.0 million on December 31, 2020 and 2019, respectively.

 

The change was primarily due to increases in cash and cash equivalents of $21.2 million, trade accounts receivable of $2.3 million, income taxes receivable of $1.2 million, prepaids of $607,000, and decreases in dividends payable of $5.2 million and deferred revenue of $769,000. Dividends payable decreased due dividends not being declared since the three-month period ended March 31, 2020. Trade accounts receivable increased due to timing of billing and payments, as well as COVID-19 causing clients payments to be delayed due to such clients’ cash-flow issues. Prepaid expenses increased due to timing of payment for services and supplies. Income taxes receivable changed due to the timing of income tax payments. Our working capital is significantly impacted by our large deferred revenue balances which will vary based on the timing and frequency of billings on annual agreements. The deferred revenue balances as of December 31, 2020 and December 31, 2019, were $15.6 million and $16.4 million, respectively.

 

The deferred revenue balance is primarily due to timing of initial billings on new and renewal contracts. We typically invoice clients for services before they have been completed. Billed amounts are recorded as billings in excess of revenue earned, or deferred revenue, on our consolidated financial statements, and are recognized as income when earned. In addition, when work is performed in advance of billing, we record this work as revenue earned in excess of billings, or unbilled revenue. Substantially all deferred revenue and all unbilled revenue will be earned and billed respectively, within 12 months of the respective period ends.

 

Cash Flow Analysis

 

A summary of operating, investing, and financing activities are shown in the following table:

 

   

For the Year Ended December 31,

  
   

2020

    

2019

    

2018

  
   

(In thousands)

  

Provided by operating activities

   $ 40,636     $ 40,917     $ 39,848  

Used in investing activities

     (3,724

)

     (4,656

)

     (5,971

)

Used in financing activities

     (15,503

)

     (36,346

)

     (54,497

)

Effect of exchange rate changes on cash

     (236

)

     611       (1,122

)

Net increase (decrease) in cash and cash equivalents

     21,173       526       (21,742

)

Cash and cash equivalents at end of period

   $ 34,690     $ 13,517     $ 12,991  

 

Cash Flows from Operating Activities

 

Cash flows from operating activities consist of net income adjusted for non-cash items including depreciation and amortization, deferred income taxes, share-based compensation and related taxes, reserve for uncertain tax positions, loss on disposal of property and equipment and the effect of working capital changes.

 

21
Table of Contents

 

Net cash provided by operating activities was $40.6 million for the year ended December 31, 2020, which included net income of $37.3 million, plus non-cash charges (benefits) for deferred income taxes, depreciation, amortization and impairment, reserve for uncertain tax positions, loss on disposal of property and equipment and non-cash share-based compensation totaling $8.0 million. Changes in working capital decreased cash flows from operating activities by $4.6 million, primarily from increases in trade accounts receivable, income taxes receivable, prepaid expenses and other current assets and deferred contact costs, and a decrease in accounts payable, which fluctuate due to the timing of payments of prepaids, accounts payable and income taxes and the timing of direct and incremental costs directly related to sales. A decrease in deferred revenue also contributed to the working capital surplus, which will vary based on the timing and frequency of billings on annual agreements. These decreases to cash flows were partially offset by increases in accrued expenses, wages and bonuses which fluctuate due to the timing of accrued expenses, wages and bonuses and included the deferral of employer payroll taxes from the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”).

 

Net cash provided by operating activities was $40.9 million for the year ended December 31, 2019, which included net income of $32.4 million, plus non-cash charges (benefits) for deferred income taxes, depreciation and amortization, reserve for uncertain tax positions, loss on disposal of property and equipment and non-cash share-based compensation totaling $7.9 million. Changes in working capital increased cash flows from operating activities by $616,000, primarily from increases in accounts payable, accrued expenses, wages, bonus and profit sharing, deferred tax incentives, and deferred contract costs, net, which fluctuate due to the timing of payments of accounts payable and accrued expenses, and the timing of direct and incremental costs directly related to sales. These increases to cash flows were partially offset by decreases in deferred contract costs and prepaid expenses and other current assets.

 

Net cash provided by operating activities was $39.8 million for the year ended December 31, 2018, which included net income of $30.0 million, plus non-cash charges (benefits) for deferred tax expense, depreciation and amortization, reserve for uncertain tax positions, loss on disposal of property and equipment and non-cash share-based compensation totaling $8.4 million. Changes in working capital increased cash flows from operating activities by $1.5 million, primarily from increases in income taxes payable and decreases in accounts receivables, which fluctuate due to the timing of income tax payments and the timing and frequency of billings on new and renewal contracts, respectively. These increases to cash flows were partially offset by an increase in prepaid expenses and other current assets and decreases due to the timing of payments on accounts payable, accrued expenses, wages, bonus and profit sharing, deferred contract costs and a decrease in deferred revenue. 

 

Cash Flows from Investing Activities

 

Net cash of $3.7 million was used for investing activities in the year ended December 31, 2020. We used cash of $4.0 million for purchases of property and equipment, consisting mainly of computer software classified in property and equipment. We received $260,000 in insurance proceeds for damaged property and equipment due to flooding.

 

Net cash of $4.7 million was used for investing activities in the year ended December 31, 2019 for purchases of property and equipment. These expenditures consisted mainly of computer software classified in property and equipment.

 

Net cash of $6.0 million was used for investing activities in the year ended December 31, 2018 for purchases of property and equipment.

 

Cash Flows from Financing Activities

 

Net cash used in financing activities was $15.5 million in the year ended December 31, 2020. In 2020 we used cash to repay borrowings under the term notes totaling $3.6 million, to pay loan commitment fees of $36,000 and for finance lease obligations of $332,000. In 2020 we also used cash to pay $10.5 million of dividends on our Common Stock and to pay payroll tax withholdings related to share-based compensation of $2.8 million. Proceeds from the exercise of stock options were $1.7 million in 2020.

 

Net cash used in financing activities was $36.3 million in the year ended December 31, 2019. In 2019 we used cash to repay borrowings under the term notes totaling $3.7 million, to repay borrowings on the line of credit of $21.0 million and for finance lease obligations of $229,000. In 2019 we also used cash to pay $31.3 million of dividends on our Common Stock and to pay payroll tax withholdings related to share-based compensation of $1.1 million. In 2019 borrowings on our line of credit provided cash of $21.0 million.

 

Net cash used in financing activities was $54.5 million in the year ended December 31, 2018. In 2018 we used cash for the Recapitalization of $72.4 million (see Note 2 to our consolidated financial statements), to repay borrowings under the term notes totaling $3.1 million, to repay borrowings on the line of credit of $2.5 million, to pay loan origination fees on the new credit agreement of $187,000 and for finance lease obligations of $157,000. In 2018, we also used cash to pay $16.9 million of dividends on our Common Stock and to pay payroll tax withholdings related to share-based compensation of $1.9 million. In 2018 borrowings on our new term loan and the new line of credit provided cash of $40 million and $2.5 million, respectively.

 

22
Table of Contents

 

Capital Expenditures

 

We paid cash of $4.0 million for capital expenditures in the year ended December 31, 2020. These expenditures consisted mainly of computer software and hardware and furniture and equipment. In addition to continued expenditures for computer software and hardware and furniture and equipment in 2021, we expect substantially higher capital expenditures for investment in our VoC platform and building improvements, with the total amount yet to be determined, which we expect to be funded through cash generated from operations.

 

Debt and Equity

 

Our credit agreement (the “Credit Agreement”) with First National Bank of Omaha (“FNB”) was amended and restated on May 28, 2020 and includes (i) a $30,000,000 revolving credit facility (the “Line of Credit”), (ii) a $33,002,069 term loan (the “Term Loan”) and (iii) a $15,000,000 delayed draw-dawn term facility (the “Delayed Draw Term Loan” and, together with the Line of Credit and the Term Loan, the “Credit Facilities”). The Delayed Draw Term Loan may be used to fund any permitted future business acquisitions or repurchases of our Common Stock and the Line of Credit can be used to fund ongoing working capital needs and for other general corporate purposes. The May 2020 amendment increased the Line of Credit from $15,000,000 to $30,000,000.

 

The amended Term Loan revised the remaining payments for the existing balance outstanding of $33,002,069 to monthly installments of $462,988 through May 2025, with a balloon payment due at maturity in May 2025. The Term Loan bears interest at a fixed rate per annum of 5%.  

 

Borrowings under the Line of Credit and the Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the 30-day London Interbank Offered Rate plus 225 basis points (2.40% at December 31, 2020). Interest on the Line of Credit accrues and is payable monthly. Principal amounts outstanding under the Line of Credit are due and payable in full at maturity, in May 2023. As of December 31, 2020, and December 31, 2019, the Line of Credit did not have a balance. There were no borrowings on the Line of Credit during 2020. There have been no borrowings on the Delayed Draw Term Loan since origination.

 

We are obligated to pay ongoing unused commitment fees quarterly in arrears pursuant to the Line of Credit and the Delayed Draw Term Loan facility at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility, respectively.

 

The Credit Agreement contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our Common Stock and acquisitions, subject in each case to certain exceptions. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of 1.10x for all testing periods throughout the term(s) of the Credit Facilities, which calculation excludes, unless our liquidity falls below a specified threshold, (i) any cash dividend in a fiscal quarter that, together with all other cash dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash dividends paid or declared, (ii) the portion of the purchase price for any permitted share repurchase of our shares paid with cash on hand, and (iii) the portion of any acquisition consideration for a permitted acquisition paid with cash on hand. We are also required to maintain a cash flow leverage ratio of 3.00x or less for all testing periods throughout the terms of the Credit Facilities. As of December 31, 2020, we were in compliance with our financial covenants.

 

All obligations under the Credit Facilities are to be guaranteed by each of our direct and indirect wholly owned domestic subsidiaries, if any, and, to the extent required by the Credit Agreement, direct and indirect wholly owned foreign subsidiaries (each, a “guarantor”).

 

The Credit Facilities are secured, subject to permitted liens and other agreed upon exceptions, by a first-priority lien on and perfected security interest in substantially all of our and our guarantors’ present and future assets (including, without limitation, fee-owned real property, and limited, in the case of the equity interests of foreign subsidiaries, to 65% of the outstanding equity interests of such subsidiaries).

 

We have finance leases for computer equipment, office equipment, printing and inserting equipment. The balance of the finance leases as of December 31, 2020 was $1.3 million.

 

We incurred expenses related to the Recapitalization of approximately $721,000 in the year ended December 31, 2018, which were included in selling and administrative expenses.

 

23
Table of Contents

 

A sales tax accrual of $775,000 was recorded in 2019 for sales taxes that should have been collected from clients in 2019 and certain previous years. We received a revenue ruling from the state of Washington noting that our services are not subject to retail sales tax, and therefore, reversed $268,000 of sales tax accrual for the state of Washington in the third quarter of 2020. We have completed voluntary disclosure agreements with certain states, remitted past due sales tax, are remitting current sales tax timely, are collecting sales tax from clients, and no accrual for past due sales tax remains as of December 31, 2020. State and local jurisdictions have differing rules and regulations governing sales, use, and other taxes and these rules and regulations can be complex and subject to varying interpretations that may change over time. As a result, we could face the possibility of tax assessment and audits, and our liability for these taxes and associated interest and penalties could exceed our original estimates.

 

Contractual Obligations

 

We had contractual obligations to make payments in the following amounts in the future as of December 31, 2020:

 

Contractual Obligations(1)

  

Total

Payments

    

Less than

One Year

    

One to

Three Years

    

Three to

Five Years

    

After

Five Years

  

(In thousands)

                                        

Operating leases

   $ 1,471     $ 509     $ 641     $ 321     $ --  

Finance leases

     1,326       527       786       13       --  

Uncertain tax positions(2)

     --       --       --       --       --  

Long-term debt

     35,544       5,556       11,112       18,876       --  

Total

   $ 38,341     $ 6,592     $ 12,539     $ 19,210     $ --  

 

(1)

Amounts are inclusive of interest payments, where applicable.

(2)

We have $783,000 in liabilities associated with uncertain tax positions. We are unable to reasonably estimate the expected cash settlement dates of these uncertain tax positions with the taxing authorities.

 

We generally do not make unconditional, non-cancelable purchase commitments. We enter into purchase orders in the normal course of business, but these purchase obligations do not exceed one year.

 

Stock Repurchase Program

 

Our Board of Directors authorized the repurchase of up to 2,250,000 then-existing class A shares and 375,000 then-existing class B shares of common stock in the open market or in privately negotiated transactions under a stock repurchase program that was originally approved in February 2006 and subsequently amended in May 2013. In connection with the Recapitalization in April 2018, our Board of Directors further amended the stock repurchase program to eliminate the repurchase of the former class B common stock. As of December 31, 2020, the remaining number of shares of Common Stock that could be purchased under this authorization was 280,491 shares. 

 

Off-Balance Sheet Obligations

 

We have no significant off-balance sheet obligations.

 

Recent Accounting Pronouncements

 

See Note 1 to our consolidated financial statements for a description of recently issued accounting pronouncements.

 

24
Table of Contents

 

Item 7A.

Quantitative and Qualitative Disclosure About Market Risk

 

Our primary market risk exposures are changes in foreign currency exchange rates and interest rates.

 

Our Canadian subsidiary uses Canadian dollars as its functional currency. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Foreign currency translation gains (losses) were ($189,550), $707,000 and ($1.3 million) in 2020, 2019 and 2018, respectively. Gains and losses related to transactions denominated in a currency other than the functional currency of the countries in which we operate and short-term intercompany accounts are included in other income (expense) in the consolidated statements of income and amounted to ($333,000), ($483,000) and $893,000 in 2020, 2019 and 2018, respectively. The change is primarily the result of exchange rate fluctuation applied to an intercompany loan from our Canadian subsidiary which was paid off in the three-month period ended September 30, 2020. A portion of our cash in our Canadian subsidiary is denominated in foreign currencies, where fluctuations in exchange rates will impact our cash balances in U.S. dollar terms. A sensitivity analysis assuming a hypothetical 10% change in the value of the U.S. dollar versus the Canadian dollar would impact our reported cash balance by approximately $686,000. We have not entered into any foreign currency hedging transactions. We do not purchase or hold any currency exchange related derivative financial instruments.

 

We are exposed to interest rate risk with both our fixed-rate Term Loan and variable rate Line of Credit. Interest rate changes for borrowings under our fixed-rate Term Loan would impact the fair value of such debt, but do not impact earnings or cash flow. At December 31, 2020, our fixed-rate Term Loan totaled $30.7 million. Based on a sensitivity analysis, a one percent per annum change in market interest rates as of December 31, 2020, would impact the estimated fair value of our fixed-rate Term Loan outstanding at December 31, 2020 by approximately $944,000.

 

Borrowings under our Line of Credit and Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the 30-day LIBOR plus 225 basis points. Borrowings under the Line of Credit and Delayed Draw Term Note may not exceed $30.0 million and $15.0 million, respectively. There were no borrowings outstanding under the Line of Credit at December 31, 2020, or at any time during 2020. There were no borrowings outstanding under the Delayed Draw Term Note at December 31, 2020, or at any time during 2020. A sensitivity analysis assuming a hypothetical 10% movement in interest rates applied to the average daily borrowings and the maximum borrowings available under the Line of Credit for 2020 indicated that such a movement would not have a material impact on our consolidated financial position, results of operations or cash flows. We have not entered into any interest rate swaps or hedging transactions.

LIBOR is currently expected to be phased out in 2021. We are required to pay interest on borrowings under our Line of Credit and Delayed Draw Term Loan at floating rates based on LIBOR. Future debt that we may incur may also require that we pay interest based upon LIBOR. Under the terms of our Credit Agreement with FNB, if LIBOR becomes unavailable during the term of the agreement, FNB may, in its discretion and in a manner consistent with market practice, designate a substitute index. We currently expect that the determination of interest under our Credit Agreement would be revised to provide for an interest rate that approximates the existing interest rate as calculated in accordance with LIBOR. Despite our current expectations, we cannot be sure that if LIBOR is phased out or transitioned, the changes to the determination of interest under our agreements would approximate the current calculation in accordance with LIBOR. We do not know what standard, if any, will replace LIBOR if it is phased out or transitioned.

 

25
Table of Contents

 

Item 8.

Financial Statements and Supplementary Data

 

Quarterly Financial Data (Unaudited)

 

The following table sets forth selected financial information for each of the eight quarters in the two-year period ended December 31, 2020. This unaudited information has been prepared on the same basis as the consolidated financial statements and includes all normal recurring adjustments necessary to present fairly this information when read in conjunction with our audited consolidated financial statements and the notes thereto.

 

   

(In thousands, except per share data)

  
   

Quarter Ended

  
   

Dec. 31,

2020

    

Sept 30,

2020

    

June 30,

2020

    

Mar. 31,

2020

    

Dec. 31,

2019

    

Sept 30,

2019

    

June 30,

2019

    

Mar. 31,

2019

  
                                                                 

Revenue

   $ 34,774     $ 33,477     $ 31,166     $ 33,860     $ 32,623     $ 32,465     $ 31,414     $ 31,480  

Insurance recoveries

     --       533       --       --       --       --       --       --  

Direct expenses

     12,818       12,189       11,634       12,546       11,166       12,109       11,506       11,654  

Selling, general and administrative expenses

     8,887       7,953       8,852       8,749       8,241       8,706       8,319       7,707  

Depreciation, amortization and impairment

     2,882       1,847       1,405       1,371       1,254       1,430       1,440       1,415  

Operating income

     10,187       12,021       9,275       11,194       11,962       10,220       10,149       10,704  

Other income (expense)

     (313

)

     (355

)

     (718

)

     176       (597

)

     (411

)

     (664

)

     (844

)

Provision for income taxes

     1,662       2,088       842       (385

)

     2,667       1,690       2,092       1,664  

Net income

   $ 8,212     $ 9,578     $ 7,715     $ 11,755     $ 8,698     $ 8,119     $ 7,393     $ 8,196  

Earnings per share of common stock:

                                                                

Basic earnings per share

                                                                

Common (formerly class A)

   $ 0.32     $ 0.38     $ 0.31     $ 0.47     $ 0.35     $ 0.33     $ 0.30     $ 0.33  

Dilutive earnings per share

                                                                

Common (formerly class A)

   $ 0.32     $ 0.37     $ 0.30     $ 0.46     $ 0.34     $ 0.31     $ 0.29     $ 0.32  

Weighted average shares outstanding – basic

                                                                

Common (formerly class A)

     25,337       25,219       25,148       24,972       24,852       24,827       24,789       24,766  

Weighted average shares outstanding – diluted

                                                                

Common (formerly class A)

     25,684       25,704       25,680       25,725       25,715       25,741       25,586       25,509  

 

26
Table of Contents

 

Report of Independent Registered Public Accounting Firm

 

 

To the Shareholders and the Board of Directors

National Research Corporation:

 

Opinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting

 

We have audited the accompanying consolidated balance sheets of National Research Corporation and subsidiary (the Company) as of December 31, 2020 and 2019, the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes (collectively, the consolidated financial statements). We also have audited the Company’s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020 based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

Basis for Opinions

 

The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s consolidated financial statements and an opinion on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

 

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

 

Definition and Limitations of Internal Control Over Financial Reporting

 

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

 

27
Table of Contents

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Evaluation of sufficiency of audit evidence over new and modified subscription-based service agreement terms

 

As discussed in Notes 1 and 3 to the consolidated financial statements, revenue consists of service arrangement contracts with customers that can include more than one separately identifiable performance obligation. The Company’s revenue for the year ended December 31, 2020 included $122.5 million for subscription-based service agreements, a portion of which was revenue from new and modified subscription-based service agreements, that was recognized ratably over the subscription period and which agreements are renewable at the option of the customer. Subscription-based service agreements represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period.

 

We identified the evaluation of sufficiency of audit evidence over the key terms within new and modified subscription-based service agreements as a critical audit matter. Specifically, the nature and extent of procedures performed over the key terms within the new and modified subscription-based service agreements required subjective auditor judgment as recognition of revenue by the Company is dependent on the accuracy of the key terms within the related information technology (IT) application used to calculate revenue. The key terms within the new subscription-based service agreements include description of service, transaction price, renewal price and contract term, and the key terms within the modified subscription-based service agreements are the transaction price and contract term.

 

The following are the primary procedures we performed to address this critical audit matter. We applied auditor judgment to determine the nature and extent of procedures to be performed over the accuracy of key terms within the IT application, including the identification of key terms. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company’s subscription-based service revenue process, including controls over the agreements entered into during the current year, and the determination of the transaction price and contract term when the agreement was modified during the current year. We also tested certain internal controls over the accurate input of the underlying key terms of the subscription-based service agreement into the related IT application. For a sample of revenue transactions, we compared the key terms used in the revenue calculation to the underlying contract with the customer. We evaluated the sufficiency of audit evidence obtained over the key terms within new and modified subscription-based service agreements by assessing the results of procedures performed, including the nature and extent of audit effort.

 

 

/s/ KPMG LLP

 

We have served as the Company’s auditor since 1997.

 

Lincoln, Nebraska

March 5, 2021

 

28
Table of Contents

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

 

  

2020

  

2019

 

Assets

        

Current assets:

        

Cash and cash equivalents

 $34,690  $13,517 

Trade accounts receivable, less allowance for doubtful accounts of $120 and $144, respectively

  13,923   11,639 

Prepaid expenses

  2,645   2,038 

Income taxes receivable

  1,235   69 

Other current assets

  1,619   1,894 

Total current assets

  54,112   29,157 
         

Net property and equipment

  11,726   13,530 

Intangible assets, net

  1,410   1,728 

Goodwill

  57,255   57,935 

Operating lease right-of-use assets

  1,308   1,628 

Deferred contract costs, net

  4,555   4,204 

Other

  3,057   2,503 
         

Total assets

 $133,423  $110,685 
         

Liabilities and Shareholders’ Equity

        

Current liabilities:

        

Current portion of notes payable, net of unamortized debt issuance costs

 $4,061  $4,378 

Accounts payable

  1,095   1,279 

Accrued wages and bonuses

  6,460   6,086 

Accrued expenses

  3,184   3,408 

Income taxes payable

  --   366 

Dividends payable

  --   5,239 

Deferred revenue

  15,585   16,354 

Other current liabilities

  1,296   1,045 

Total current liabilities

  31,681   38,155 
         

Notes payable, net of current portion and unamortized debt issuance costs

  26,547   29,795 

Deferred income taxes

  7,265   7,399 

Other long-term liabilities

  3,615   2,444 

Total liabilities

  69,108   77,793 
         

Shareholders’ equity:

        

Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued

  --   -- 

Common stock, $0.001 par value; authorized 60,000,000 shares, issued 30,775,154 in 2020 and 30,151,574 in 2019, outstanding 25,390,968 in 2020 and 24,947,500 in 2019

  31   30 

Additional paid-in capital

  171,785   162,154 

Retained earnings (accumulated deficit)

  (61,375

)

  (93,357

)

Accumulated other comprehensive loss, foreign currency translation adjustment

  (2,399

)

  (2,209

)

Treasury stock, at cost; 5,384,186 Common shares in 2020 and 5,204,074 Common shares in 2019

  (43,727

)

  (33,726

)

Total shareholders’ equity

  64,315   32,892 
         

Total liabilities and shareholders’ equity

 $133,423  $110,685 

 

See accompanying notes to consolidated financial statements.

 

29
Table of Contents

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except share amounts)

 

  

2020

  

2019

  

2018

 
             

Revenue

 $133,277  $127,982  $119,686 
             

Insurance recoveries

  533   --   -- 
             

Operating expenses:

            

Direct

  49,187   46,435   47,577 

Selling, general and administrative

  34,441   32,973   31,371 

Depreciation, amortization and impairment

  7,505   5,539   5,463 

Total operating expenses

  91,133   84,947   84,411 
             

Operating income

  42,677   43,035   35,275 
             

Other income (expense):

            

Interest income

  18   37   62 

Interest expense

  (1,813

)

  (2,091

)

  (1,513

)

Other, net

  585   (462

)

  885 
             

Total other income (expense)

  (1,210

)

  (2,516

)

  (566

)

             

Income before income taxes

  41,467   40,519   34,709 
             

Provision for income taxes

  4,207   8,113   4,662 
             

Net income

 $37,260  $32,406  $30,047 
             

Earnings per share of common stock:

            

Basic earnings per share:

            

Common (formerly Class A)

 $1.48  $1.30  $1.08 

Class B

 $--  $--  $1.31 

Diluted earnings per share:

            

Common (formerly Class A)

 $1.45  $1.26  $1.04 

Class B

 $--  $--  $1.27 
             

Weighted average shares and share equivalents outstanding

            

Common (formerly Class A) - basic

  25,170   24,809   23,562 

Class B - basic

  --   --   3,527 

Common (formerly Class A) - diluted

  25,696   25,653   24,448 

Class B - diluted

  --   --   3,628 

 

See accompanying notes to consolidated financial statements.

 

30
Table of Contents

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

 

   

2020

    

2019

    

2018

  
                         

Net income

   $ 37,260     $ 32,406     $ 30,047  
                         

Other comprehensive income (loss):

                        

Cumulative translation adjustment

   $ (190 )   $ 707     $ (1,281

)

Other comprehensive income (loss)

   $ (190 )   $ 707     $ (1,281

)
                         

Comprehensive income

   $ 37,070     $ 33,113     $ 28,766  

 

See accompanying notes to consolidated financial statements.

 

31
Table of Contents

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(In thousands except share and per share amounts)

 

  

Common
Stock

(formerly

Class A)

  

Class B

Common
Stock

  

Additional
Paid-in
Capital

  

Retained
Earnings

  

Accumulated

Other
Comprehensive
Income (Loss)

  

Treasury

Stock

  

Total

 

Balances at December 31, 2017

 $26  $4  $51,025  $77,574  $(1,635

)

 $(36,953

)

 $90,041 

Purchase of 218,344 class A and 3,677 class B shares of treasury stock

  --   --   --   --   --   (7,950

)

  (7,950

)

Issuance of 468,318 class A and 9,296 class B common shares for the exercise of stock options

  --   --   6,098   --   --   --   6,098 

Issuance of 3,496 class A restricted common shares, net of (forfeitures)

  --   --   --   --   --   --   -- 

Non-cash stock compensation expense

  --   --   1,514   --   --   --   1,514 

Settlement of class B restricted common shares and stock options in connection with Recapitalization for cash of $3,271 and 90,369 class A common shares

  -   --   (2,548

)

  --   --   (723

)

  (3,271

)

Settlement of class B common shares in connection with Recapitalization (3,527,246 class B common shares exchanged for $69,099 cash and 3,527,246 class A common shares)

  4   --   118,335   --   --   (187,438

)

  (69,099

)

Retirement of 4,328,552 class B common shares in connection with Recapitalization

  --   (4

)

  (17,112

)

  (186,944

)

  --   204,060   -- 

Dividends declared of $1.13 and $0.60 per A and B common share, respectively

  --   --   --   (29,751

)

  --   --   (29,751

)

Cumulative effect adjustment for adoption of ASC 606, net of income tax

  --   --   --   2,735   --   --   2,735 

Other comprehensive income, foreign currency translation adjustment

  --   --   --   --   (1,281

)

  --   (1,281

)

Net income

  --   --   --   30,047   --   --   30,047 

Balances at December 31, 2018

 $30  $--  $157,312  $(106,339

)

 $(2,916

)

 $(29,004

)

 $19,083 

Purchase of 87,203 shares of treasury stock

  --   --   --   --   --   (4,722

)

  (4,722

)

Issuance of 227,902 common shares for the exercise of stock options

  --   --   3,618   --   --   --   3,618 

Issuance of 6,005 restricted common shares

  --   --   --   --   --   --   -- 

Non-cash stock compensation expense

  --   --   1,224   --   --   --   1,224 

Dividends declared of $0.78 per common share

  --   --   --   (19,424

)

  --   --   (19,424

)

Other comprehensive income, foreign currency translation adjustment

  --   --   --   --   707   --   707 

Net income

  --   --   --   32,406   --   --   32,406 

Balances at December 31, 2019

 $30  $--  $162,154  $(93,357

)

 $(2,209

)

 $(33,726

)

 $32,892 

Purchase of 180,112 shares of treasury stock

  --   --   --   --   --   (10,001

)

  (10,001)

Issuance of 630,373 common shares for the exercise of stock options

  1   --   8,951   --   --   --   8,952 

Forfeiture of 6,793 restricted common shares

  --   --   --   --   --   --   -- 

Non-cash stock compensation expense

  --   --   680   --   --   --   680 

Dividends declared of $0.21 per common share

  --   --   --   (5,278

)

  --   --   (5,278)

Other comprehensive income, foreign currency translation adjustment

  --   --   --   --   (190)  --   (190)

Net income

  --   --   --   37,260   --   --   37,260 

Balances at December 31, 2020

 $31  $--  $171,785  $(61,375

)

 $(2,399

)

 $(43,727

)

 $64,315 

 

See accompanying notes to consolidated financial statements.

 

32
Table of Contents

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

  

2020

  

2019

  

2018

 

Cash flows from operating activities:

            

Net income

 $37,260  $32,406  $30,047 

Adjustments to reconcile net income to net cash provided by operating activities:

            

Depreciation, amortization and impairment

  7,505   5,539   5,463 

Deferred income taxes

  (134

)

  1,099   1,476 

Reserve for uncertain tax positions

  185   39   (288

)

Gain on insurance recoveries for damaged property

  (260

)

  --   -- 

Loss on disposal of property and equipment

  12   (6

)

  186 

Non-cash share-based compensation expense

  680   1,224   1,514 

Change in assets and liabilities:

            

Trade accounts receivable

  (2,271

)

  311   2,767 

Prepaid expenses and other current assets

  (827

)

  (529

)

  (833

)

Operating lease assets and liability, net

  16   (8

)

  -- 

Deferred contract costs, net

  (351

)

  (719

)

  (113

)

Accounts payable

  (247

)

  647   (39

)

Accrued expenses, wages and bonuses

  1,370   806   (566

)

Income taxes receivable and payable

  (1,529

)

  11   686 

Deferred revenue

  (773

)

  97   (452

)

Net cash provided by operating activities

  40,636   40,917   39,848 
             

Cash flows from investing activities:

            

Purchases of property and equipment

  (3,984

)

  (4,656

)

  (5,971

)

Insurance proceeds for damaged property

  260   --   -- 

Net cash used in investing activities

  (3,724

)

  (4,656

)

  (5,971

)

             

Cash flows from financing activities:

            

Payments related to Recapitalization

  --   --   (72,370

)

Proceeds from issuance of note payable

  --   --   40,000 

Borrowings on line of credit

  --   21,000   2,500 

Payments on line of credit

  --   (21,000

)

  (2,500

)

Payments on notes payable

  (3,568

)

  (3,715

)

  (3,071

)

Payment of debt issuance costs

  (36

)

  --   (187

)

Payments on finance lease obligations

  (332

)

  (229

)

  (157

)

Proceeds from the exercise of stock options

  1,734   --   -- 

Payment of employee payroll tax withholdings on share-based awards exercised

  (2,784

)

  (1,103

)

  (1,853

)

Payment of dividends on common stock

  (10,517

)

  (31,299

)

  (16,859

)

Net cash used in financing activities

  (15,503

)

  (36,346

)

  (54,497

)

             

Effect of exchange rate changes on cash

  (236

)

  611   (1,122

)

Net increase (decrease) in cash and cash equivalents

  21,173   526   (21,742

)

             

Cash and cash equivalents at beginning of period

  13,517   12,991   34,733 
             

Cash and cash equivalents at end of period

 $34,690  $13,517  $12,991 
             

Supplemental disclosure of cash paid for:

            

Interest expense, net of capitalized amounts

 $1,735  $2,014  $1,282 

Income taxes

 $5,217  $6,946  $2,635 

Supplemental disclosure of non-cash investing and financing activities:

            

Common stock (formerly class A) issued in the Recapitalization in exchange for then-existing class B shares and options.

 $--  $--  $121,371 

Finance lease obligations originated for property and equipment

 $817  $192  $879 

Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans

 $7,217  $3,618  $6,098 

 

See accompanying notes to consolidated financial statements.

 

33
Table of Contents

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

 

(1)

Summary of Significant Accounting Policies

 

Description of Business and Basis of Presentation

 

National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), is a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States and Canada. Our purpose is to establish human understanding. Our solutions enable health care organizations to understand what matters most to each person they serve. Our portfolio of solutions represents a unique set of capabilities that individually and collectively provide value to our clients. The solutions are offered at an enterprise level through the Voice of the Customer ("VoC") platform, The Governance Institute, and legacy Experience solutions. 

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Translation of Foreign Currencies

 

Our Canadian subsidiary uses Canadian dollars as its functional currency. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the consolidated statements of income.

 

Revenue Recognition

 

On January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers and all related amendments (“ASC 606” or “new revenue standard”) using the modified retrospective method for all incomplete contracts as of the date of adoption. We applied the practical expedient to reflect the total of all contract modifications occurring before January 1, 2018 in the transaction price and performance obligations at transition rather than accounting for each modification separately. Results for reporting periods beginning on or after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. As discussed in more detail below and under “Deferred Contract Costs”, the largest impact of implementing the new revenue standard was the deferral and amortization of direct and incremental costs of obtaining contracts. In addition, there were other revisions to revenue recognition primarily related to performance obligation determinations and estimating variable consideration. We recorded a transition adjustment of approximately $2.7 million, net of $814,000 of tax, to the opening balance of retained earnings.

 

We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or no notice without penalty. See Note 3 for further information about our contracts with customers. We account for revenue using the following steps:

 

 

●

Identify the contract, or contracts, with a customer;

 

●

Identify the performance obligations in the contract;

 

●

Determine the transaction price;

 

●

Allocate the transaction price to the identified performance obligations; and

 

●

Recognize revenue when, or as, we satisfy the performance obligations.

 

34
Table of Contents
 

Our revenue arrangements with a client may include combinations of more than one service offering which may be executed at the same time, or within close proximity of one another. We combine contracts with the same client into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together, consideration in one contract depends on another contract, or services in one or more contracts are a single performance obligation. For contracts that contain more than one separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable clients, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do not contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.

 

Our arrangements with customers consist principally of four different types of arrangements: 1) subscription-based service agreements; 2) one-time specified services performed at a single point in time; 3) fixed, non-subscription service agreements; and 4) unit-priced service agreements.

 

Subscription-based services - Services that are provided under subscription-based service agreements are usually for a twelve month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the client. These agreements are renewable at the option of the client at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the client as the client receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but may also be billed on a quarterly and monthly basis.

 

One-time services – These agreements typically require us to perform a specific one-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the client.

 

Fixed, non-subscription services – These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch up adjustment which could impact the amount and timing of revenue for any period.

 

Unit-price services – These arrangements typically require us to perform certain services on a periodic basis as requested by the client for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.

 

Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but not invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.

 

35
Table of Contents
 

Deferred Contract Costs

 

Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable client contract. In 2020, we began providing information technology development work for certain clients specific to their implementation, which are capitalized as deferred contract costs. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. The contract term was estimated by considering factors such as historical client attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract. An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services. We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of one year or less. Prior to 2018, all commissions and incentives were expensed as incurred. We recorded a transition adjustment on January 1, 2018 as an increase to retained earnings of $2.6 million, net of $776,000 of tax, to reflect $3.4 million of commissions and incentives related to contracts that began prior to 2018, net of accumulated amortization. We deferred incremental costs of obtaining a contract of $3.7 million, $3.6 million and $2.6 million in the years ended December 31, 2020, 2019 and 2018, respectively. Deferred contract costs, net of accumulated amortization was $4.6 million and $4.2 million at December 31, 2020 and 2019, respectively. Total amortization by expense classification for the years ended December 31, 2020, 2019 and 2018 was as follows:

 

  

2020

  

2019

  

2018

 
  

(In thousands)

 

Direct expenses

 $272  $34  $83 

Selling, general and administrative expenses

 $2,970  $2,874  $2,400 

Total amortization

 $3,242  $2,908  $2,483 

 

Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $63,000, $22,000 and $51,000 for the years December 31, 2020, 2019 and 2018, respectively.

 

Trade Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount. Effective January 1, 2020, we adopted Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments. This ASU requires the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The adoption of this standard did not have an impact on our consolidated financial statements. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The COVID-19 pandemic has resulted in an increase in accounts receivables as some clients have delayed payments or are slower paying due to such clients’ cash-flow issues.

 

The following table provides the activity in the allowance for doubtful accounts for the years ended December 31, 2020, 2019 and 2018 (in thousands):

 

  

Balance at

Beginning

of Year

  

Bad Debt

Expense

  

Write-offs,

net of

Recoveries

  

Balance

at End

of Year

 
                 

Year Ended December 31, 2018

 $200  $80  $105  $175 

Year Ended December 31, 2019

 $175  $75  $106  $144 

Year Ended December 31, 2020

 $144  $46  $70  $120 

 
36
Table of Contents
 

Property and Equipment

 

Property and equipment is stated at cost. Major expenditures to purchase property or to substantially increase useful lives of property are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in income.

 

We capitalize certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software projects and external direct costs of materials and services. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs are expensed as incurred. We capitalized approximately $2.7 million and $4.1 million of costs incurred for the development of internal-use software for the years ended December 31, 2020 and 2019, respectively.

 

When a software license is included in a cloud computing arrangement and we have the legal right, ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is not included or we do not have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective January 1, 2020, we prospectively adopted ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did not significantly impact our results of operations and financial position.

 

We provide for depreciation and amortization of property and equipment using annual rates which are sufficient to amortize the cost of depreciable assets over their estimated useful lives. We use the straight-line method of depreciation and amortization over estimated useful lives of three to ten years for furniture and equipment, three to five years for computer equipment, one to five years for capitalized software, and seven to forty years for our office building and related improvements. Software licenses are amortized over the term of the license.

 

Impairment of Long-Lived Assets and Amortizing Intangible Assets

 

Long-lived assets, such as property and equipment and purchased intangible assets subject to depreciation or amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we first compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. No significant impairments were recorded during the years ended December 31, 2020, 2019, or 2018.

 

Among others, management believes the following circumstances are important indicators of potential impairment of such assets and as a result may trigger an impairment review:

 

 

●

Significant underperformance in comparison to historical or projected operating results;

 

●

Significant changes in the manner or use of acquired assets or our overall strategy;

 

●

Significant negative trends in our industry or the overall economy;

 

●

A significant decline in the market price for our common stock for a sustained period; and

 

●

Our market capitalization falling below the book value of our net assets.

 

Goodwill and Intangible Assets

 

Intangible assets include customer relationships, trade names, technology, and goodwill. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review intangible assets with indefinite lives for impairment annually as of October 1 and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.

 

37
Table of Contents
 

When performing the impairment assessment, we will first assess qualitative factors to determine whether it is necessary to recalculate the fair value of the intangible assets with indefinite lives. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of the indefinite-lived intangibles is less than their carrying amount, we calculate the fair value using a market or income approach. If the carrying value of intangible assets with indefinite lives exceeds their fair value, then the intangible assets are written-down to their fair values. We did not recognize any impairments related to indefinite-lived intangibles during 2020, 2019 or 2018.

 

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. All of our goodwill is allocated to our reporting units, which are the same as our operating segments. Goodwill is reviewed for impairment at least annually, as of October 1, and whenever events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable.

 

We review goodwill for impairment by first assessing qualitative factors to determine whether any impairment may exist. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative analysis will be performed, and the fair value of the reporting unit is compared with its carrying value (including goodwill). If the carrying value of the reporting unit exceeds the fair value, then goodwill is written down by this difference. We performed a qualitative analysis as of October 1, 2020 and determined the fair value of each reporting unit likely exceeded the carrying value. No impairments were recorded during the years ended December 31, 2019 or 2018. A substantial portion of the revenue earned by our Canadian subsidiary is concentrated with one customer. While the customer has exercised its option to extend its existing contract to September 2022, during December 2020 we chose not to enter into a new contract with this customer or otherwise extend the term of the contract beyond September 2022. We subsequently announced that we would close the Canada office at the end of the contract.  As a result, we tested for impairment of the Canada reporting unit’s goodwill at December 31, 2020. We recognized an impairment of $714,000 for the excess of the Canada reporting unit’s carrying value over the fair value, using discounted cash flows. The remaining balance of goodwill of our Canada reporting unit at December 31, 2020 was $1.6 million. Changes in the actual amount or timing of cash flows or other assumptions used to discount cash flows to estimate fair value of the Canada reporting unit could result in additional impairment.

 

Insurance Recoveries

 

We record insurance recoveries when the realization of the claim is probable. In 2020 we received $3.3 million in insurance recoveries, and $447,000 was paid directly to certain vendors from the insurer related to a cyber-attack in February 2020 (the “February incident”). We recorded $533,000, representing reimbursement for lost revenues, as insurance recoveries, and the remainder as a reduction to operating expenses. Due to insurance recoveries, the February incident did not have a significant impact on our consolidated financial statements. In 2020, we also recorded a gain in other income of $260,000 from insurance recoveries for property damage due to a flooding.

 

Income Taxes

 

We use the asset and liability method of accounting for income taxes. Under that method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis using enacted tax rates. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances, if any, are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. We use the deferral method of accounting for our investment tax credits related to state tax incentives. During the years ended December 31, 2020, 2019 and 2018, we recorded income tax benefits relating to these tax credits of $45,000, $24,000, and $0, respectively. Interest and penalties related to income taxes are included in income taxes in the Consolidated Statements of Income.

 

We recognize the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

 

38
Table of Contents
 

Share-Based Compensation

 

All of our existing stock option awards and non-vested stock awards have been determined to be equity-classified awards. The compensation expense on share-based payments is recognized based on the grant-date fair value of those awards. We recognize the excess tax benefits and tax deficiencies in the income statement when options are exercised. Amounts recognized in the financial statements with respect to these plans are as follows:

 

  

2020

  

2019

  

2018

 
  

(In thousands)

 

Amounts charged against income, before income tax benefit

 $680  $1,224  $1,514 

Amount of related income tax benefit

  (6,764

)

  (2,081

)

  (3,566

)

Net (benefit) expense to net income

 $(6,084

)

 $(857

)

 $(2,052

)

 

We refer to our restricted stock awards as “non-vested” stock in these consolidated financial statements.  

 

Cash and Cash Equivalents

 

We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents were $5.0 million and $3.7 million as of December 31, 2020, and 2019, respectively, consisting primarily of money market accounts. At certain times, cash equivalent balances may exceed federally insured limits.

 

Leases

 

We adopted Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) (“Topic 842” or the “New Leases Standard”) effective January 1, 2019 using a modified retrospective transition and did not adjust prior periods. We elected practical expedients related to existing leases at transition to not reassess whether contracts are or contain leases, to not reassess lease classification, initial direct costs, or lease terms. Additionally, we elected the practical expedient to account for lease and non-lease components as a single lease component for all asset classifications. We have also made a policy election to not record short-term leases with a duration of 12 months or less on the balance sheet.

 

Topic 842 requires lessees to recognize a lease liability and a right-of-use (“ROU”) asset on the balance sheet for operating leases. We recorded $2.3 million of ROU assets and $2.3 million of lease liabilities related to operating leases at the date of transition. The ROU assets recorded were net of $43,000 of accrued liabilities and prepaid expenses representing previously deferred (prepaid) rent. There was no significant impact to the consolidated statements of income, comprehensive income, shareholders’ equity or cash flows. Accounting for finance leases is substantially unchanged.

 

We determine whether a lease is included in an agreement at inception. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long-term liabilities. Certain lease arrangements may include options to extend or terminate the lease. We include these provisions in the ROU asset and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do not contain any residual value guarantees.

 

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is not readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.

 

Fair Value Measurements

 

Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (1) Level 1 Inputs—quoted prices in active markets for identical assets and liabilities; (2) Level 2 Inputs—observable market-based inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; (3) Level 3 Inputs—unobservable inputs.

 

39
Table of Contents
 

The following details our financial assets within the fair value hierarchy at December 31, 2020 and 2019:

 

  

Level 1

  

Level 2

  

Level 3

  

Total

 
  

(In thousands)

 

As of December 31, 2020

                

Money Market Funds

 $5,015  $--  $--  $5,015 

Total Cash Equivalents

 $5,015  $--  $--  $5,015 
                 

As of December 31, 2019

                

Money Market Funds

 $3,662  $--  $--  $3,662 

Total Cash Equivalents

 $3,662  $--  $--  $3,662 

 

There were no transfers between levels during the years ended December 31, 2020 and 2019.

 

Our long-term debt described in Note 8 is recorded at historical cost. The fair value of long-term debt is classified in Level 2 of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit.

 

The following are the carrying amount and estimated fair values of long-term debt:

 

  

December 31,

2020

  

December 31,

2019

 
  

(In thousands)

 

Total carrying amount of long-term debt

 $30,713  $34,281 

Estimated fair value of long-term debt

 $32,943  $35,205 

 

The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are not recognized or disclosed at fair value in the financial statements on a recurring basis, which includes property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). As of December 31, 2020 and 2019, there was no indication of impairment related to these assets, other than for the Canada reporting unit’s goodwill as discussed above. We estimated the fair value of the Canada reporting unit using discounted cash flows based on management’s most recent projections which are considered level 3 inputs in the fair value hierarchy.

 

Commitments and Contingencies

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. We do not believe the final disposition of claims at December 31, 2020 will have material adverse effect on our consolidated financial position, results of operations or liquidity.

 

A sales tax accrual of $775,000 was recorded in 2019 for sales taxes that should have been collected from clients in 2019 and certain previous years. We received a revenue ruling from the state of Washington noting that our services are not subject to retail sales tax, and therefore, reversed $268,000 of sales tax accrual for the state of Washington in the third quarter of 2020. We have completed voluntary disclosure agreements with certain states, remitted past due sales tax, are remitting sales tax timely, are collecting sales tax from clients and no accrual for past due sales tax remains as of December 31, 2020. State and local jurisdictions have differing rules and regulations governing sales, use, and other taxes and these rules and regulations can be complex and subject to varying interpretations that may change over time. As a result, we could face the possibility of tax assessment and audits, and our liability for these taxes and associated interest and penalties could exceed our original estimates.

 

We became self-insured for group medical and dental insurance on January 1, 2019.   We carry excess loss coverage in the amount of $150,000 per covered person per year for group medical insurance.  We do not self-insure for any other types of losses, and therefore do not carry any additional excess loss insurance.  We record a reserve for our group medical and dental insurance for all unresolved claims and for an estimate of incurred but not reported (“IBNR”) claims.  On a quarterly basis, we adjust our accrual based on a review of our claims experience and a third-party actuarial IBNR analysis.  As of December 31, 2020 and 2019, our accrual related to self-insurance was $418,000 and $270,000, respectively.

 

40
Table of Contents
 

Earnings Per Share

 

Prior to the Recapitalization, net income per share of our former class A common stock and former class B common stock was computed using the two-class method. Basic net income per share was computed by allocating undistributed earnings to common shares and using the weighted-average number of common shares outstanding during the period.

 

Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.

 

The liquidation rights and the rights upon the consummation of an extraordinary transaction were the same for the holders of our former class A common stock and former class B common stock. Other than share distributions and liquidation rights, the amount of any dividend or other distribution payable on each share of former class A common stock was equal to one-sixth (1/6th) of the amount of any such dividend or other distribution payable on each share of former class B common stock. As a result, the undistributed earnings for each period were allocated based on the participation rights of the former class A and former class B common stock under our then-effective Articles of Incorporation as if the earnings for the year had been distributed.

 

As described in Note 2, we completed a Recapitalization in April 2018, resulting in the elimination of the class B common stock and settlement of all then-existing outstanding class B share-based awards and reclassification of all class A common stock to Common Stock. The Recapitalization was effective on April 17, 2018. Therefore, income was allocated between the former class A and class B stock using the two-class method through April 16, 2018, and fully allocated to the Common Stock (formerly class A) following the Recapitalization.

 

We had 65,127, 16,221 and 93,346 options of Common Stock (former class A shares) for the years ended December 31, 2020, 2019 and 2018, respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.

 

  

2020

  

2019

  

2018

 
  

Common

Stock

  

Common

Stock

  

Common

Stock

(formerly

Class A)

  

Class B

Common

Stock

 
  

(In thousands, except per share data)

 

Numerator for net income per share - basic:

                

Net income

 $37,260  $32,406  $25,423  $4,624 

Allocation of distributed and undistributed income to unvested restricted stock shareholders

  (57

)

  (109

)

  (82

)

  (18

)

Net income attributable to common shareholders

 $37,203  $32,297  $25,341  $4,606 

Denominator for net income per share - basic:

                

Weighted average common shares outstanding – basic

  25,170   24,809   23,562   3,527 

Net income per share - basic

 $1.48  $1.30  $1.08  $1.31 

Numerator for net income per share - diluted:

                

Net income attributable to common shareholders for basic computation

 $37,203  $32,297  $25,341  $4,606 

Denominator for net income per share - diluted:

                

Weighted average common shares outstanding – basic

  25,170   24,809   23,562   3,527 

Weighted average effect of dilutive securities – stock options

  526   844   886   101 

Denominator for diluted earnings per share – adjusted weighted average shares

  25,696   25,653   24,448   3,628 

Net income per share - diluted

 $1.45  $1.26  $1.04  $1.27 

 

41
Table of Contents
 

Recent Accounting Pronouncements Not Yet Adopted

 

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years.  Early adoption is permitted in interim or annual periods with any adjustments reflected as of the beginning of the annual period that includes that interim period.  Additionally, entities that elect early adoption must adopt all the amendments in the same period.  Amendments are to be applied prospectively, except for certain amendments that are to be applied either retrospectively or with a modified retrospective approach through a cumulative effect adjustment recorded to retained earnings.  We believe the adoption will not significantly impact our results of operations and financial position.

 

In March 2020, FASB issued ASU No. 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022. We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate.

 

 

(2)

Recapitalization

 

On April 16, 2018, our shareholders approved, among other things, an amendment to our Amended and Restated Articles of Incorporation (the “Articles”) to effect a recapitalization (the “Recapitalization”) pursuant to which each share of our then-existing class B common stock was exchanged for one share of the our then-existing Class A common stock plus $19.59 in cash, without interest. On April 17, 2018, we filed an amendment to our Articles effecting the Recapitalization, followed by an amendment and restatement of our Articles, which resulted in the elimination of our class B common stock and the reclassification of our class A common stock as a share of Common Stock, par value $0.001 per share (“Common Stock”). We issued 3,617,615 shares of Common Stock and paid $72.4 million in exchange for all class B shares outstanding and to settle outstanding share-based awards for class B common stock. The Common Stock continues to trade on the NASDAQ Global Market under the revised symbol “NRC.”

 

In connection with the Recapitalization, on April 18, 2018, we entered into a credit agreement with First National Bank of Omaha, a national banking association (“FNB”), as described in Note 8. 

 
 

(3)

Contracts with Customers

 

The following table disaggregates revenue for the years ended December 31, 2020 and 2019 based on timing of revenue recognition (In thousands):

 

  

2020

  

2019

  2018 

Subscription services recognized ratably over time

 $122,499  $114,216  $104,777 

Services recognized at a point in time

  2,932   4,992   4,775 

Fixed, non-subscription recognized over time

  2,907   3,248   3,163 

Unit price services recognized over time

  4,939   5,526   6,971 

Total revenue

 $133,277  $127,982  $119,686 

 

Our solutions within the digital VoC platform in 2020, 2019 and 2018 accounted for 73.3%, 62.7% and 49.6% of total revenue, respectively. The remaining revenue consists of legacy Experience and Governance Solutions.  

 

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (In thousands):

 

  

December 31,

2020

  

December 31,

2019

 

Accounts receivables

 $13,923  $11,639 

Contract assets included in other current assets

 $311  $103 

Deferred revenue

 $(15,585

)

 $(16,354

)

 

42
Table of Contents
 

Significant changes in contract assets and contract liabilities during the years ended December 31, 2020 and 2019 are as follows (in thousands):

 

  

2020

  

2019

 
  

Contract

Asset

  

Deferred

Revenue

  

Contract

Asset

  

Deferred

Revenue

 
  

Increase (Decrease)

 

Revenue recognized that was included in deferred revenue at beginning of year due to completion of services

 $-  $(16,083

)

 $-  $(15,785

)

Increases due to invoicing of client, net of amounts recognized as revenue

  -   15,338   -   15,631 

Decreases due to completion of services (or portion of services) and transferred to accounts receivable

  (103

)

  -   (53

)

  - 

Change due to cumulative catch-up adjustments arising from changes in expected contract consideration

  -   (24

)

  -   264 

Increases due to revenue recognized in the period with additional performance obligations before invoicing

  311   -   103   - 

 

We have elected to apply the practical expedient to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Total remaining contract revenue for contracts with original duration of greater than one year expected to be recognized in the future related to performance obligations that are unsatisfied at December 31, 2020 approximated $205,000, which is expected to be recognized during 2021.

 
 

(4)

Equity Investments

 

We make equity investments to promote business and strategic objectives. For investments that do not have a readily determinable fair value, we apply either cost or equity method of accounting depending on the nature of our investment and our ability to exercise significant influence. Investments are periodically analyzed to determine whether or not there are any indicators of impairment and written down to fair value if the investment has incurred an other than temporary impairment. Our investment of $1.3 million in convertible preferred stock of PracticingExcellence.com, Inc., a privately-held Delaware corporation (“PX”) is included in non-current assets. It is not practicable for us to estimate fair value at each reporting date due to the cost and complexity of the calculations for this non-public entity. Therefore, it is carried at cost less impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, if any. We have a seat on PX's board of directors and our investment, which is not considered to be in-substance common stock, represents approximately 15.7% of the issued and outstanding equity interests in PX.

 
 

(5)

Property and Equipment

 

At December 31, 2020, and 2019, property and equipment consisted of the following:

 

  

2020

  

2019

 
  

(In thousands)

 

Furniture and equipment

 $4,808  $5,025 

Computer equipment

  2,638   2,706 

Computer software

  27,087   24,532 

Building

  7,515   9,349 

Leaseholds

  232   41 

Land

  425   425 

Property and equipment at cost

  42,705   42,078 

Less accumulated depreciation and amortization

  30,979   28,548 

Net property and equipment

 $11,726  $13,530 

 

Depreciation and amortization expense related to property and equipment, including assets under capital lease, for the years ended December 31, 2020, 2019, and 2018 was $6.5 million, $5.4 million, and $4.8 million, respectively. There were no significant impairments in property and equipment during 2020, 2019, and 2018. However, we did shorten the useful lives of certain assets to reflect our best estimate of when assets are expected to be disposed of or replaced.

 

43
Table of Contents
 
 

(6)

Goodwill and Intangible Assets

 

Goodwill and intangible assets consisted of the following at December 31, 2020:

 

   

Gross

    

Accumulated

Impairment

    

Net

  
   

(In thousands)

  

Goodwill

   $ 57,969     $ (714 )   $ 57,255  

 

 

 

   

Useful Life

    

Gross

    

Accumulated

Amortization

    

Net

  
   

(In years)

            

(In thousands)

          

Non-amortizing intangible assets:

                                  

Indefinite trade name

               1,191               1,191  

Amortizing intangible assets:

                                  

Customer related

   5 - 15       9,344       9,256       88  

Technology

     7         1,360       1,229       131  

Trade names

   5 - 10       1,572       1,572       --  

Total amortizing intangible assets

               12,276       12,057       219  

Total intangible assets other than goodwill

             $ 13,467     $ 12,057     $ 1,410  

 

Goodwill and intangible assets consisted of the following at December 31, 2019:

 

   

Gross

    

Accumulated

Impairment

    

Net

  
   

(In thousands)

  

Goodwill

   $ 57,935     $ -     $ 57,935  

 

 

 

   

Useful Life

    

Gross

    

Accumulated

Amortization

    

Net

  
   

(In years)

            

(In thousands)

          

Non-amortizing intangible assets:

                                  

Indefinite trade name

               1,191               1,191  

Amortizing intangible assets:

                                  

Customer related

   5 - 15       9,338       9,154       184  

Technology

     7         1,360       1,007       353  

Trade names

   5 - 10       1,572       1,572       --  

Total amortizing intangible assets

               12,270       11,733       537  

Total intangible assets other than goodwill

             $ 13,461     $ 11,733     $ 1,728  

 

The following represents a summary of changes in the carrying amount of goodwill for the years ended December 31, 2020 and 2019 (in thousands):

 

Balance as of December 31, 2018

   $ 57,831  

Foreign currency translation

     104  

Balance as of December 31, 2019

   $ 57,935  

Impairment

     (714

)

Foreign currency translation

     34  

Balance as of December 31, 2020

   $ 57,255  

 

As discussed in Note 1, we recorded an impairment of $714,000 to the Canada reporting unit’s goodwill in December 2020.

 

Aggregate amortization expense for customer related intangibles, trade names, and technology for the years ended December 31, 2020, 2019 and 2018 was $318,000, $374,000, and $662,000, respectively. Estimated future amortization expense for 2021, 2022 and 2023 is $180,000, $40,000, and -0-, respectively.

 

44
Table of Contents
 
 

(7)

Income Taxes

 

For the years ended December 31, 2020, 2019, and 2018, income before income taxes consists of the following:

 

  

2020

  

2019

  

2018

 
  

(In thousands)

 

U.S. Operations

 $41,357  $40,045  $32,056 

Foreign Operations

  110   474   2,653 

Income before income taxes

 $41,467  $40,519  $34,709 

 

Income tax expense consisted of the following components:

 

  

2020

  

2019

  

2018

 
  

(In thousands)

 

Federal:

            

Current

 $3,546  $5,574  $2,144 

Deferred

  (308

)

  718   1,328 

Total

 $3,238  $6,292  $3,472 
             

Foreign:

            

Current

 $225  $94  $882 

Deferred

  (6

)

  33   (178

)

Total

 $219  $127  $704 
             

State:

            

Current

 $578  $1,322  $204 

Deferred

  172   372   282 

Total

 $750  $1,694  $486 
             

Total

 $4,207  $8,113  $4,662 

 

Federal Tax Reform

 

On December 22, 2017, the Tax Cut and Jobs Act (the “Tax Act”) was enacted which made broad and complex changes to the U.S. tax code, including the following:

 

 

●

Reduction in the U.S. Federal Corporate Tax Rate: The Tax Act reduced the corporate tax rate to 21%, effective
January 1, 2018

 

●

Availability of 100% bonus depreciation on assets placed in service after September 27, 2017

 

●

Certain stock compensation plans potentially subject to limitations on excess tax benefits

 

●

The Global Intangible Low Taxed Income (GILTI) provision

 

As a result of the Tax Act, we determined that we would no longer indefinitely reinvest the earnings of our Canadian subsidiary. Our Canadian subsidiary declared a deemed dividend to the Company for $9.6 million and $3 million in 2020 and 2018, respectively. Additionally, a withholding tax of 5% was paid for each dividend distribution.

 

The Tax Act subjects a U.S. corporation to tax on its Global Intangible Low Taxed Income (“GILTI”). Due to the complexity of the new GILTI tax rules, we are continuing to evaluate this provision of the Tax Act. Under Generally Accepted Accounting Principles, we can make an accounting policy election to either treat taxes due on the GILTI inclusion as a current period expense or factor such amounts into the measurement of deferred taxes. We elected the current period expense method and have not reflected any corresponding deferred tax assets and liabilities associated with the GILTI tax in the table of deferred tax assets and liabilities. GILTI tax has been recorded as current period expense of $10,000, $13,000, and $40,000 in 2020, 2019, and 2018, respectively.

 

We received notice in December 2019, that we met qualification requirements for the Nebraska Advantage LB312 Act (“NAA”) related to certain investment and full-time equivalent employee thresholds in the year ended 2017. NAA provides direct refunds of sales tax on qualified property, as well as investment credits and employment credits that can be claimed through credits of Nebraska income tax, employment tax, and sales tax on non-qualified property. We will receive direct refunds of Nebraska sales tax on qualified property incurred from 2014 to 2023. Investment credits started to accumulate in 2014 and can be earned through 2023. These credits can be claimed against Nebraska income taxes or through sales tax on non-qualified property through 2028. The employment credits are earned from 2017 through 2023, and they can be claimed against Nebraska payroll taxes through 2028. In 2019, we recorded cumulative adjustments for direct refunds and credits earned through the year ending December 31, 2019, which reduced operating expenses by approximately $1.9 million. For the year ended December 31, 2020, adjustments for credits reduced operating expenses by approximately $435,000. In addition, income tax credits of $45,000 and $24,000 were recorded as a reduction to income tax expense for the years ended December 31, 2020 and 2019, respectively.

 

45
Table of Contents
 

The differences between income taxes expected at the U.S. federal statutory income tax rate of 21 percent and the reported income tax (benefit) expense are summarized as follows:

 

  

2020

  

2019

  

2018

 
  

(In thousands)

 

Expected federal income taxes

 $8,708  $8,509  $7,285 

Foreign tax rate differential

  6   26   146 

State income taxes, net of federal benefit and state tax credits

  607   1,344   376 

Share-based compensation

  (5,713

)

  (1,579

)

  (3,041

)

Compensation limit for covered employees

  463   --   -- 

Federal tax credits

  (261

)

  (419

)

  (150

)

Uncertain tax positions

  157   34   90 

Nondeductible expenses (income) related to recapitalization

  --   (24

)

  151 

Goodwill Impairment

  184   --   -- 

Tax depreciation method change

  --   --   (308)

Withholding tax on repatriation of foreign earnings

  18   107   -- 

GILTI

  10   13   40 

Other

  28   102   73 
  $4,207  $8,113  $4,662 

 

Deferred tax assets and liabilities at December 31, 2020 and 2019, were comprised of the following:

 

  

2020

  

2019

 
  

(In thousands)

 

Deferred tax assets:

        

Allowance for doubtful accounts

 $29  $35 

Accrued expenses

  696   537 

Share-based compensation

  735   1,267 

Accrued bonuses

  145   120 

Employer payroll tax deferral

  323   -- 

Foreign tax credit from repatriation

  --   535 

Other

  27   -- 

Gross deferred tax assets

  1,955   2,494 

Less valuation allowance

  --   (535

)

Deferred tax assets

  1,955   1,959 

Deferred tax liabilities:

        

Prepaid expenses

  93   135 

Deferred contract costs

  1,111   990 

Property and equipment

  1,725   1,926 

Intangible assets

  6,109   5,553 

Repatriation withholding

  174   528 

Unrealized translation gain on intercompany loan

  --   214 

Other

  8   12 

Deferred tax liabilities

  9,220   9,358 

Net deferred tax liabilities

 $(7,265

)

 $(7,399

)

 

In March 27, 2020, the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The CARES Act is an emergency economic stimulus package in response to the coronavirus outbreak which, among other things, contains numerous income tax provisions. As a result of the CARES Act, we have deferred $1,323,000 of employer social security tax payments into future years. We have had no other impacts to our consolidated financial statements or related disclosures from the CARES Act.

 

46
Table of Contents
 

In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider projected future taxable income, carry-back opportunities, and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods which the deferred tax assets are deductible, we believe it is more likely than not that we will realize the benefits of these deductible differences excluding the foreign tax credit carryforward. In 2020, we wrote off the deferred tax asset for prior year foreign tax credit carryforwards of $535,000 and the related valuation allowance. We made the assessment that due to our Canadian subsidiary’s decreased projected future income and the lower US tax rate compared to the Canadian tax rate, it was unlikely we would realize this asset.

 

We had an unrecognized tax benefit at December 31, 2020 and 2019, of $768,000 and $592,000, respectively, excluding interest of $15,000 and $7,000 at December 31, 2020 and 2019, respectively. Of these amounts, $668,000 and $515,000 at December 31, 2020 and 2019, respectively, represents the net unrecognized tax benefits that, if recognized, would favorably impact the effective income tax rate. The change in the unrecognized tax benefits for 2020 and 2019 is as follows:

 

  

(In thousands)

 

Balance of unrecognized tax benefits at December 31, 2018

 $554 

Reductions due to lapse of applicable statute of limitations

  (43

)

Reductions due to tax positions of prior years

  -- 

Reductions due to settlement with taxing authorities

  (300

)

Additions based on tax positions related to the current year

  381 

Balance of unrecognized tax benefits at December 31, 2019

 $592 

Reductions due to lapse of applicable statute of limitations

  (34

)

Additions due to tax positions of prior years

  4 

Reductions due to settlement with taxing authorities

  -- 

Additions based on tax positions related to the current year

  206 

Balance of unrecognized tax benefits at December 31, 2020

 $768 

 

We file income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and Canada federal and provincial jurisdictions. Tax years 2017 and forward remain subject to U.S. federal examination. Tax years 2014 and forward remain subject to state examination. Tax years 2016 and forward remain subject to Canadian federal and provincial examination.

 
 

(8)

Notes Payable

 

Our long-term debt consists of the following:  

 

  

2020

  

2019

 
  

(In thousands)

 

Term Loans

 $30,713  $34,281 

Less: current portion

  (4,061

)

  (4,378

)

Less: unamortized debt issuance costs

  (105

)

  (108

)

Notes payable, net of current portion

 $26,547  $29,795 

 

Our credit agreement (the “Credit Agreement”) with First National Bank of Omaha (“FNB”) was amended and restated on May 28, 2020 and includes (i) a $30,000,000 revolving credit facility (the “Line of Credit”), (ii) a $33,002,069 term loan (the “Term Loan”) and (iii) a $15,000,000 delayed draw-dawn term facility (the “Delayed Draw Term Loan” and, together with the Line of Credit and the Term Loan, the “Credit Facilities”). The Delayed Draw Term Loan may be used to fund any permitted future business acquisitions or repurchases of our Common Stock and the Line of Credit can be used to fund ongoing working capital needs and for other general corporate purposes. The May 2020 amendment increased the Line of Credit from $15,000,000 to $30,000,000.

 

The amended Term Loan revised the remaining payments for the existing balance outstanding of $33,002,069 to monthly installments of $462,988 through May 2025, with a balloon payment due at maturity in May 2025. The Term Loan bears interest at a fixed rate per annum of 5%. Borrowings under the Line of Credit and the Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the 30-day London Interbank Offered Rate plus 225 basis points (2.40% at December 31, 2020). Interest on the Line of Credit accrues and is payable monthly. Principal amounts outstanding under the Line of Credit are due and payable in full at maturity, in May 2023. There were no borrowings on the Line of Credit during 2020. There have been no borrowings on the Delayed Draw Term Loan since origination.

 

47
Table of Contents
 

We are obligated to pay ongoing unused commitment fees quarterly in arrears pursuant to the Line of Credit and the Delayed Draw Term Loan facility at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility, respectively.

 

The Credit Agreement is collateralized by substantially all of our assets, subject to permitted liens and other agreed exceptions, and contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our Common Stock and acquisitions, subject in each case to certain exceptions. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of 1.10x for all testing periods throughout the terms of the Credit Facilities, which calculation excludes, unless our liquidity falls below a specified threshold, (i) any cash dividend in a fiscal quarter that, together with all other cash dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash dividends paid or declared, (ii) the portion of the purchase price for any permitted share repurchase of our shares paid with cash on hand, and (iii) the portion of any acquisition consideration for a permitted acquisition paid with cash on hand. We are also required to maintain a cash flow leverage ratio of 3.00x or less for all testing periods throughout the term(s) of the Credit Facilities. As of December 31, 2020, we were in compliance with our financial covenants.

 

Scheduled maturities of notes payable at December 31, 2020 are as follows:

 

2021

 $4,093 

2022

  4,306 

2023

  4,529 

2024

  4,762 

2025

  13,023 

 
 

(9)

Share-Based Compensation

 

We measure and recognize compensation expense for all share-based payments based on the grant-date fair value of those awards. All of our existing stock option awards and unvested stock awards have been determined to be equity-classified awards. We account for forfeitures as they occur. As described in Note 2, we completed a Recapitalization in April 2018 which, among other things, settled all then-existing outstanding class B share-based awards and resulted in the elimination of the class B common stock. As a result, we accelerated vesting of all outstanding class B share-based awards, resulting in accelerated share-based compensation of $331,000 in the year ended December 31, 2018. All outstanding class B share-based awards were then settled for the same stock to cash proportion of the class B common stock described in Note 2, less the exercise price, if any, which approximated the awards’ intrinsic values.

 

Our 2001 Equity Incentive Plan provided for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of our former class A common stock and 300,000 shares of our former class B common stock. Stock options granted could have been either nonqualified or incentive stock options. Stock options vest over one to five years following the date of grant and option terms are generally five to ten years following the date of grant. Due to the expiration of the 2001 Equity Incentive Plan, at December 31, 2015, there were no shares of stock available for future grants.

 

Our 2004 Non-Employee Director Stock Plan, as amended (the “2004 Director Plan”), is a nonqualified plan that provides for the granting of options with respect to 3,000,000 shares of our Common Stock and, prior to the Recapitalization, 500,000 shares of our former class B common stock. The 2004 Director Plan provides for grants of nonqualified stock options to each of our directors who we do not employ. Beginning in 2018, on the date of each annual meeting of shareholders, options to purchase shares of Common Stock equal to an aggregate grant date fair value of $100,000 are granted to each non-employee director that is elected or retained as a director at each such meeting. Stock options vest approximately one year following the date of grant and option terms are generally the earlier of ten years following the date of grant, or three years from the termination of the outside director’s service. At December 31, 2020, there were 830,419 shares of Common Stock available for issuance pursuant to future grants under the 2004 Director Plan. We have accounted for grants of 2,169,581 shares of Common Stock under the 2004 Director Plan using the date of grant as the measurement date for financial accounting purposes.

 

Our 2006 Equity Incentive Plan (the “2006 Equity Incentive Plan”), as amended, provides for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of Common Stock and, prior to the Recapitalization, 300,000 shares of our former class B common stock. Stock options granted may be either incentive stock options or nonqualified stock options. Vesting terms vary with each grant and option terms are generally five to ten years following the date of grant. At December 31, 2020, there were 779,800 shares of Common Stock available for issuance pursuant to future grants under the 2006 Equity Incentive Plan. We have accounted for grants of 1,020,200 shares of Common Stock and restricted stock under the 2006 Equity Incentive Plan using the date of grant as the measurement date for financial accounting purposes.

 

48
Table of Contents
 

During 2020, 2019 and 2018, we granted options to purchase 70,471, 100,615 and 116,276 shares of Common Stock, respectively. Options to purchase shares of common stock are typically granted with exercise prices equal to the fair value of the common stock on the date of grant. We do, in certain limited situations, grant options with exercise prices that exceed the fair value of the common shares on the date of grant. The fair value of stock options granted was estimated using a Black-Scholes valuation model with the following weighted average assumptions:

 

  

2020

  

2019

  

2018

 
  

Common

Stock

  

Common

Stock

  

Common

Stock

 

Expected dividend yield at date of grant

  1.84

%

  2.60

%

  2.59

%

Expected stock price volatility

  33.62

%

  34.01

%

  32.47

%

Risk-free interest rate

  1.35

%

  2.38

%

  2.51

%

Expected life of options (in years)

  7.39   7.46   7.28 

 

The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of our stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years we estimate that options will be outstanding. We consider groups of associates that have similar historical exercise behavior separately for valuation purposes.

 

The following table summarizes stock option activity under the 2001 and 2006 Equity Incentive Plans and the 2004 Director Plan for the year ended December 31, 2020:

 

  

Number of
Options

  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Contractual

Terms

(Years)

  

Aggregate

Intrinsic

Value

(In

thousands)

 

Common Stock

                

Outstanding at December 31, 2019

  1,245,922  $18.08         

Granted

  70,471  $62.23         

Exercised

  (630,373

)

 $14.20      $25,912 

Forfeited

  (85,449) $32.28         

Outstanding at December 31, 2020

  600,571  $25.31   5.58  $11,665 

Exercisable at December 31, 2020

  270,876  $18.00   4.14  $6,811 

 

The following table summarizes information related to stock options for the years ended December 31, 2020, 2019 and 2018:

 

  

2020

  

2019

  

2018

 
  

Common

Stock

  

Common

Stock

  

Common

Stock

 

Weighted average grant date fair value of stock options granted

 $18.67  $11.99  $10.02 

Intrinsic value of stock options exercised (in thousands)

 $25,912  $8,280  $10,621 

Intrinsic value of stock options vested (in thousands)

 $1,965  $1,891  $2,719 

 

As of December 31, 2020, the total unrecognized compensation cost related to non-vested stock option awards was approximately $1.4 million which was expected to be recognized over a weighted average period of 2.96 years.

 

There was $1.7 million in cash received from stock options exercised for the year ended December 31, 2020 and no cash received from options exercised in 2019 or 2018. We recognized $680,000, $934,000 and $1.1 million of non-cash compensation for the years ended December 31, 2020, 2019, and 2018, respectively, related to options, which is included in direct and selling, general and administrative expenses. The actual tax benefit realized for the tax deduction from stock options exercised was $6.3 million, $2.0 million and $3.8 million for the years ended December 31, 2020, 2019 and 2018, respectively.

 

49
Table of Contents
 

During 2019 and 2018, we granted 6,005 and 6,793 non-vested shares of Common Stock, respectively, under the 2006 Equity Incentive Plan. No shares of non-vested Common Stock were granted during the year ended December 31, 2020. As of December 31, 2020, we had 6,005 non-vested shares of Common Stock outstanding under the 2006 Equity Incentive Plan. These shares vest over five years following the date of grant and holders thereof are entitled to receive dividends from the date of grant, whether or not vested. The fair value of the awards is calculated as the fair market value of the shares on the date of grant. We recognized $23,000, $290,000 and $428,000 of non-cash compensation for the years ended December 31, 2020, 2019, and 2018, respectively, related to this non-vested stock, which is included in direct and selling, general and administrative expenses. The actual tax benefit realized for the tax deduction from vesting of restricted stock was $235,000 and $168,000 for the years ended December 31, 2020 and 2018, respectively. No restricted stock vested during the year end December 31, 2019.

 

The following table summarizes information regarding non-vested stock granted to associates under the 2006 Equity Incentive Plans for the year ended December 31, 2020:

 

  

Common Stock

Outstanding

  

Common Stock

Weighted

Average Grant

Date Fair Value

Per Share

 

Outstanding at December 31, 2019

  84,176  $17.23 

Granted

  --  $-- 

Vested

  (71,378) $13.59 

Forfeited

  (6,793) $36.80 

Outstanding at December 31, 2020

  6,005  $38.30 

 

As of December 31, 2020, the total unrecognized compensation cost related to non-vested stock awards was approximately $138,000 and is expected to be recognized over a weighted average period of 3.00 years.

 
 

(10)

Leases

 

We lease printing, computer, other equipment and office space in the United States and Canada. The leases remaining terms as of December 31, 2020 range from less than one year to 4.7 years.

 

Certain equipment and office lease agreements include provisions for periodic adjustments to rates and charges. The rates and charges are adjusted based on actual usage or actual costs for internet, common area maintenance, taxes or insurance, as determined by the lessor and are considered variable lease costs.

 

The components of lease expense for the years ended December 31, 2020 and 2019 included (in thousands):

 

  

2020

  

2019

 

Operating leases

 $600  $781 

Finance leases:

        

Asset amortization

  355   252 

Interest on lease liabilities

  37   39 

Variable lease cost

  62   86 

Short-term lease cost

  42   42 

Total net lease cost

 $1,096  $1,200 

 

In 2020, we adjusted the useful life of the operating right of use assts associated with our Atlanta, Georgia and Markham, Ontario office leases based on the expectation that we will vacate the office space before the end of the lease term. We recorded rent expense in connection with our operating leases of $779,000 in 2018.

 

50
Table of Contents
 

Supplemental balance sheet information related to leases (in thousands):     

 

  

December 31,

2020

  

December 31,

2019

 

Operating leases:

        

Operating ROU assets

 $1,308  $1,628 
         

Current operating lease liabilities

  461   524 

Noncurrent operating lease liabilities

  896   1,139 

Total operating lease liabilities

 $1,357  $1,663 

 

  

December 31,

2020

  

December 31,

2019

 

Finance leases:

        

Furniture and equipment

 $1,014  $802 

Computer Equipment

  662   511 

Computer Software

  207   207 

Property and equipment under finance lease, gross

  1,883   1,520 

Less accumulated amortization

  (605

)

  (734

)

Property and equipment under finance lease, net

 $1,278  $786 
         

Current obligations of finance leases

 $493  $227 

Noncurrent obligations of finance leases

  778   559 

Total finance lease liabilities

 $1,271  $786 
         
Weighted average remaining lease term (in years):        
Operating leases  3.68   4.17 
Finance leases  2.69   3.56 
         
Weighted average discount rate:        
Operating leases  4.40%  4.81%
Finance leases  3.38%  4.60%

 

Supplemental cash flow and other information related to leases were as follows (in thousands):

 

  

2020

  

2019

 

Cash paid for amounts included in the measurement of lease liabilities:

        

Operating cash flows from operating leases

 $596  $789 

Operating cash flows from finance leases

  36   38 

Financing cash flows from finance leases

  332   229 
         

ROU assets obtained in exchange for operating lease liabilities

  276   16 

ROU assets obtained in exchange for finance lease liabilities

  817   192 

 

Undiscounted payments under non-cancelable finance and operating leases at December 31, 2020 were as follows (in thousands):

 

  

Finance Leases

  

Operating Leases

 

2021

 $527  $509 

2022

  481   322 

2023

  305   319 

2024

  13   203 

2025

  --   118 

Thereafter

  --   -- 

Total minimum lease payments

  1,326   1,471 

Less: Amount representing interest

  (55

)

  (114

)

Present value of minimum lease payments

  1,271   1,357 

Current portion

  (493

)

  (461

)

Lease obligations, net of current portion

 $778  $896 

 

In addition to the above, we have an operating lease for office space commencing February 2021 which requires monthly base rent payments of $14,288 through January 2024. 

 

51
Table of Contents
 
 

(11)

Related Party

 

Until January 2020, one of our directors served as an officer and director of Ameritas Life Insurance Corp. (“Ameritas”) and continues to service on the board of directors of Ameritas. In connection with our regular assessment of our insurance-based associate benefits, which is conducted by an independent insurance broker, and the costs associated therewith, we purchase dental and vision insurance for certain of our associates from Ameritas. The total value of these purchases was $248,000, $242,000 and $200,000 in 2020, 2019 and 2018 respectively.

 

A director, who served on our board through May 2020, also served as a board member of IMA Financial Group. In connection with our regular assessment of our liability coverage, during 2020 we began purchasing directors and officers and employment practices liability insurance through IMA Financial Group. Total payments for these services totaled $1.1 million with $478,000 recorded as expense in 2020.

 

During 2017, we acquired a cost method investment in convertible preferred stock of PX (see Note 4). Also in 2017, we paid $250,000 to acquire certain perpetual content licenses from PX for content we include in certain of our subscription services. We also have an agreement with PX which commenced in 2016 under which we act as a reseller of PX services and receive a portion of the revenues. The total revenue earned from the PX reseller agreement in the years ended December 31, 2020, 2019 and 2018 was $294,000, $578,000 and $439,000, respectively. We will no longer earn revenue under this agreement after September 30, 2021 due to termination of the reseller agreement.

 
 

(12)

Associate Benefits

 

We sponsor a qualified 401(k) plan covering substantially all associates with no eligibility service requirement. Under the 401(k) plan, we match 25.0% of the first 6.0% of compensation contributed by each associate. Employer contributions, which are discretionary, vest to participants at a rate of 20% per year. We contributed $521,000, $447,000 and $396,000 in 2020, 2019 and 2018, respectively, as a matching percentage of associate 401(k) contributions.

 
 

(13)

Segment Information

 

Our six operating segments are aggregated into one reporting segment because they have similar economic characteristics and meet the other aggregation criteria from the FASB guidance on segment disclosure. The six operating segments are Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Transitions, which offer a portfolio of solutions that address specific needs around market insight, experience, transparency and governance for healthcare providers, payers and other healthcare organizations.

 

The table below presents entity-wide information regarding our revenue and assets by geographic area (in thousands):

 

   

2020

    

2019

    

2018

  

Revenue:

                        

United States

   $ 130,305     $ 124,369     $ 115,451  

Canada

     2,972       3,613       4,235  

Total

   $ 133,277     $ 127,982     $ 119,686  

Long-lived assets:

                        

United States

   $ 77,448     $ 78,906     $ 77,330  

Canada

     1,863       2,622       2,291  

Total

   $ 79,311     $ 81,528     $ 79,621  

Total assets:

                        

United States

   $ 128,319     $ 95,668     $ 91,080  

Canada

     5,104       15,017       16,952  

Total

   $ 133,423     $ 110,685     $ 108,032  

 
 

(14)

Subsequent Event

 

On January 4, 2021, we acquired substantially all assets and assumed certain liabilities of PatientWisdom, Inc., a company with a health engagement solution that will further our purpose of operationalizing human understanding through tangible and actionable insights. $3.0 million of the total $5.0 million all-cash consideration was paid at closing. We are required to pay the remaining $2.0 million no later than February 1, 2022, subject to offset for indemnification claims as provided in the purchase agreement. The closing payment was funded, and we expect to fund the deferred portion of the purchase price, with cash on hand.

 

52
Table of Contents
 

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

Not applicable.

 

Item 9A.

Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

In accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), our management evaluated, with the participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2020. Based upon their evaluation of these disclosure controls and procedures, the Chief Executive Officer and the Chief Financial Officer concluded that the disclosure controls and procedures were effective as of December 31, 2020.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, however, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies of procedures may deteriorate.

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our internal control over financial reporting using the framework in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on such evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2020.

 

The effectiveness of our internal control over financial reporting as of December 31, 2020, has been audited by KPMG LLP, an independent registered public accounting firm, as stated in their report, a copy of which is included in this Annual Report on Form 10-K.

 

Changes in Internal Control over Financial Reporting

 

There was no change in our internal control over financial reporting that occurred during the quarter ended December 31, 2020, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B.

Other Information

 

We have no other information to report pursuant to this item.

 

53
Table of Contents

 

PART III

 

Item 10.

Directors, Executive Officers and Corporate Governance

 

The information required by this Item with respect to directors, executive officers and Section 16 compliance is included under the captions “Election of Directors,” “Corporate Governance – Committees”, “Information About Our Executive Officers” and “Delinquent Section 16(a) Reports,” respectively, in our definitive Proxy Statement for our 2021 Annual Meeting of Shareholders (“Proxy Statement”) and is hereby incorporated herein by reference. The information required by this Item with respect to audit committees and audit committee financial experts is included under the caption “Corporate Governance” in the Proxy Statement and is incorporated herein by reference.

 

We have adopted a Code of Business Conduct and Ethics that applies to all of our associates, including our Chief Executive Officer and Chief Financial Officer and other persons performing similar functions. We have posted a copy of the Code of Business Conduct and Ethics on our website at www.nrchealth.com, and such Code of Business Conduct and Ethics is available, in print, without charge, to any shareholder who requests it from our Secretary. We intend to satisfy the disclosure requirements under Item 5.05 of Form 8-K regarding amendments to, or waivers from, the Code of Business Conduct and Ethics by posting such information on our website at www.nrchealth.com. We are not including the information contained on our website as part of, or incorporating it by reference into, this report.

 

Item 11. 

Executive Compensation

 

The information required by this Item is included under the captions “Compensation Discussion and Analysis,” “2020 Summary Compensation Table,” “Grants of Plan-Based Awards in 2020,” “Outstanding Equity Awards at December 31, 2020,” “2020 Director Compensation,” “Compensation Committee Report,” “Corporate Governance-Transactions with Related Persons,” “Compensation Committee Interlocks and Insider Participation” and “CEO Pay Ratio” in the Proxy Statement and is hereby incorporated herein by reference.

 

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

 

The information required by this Item with respect to security ownership of certain beneficial owners and management is included under the caption “Principal Shareholders” in the Proxy Statement and is hereby incorporated by reference.

 

The following table sets forth information with respect to compensation plans under which equity securities of the Company are authorized for issuance as of December 31, 2020.

 

Plan Category Common Shares

  

Number of

securities

to be issued

upon

the exercise of

outstanding

options,

warrants and

rights

    

Weighted-

average

exercise price

of

outstanding

options,

warrants and

rights

    

Number of

securities

remaining available

for future issuance

under equity

compensation

plans (excluding

securities

reflected

in the first

column)

  

Equity compensation plans approved by security holders(1)

     600,571     $ 25.31       1,610,219  (2)

Equity compensation plans not approved by security holders

     --       --       --  

Total

     600,571     $ 25.31       1,610,219  

 

 

(1)

Includes our 2006 Equity Incentive Plan, 2004 Director Plan, and the 2001 Equity Incentive Plan.
 

(2)

Under the 2006 Equity Incentive Plan, we had authority to award up to 331,874 additional shares of restricted Common Stock provided that the total of such shares awarded may not exceed the total number of shares remaining available for issuance under the 2006 Equity Incentive Plan, which totaled 779,800 shares of Common Stock as of December 31, 2020. The Director Plan provides for granting options for 3,000,000 shares of Common Stock. Option awards through December 31, 2020 totaled 2,169,581 shares of Common Stock. No future awards are available under the 2001 Equity Incentive Plan due to its expiration. 

 

54
Table of Contents

 

Item 13.

Certain Relationships and Related Transactions, and Director Independence

 

The information required by this Item is included under the caption “Corporate Governance” in the Proxy Statement and is hereby incorporated by reference.

 

Item 14.

Principal Accountant Fees and Services

 

The information required by this Item is included under the caption “Miscellaneous — Independent Registered Public Accounting Firm” in the Proxy Statement and is hereby incorporated by reference.

 

55
Table of Contents

 

PART IV

 

Item 15.

Exhibits, Financial Statement Schedules

 

1.

Consolidated financial statements. The consolidated financial statements listed in the accompanying index to the consolidated financial statements are filed as part of this Annual Report on Form 10-K.

 

2.

Financial statement schedules. All financial statement schedules have been omitted because they are not applicable or the required information is included in the consolidated financial statements and the related notes thereto.

 

3.

Exhibits. The exhibits listed in the exhibit index below are filed as part of this Annual Report on Form 10-K.

 

EXHIBIT INDEX

 

Exhibit
Number

Exhibit Description
   

(3.1)

Amended and Restated Articles of Incorporation of National Research Corporation, effective as of 5:01 pm, CT, on April 17, 2018 [Incorporated by reference to Exhibit 3.3 to National Research Corporation’s Current Report on Form 8-K dated April 16, 2018 and filed on April 20, 2018 (File No. 001-35929)] 
   

(3.2)

By-Laws of National Research Corporation, as amended to date [Incorporated by reference to Exhibit 3.1 to National Research Corporation’s Current Report on Form 8-K dated May 14, 2020 and filed on May 15, 2020 (File No. 001-35929)]
   

(4.1)

Amended and Restated Articles of Incorporation of National Research Corporation, effective as of 5:01 pm, CT, on April 17, 2018 [Incorporated by reference to Exhibit 3.3 to National Research Corporation’s Current Report on Form 8-K dated April 16, 2018 and filed on April 20, 2018 (File No. 001-35929)] 
   

(4.2)

By-Laws of National Research Corporation, as amended to date [Incorporated by reference to Exhibit 3.1 to National Research Corporation’s Current Report on Form 8-K dated May 14, 2020 and filed on May 15, 2020 (File No. 001-35929)]
   

(4.3)

Description of the Securities of the Registrant [Incorporated by reference to Exhibit 4.3 to National Research Corporation’s Annual Report on Form 10-K for the year ended December 31, 2019 and filed on March 6, 2020 (File No. 001-35929)]
   

(10.1)

Amended and Restated Credit Agreement dated May 28, 2020, between National Research Corporation and First National Bank of Omaha [Incorporated by reference to Exhibit 10.1 to National Research Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and filed on August 7, 2020 (File No. 001-35929)]
   

(10.2)*

National Research Corporation 2004 Non-Employee Director Stock Plan, as amended [Incorporated by reference to Appendix A to National Research Corporation’s Proxy Statement for the 2018 Annual Meeting of Shareholders filed on April 27, 2018 (File No. 001-35929)]
   

(10.3)*

Form of Nonqualified Stock Option Agreement (for new associates) used in connection with the National Research Corporation 2001 Equity Incentive Plan [Incorporated by reference to Exhibit 4.4 to National Research Corporation’s Registration Statement on Form S-8 (Registration No. 333-120530) filed on November 16, 2004]
   

(10.4)*

Form of Nonqualified Stock Option Agreement (for officers) used in connection with the National Research Corporation 2001 Equity Incentive Plan [Incorporated by reference to Exhibit 4.5 to National Research Corporation’s Registration Statement on Form S-8 (Registration No. 333-120530) filed on November 16, 2004]
   

(10.5)*

Form of Restricted Stock Agreement for executive officers used in connection with the National Research Corporation 2001 Equity Incentive Plan [Incorporated by reference to Exhibit 10.2 to National Research Corporation’s Current Report on Form 8-K dated March 19, 2005 and filed on March 23, 2005 (File No. 000-29466)]

 

56
Table of Contents

 

Exhibit
Number

Exhibit Description

 

(10.6)*

Form of Restricted Stock Agreement (one year vesting) used in connection with the National Research Corporation 2001 Equity Incentive Plan [Incorporated by reference to Exhibit 4.6 to National Research Corporation’s Registration Statement on Form S-8 (Registration No. 333-120530) filed on November 16, 2004]

 

(10.7)*

Form of Restricted Stock Agreement (five year vesting) used in connection with the National Research Corporation 2001 Equity Incentive Plan [Incorporated by reference to Exhibit 4.7 to National Research Corporation’s Registration Statement on Form S-8 (Registration No. 333-120530) filed on November 16, 2004]
   

(10.8)*

Form of Nonqualified Stock Option Agreement used in connection with the National Research Corporation 2006 Equity Incentive Plan [Incorporated by reference to Exhibit (10.14) to National Research Corporation’s Annual Report on Form 10-K for the year ended December 31, 2006 and filed on April 2, 2007 (File No. 000-29466)]
   

(10.9)*

Form of Restricted Stock Agreement used in connection with the National Research Corporation 2006 Equity Incentive Plan [Incorporated by reference to Exhibit (10.15) to National Research Corporation’s Annual Report on Form 10-K for the year ended December 31, 2006 and filed on April 2, 2007 (File No. 000-29466)]
   

(10.10)*

National Research Corporation 2001 Equity Incentive Plan [Incorporated by reference to Appendix A to National Research Corporation’s Proxy Statement for the 2002 Annual Meeting of Shareholders filed on April 3, 2002 (File No. 000-29466)]]
   

(10.11)*

National Research Corporation 2006 Equity Incentive Plan, [Incorporated by reference to Appendix A to National Research Corporation’s Proxy Statement for the 2006 Annual Meeting of Shareholders filed on April 3, 2006 (File No. 000-29466)]
   

(10.12)*

Form of Grant used in connection with the National Research Corporation 2004 Non-Employee Director Stock Plan, as amended [Incorporated by reference to Exhibit 10.2 to National Research Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and filed on August 7, 2020 (File No. 001-35929)]
   

(21)**

Subsidiary of National Research Corporation
   

(23)**

Consent of Independent Registered Public Accounting Firm
   

(31.1)**

Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   

(31.2)**

Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   

(32)**

Certification of Periodic Financial Report by the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   
   

(101)**

Financial statements from the Annual Report on Form 10-K of National Research Corporation for the year ended December 31, 2020, formatted in Inline eXtensible Business Reporting Language (iXBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Income, (iii) Consolidated Statements of Comprehensive Income, (iv) Consolidated Statements of Shareholders’ Equity, (v) the Consolidated Statements of Cash Flows, (vi) the Notes to the Consolidated Financial Statements, and (vii) document and entity information.

 

(104)**

Cover Page Interactive Data File (formatted in the Inline XBRL and contained in Exhibit 101).

 

*

A management contract or compensatory plan or arrangement.

 

**

Filed herewith.

 

Item 16.

Form 10-K Summary

 

None.

 

57
Table of Contents

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

 

Page in

this
Form 10-K
   

Report of Independent Registered Public Accounting Firm

27
   

Consolidated Balance Sheets as of December 31, 2020 and 2019

29
   

Consolidated Statements of Income for the Three Years Ended December 31, 2020

30
   

Consolidated Statements of Comprehensive Income for the Three Years Ended December 31, 2020

31
   

Consolidated Statements of Shareholders’ Equity for the Three Years Ended December 31, 2020

32
   

Consolidated Statements of Cash Flows for the Three Years Ended December 31, 2020

33
   

Notes to Consolidated Financial Statements

34

 

 

All other financial statement schedules are omitted since the required information is not present or is not present in amounts sufficient to require submission of the schedules, or because the information required is included in the consolidated financial statements and notes thereto.

 

58
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 5th day of March 2021.

 

 

NATIONAL RESEARCH CORPORATION

  
       
 

By:

/s/ Michael D. Hays

  
   

Michael D. Hays

  
   

Chief Executive Officer and President

  

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

 

Signature

  

Title

  

Date
         

/s/ Michael D. Hays

  

Chief Executive Officer, President and Director

  

March 5, 2021

Michael D. Hays

  

(Principal Executive Officer)

    
         
         

/s/ Kevin R. Karas

  

Senior Vice President Finance, Chief Financial

  

March 5, 2021

Kevin R. Karas

  

Officer, Treasurer and Secretary (Principal

    
   

Financial and Accounting Officer)

    
         

/s/ Donald M. Berwick

  

Director

  

March 5, 2021

Donald M. Berwick

        
         

/s/ JoAnn M. Martin

  

Director

  

March 5, 2021

JoAnn M. Martin

        
         

/s/ John N. Nunnelly

  

Director

  

March 5, 2021

John N. Nunnelly

        

 

59
EX-21 2 ex_228150.htm EXHIBIT 21 ex_228150.htm

Exhibit 21

 

Subsidiary of National Research Corp.

 

 National Research Corporation’s subsidiary as of December 31, 2020 is listed below:

 

Subsidiary

Jurisdiction of organization
   

National Research Corporation Canada 

Ontario

 

 
 EX-23 3 ex_228151.htm EXHIBIT 23 ex_228151.htm

Exhibit 23

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors

National Research Corporation:

 

We consent to the incorporation by reference in the registration statements (File Nos. 333-120530, 333-137763, 333-137769, 333-173097, 333-189139, 333-189140, 333-189141, 333-209934, 333-226715, and 333-226716) on Forms S-8 and (File Nos. 333-120529, 333-211190, and 333-232534) on Forms S-3 of National Research Corporation of our report dated March 5, 2021, with respect to the consolidated balance sheets of National Research Corporation and subsidiary as of December 31, 2020 and 2019, and the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes, and the effectiveness of internal control over financial reporting as of December 31, 2020, which report appears in the December 31, 2020 annual report on Form 10-K of National Research Corporation.

 

 

 

 

/s/ KPMG LLP

 

Lincoln, Nebraska

March 5, 2021

 

 

 

 
 EX-31.1 4 ex_228152.htm EXHIBIT 31.1 ex_228152.htm

Exhibit 31.1

 

Certification of Chief Executive Officer

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

 

I, Michael D. Hays, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of National Research Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 Date: March 5, 2021

By:

/s/ Michael D. Hays

 

 

 

Michael D. Hays

 

 

 

Chief Executive Officer and President

 

 

 
 EX-31.2 5 ex_228153.htm EXHIBIT 31.2 ex_228153.htm

Exhibit 31.2

 

Certification of Chief Financial Officer

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

 

I, Kevin R. Karas, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of National Research Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 Date: March 5, 2021

By:

/s/ Kevin R. Karas

 

 

 

Kevin R. Karas

 

 

 

Chief Financial Officer

 

 

 
 EX-32 6 ex_228154.htm EXHIBIT 32 ex_228154.htm

Exhibit 32

 

 

Certification Pursuant to 18 U.S.C. Section 1350
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the accompanying Annual Report on Form 10-K of National Research Corporation (the “Company”) for the year ended December 31, 2020 (the “Report”), I, Michael D. Hays, Chief Executive Officer and President of the Company, and I, Kevin R. Karas, Chief Financial Officer, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, based on my knowledge, that:

 

 

1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

 

2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

/s/ Michael D. Hays

 

 

 

Michael D. Hays

 

 

 

Chief Executive Officer and President

 

 

 

 

 

 

/s/ Kevin R. Karas

 

 

 

Kevin R. Karas

 

 

 

Chief Financial Officer

 

 

    Date: March 5, 2021  

 

 

 

A signed original of this written statement required by Section 906 has been provided to National Research Corporation and will be retained by National Research Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

 

 
 EX-101.SCH 7 nrc-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Income link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Comprehensive Income link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 1 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 2 - Recapitalization link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 3 - Contracts With Customers link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 4 - Equity Investments link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 5 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 6 - Goodwill and Intangible Assets link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 7 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 8 - Notes Payable link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 9 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 10 - Leases link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 11 - Related Party link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 12 - Associate Benefits link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 13 - Segment Information link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 14 - Subsequent Event link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 3 - Contracts With Customers (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 5 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 6 - Goodwill and Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 7 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 8 - Notes Payable (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 9 - Share-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 10 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 13 - Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 2 - Recapitalization (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 3 - Contracts With Customers 1 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 3 - Contracts With Customers 2 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 3 - Contracts With Customers - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 4 - Equity Investments (Details Textual) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 5 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 6 - Goodwill and Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 7 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 7 - Income Taxes - Income Before Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 7 - Income Taxes - Income Tax Expense (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 7 - Income Taxes - Income Tax Reconciliation (Details) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 8 - Notes Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 8 - Notes Payable - Summary of Notes Payable (Details) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note 9 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note 9 - Share-based compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note 9 - Share-based Compensation - Non-vested Stock (Details) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note 10 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note 10 - Leases - Lease Expense (Details) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details) link:calculationLink link:definitionLink link:presentationLink 066 - Disclosure - Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) link:calculationLink link:definitionLink link:presentationLink 067 - Disclosure - Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details) link:calculationLink link:definitionLink link:presentationLink 068 - Disclosure - Note 11 - Related Party (Details Textual) link:calculationLink link:definitionLink link:presentationLink 069 - Disclosure - Note 12 - Associate Benefits (Details Textual) link:calculationLink link:definitionLink link:presentationLink 070 - Disclosure - Note 13 - Segment Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 071 - Disclosure - Note 13 - Segment Information - Assets by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 072 - Disclosure - Note 14 - Subsequent Event (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 nrc-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 nrc-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 nrc-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Expected dividend yield at date of grant Note To Financial Statement Details Textual Significant Accounting Policies Note 1 - Summary of Significant Accounting Policies Expected federal income taxes Note 3 - Contracts With Customers Risk-free interest rate Note 5 - Property and Equipment Note 6 - Goodwill and Intangible Assets Note 7 - Income Taxes Note 8 - Notes Payable Note 9 - Share-based Compensation Note 10 - Leases Income Tax Disclosure [Text Block] Note 13 - Segment Information Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) Nondeductible expenses (income) related to recapitalization Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to recapitalization. us-gaap_SelfInsuranceReserveCurrent Self Insurance Reserve, Current Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) nrc_DebtInstrumentPercentageBearingVariableInterestPercentageRate Debt Instrument, Percentage Bearing Variable Interest, Percentage Rate The interest rate applicable to the portion of the carrying amount of debt instrument borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time. Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details) Expected stock price volatility us-gaap_LiabilitiesCurrent Total current liabilities Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) Schedule of Maturities of Long-term Debt [Table Text Block] Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details) Schedule of Debt [Table Text Block] Note 3 - Contracts With Customers - Disaggregation of Revenue (Details) Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) Other current liabilities Note 5 - Property and Equipment - Summary of Property and Equipment (Details) Expected life of options (in years) (Year) Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) us-gaap_BusinessCombinationConsiderationTransferred1 Business Combination, Consideration Transferred, Total Lease, Cash flow [Table Text Block] Tabular disclosure of supplemental cash flow and other information related to leases. Note 7 - Income Taxes - Income Before Income Taxes (Details) Note 7 - Income Taxes - Income Tax Expense (Details) nrc_GainOnPropertyInsuranceRecoveries Gain on insurance recoveries for damaged property The net amount by which an insurance settlement exceeds net book value of property damaged from an event, such as a natural catastrophe, explosion or fire. Note 7 - Income Taxes - Income Tax Reconciliation (Details) Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Settlement of class B common shares in connection with recapitalization, shares exchanged (in shares) Represents the number of Class B shares settled and exchanged in connection with a recapitalization. Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details) us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred Business Combination, Consideration Transferred, Liabilities Incurred Note 8 - Notes Payable - Summary of Notes Payable (Details) Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details) Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details) Insurance recoveries The amount recovered from insurance for lost revenues that are reported as a separate line item. Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) Share-based Payment Arrangement, Activity [Table Text Block] Note 9 - Share-based compensation - Stock Option Activity (Details) Cumulative translation adjustment Other comprehensive income, foreign currency translation adjustment Note 9 - Share-based Compensation - Non-vested Stock (Details) Vested (in dollars per share) Note 10 - Leases - Lease Expense (Details) Forfeited (in dollars per share) Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Outstanding (in dollars per share) Outstanding (in dollars per share) Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited (in shares) Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details) Note 13 - Segment Information - Assets by Geographic Area (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Outstanding (in shares) Outstanding (in shares) Notes To Financial Statements Notes To Financial Statements [Abstract] Schedule of Nonvested Share Activity [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested (in shares) First National Bank of Omaha [Member] Related to the entity First National Bank of Omaha. Recapitalization [Text Block] The complete disclosure of recapitalization of the company. Other comprehensive income (loss): Weighted average exercise price (in dollars per share) Exercisable, weighted average remaining contractual term (Year) Current portion of notes payable, net of unamortized debt issuance costs Exercisable, aggregate intrinsic value Exercised, aggregate intrinsic value us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance Exercisable, number of options (in shares) Outstanding, weighted average remaining contractual term (Year) Outstanding, aggregate intrinsic value Weighted average grant date fair value of stock options granted (in dollars per share) nrc_CostMethodInvestmentOwnershipPercentage Cost Method Investment, Ownership Percentage The percentage of ownership of common stock or equity participation in the investee accounted for under the cost method of accounting. us-gaap_GoodwillGross Goodwill, gross us-gaap_GoodwillImpairedAccumulatedImpairmentLoss Goodwill, accumulated impairment us-gaap_SecuredDebtCurrent Less: current portion us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Deferred revenue Deferred revenue Forfeited, weighted average exercise price (in dollars per share) Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Goodwill [Table Text Block] Granted, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) Accrued expenses Accrued wages and bonuses Income taxes payable Dividends payable Accounts payable Revolving Credit Facility [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding, number of options (in shares) Outstanding, number of options (in shares) Cash paid settlement of restricted common shares and stock options in connection with recapitalization Represents the amount of cash paid during the period related to the settlement of restricted common shares and stock options in connection with recapitalization. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Forfeited, number of options (in shares) Credit Facility [Axis] Credit Facility [Domain] us-gaap_PolicyTextBlockAbstract Accounting Policies Trade Names [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost Share-based Payment Arrangement, Accelerated Cost us-gaap_PaymentsToAcquireIntangibleAssets Payments to Acquire Intangible Assets Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Finance lease obligations originated for property and equipment us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Weighted average effect of dilutive securities – stock options (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) Weighted average shares and share equivalents outstanding Income taxes Current liabilities: us-gaap_Assets Total assets Total assets Estimated fair value of long-term debt Plan Name [Axis] Technology-Based Intangible Assets [Member] Plan Name [Domain] Compensation and Employee Benefit Plans [Text Block] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Net income attributable to common shareholders us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions Share-based Payment Arrangement, Exercise of Option, Tax Benefit Customer Relationships [Member] us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Amount of related income tax benefit Depreciation, amortization and impairment Depreciation, Amortization and Impairment The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets and the total loss recognized during the period from the impairment of goodwil Recoveries Received Direct by the Company [Member] Related to recoveries received direct by the company. Reimbursement for Lost Revenue [Member] Related to reimbursement for lost revenue. Recoveries Paid Directly by Insurer to Outside Vendor [Member] Related to recoveries paid directly by insurer to outside vendor. Share-based Payment Arrangement [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Direct, Selling, General and Administrative Expenses [Member] Related to direct, selling, general and administrative expenses. Property Damage Excluding Cyber Attack [Member] Related to property damage excluding cyber attack. Revenue Recognition [Member] Related to revenue Recognition. Income Tax Related to Revenue Adjustment [Member] Related to income tax related to revenue adjustment. Changes Related to Contract Costs, Income Tax Effect [Member] Related to the income tax effect of changes related to contract costs. Award Type [Domain] Award Type [Axis] us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Finite-lived intangible assets, accumulated amortization us-gaap_FiniteLivedIntangibleAssetsNet Finite-lived intangible assets, net Intangible assets, net Total intangible assets other than goodwill Numerator for net income per share - basic: Insurance proceeds for damaged property Proceeds from Insurance Settlement, Investing Activities us-gaap_FiniteLivedIntangibleAssetsGross Finite-lived intangible assets, gross Common Stock Options [Member] Related to common stock options. Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value, Intrinsic Value of Exercised and Vested in Period, and Fair Value of Vested in Period [Table Text Block] Tabular disclosure of the weighted-average grant-date fair value, aggregate intrinsic value of equity options exercised and intrinsic value and fair value of options vested. Share-based Payment Arrangement, Option [Member] us-gaap_GoodwillForeignCurrencyTranslationGainLoss Foreign currency translation us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Indefinite trade name us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation and amortization Less accumulated amortization Net property and equipment Net property and equipment Property and equipment under finance lease, net Goodwill Goodwill, Ending Balance Balance Balance us-gaap_PropertyPlantAndEquipmentGross Property and equipment at cost Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Net income Net income Net income Net income us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic Allocation of distributed and undistributed income to unvested restricted stock shareholders Leases of Lessee Disclosure [Text Block] Cash flows from investing activities: us-gaap_RevenueFromRelatedParties Revenue from Related Parties us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty Related Party Transaction, Expenses from Transactions with Related Party us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction CANADA Related Party Transactions Disclosure [Text Block] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income before income taxes Provision for income taxes Income Tax Expense (Benefit), Total us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay us-gaap_CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value, Total Cash and cash equivalents us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax Net (benefit) expense to net income us-gaap_AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense Accrued expenses, wages and bonuses The net change during the reporting period in the aggregate amount of expenses and accrued compensation incurred but not yet paid. Amendment Flag us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income City Area Code Use of Estimates, Policy [Policy Text Block] us-gaap_DebtInstrumentPeriodicPayment Debt Instrument, Periodic Payment, Total New Accounting Pronouncements, Policy [Policy Text Block] Shares of treasury stock purchased (in shares) us-gaap_IncreaseDecreaseInIncomeTaxes Income taxes receivable and payable us-gaap_IncreaseDecreaseInContractWithCustomerLiability Deferred revenue Common stock, shares outstanding (in shares) Financing Receivable, Allowance for Credit Loss [Table Text Block] Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Variable lease cost us-gaap_LeaseCost Total net lease cost us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Operating leases Document Fiscal Period Focus us-gaap_OperatingLeaseCost Operating leases Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Short-term lease cost Lease, Cost [Table Text Block] ROU assets obtained in exchange for finance lease liabilities Document Period End Date ROU assets obtained in exchange for operating lease liabilities Operating leases (Year) us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type us-gaap_AssetImpairmentCharges Asset Impairment Charges, Total Entity Small Business Entity Shell Company us-gaap_DividendsCommonStockCash Dividends declared Document Information [Line Items] Document Information [Table] Service [Member] Entity Public Float Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Entity Voluntary Filers Entity Well-known Seasoned Issuer London Interbank Offered Rate (LIBOR) [Member] us-gaap_CapitalizedComputerSoftwareAdditions Capitalized Computer Software, Additions Variable Rate [Domain] us-gaap_CapitalizedContractCostGross Capitalized Contract Cost, Gross us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use Uncertain tax positions The sum of the differences between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable uncertain tax positions. us-gaap_GoodwillImpairmentLoss Goodwill, Impairment Loss Impairment Variable Rate [Axis] Capitalized contract cost us-gaap_CapitalizedContractCostImpairmentLoss Capitalized Contract Cost, Impairment Loss us-gaap_IncreaseDecreaseInAccountsReceivable Trade accounts receivable Non-cash stock compensation expense Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key Capitalized Contract Cost [Axis] Entity Registrant Name Capitalized Contract Cost [Domain] Entity [Domain] us-gaap_CapitalizedContractCostAmortizationPeriod Capitalized Contract Cost, Amortization Period (Year) Legal Entity [Axis] Entity Address, Address Line One us-gaap_AmortizationOfIntangibleAssets Amortization of Intangible Assets, Total us-gaap_TreasuryStockValueAcquiredCostMethod Purchase of shares of treasury stock Entity Address, City or Town Entity Address, Postal Zip Code Supplemental disclosure of cash paid for: Entity Address, State or Province us-gaap_TreasuryStockValue Treasury stock, at cost; 5,384,186 Common shares in 2020 and 5,204,074 Common shares in 2019 us-gaap_AllowanceForDoubtfulAccountsReceivable Balance Balance Entity Common Stock, Shares Outstanding Trading Symbol Settlement of restricted common shares and stock options in connection with recapitalization (in shares) Represents the amount of shares issued during the period related to the settlement of restricted common shares and stock options in connection with recapitalization. Reserve for uncertain tax positions The current period expense charged against earnings to reserve for uncertain tax positions. Settlement of class B restricted common shares and stock options in connection with Recapitalization for cash of $3,271 and 90,369 class A common shares Represents the value related to the settlement of restricted common shares and stock options in connection with a recapitalization. nrc_PaymentsRelatedToRecapitalization Payments Related to Recapitalization Payments related to Recapitalization Represents the amount of payment made during the period related to recapitalization. nrc_StockRetiredDuringPeriodValueRecapitalization Retirement of 4,328,552 class B common shares in connection with Recapitalization Represents the value of the retirement of class b common shares in connection with a recapitalization. Settlement of class B common shares in connection with recapitalization, shares issued (in shares) Represents the amount of shares issued during the period related to the settlement of class B common shares in connection with recapitalization. Local Phone Number Settlement of class B common shares in connection with Recapitalization (3,527,246 class B common shares exchanged for $69,099 cash and 3,527,246 class A common shares) Represents the value associated with the settlement of Class B common shares in connection with a recapitalization. Shares of common stock issued for the exercise of stock option (in shares) Exercised, number of options (in shares) Purchasing Directors and Officers and Employment Practices Liability Insurance [Member] Represents information about purchasing directors and officers and employment practices liability insurance in a related party transaction. us-gaap_TableTextBlock Notes Tables IMA Financial Group [Member] Represents information pertaining to IMA Financial Group. Retirement of class B common shares in connection with recapitalization, shares retired (in shares) Represents the number of shares retired during the period related to recapitalization. us-gaap_GainLossOnDispositionOfAssets1 Loss on disposal of property and equipment us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) Forfeitures of restricted common shares (in shares) The 2001 Equity Incentive Plan [Member] Represents the 2001 equity incentive plan. Issuance of restricted common shares, net of forfeitures (in shares) us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Director Plan 2004 [Member] Represents the 2004 director plan. Issuance of common shares for the exercise of stock options us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Related Party [Axis] The 2006 Equity Incentive Plan [Member] Represents the 2006 Equity Incentive plan. Related Party [Domain] Trade Names 1 [Member] Rights acquired through registration of a business name to gain or protect exclusive use thereof. Ameritas Life Insurance Corp [Member] Represents information about related party. Selling, general and administrative Bad Debt Expense (Benefit) nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsCumulative Share-based Compensation Arrangement by Share-based Payment Award, Options Grants Cumulative (in shares) Gross number of share options (or share units) granted for plan to date. Granted, number of options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) Line of Credit Facility, Lender [Domain] Nonvested [Member] Information pertaining to nonvested shares. Collaborative Arrangement and Arrangement Other than Collaborative [Domain] nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Restricted Stock, Outstanding Number (in shares) Number of nonvested restricted shares outstanding. Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and shareholders’ equity us-gaap_InsuranceRecoveries Insurance Recoveries UNITED STATES Related Party Transaction [Axis] Related Party Transaction [Domain] Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans The value of stock tendered to the company for cashless exercise of stock options in connection with equity incentive plans. Retained earnings (accumulated deficit) Money Market Funds [Member] Debt Disclosure [Text Block] us-gaap_InterestExpense Interest expense nrc_ExcessLossCoveragePerPerson Excess Loss Coverage Per Person Amount of excess loss coverage per covered person related to self-insurance group medical and dental insurance. nrc_NumberOfCustomers Number of Customers Number of customers accounting for a substantial portion of one reporting unit's revenue. Change in assets and liabilities: Canadian Subsidiary [Member] Related to Canadian Subsidiary. Intrinsic value of stock options vested (in thousands) Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently vested. us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements nrc_StockOptionsExcludedFromComputationOfEarningsPerShareAmount Stock Options Excluded from Computation of Earnings Per Share, Amount (in shares) Stock options that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because the exercise price exceeds the fair market value. nrc_DeferredTaxLiabilitiesUnrealizedTranslationGainOnIntercompanyLoan Unrealized translation gain on intercompany loan The amount of deferred tax liabilities related to unrealized translation gain on intercompany loans. nrc_CumulativeTaxIncentives Cumulative Tax Incentives The amount of cumulative state tax incentives that reduced the operating expenses. Subsequent Event [Member] Operating lease obligations, net of current portion Total operating lease liabilities Operating Lease, Liability, Total Subsequent Event Type [Axis] Current operating lease liabilities Current portion, operating leases Subsequent Event Type [Domain] us-gaap_IncomeTaxCreditsAndAdjustments Income Tax Credits and Adjustments Current obligations of finance leases Current portion, finance leases Noncurrent obligations of finance leases Finance leases obligations, net of current portion us-gaap_IntangibleAssetsGrossExcludingGoodwill Total intangible assets other than goodwill Subsequent Events [Text Block] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Operating leases, total minimum lease payments Financing cash flows from finance leases Payments on finance lease obligations us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Operating leases, less: Amount representing interest us-gaap_FinanceLeaseLiability Present value of minimum finance lease payments Total finance lease liabilities us-gaap_DeferredIncomeTaxExpenseBenefit Deferred income taxes us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Operating leases, 2023 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Operating leases, 2024 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive Operating leases, 2025 Fair Value Measurement, Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Finite-Lived Intangible Asset, Expected Amortization, Year Two us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Finite-Lived Intangible Asset, Expected Amortization, Year Three nrc_DefinedContributionPlanMaximumPercentageOfAnnualContributionEmployeeSubjectToMatch Defined Contribution Plan, Maximum Percentage of Annual Contribution Employee Subject to Match Maximum percentage of employee gross pay, by the terms of the plan, that the employer may apply a percentage match contribution to a defined contribution plan. us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Operating leases, 2021 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Operating leases, 2022 Increases due to invoicing of client, net of amounts recognized as revenue Amount of increase in obligation to transfer good or service to customer due to billings to customer in excess of revenue us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Finite-Lived Intangible Asset, Expected Amortization, Year One Increases due to revenue recognized in the period with additional performance obligations before invoicing Amount of increase in right to consideration in exchange for good or service transferred to customer with right conditioned on satisfaction of other performance obligations. Accumulated other comprehensive loss, foreign currency translation adjustment Foreign Currency Transactions and Translations Policy [Policy Text Block] Deferred contract costs, net Capitalized Contract Cost, Net, Noncurrent Non-cash share-based compensation expense Other Lessee, Leases [Policy Text Block] Cyber Attack [Member] Represents cyber attack. us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-lived intangible assets, useful life (Year) Earnings Per Share, Policy [Policy Text Block] Including Assets Held under Capital Lease [Member] Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale, including long lived property, plant or equipment assets held by a lessee through a capital lease arrangement. Operating expenses: Income Tax, Policy [Policy Text Block] Common stock (formerly class A) issued in the Recapitalization in exchange for then-existing class B shares and options. us-gaap_ConversionOfStockSharesIssued1 Conversion of Stock, Shares Issued (in shares) Stock Conversion Description [Axis] Conversion of Stock, Name [Domain] us-gaap_AssetsCurrent Total current assets Assets, fair value Share-based Payment Arrangement [Policy Text Block] Income taxes receivable us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill Impairment of Intangible Assets (Excluding Goodwill), Total Treasury stock, shares (in shares) Common stock, $0.001 par value; authorized 60,000,000 shares, issued 30,775,154 in 2020 and 30,151,574 in 2019, outstanding 25,390,968 in 2020 and 24,947,500 in 2019 Adjustments to reconcile net income to net cash provided by operating activities: Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) us-gaap_DeferredTaxAssetsValuationAllowance Less valuation allowance Statistical Measurement [Domain] Operating cash flows from operating leases Maximum [Member] Supplemental disclosure of non-cash investing and financing activities: Commitments and Contingencies, Policy [Policy Text Block] Minimum [Member] Product and Service [Axis] Other current assets Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Deferred tax assets Statistical Measurement [Axis] nrc_SalesAndExciseTaxPayableReversalOfLiability Sales and Excise Tax Payable (Reversal of Liability) Amount of sales and excise tax payable (reversal of liability). Operating cash flows from finance leases Investment, Name [Domain] Deferred Charges, Policy [Policy Text Block] Nonqualified Stock Options [Member] Represents nonqualified stock options. us-gaap_OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net, Total Contract assets included in other current assets Preferred stock, shares issued (in shares) Interest expense, net of capitalized amounts Investment, Name [Axis] Prepaid expenses Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] us-gaap_DeferredTaxAssetsOther Other us-gaap_NoncurrentAssets Long-lived assets Geographical [Axis] Property, Plant and Equipment Disclosure [Text Block] Goodwill and Intangible Assets, Policy [Policy Text Block] Geographical [Domain] Property, Plant and Equipment [Table Text Block] us-gaap_DeferredTaxAssetsGross Gross deferred tax assets Preferred stock, shares authorized (in shares) us-gaap_DeferredIncomeTaxLiabilities Deferred tax liabilities Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Preferred stock, par value (in dollars per share) nrc_IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet Operating lease assets and liability, net Amount of increase (decrease) in operating lease assets after deduction of operating lease liabilities. us-gaap_ProceedsFromInsuranceSettlementOperatingActivities Proceeds from Insurance Settlement, Operating Activities Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value Hierarchy and NAV [Axis] Amortization of Capitalized Contract Cost [Table Text Block] Tabular disclosure of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer. us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Accrued expenses Cumulative Effect, Period of Adoption [Domain] Software and Software Development Costs [Member] Noncatastrophic Event [Domain] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption, Adjustment [Member] us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Cash flows from operating activities: Noncatastrophic Event [Axis] us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts Allowance for doubtful accounts Revenue [Policy Text Block] Statement [Line Items] Lessee, Lease, Balance Sheet Information [Table Text Block] Tabular disclosure of balance sheet information related lessee's lease . Allowance for doubtful accounts Furniture and Fixtures [Member] us-gaap_NumberOfOperatingSegments Number of Operating Segments Trade accounts receivable, less allowance for doubtful accounts of $120 and $144, respectively Accounts receivables us-gaap_NumberOfReportableSegments Number of Reportable Segments us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Share-based compensation Computer Software Held under Finance Leases [Member] Computer software held by a lessee through a finance lease arrangement. Building and Building Improvements [Member] WASHINGTON Computer Equipment Held under Finance Leases [Member] Computer equipment held by a lessee through a finance lease arrangement. us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses Accrued bonuses Furniture and Equipment Held under Finance Leases [Member] Furniture and equipment held by a lessee through a finance lease arrangement. Assets Held under Finance Leases [Member] Long lived property, plant or equipment assets held by a lessee through a finance lease arrangement. Lessee, Operating and Finance Lease, Liability, Maturity [Table Text Block] Tabular disclosure of undiscounted cash flows of lessee's operating and finance lease liability. AOCI Attributable to Parent [Member] Additional paid-in capital Shareholders’ equity: Land [Member] Leasehold Improvements [Member] Property, Plant and Equipment, Policy [Policy Text Block] Change in Accounting Principle, Type [Axis] Other, net Change in Accounting Principle, Type [Domain] Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total other income (expense) Long-Lived Tangible Asset [Domain] Segment Reporting Disclosure [Text Block] us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign Foreign tax credit from repatriation Current assets: Fair Value, by Balance Sheet Grouping [Table Text Block] nrc_AccruedLiabilitiesAndPrepaidExpensesNet Accrued Liabilities and Prepaid Expenses, Net Represents the net amount of accrued liabilities and prepaid expenses adjusted in transition to new lease standard. Deferred tax assets: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period us-gaap_ContractWithCustomerAssetReclassifiedToReceivable Decreases due to completion of services (or portion of services) and transferred to accounts receivable Interest income us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase (decrease) in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities us-gaap_Liabilities Total liabilities us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice Change due to cumulative catch-up adjustments arising from changes in expected contract consideration Director [Member] us-gaap_OperatingIncomeLoss Operating income us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities us-gaap_ContractWithCustomerLiabilityRevenueRecognized Revenue recognized that was included in deferred revenue at beginning of year due to completion of services us-gaap_DeferredTaxLiabilitiesOther Other Other income (expense): us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities us-gaap_DeferredTaxLiabilities Net deferred tax liabilities Effect of exchange rate changes on cash us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets Intangible assets Accounting Standards Update 2014-09 [Member] Deferred income taxes us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent Sales and Excise Tax Payable Consolidated Entities [Axis] Consolidated Entities [Domain] Accounting Standards Update [Domain] Direct us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment of employee payroll tax withholdings on share-based awards exercised us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Property and equipment us-gaap_DeferredTaxLiabilitiesPrepaidExpenses Prepaid expenses Accounting Standards Update [Axis] Deferred tax liabilities: us-gaap_PaymentsOfDividendsCommonStock Payment of dividends on common stock us-gaap_CostsAndExpenses Total operating expenses Direct Expenses [Member] Related to direct expenses. Retained Earnings [Member] Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Revenue Revenue Title of Individual [Domain] us-gaap_CurrentStateAndLocalTaxExpenseBenefit Current Title of Individual [Axis] Treasury Stock [Member] us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations Total us-gaap_CurrentForeignTaxExpenseBenefit Current us-gaap_DeferredForeignIncomeTaxExpenseBenefit Deferred nrc_IncrementalCostsOfObtainingAContractDeferredDuringPeriod Incremental Costs of Obtaining a Contract, Deferred During Period Represents the amount of incremental costs of obtaining a contract deferred during the period. Additional Paid-in Capital [Member] us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations Total Common Stock [Member] us-gaap_CurrentFederalTaxExpenseBenefit Current us-gaap_DeferredFederalIncomeTaxExpenseBenefit Deferred us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations Total Equity Components [Axis] Equity Component [Domain] Total carrying amount of long-term debt us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) us-gaap_RevenueRemainingPerformanceObligation Revenue, Remaining Performance Obligation, Amount Other Current Liabilities [Member] Other Noncurrent Liabilities [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Foreign Operations Other Current Assets [Member] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income before income taxes us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic U.S. Operations Tax depreciation method change Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in income taxes accrued due to a tax depreciation methodology change. us-gaap_LineOfCredit Long-term Line of Credit, Total us-gaap_PaymentsOfDebtIssuanceCosts Payment of debt issuance costs Timing of Transfer of Good or Service [Domain] Transferred at Point in Time [Member] us-gaap_DeferredFinanceCostsNet Less: unamortized debt issuance costs Transferred over Time [Member] us-gaap_SecuredDebt Term Loans Subscription Services [Member] Represents information pertaining to subscription services. Disaggregation of Revenue [Table Text Block] Insurance Recoveries [Policy Text Block] The disclosure for accounting policies related to insurance recoveries. Timing of Transfer of Good or Service [Axis] Unit Price Services [Member] Represents information pertaining to unit price services. Revenue from Contract with Customer [Text Block] Fixed, Non-subscription Services [Member] Represents information pertaining to fixed, non-subscription services. Document Annual Report Accounts Receivable [Policy Text Block] nrc_ChangeInTaxLawDeferralOfSocialSecurityTaxPayments Change in Tax Law, Deferral of Social Security Tax Payments The amount of deferral of social security tax payments due to a change in tax law. nrc_DeferredTaxAssetPriorYearForeignTaxCreditCarryforwardsWriteOff Deferred Tax Asset, Prior Year Foreign Tax Credit Carryforwards, Write Off The amount of prior year foreign tax credit carryforwards deferred tax assets and valuation allowance written off. Computer Equipment [Member] Cash and Cash Equivalents, Policy [Policy Text Block] Balance Sheet Location [Axis] Conversion of Class B Common Stock Into Class A Common Stock [Member] Represents information pertaining to the conversion of class B common stock into class A common stock. Balance Sheet Location [Domain] nrc_ConversionOfStockNumberOfSharesExchangedForEachShare Conversion of Stock, Number of Shares Exchanged for Each Share (in shares) Represents the number of shares of one class of stock exchanged for each share of another class of stock in a stock conversion transaction. Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits, Ending Balance Balance of unrecognized tax benefits Balance of unrecognized tax benefits us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Credit Agreement [Member] Represents information pertaining to a credit agreement, providing a revolving credit facility, term loan facility, and delayed draw-down term facility. Document Transition Report nrc_ConversionOfStockCashPaidPerShareConverted Conversion of Stock, Cash Paid Per Share Converted (in dollars per share) Represents the amount of cash paid to shareholders per share of stock converted in a stock conversion transaction. Term Loan [Member] Represents information pertaining to a term loan. us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations Reductions due to lapse of applicable statute of limitations Employer payroll tax deferral Amount before allocation of valuation allowances of deferred tax asset attributable to employer payroll tax deferral. Selling, General and Administrative Expenses [Member] Entity Interactive Data Current Dividends declared per common share (in dollars per share) us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities Reductions due to settlement with taxing authorities Delayed Draw Term Loan [Member] Represents information pertaining to a delayed draw term loan. Additions due to tax positions of prior years Security Exchange Name us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Additions based on tax positions related to the current year Title of 12(b) Security Write-offs us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued Unrecognized Tax Benefits, Interest on Income Taxes Accrued nrc_LesseeOperatingLeaseMonthlyBaseRentPayments Lessee, Operating Lease, Monthly Base Rent Payments The amount of monthly base rent payments for the operating lease of a lessee. Other Current Liabilities and Other Noncurrent Liabilities [Member] Primary financial statement caption encompassing other current liabilities and other noncurrent liabilities. Other Income [Member] PatientWisdom, Inc. [Member] Related to PatientWisdom, Inc. Income Statement Location [Axis] Income Statement Location [Domain] Settlement of class B common shares in connection with Recapitalization, cash exchanged Represents the amount of cash exchanged for shares during the period related to the settlement of class B common shares in connection with recapitalization. Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Compensation limit for covered employees Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation limits for covered employees. Changes Related to Contract Costs [Member] Represents information pertaining to changes related to contract costs. nrc_DeferredTaxLiabilitiesRepatriationWithholding Repatriation withholding Amount of deferred tax liability attributable to taxable temporary differences attributable to repatriation withholding. nrc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardAnnualOptionsGrantAmount Share Based Compensation Arrangement By Share Based Payment Award, Award Annual Options Grant Amount Represents the fair value granted for share based compensation arrangement to each non-employee director at the annual meeting. us-gaap_RepaymentsOfNotesPayable Payments on notes payable us-gaap_RepaymentsOfLinesOfCredit Payments on line of credit Weighted average shares and share equivalents outstanding, diluted (in shares) Denominator for diluted earnings per share – adjusted weighted average shares (in shares) Proceeds from issuance of note payable Borrowings on line of credit Asset Class [Axis] Asset Class [Domain] Statement [Table] Statement of Financial Position [Abstract] Diluted earnings per share (in dollars per share) Net income per share - diluted (in dollars per share) Weighted average shares and share equivalents outstanding, basic (in shares) Weighted average common shares outstanding – basic (in shares) Diluted earnings per share: Business Acquisition [Axis] Basic earnings per share (in dollars per share) Net income per share - basic (in dollars per share) us-gaap_CostMethodInvestments Cost Method Investments Business Acquisition, Acquiree [Domain] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Long-term Contract with Customer [Member] Basic earnings per share: Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Domain] Income Statement [Abstract] us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other comprehensive income (loss) us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2023 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour 2024 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive 2025 nrc_DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold Debt Instrument, Covenant, Exception, Fixed Charge Coverage Ratio, Dividend Threshold The maximum amount of quarterly dividends included in the fixed charge coverage calculation unless liquidity falls below a specified threshold. nrc_TaxBenefitRealizedRestrictedStockVested Tax Benefit Realized Restricted Stock Vested The tax benefit realized from the vesting of restricted stock during the period. us-gaap_LesseeOperatingLeaseRemainingLeaseTerm Lessee, Operating Lease, Remaining Lease Term (Year) us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2021 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2022 Interest on lease liabilities VoC Platform [Member] Represents the Voice of the Customer Platform. Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] us-gaap_FinanceLeaseLiabilityPaymentsDue Finance leases, total minimum lease payments Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Asset amortization Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] GILTI Provisional Tax Expense (Benefit) for Global Intangible Low Taxed Income Amount of tax expense (benefit) from the December 22, 2017 Tax Cut and Jobs Act related to the GILTI tax. Schedule of Deferred Tax Assets and Liabilities [Table Text Block] nrc_RevenueFromContractWithCustomerPercentOfTotalRevenue Revenue from Contract with Customer, Percent of Total Revenue The percent of total revenue from contracts with customers. Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount Finance leases, less: Amount representing interest us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Finance leases, 2021 us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo Finance leases, 2022 us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree Finance leases, 2023 us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour Finance leases, 2024 Schedule of Intangible Assets and Goodwill [Table Text Block] Cost and Equity Method Investments Disclosure [Text Block] Finance leases nrc_IncreaseDecreaseCapitalizedContractCost Deferred contract costs, net Capitalized costs incurred to obtain or fulfill contract with customer net of amortization recorded during the period. Finance leases (Year) us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Cash flows from financing activities: us-gaap_IncomeTaxReconciliationOtherReconcilingItems Other us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Other long-term liabilities nrc_DeferredTaxLiabilitiesContractCosts Deferred contract costs Amount of deferred tax liability attributable to contract costs. Share-based compensation Withholding tax on repatriation of foreign earnings PracticingExcellence.com [Member] Related to the entity PracticingExcellence.com. us-gaap_StockholdersEquity Total shareholders’ equity Balances Balances nrc_DeemedDividendPaidByForeignSubsidiary Deemed Dividend Paid by Foreign Subsidiary Represents the amount of deemed dividend paid by foreign subsidiary. Common Class A [Member] Common Class B [Member] Class of Stock [Axis] Goodwill Impairment us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses Class of Stock [Domain] us-gaap_LongTermDebtNoncurrent Notes payable, net of current portion nrc_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio Debt Instrument, Covenant, Minimum Fixed Charge Coverage Ratio The minimum fixed charge coverage ratio the borrower is required to maintain under a debt instrument agreement. Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_PaymentsToAcquireBusinessesGross Payments to Acquire Businesses, Gross Notes payable, net of current portion and unamortized debt issuance costs nrc_DebtInstrumentCovenantMaximumCashFlowLeverageRatio Debt Instrument, Covenant, Maximum Cash Flow Leverage Ratio The maximum cash flow leverage ratio the borrower is allowable to maintain under a debt instrument agreement. us-gaap_IncomeTaxReconciliationTaxCredits Federal tax credits State income taxes, net of federal benefit and state tax credits Foreign tax rate differential EX-101.PRE 11 nrc-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 picture1copy2.gif begin 644 picture1copy2.gif M1TE&.#EA( .; O< /___^_O[[^_OX^/CW]_?Y>7E\_/SZ^OK]?7UT! 0 M ! 0$%!04/?W]]_?WTA(2" @(&AH:'!P<.?GYZ>GI[>WMY^?GV!@8!@8&# P M,'AX>%A86,?'QP@(""@H*#@X.(>'AXF)B>'AX4U-35]?7X.#@WU]?1(2$C$Q M,3HZ.HN+BQX>'K.SLRTM+0T-#00$!"\O+Q<7%RHJ*IN;FP<'!\K*RJ&AH=C8 MV!45%79V=FMK:T9&1C8V-E145$Y.3I24E"XN+DM+2X:&A@D)"0\/#Q86%@,# M S0T-&QL; 4%!8B(B)J:FHZ.CB(B(@H*"@P,#.CHZ+FYN=G9V:BHJ $! 0X. M#I65E0(" G1T= 8&!G=W=T)"0C,S,V=G9SX^/@L+"RLK*SP\/%5556]O;WIZ M>AL;&QP<'$%!08V-C1$1$;R\O"8F)B4E)2DI*104%*VMK1\?'[2TM+6UM:"@ MH(*"@FEI:;&QL:*BHA,3$Y*2DBY&1D3\_/T-#0ZJJJG)R M7H6%A8" @'Y^?M/3T]'1TGIZBHJ*FIJ:JJJJNKJZRLK*VMK:ZNKJ^O MK["PL+&QL;*RLK.SL[2TM+6UM;:VMK>WM[BXN+FYN;JZNKN[N[R\O+V]O;Z^ MOK^_O\# P,'!P<+"PL/#P\3$Q,7%Q<;&QL?'Q\C(R,G)RWM_?W^#@X.'AX>+BXN/CX^3DY.7EY>;FYN?GY^CHZ.GIZ>KJZNOK MZ^SL[.WM[>[N[N_O[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ M^OO[^_S\_/W]_?[^_O___R'Y! $ )\ + @ YL" C_ $('$BPH,&# M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRIO8,.*'4NVK-FS:-.J7//JW/'D"-+GDRYLN7+F#-KWAS4@8+/:1(2^JQ 3<$: MA AQZ4*02VI" @-P]!QZ!MU'5ZW87G7<7$<:O\-U 6!'Y9'HGIB%.1: -YQAEF MQ1574!-!?D:0&D(.E.1[1184 &D%,=FD0$L8*5"15@Y$Y)0",7EDE@=M&61Z M & ))D%8&D3:<4H:*660:D*)IID*+(2E;5>>*2>26AAD*:9)N.VFDFFX\V26=I -1P9G*8%LDIH(AR6N:/ MEA6G1!>DQ?\HIAAJ1 ?JNI M NC>2W"$]65+KP*X'2=M?EF>F]JEO1H' )%ID'8CJX[QN42D[](,@+QL:K$D MF( :"^9[!>GL*'&.]ERRGN!>.O)! F<*6D-",\3GLO#I6C%"#QM=:)M;%T3T MS#4W+1#.>=)KL<7XPDL:G@.)>C6B IH])YM50]2MV%^^#4#6"K#_W6A#3P\4 M=9[;QGGUT@+)C6C7B)8*=JIC@^8WS(VAJIUW^.X)&L%Y/FQUWC(:N>BO5P,- MP+!G8_BVG&]&KC=_^#ZI -B!7PRXD8J;KI#+/'-NL^'4_>XMGRT7^ID8 U^M ML:9>@@[OM/%H5UPCR)8F)SVF(EGJ_[2G. 9NJ4UN*YK*&I? ]AVF;M[3 MVV=F)JV!V>]-* -AEK#8IQ1NJ$@Q>M\4:U@G*&FO@V&CE-J*LZR#( ]07 13 MRY3H0C,E!(H>5%Z\1%>G.;XQ= MMK;#-0;I<9(JH>M4QZWB8+(T1X2<$RF#1^#%R395G!VIDD8IC3F*BVT$@/\( M\L8DB;%O9 2 ['R3P%O2<9$AJF,#EV@U-0;N/0'L%&C4Y;W"H5%S98RF Q ) MR*,E1'> *J0"KC4]!2JSDM5TI-^T62AL-E&1T4/GW<[$OR(6*0W,1)1IH/09 M58T2,N#L%M'D9_^D.1J2E;C10CPS:;KF_>]US=.G#4U'&K=%,8]Y:H)$')H0 M21*$?]G+I+'\%$]3/M1FTFH9_?[H304VD4Z/TR8WZ0FR.3F3D9H4R#XA*:_B MX F<;9)H24L)T8N.ZF@Z)-]KSGHY!E=Q("E(CR7/D_4)D;MZ M5N^:F-Y$L2NGMZL3T0A[$(N2#DOS4=R[&.@R1DHG92/LTWKK"0"Y/@J_.D2P M8*$9)VX^2HATVBL-^_NQMR%.P?JS(P]_%]BU%F5'%H8,4_\")X0S-B< )22).A4Q&+,&F6ZACH M>1HL<;/'5F*JE*VE3HPAZG$U6VXQ(1BDEVZY_\EI0]QSOYDV!B:Q4L#<,I+- M9S,:^\FQ-V;,EAA%V6X%($"Q$=% %*U+1!MD@E(-4 831!(.\#1F",8H(<% MY4;K>+,,J2P' Z1CA1PPU)B.#7(WJX69B2B90=/"I96@XUD+T2 ^/DAE&77H M:_5Z;*DV[54)PNK9+@&(!W& B([SZQ!I =8" ;6S64WK5BL$T@CA=$*:'>UG M&T39LJ;V; ]"ZJ")B$?B9K6Y;UW,O9;[HN?>FZR=W=% V_O>^,ZWOO?-[W[[ M^]\ #[C !T[P@AO\X A/N,(7SO"&._SA$!_)P4XR\0TUA OUCL@2]NHQ+L02 M)1M7K6%;(N**E%PA7/^ =G(ONE=$3LAC[.8"!QN5<1I2O.8G=,C)(W[PP1AGY*@_!EDE8S6 MR='QF5K&&B\.Z;M58HG*KJZDZO'6A:6>*W?B6?%KIBQ"'7QV^F/)<$_O)O;SBH,I5(*%0!^7_Q $.\G$C')]>]EF&&C"?O7]W?RKB^Z:+^^3*)'B.C[YDHIENDW6N\]U;4PMJ_,$I!>)M #ZV#2L5$,GC:O%>*7H?Q%C=221E4:3^7X7#4]^9R51 M5R:%0GLM528"$GDF="7SH0#)5#33$8!#5R8/.#-^]R17$H%U$GMMIUMT\X"V MX317 H)[(X*-()E\A^^Y8)%HU--%W2%9U7NQX!74FK[ M(H/&(R #F'UM)RH"07ME"6P883<9X=#EW9M%WO6=X/<0EAMB($'N(.,N'C?_W4_C$*(+*@FF)0CC[A] M981)>[AX!)*)2F*)6C)W"2*#^Y*'31AT1I)]CF*(:7@O>Y:B)5/>"R.2&^V8J)<@L_S%^F%B'A&"*':@D MN9%W5[@K+U@T#H"$JW*+0H-Q&[@Z:/(;.F,AN4%:L,(;_S)%VAAM&G*#XE@0 M,U,QB$=,=D>/>RA_Q$**]%A&WL$X^?$OWI&'$3*)!*-URJA+PU$TY"*#OJ*' MIWB)5-**B7>+0:<%A%4GW%A' ;1V#%@=V\*0"9*'S%0TYB@HR)AO',B+?E

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end GRAPHIC 13 picture2copy6.jpg begin 644 picture2copy6.jpg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end XML 14 nrc20201231_10k_htm.xml IDEA: XBRL DOCUMENT 0000070487 2020-01-01 2020-12-31 0000070487 2020-06-30 0000070487 2021-02-26 0000070487 2020-12-31 0000070487 2019-12-31 0000070487 2019-01-01 2019-12-31 0000070487 2018-01-01 2018-12-31 0000070487 us-gaap:CommonClassAMember 2020-01-01 2020-12-31 0000070487 us-gaap:CommonClassAMember 2019-01-01 2019-12-31 0000070487 us-gaap:CommonClassAMember 2018-01-01 2018-12-31 0000070487 us-gaap:CommonClassBMember 2018-01-01 2018-12-31 0000070487 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2017-12-31 0000070487 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2017-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000070487 us-gaap:RetainedEarningsMember 2017-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000070487 us-gaap:TreasuryStockMember 2017-12-31 0000070487 2017-12-31 0000070487 us-gaap:TreasuryStockMember 2018-01-01 2018-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000070487 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000070487 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000070487 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000070487 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-12-31 0000070487 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000070487 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2018-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000070487 us-gaap:RetainedEarningsMember 2018-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000070487 us-gaap:TreasuryStockMember 2018-12-31 0000070487 2018-12-31 0000070487 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000070487 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000070487 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2019-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000070487 us-gaap:RetainedEarningsMember 2019-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000070487 us-gaap:TreasuryStockMember 2019-12-31 0000070487 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0000070487 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000070487 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000070487 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000070487 us-gaap:RetainedEarningsMember 2020-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000070487 us-gaap:TreasuryStockMember 2020-12-31 0000070487 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember nrc:RevenueRecognitionMember us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000070487 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember nrc:IncomeTaxRelatedToRevenueAdjustmentMember us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000070487 srt:MinimumMember 2020-12-31 0000070487 srt:MaximumMember 2020-12-31 0000070487 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember nrc:ChangesRelatedToContractCostsMember us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000070487 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember nrc:ChangesRelatedToContractCostsIncomeTaxEffectMember us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000070487 nrc:ChangesRelatedToContractCostsMember us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000070487 nrc:DirectExpensesMember 2020-01-01 2020-12-31 0000070487 nrc:DirectExpensesMember 2019-01-01 2019-12-31 0000070487 nrc:DirectExpensesMember 2018-01-01 2018-12-31 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0000070487 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0000070487 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0000070487 srt:MinimumMember us-gaap:ComputerEquipmentMember 2020-01-01 2020-12-31 0000070487 srt:MaximumMember us-gaap:ComputerEquipmentMember 2020-01-01 2020-12-31 0000070487 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-01-01 2020-12-31 0000070487 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-01-01 2020-12-31 0000070487 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2020-01-01 2020-12-31 0000070487 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2020-01-01 2020-12-31 0000070487 nrc:CanadianSubsidiaryMember 2020-12-31 0000070487 nrc:CanadianSubsidiaryMember 2020-01-01 2020-12-31 0000070487 nrc:CyberAttackMember nrc:RecoveriesReceivedDirectByTheCompanyMember 2020-01-01 2020-12-31 0000070487 nrc:CyberAttackMember nrc:RecoveriesPaidDirectlyByInsurerToOutsideVendorMember 2020-01-01 2020-12-31 0000070487 nrc:CyberAttackMember nrc:ReimbursementForLostRevenueMember 2020-01-01 2020-12-31 0000070487 us-gaap:OtherIncomeMember nrc:PropertyDamageExcludingCyberAttackMember 2020-01-01 2020-12-31 0000070487 2019-01-01 0000070487 nrc:OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember 2019-01-01 0000070487 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000070487 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000070487 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000070487 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000070487 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000070487 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000070487 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000070487 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000070487 stpr:WA 2020-09-30 0000070487 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000070487 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000070487 nrc:ConversionOfClassBCommonStockIntoClassACommonStockMember 2018-04-16 2018-04-16 0000070487 2018-04-17 0000070487 nrc:ConversionOfClassBCommonStockIntoClassACommonStockMember 2018-04-17 2018-04-17 0000070487 nrc:SubscriptionServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0000070487 nrc:SubscriptionServicesMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0000070487 nrc:SubscriptionServicesMember us-gaap:TransferredOverTimeMember 2018-01-01 2018-12-31 0000070487 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-12-31 0000070487 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-12-31 0000070487 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2018-01-01 2018-12-31 0000070487 nrc:FixedNonSubscriptionServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0000070487 nrc:FixedNonSubscriptionServicesMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0000070487 nrc:FixedNonSubscriptionServicesMember us-gaap:TransferredOverTimeMember 2018-01-01 2018-12-31 0000070487 nrc:UnitPriceServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0000070487 nrc:UnitPriceServicesMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0000070487 nrc:UnitPriceServicesMember us-gaap:TransferredOverTimeMember 2018-01-01 2018-12-31 0000070487 nrc:VoCPlatformMember 2020-01-01 2020-12-31 0000070487 nrc:VoCPlatformMember 2019-01-01 2019-12-31 0000070487 nrc:VoCPlatformMember 2018-01-01 2018-12-31 0000070487 us-gaap:OtherCurrentAssetsMember 2020-12-31 0000070487 us-gaap:OtherCurrentAssetsMember 2019-12-31 0000070487 us-gaap:LongTermContractWithCustomerMember 2021-01-01 2020-12-31 0000070487 nrc:PracticingExcellencecomMember 2020-12-31 0000070487 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000070487 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000070487 us-gaap:ComputerEquipmentMember 2020-12-31 0000070487 us-gaap:ComputerEquipmentMember 2019-12-31 0000070487 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0000070487 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-12-31 0000070487 us-gaap:BuildingAndBuildingImprovementsMember 2020-12-31 0000070487 us-gaap:BuildingAndBuildingImprovementsMember 2019-12-31 0000070487 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000070487 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000070487 us-gaap:LandMember 2020-12-31 0000070487 us-gaap:LandMember 2019-12-31 0000070487 nrc:IncludingAssetsHeldUnderCapitalLeaseMember 2020-01-01 2020-12-31 0000070487 nrc:IncludingAssetsHeldUnderCapitalLeaseMember 2019-01-01 2019-12-31 0000070487 nrc:IncludingAssetsHeldUnderCapitalLeaseMember 2018-01-01 2018-12-31 0000070487 nrc:TradeNames1Member 2020-12-31 0000070487 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-12-31 0000070487 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-12-31 0000070487 us-gaap:CustomerRelationshipsMember 2020-12-31 0000070487 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-01-01 2020-12-31 0000070487 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-12-31 0000070487 srt:MinimumMember us-gaap:TradeNamesMember 2020-01-01 2020-12-31 0000070487 srt:MaximumMember us-gaap:TradeNamesMember 2020-01-01 2020-12-31 0000070487 us-gaap:TradeNamesMember 2020-12-31 0000070487 nrc:TradeNames1Member 2019-12-31 0000070487 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2019-01-01 2019-12-31 0000070487 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2019-01-01 2019-12-31 0000070487 us-gaap:CustomerRelationshipsMember 2019-12-31 0000070487 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000070487 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000070487 srt:MinimumMember us-gaap:TradeNamesMember 2019-01-01 2019-12-31 0000070487 srt:MaximumMember us-gaap:TradeNamesMember 2019-01-01 2019-12-31 0000070487 us-gaap:TradeNamesMember 2019-12-31 0000070487 nrc:TermLoanMember 2020-12-31 0000070487 nrc:TermLoanMember 2019-12-31 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:TermLoanMember 2020-05-28 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:DelayedDrawTermLoanMember 2020-05-28 0000070487 us-gaap:RevolvingCreditFacilityMember nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2020-06-30 0000070487 us-gaap:RevolvingCreditFacilityMember nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2020-12-31 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:TermLoanMember 2020-01-01 2020-12-31 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:TermLoanMember 2020-12-31 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-12-31 0000070487 us-gaap:RevolvingCreditFacilityMember nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2020-01-01 2020-12-31 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2020-01-01 2020-12-31 0000070487 nrc:The2001EquityIncentivePlanMember us-gaap:CommonStockMember 2020-12-31 0000070487 nrc:The2001EquityIncentivePlanMember us-gaap:CommonClassBMember 2020-12-31 0000070487 srt:MinimumMember us-gaap:EmployeeStockOptionMember nrc:The2001EquityIncentivePlanMember 2020-01-01 2020-12-31 0000070487 srt:MaximumMember us-gaap:EmployeeStockOptionMember nrc:The2001EquityIncentivePlanMember 2020-01-01 2020-12-31 0000070487 nrc:The2001EquityIncentivePlanMember 2015-12-31 0000070487 nrc:DirectorPlan2004Member us-gaap:CommonStockMember 2020-12-31 0000070487 nrc:DirectorPlan2004Member us-gaap:CommonClassBMember 2020-12-31 0000070487 srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2018-01-01 2018-12-31 0000070487 srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2019-01-01 2019-12-31 0000070487 srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2020-01-01 2020-12-31 0000070487 srt:MaximumMember srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2020-01-01 2020-12-31 0000070487 srt:MinimumMember srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2020-01-01 2020-12-31 0000070487 nrc:DirectorPlan2004Member 2020-12-31 0000070487 nrc:The2006EquityIncentivePlanMember us-gaap:CommonStockMember 2020-12-31 0000070487 nrc:The2006EquityIncentivePlanMember us-gaap:CommonClassBMember 2020-12-31 0000070487 srt:MinimumMember nrc:The2006EquityIncentivePlanMember 2020-01-01 2020-12-31 0000070487 srt:MaximumMember nrc:The2006EquityIncentivePlanMember 2020-01-01 2020-12-31 0000070487 nrc:The2006EquityIncentivePlanMember 2020-12-31 0000070487 nrc:CommonStockOptionsMember 2020-01-01 2020-12-31 0000070487 nrc:CommonStockOptionsMember 2019-01-01 2019-12-31 0000070487 nrc:CommonStockOptionsMember 2018-01-01 2018-12-31 0000070487 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000070487 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000070487 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000070487 nrc:CommonStockOptionsMember 2019-12-31 0000070487 nrc:CommonStockOptionsMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000070487 nrc:CommonStockOptionsMember 2020-12-31 0000070487 nrc:CommonStockOptionsMember us-gaap:CommonStockMember 2020-12-31 0000070487 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000070487 us-gaap:EmployeeStockOptionMember 2020-12-31 0000070487 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000070487 us-gaap:EmployeeStockOptionMember nrc:DirectSellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000070487 us-gaap:EmployeeStockOptionMember nrc:DirectSellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000070487 us-gaap:EmployeeStockOptionMember nrc:DirectSellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2019-01-01 2019-12-31 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2018-01-01 2018-12-31 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2020-01-01 2020-12-31 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2020-12-31 0000070487 nrc:NonvestedMember 2020-01-01 2020-12-31 0000070487 nrc:NonvestedMember nrc:DirectSellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000070487 nrc:NonvestedMember nrc:DirectSellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000070487 nrc:NonvestedMember nrc:DirectSellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0000070487 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0000070487 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0000070487 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000070487 us-gaap:CommonStockMember 2019-12-31 0000070487 us-gaap:CommonStockMember 2020-12-31 0000070487 nrc:NonvestedMember 2020-12-31 0000070487 us-gaap:OtherCurrentLiabilitiesMember 2020-12-31 0000070487 us-gaap:OtherCurrentLiabilitiesMember 2019-12-31 0000070487 us-gaap:OtherNoncurrentLiabilitiesMember 2020-12-31 0000070487 us-gaap:OtherNoncurrentLiabilitiesMember 2019-12-31 0000070487 nrc:OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember 2020-12-31 0000070487 nrc:OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember 2019-12-31 0000070487 nrc:FurnitureAndEquipmentHeldUnderFinanceLeasesMember 2020-12-31 0000070487 nrc:FurnitureAndEquipmentHeldUnderFinanceLeasesMember 2019-12-31 0000070487 nrc:ComputerEquipmentHeldUnderFinanceLeasesMember 2020-12-31 0000070487 nrc:ComputerEquipmentHeldUnderFinanceLeasesMember 2019-12-31 0000070487 nrc:ComputerSoftwareHeldUnderFinanceLeasesMember 2020-12-31 0000070487 nrc:ComputerSoftwareHeldUnderFinanceLeasesMember 2019-12-31 0000070487 nrc:AssetsHeldUnderFinanceLeasesMember 2020-12-31 0000070487 nrc:AssetsHeldUnderFinanceLeasesMember 2019-12-31 0000070487 us-gaap:SubsequentEventMember 2021-02-01 2021-02-28 0000070487 nrc:AmeritasLifeInsuranceCorpMember 2020-01-01 2020-12-31 0000070487 nrc:AmeritasLifeInsuranceCorpMember 2019-01-01 2019-12-31 0000070487 nrc:AmeritasLifeInsuranceCorpMember 2018-01-01 2018-12-31 0000070487 nrc:PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMember nrc:IMAFinancialGroupMember 2020-01-01 2020-12-31 0000070487 nrc:PracticingExcellencecomMember 2017-01-01 2017-12-31 0000070487 nrc:PracticingExcellencecomMember 2020-01-01 2020-12-31 0000070487 nrc:PracticingExcellencecomMember 2019-01-01 2019-12-31 0000070487 nrc:PracticingExcellencecomMember 2018-01-01 2018-12-31 0000070487 country:US 2020-01-01 2020-12-31 0000070487 country:US 2019-01-01 2019-12-31 0000070487 country:US 2018-01-01 2018-12-31 0000070487 country:CA 2020-01-01 2020-12-31 0000070487 country:CA 2019-01-01 2019-12-31 0000070487 country:CA 2018-01-01 2018-12-31 0000070487 country:US 2020-12-31 0000070487 country:US 2019-12-31 0000070487 country:US 2018-12-31 0000070487 country:CA 2020-12-31 0000070487 country:CA 2019-12-31 0000070487 country:CA 2018-12-31 0000070487 nrc:PatientWisdomIncMember us-gaap:SubsequentEventMember 2021-01-04 2021-01-04 iso4217:USD shares thunderdome:item iso4217:USD shares utr:Y pure 0000070487 National Research Corporation false --12-31 FY 2020 120000 144000 0.01 0.01 2000000 2000000 0 0 0.001 0.001 60000000 60000000 30775154 30151574 25390968 24947500 5384186 5204074 218344 3677 468318 9296 3496 3271000 90369 3527246 69099000 3527246 4328552 1.13 0.60 87203 227902 6005 0.78 180112 630373 6793 0.21 P3Y P5Y P3Y P10Y P3Y P5Y P1Y P5Y P7Y P40Y 0 0 0 0 0 0 1 1 P1Y 0 0 0 0.21 0.21 0 1.10 3.00 P1Y P5Y P5Y P10Y 100000 100000 P1Y P10Y P3Y P5Y P10Y 0 0 0 P5Y P1Y 6 1 10-K true 2020-12-31 false 001-35929 WI 47-0634000 1245 Q Street Lincoln NE 68508 402 475-2525 Common Stock, $.001 par value NRC NASDAQ No No Yes Yes Accelerated Filer false false false 653540609 25420408 34690000 13517000 13923000 11639000 2645000 2038000 1235000 69000 1619000 1894000 54112000 29157000 11726000 13530000 1410000 1728000 57255000 57935000 1308000 1628000 4555000 4204000 3057000 2503000 133423000 110685000 4061000 4378000 1095000 1279000 6460000 6086000 3184000 3408000 366000 5239000 15585000 16354000 1296000 1045000 31681000 38155000 26547000 29795000 7265000 7399000 3615000 2444000 69108000 77793000 31000 30000 171785000 162154000 -61375000 -93357000 -2399000 -2209000 43727000 33726000 64315000 32892000 133423000 110685000 133277000 127982000 119686000 533000 49187000 46435000 47577000 34441000 32973000 31371000 7505000 5539000 5463000 91133000 84947000 84411000 42677000 43035000 35275000 18000 37000 62000 1813000 2091000 1513000 585000 -462000 885000 -1210000 -2516000 -566000 41467000 40519000 34709000 4207000 8113000 4662000 37260000 32406000 30047000 1.48 1.30 1.08 1.31 1.45 1.26 1.04 1.27 25170000 24809000 23562000 3527000 25696000 25653000 24448000 3628000 37260000 32406000 30047000 -190000 707000 -1281000 -190000 707000 -1281000 37070000 33113000 28766000 26000 4000 51025000 77574000 -1635000 -36953000 90041000 7950000 7950000 6098000 6098000 1514000 1514000 -2548000 -723000 -3271000 4000 118335000 -187438000 -69099000 4000 17112000 186944000 -204060000 29751000 29751000 2735000 2735000 -1281000 -1281000 30047000 30047000 30000 157312000 -106339000 -2916000 -29004000 19083000 4722000 4722000 3618000 3618000 1224000 1224000 19424000 19424000 707000 707000 32406000 32406000 30000 162154000 -93357000 -2209000 -33726000 32892000 10001000 10001000 1000 8951000 8952000 680000 680000 5278000 5278000 -190000 -190000 37260000 37260000 31000 171785000 -61375000 -2399000 -43727000 64315000 37260000 32406000 30047000 7505000 5539000 5463000 -134000 1099000 1476000 185000 39000 -288000 260000 -12000 6000 -186000 680000 1224000 1514000 2271000 -311000 -2767000 827000 529000 833000 -16000 8000 351000 719000 113000 -247000 647000 -39000 1370000 806000 -566000 -1529000 11000 686000 -773000 97000 -452000 40636000 40917000 39848000 3984000 4656000 5971000 260000 -3724000 -4656000 -5971000 72370000 40000000 21000000 2500000 21000000 2500000 3568000 3715000 3071000 36000 187000 332000 229000 157000 1734000 2784000 1103000 1853000 10517000 31299000 16859000 -15503000 -36346000 -54497000 -236000 611000 -1122000 21173000 526000 -21742000 13517000 12991000 34733000 34690000 13517000 12991000 1735000 2014000 1282000 5217000 6946000 2635000 121371000 817000 192000 879000 7217000 3618000 6098000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">1</em>)</b></p> </td><td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Summary of Significant Accounting Policies</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Description of Business and Basis of Presentation</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), is a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States and Canada. Our purpose is to establish human understanding. Our solutions enable health care organizations to understand what matters most to each person they serve. Our portfolio of solutions represents a unique set of capabilities that individually and collectively provide value to our clients. The solutions are offered at an enterprise level through the Voice of the Customer ("VoC") platform, The Governance Institute, and legacy Experience solutions. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Principles of Consolidation</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Use of Estimates</b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Translation of Foreign Currencies</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our Canadian subsidiary uses Canadian dollars as its functional currency. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the consolidated statements of income.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Revenue Recognition</b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">On <em style="font: inherit;"> January 1, 2018, </em>we adopted Accounting Standards Update (“ASU”) <em style="font: inherit;">2014</em>-<em style="font: inherit;">09,</em> <i>Revenue from Contracts with Customers </i>and all related amendments (“ASC <em style="font: inherit;">606”</em> or “new revenue standard”) using the modified retrospective method for all incomplete contracts as of the date of adoption. We applied the practical expedient to reflect the total of all contract modifications occurring before <em style="font: inherit;"> January 1, 2018 </em>in the transaction price and performance obligations at transition rather than accounting for each modification separately. Results for reporting periods beginning on or after <em style="font: inherit;"> January 1, 2018 </em>are presented under ASC <em style="font: inherit;">606,</em> while prior period amounts are <em style="font: inherit;">not</em> adjusted and continue to be reported under the accounting standards in effect for the prior period. As discussed in more detail below and under “Deferred Contract Costs”, the largest impact of implementing the new revenue standard was the deferral and amortization of direct and incremental costs of obtaining contracts. In addition, there were other revisions to revenue recognition primarily related to performance obligation determinations and estimating variable consideration. We recorded a transition adjustment of approximately $2.7 million, net of $814,000 of tax, to the opening balance of retained earnings.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or <em style="font: inherit;">no</em> notice without penalty. See Note <em style="font: inherit;">3</em> for further information about our contracts with customers. We account for revenue using the following steps:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Identify the contract, or contracts, with a customer;</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Identify the performance obligations in the contract;</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Determine the transaction price;</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Allocate the transaction price to the identified performance obligations; and</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recognize revenue when, or as, we satisfy the performance obligations.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our revenue arrangements with a client <em style="font: inherit;"> may </em>include combinations of more than <em style="font: inherit;">one</em> service offering which <em style="font: inherit;"> may </em>be executed at the same time, or within close proximity of <em style="font: inherit;">one</em> another. We combine contracts with the same client into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together, consideration in <em style="font: inherit;">one</em> contract depends on another contract, or services in <em style="font: inherit;">one</em> or more contracts are a single performance obligation. For contracts that contain more than <em style="font: inherit;">one</em> separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable clients, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will <em style="font: inherit;">not</em> occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do <em style="font: inherit;">not</em> contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our arrangements with customers consist principally of <em style="font: inherit;">four</em> different types of arrangements: <em style="font: inherit;">1</em>) subscription-based service agreements; <em style="font: inherit;">2</em>) <em style="font: inherit;">one</em>-time specified services performed at a single point in time; <em style="font: inherit;">3</em>) fixed, non-subscription service agreements; and <em style="font: inherit;">4</em>) unit-priced service agreements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Subscription-based services - </i>Services that are provided under subscription-based service agreements are usually for a <em style="font: inherit;">twelve</em> month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the client. These agreements are renewable at the option of the client at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the client as the client receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but <em style="font: inherit;"> may </em>also be billed on a quarterly and monthly basis.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>One-time services </i>–<i> </i>These agreements typically require us to perform a specific <em style="font: inherit;">one</em>-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the client.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Fixed, non-subscription services </i>–<i> </i>These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch up adjustment which could impact the amount and timing of revenue for any period.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Unit-price services </i>–<i> </i>These arrangements typically require us to perform certain services on a periodic basis as requested by the client for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but <em style="font: inherit;">not</em> invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Deferred Contract Costs </b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable client contract. In <em style="font: inherit;">2020,</em> we began providing information technology development work for certain clients specific to their implementation, which are capitalized as deferred contract costs. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from <span style="-sec-ix-hidden:c70061795">three</span> to <span style="-sec-ix-hidden:c70061796">five</span> years. The contract term was estimated by considering factors such as historical client attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract. An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services. We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of <em style="font: inherit;">one</em> year or less. Prior to <em style="font: inherit;">2018,</em> all commissions and incentives were expensed as incurred. We recorded a transition adjustment on <em style="font: inherit;"> January 1, 2018 </em>as an increase to retained earnings of $2.6 million, net of $776,000 of tax, to reflect $3.4 million of commissions and incentives related to contracts that began prior to <em style="font: inherit;">2018,</em> net of accumulated amortization. We deferred incremental costs of obtaining a contract of $3.7 million, $3.6 million and $2.6 million in the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively. Deferred contract costs, net of accumulated amortization was $4.6 million and $4.2 million at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. Total amortization by expense classification for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Direct expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,970</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,874</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,242</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $63,000, $22,000 and $51,000 for the years <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Trade Accounts Receivable</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Trade accounts receivable are recorded at the invoiced amount. Effective <em style="font: inherit;"> January 1, 2020, </em>we adopted Accounting Standards Update (“ASU”) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Measurement of Credit Losses on Financial Instruments.</i> This ASU requires the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The adoption of this standard did <em style="font: inherit;">not</em> have an impact on our consolidated financial statements. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The COVID-<em style="font: inherit;">19</em> pandemic has resulted in an increase in accounts receivables as some clients have delayed payments or are slower paying due to such clients’ cash-flow issues.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table provides the activity in the allowance for doubtful accounts for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Beginning</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Year</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Bad Debt</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expense</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Write-offs,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">net of</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Recoveries</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">at End</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Year</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2018</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">106</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Property and Equipment</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Property and equipment is stated at cost. Major expenditures to purchase property or to substantially increase useful lives of property are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in income.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We capitalize certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software projects and external direct costs of materials and services. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs are expensed as incurred. We capitalized approximately $2.7 million and $4.1 million of costs incurred for the development of internal-use software for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">When a software license is included in a cloud computing arrangement and we have the legal right, ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is <em style="font: inherit;">not</em> included or we do <em style="font: inherit;">not</em> have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective <em style="font: inherit;"> January 1, 2020, </em>we prospectively adopted ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> Intangibles-Goodwill and Other-Internal Use Software (Subtopic <em style="font: inherit;">350</em>-<em style="font: inherit;">40</em>). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did <em style="font: inherit;">not</em> significantly impact our results of operations and financial position.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We provide for depreciation and amortization of property and equipment using annual rates which are sufficient to amortize the cost of depreciable assets over their estimated useful lives. We use the straight-line method of depreciation and amortization over estimated useful lives of <span style="-sec-ix-hidden:c70061835">three</span> to <span style="-sec-ix-hidden:c70061836">ten</span> years for furniture and equipment, <span style="-sec-ix-hidden:c70061837">three</span> to <span style="-sec-ix-hidden:c70061838">five</span> years for computer equipment, <span style="-sec-ix-hidden:c70061839">one</span> to <span style="-sec-ix-hidden:c70061840">five</span> years for capitalized software, and <span style="-sec-ix-hidden:c70061841">seven</span> to <span style="-sec-ix-hidden:c70061842">forty</span> years for our office building and related improvements. Software licenses are amortized over the term of the license.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Impairment of Long-Lived Assets and Amortizing Intangible Assets</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Long-lived assets, such as property and equipment and purchased intangible assets subject to depreciation or amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we <em style="font: inherit;">first</em> compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is <em style="font: inherit;">not</em> recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and <em style="font: inherit;">third</em>-party independent appraisals, as considered necessary. No significant impairments were recorded during the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019,</em> or <em style="font: inherit;">2018.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Among others, management believes the following circumstances are important indicators of potential impairment of such assets and as a result <em style="font: inherit;"> may </em>trigger an impairment review:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant underperformance in comparison to historical or projected operating results;</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant changes in the manner or use of acquired assets or our overall strategy;</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant negative trends in our industry or the overall economy;</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A significant decline in the market price for our common stock for a sustained period; and</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our market capitalization falling below the book value of our net assets.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Goodwill and Intangible Assets</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Intangible assets include customer relationships, trade names, technology, and goodwill. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. We review intangible assets with indefinite lives for impairment annually as of <em style="font: inherit;"> October 1 </em>and whenever events or changes in circumstances indicate that the carrying value of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">When performing the impairment assessment, we will <em style="font: inherit;">first</em> assess qualitative factors to determine whether it is necessary to recalculate the fair value of the intangible assets with indefinite lives. If we believe, as a result of the qualitative assessment, that it is more likely than <em style="font: inherit;">not</em> that the fair value of the indefinite-lived intangibles is less than their carrying amount, we calculate the fair value using a market or income approach. If the carrying value of intangible assets with indefinite lives exceeds their fair value, then the intangible assets are written-down to their fair values. We did <span style="-sec-ix-hidden:c70061857"><span style="-sec-ix-hidden:c70061858"><span style="-sec-ix-hidden:c70061859">not</span></span></span> recognize any impairments related to indefinite-lived intangibles during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> or <em style="font: inherit;">2018.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are <em style="font: inherit;">not</em> individually identified and separately recognized. All of our goodwill is allocated to our reporting units, which are the same as our operating segments. Goodwill is reviewed for impairment at least annually, as of <em style="font: inherit;"> October 1, </em>and whenever events or changes in circumstances indicate that the carrying value of goodwill <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We review goodwill for impairment by <em style="font: inherit;">first</em> assessing qualitative factors to determine whether any impairment <em style="font: inherit;"> may </em>exist. If we believe, as a result of the qualitative assessment, that it is more likely than <em style="font: inherit;">not</em> that the fair value of a reporting unit is less than its carrying amount, a quantitative analysis will be performed, and the fair value of the reporting unit is compared with its carrying value (including goodwill). If the carrying value of the reporting unit exceeds the fair value, then goodwill is written down by this difference. We performed a qualitative analysis as of <em style="font: inherit;"> October 1, 2020 </em>and determined the fair value of each reporting unit likely exceeded the carrying value. No impairments were recorded during the years ended <em style="font: inherit;"> December 31, 2019 </em>or <em style="font: inherit;">2018.</em> A substantial portion of the revenue earned by our Canadian subsidiary is concentrated with <span style="-sec-ix-hidden:c70061870">one</span> customer. While the customer has exercised its option to extend its existing contract to <em style="font: inherit;"> September 2022, </em>during <em style="font: inherit;"> December 2020 </em>we chose <em style="font: inherit;">not</em> to enter into a new contract with this customer or otherwise extend the term of the contract beyond <em style="font: inherit;"> September 2022. </em>We subsequently announced that we would close the Canada office at the end of the contract.  As a result, we tested for impairment of the Canada reporting unit’s goodwill at <em style="font: inherit;"> December 31, 2020. </em>We recognized an impairment of $714,000 for the excess of the Canada reporting unit’s carrying value over the fair value, using discounted cash flows. The remaining balance of goodwill of our Canada reporting unit at <em style="font: inherit;"> December 31, 2020 </em>was $1.6 million. Changes in the actual amount or timing of cash flows or other assumptions used to discount cash flows to estimate fair value of the Canada reporting unit could result in additional impairment.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Insurance Recoveries</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We record insurance recoveries when the realization of the claim is probable. In <em style="font: inherit;">2020</em> we received $3.3 million in insurance recoveries, and $447,000 was paid directly to certain vendors from the insurer related to a cyber-attack in <em style="font: inherit;"> February 2020 (</em>the <em style="font: inherit;"> “February </em>incident”). We recorded $533,000, representing reimbursement for lost revenues, as insurance recoveries, and the remainder as a reduction to operating expenses. Due to insurance recoveries, the <em style="font: inherit;"> February </em>incident did <em style="font: inherit;">not</em> have a significant impact on our consolidated financial statements. In <em style="font: inherit;">2020,</em> we also recorded a gain in other income of $260,000 from insurance recoveries for property damage due to a flooding.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Income Taxes</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We use the asset and liability method of accounting for income taxes. Under that method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis using enacted tax rates. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances, if any, are established when necessary to reduce deferred tax assets to the amount that is more likely than <em style="font: inherit;">not</em> to be realized. We use the deferral method of accounting for our investment tax credits related to state tax incentives. During the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> we recorded income tax benefits relating to these tax credits of $45,000, $24,000, and $0, respectively. Interest and penalties related to income taxes are included in income taxes in the Consolidated Statements of Income.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We recognize the effect of income tax positions only if those positions are more likely than <em style="font: inherit;">not</em> of being sustained. Recognized income tax positions are measured at the largest amount that is greater than <em style="font: inherit;">50%</em> likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Share-Based Compensation</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">All of our existing stock option awards and non-vested stock awards have been determined to be equity-classified awards. The compensation expense on share-based payments is recognized based on the grant-date fair value of those awards. We recognize the excess tax benefits and tax deficiencies in the income statement when options are exercised. Amounts recognized in the financial statements with respect to these plans are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amounts charged against income, before income tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">680</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,224</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,514</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amount of related income tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,764</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,566</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net (benefit) expense to net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,084</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(857</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We refer to our restricted stock awards as “non-vested” stock in these consolidated financial statements.  </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Cash and Cash Equivalents</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We consider all highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Cash equivalents were $5.0 million and $3.7 million as of <em style="font: inherit;"> December 31, 2020, </em>and <em style="font: inherit;">2019,</em> respectively, consisting primarily of money market accounts. At certain times, cash equivalent balances <em style="font: inherit;"> may </em>exceed federally insured limits.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Leases</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We adopted Accounting Standards Update (“ASU”) <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> Leases (Topic <em style="font: inherit;">842</em>) (“Topic <em style="font: inherit;">842”</em> or the “New Leases Standard”) effective <em style="font: inherit;"> January 1, 2019 </em>using a modified retrospective transition and did <em style="font: inherit;">not</em> adjust prior periods. We elected practical expedients related to existing leases at transition to <em style="font: inherit;">not</em> reassess whether contracts are or contain leases, to <em style="font: inherit;">not</em> reassess lease classification, initial direct costs, or lease terms. Additionally, we elected the practical expedient to account for lease and non-lease components as a single lease component for all asset classifications. We have also made a policy election to <em style="font: inherit;">not</em> record short-term leases with a duration of <em style="font: inherit;">12</em> months or less on the balance sheet.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Topic <em style="font: inherit;">842</em> requires lessees to recognize a lease liability and a right-of-use (“ROU”) asset on the balance sheet for operating leases. We recorded $2.3 million of ROU assets and $2.3 million of lease liabilities related to operating leases at the date of transition. The ROU assets recorded were net of $43,000 of accrued liabilities and prepaid expenses representing previously deferred (prepaid) rent. There was <em style="font: inherit;">no</em> significant impact to the consolidated statements of income, comprehensive income, shareholders’ equity or cash flows. Accounting for finance leases is substantially unchanged.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We determine whether a lease is included in an agreement at inception. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long-term liabilities. Certain lease arrangements <em style="font: inherit;"> may </em>include options to extend or terminate the lease. We include these provisions in the ROU asset and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do <em style="font: inherit;">not</em> contain any residual value guarantees.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is <em style="font: inherit;">not</em> readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Fair Value Measurements</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (<em style="font: inherit;">1</em>) Level <em style="font: inherit;">1</em> Inputs—quoted prices in active markets for identical assets and liabilities; (<em style="font: inherit;">2</em>) Level <em style="font: inherit;">2</em> Inputs—observable market-based inputs other than Level <em style="font: inherit;">1</em> inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are <em style="font: inherit;">not</em> active, or other inputs that are observable or can be corroborated by observable market data; (<em style="font: inherit;">3</em>) Level <em style="font: inherit;">3</em> Inputs—unobservable inputs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following details our financial assets within the fair value hierarchy at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 1</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 2</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 3</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2020</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2019</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">There were <em style="font: inherit;">no</em> transfers between levels during the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our long-term debt described in Note <em style="font: inherit;">8</em> is recorded at historical cost. The fair value of long-term debt is classified in Level <em style="font: inherit;">2</em> of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following are the carrying amount and estimated fair values of long-term debt:</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total carrying amount of long-term debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of long-term debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,943</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,205</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are <em style="font: inherit;">not</em> recognized or disclosed at fair value in the financial statements on a recurring basis, which includes property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> there was <em style="font: inherit;">no</em> indication of impairment related to these assets, other than for the Canada reporting unit’s goodwill as discussed above. We estimated the fair value of the Canada reporting unit using discounted cash flows based on management’s most recent projections which are considered level <em style="font: inherit;">3</em> inputs in the fair value hierarchy.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Commitments and Contingencies</b><br/> <br/> From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. We do <em style="font: inherit;">not</em> believe the final disposition of claims at <em style="font: inherit;"> December 31, 2020 </em>will have material adverse effect on our consolidated financial position, results of operations or liquidity.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">A sales tax accrual of $775,000 was recorded in <em style="font: inherit;">2019</em> for sales taxes that should have been collected from clients in <em style="font: inherit;">2019</em> and certain previous years. We received a revenue ruling from the state of Washington noting that our services are <em style="font: inherit;">not</em> subject to retail sales tax, and therefore, reversed $268,000 of sales tax accrual for the state of Washington in the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2020.</em> We have completed voluntary disclosure agreements with certain states, remitted past due sales tax, are remitting sales tax timely, are collecting sales tax from clients and <em style="font: inherit;">no</em> accrual for past due sales tax remains as of <em style="font: inherit;"> December 31, 2020. </em>State and local jurisdictions have differing rules and regulations governing sales, use, and other taxes and these rules and regulations can be complex and subject to varying interpretations that <em style="font: inherit;"> may </em>change over time. As a result, we could face the possibility of tax assessment and audits, and our liability for these taxes and associated interest and penalties could exceed our original estimates.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We became self-insured for group medical and dental insurance on <em style="font: inherit;"> January 1, 2019.   </em>We carry excess loss coverage in the amount of $150,000 per covered person per year for group medical insurance.  We do <em style="font: inherit;">not</em> self-insure for any other types of losses, and therefore do <em style="font: inherit;">not</em> carry any additional excess loss insurance.  We record a reserve for our group medical and dental insurance for all unresolved claims and for an estimate of incurred but <em style="font: inherit;">not</em> reported (“IBNR”) claims.  On a quarterly basis, we adjust our accrual based on a review of our claims experience and a <em style="font: inherit;">third</em>-party actuarial IBNR analysis.  As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> our accrual related to self-insurance was $418,000 and $270,000, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Earnings Per Share</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Prior to the Recapitalization, net income per share of our former class A common stock and former class B common stock was computed using the <em style="font: inherit;">two</em>-class method. Basic net income per share was computed by allocating undistributed earnings to common shares and using the weighted-average number of common shares outstanding during the period.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The liquidation rights and the rights upon the consummation of an extraordinary transaction were the same for the holders of our former class A common stock and former class B common stock. Other than share distributions and liquidation rights, the amount of any dividend or other distribution payable on each share of former class A common stock was equal to <em style="font: inherit;">one</em>-<em style="font: inherit;">sixth</em> (<em style="font: inherit;">1/6th</em>) of the amount of any such dividend or other distribution payable on each share of former class B common stock. As a result, the undistributed earnings for each period were allocated based on the participation rights of the former class A and former class B common stock under our then-effective Articles of Incorporation as if the earnings for the year had been distributed.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">As described in Note <em style="font: inherit;">2,</em> we completed a Recapitalization in <em style="font: inherit;"> April 2018, </em>resulting in the elimination of the class B common stock and settlement of all then-existing outstanding class B share-based awards and reclassification of all class A common stock to Common Stock. The Recapitalization was effective on <em style="font: inherit;"> April 17, 2018. </em>Therefore, income was allocated between the former class A and class B stock using the <em style="font: inherit;">two</em>-class method through <em style="font: inherit;"> April 16, 2018, </em>and fully allocated to the Common Stock (formerly class A) following the Recapitalization.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We had 65,127, 16,221 and 93,346 options of Common Stock (former class A shares) for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(formerly</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Class A)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Class B</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands, except per share data)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator for net income per share - basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,406</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,423</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,624</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Allocation of distributed and undistributed income to unvested restricted stock shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(57</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income attributable to common shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,341</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,606</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator for net income per share - basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Weighted average common shares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,562</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,527</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per share - basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.08</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator for net income per share - diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income attributable to common shareholders for basic computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,341</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,606</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator for net income per share - diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common <b>s</b>hares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23,562</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,527</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average effect of dilutive securities – stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">526</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">844</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">886</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Denominator for diluted earnings per share – adjusted weighted average shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,628</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per share - diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.04</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.27</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted </b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> Simplifying the Accounting for Income Taxes (Topic <em style="font: inherit;">740</em>). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The guidance is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2020 </em>and interim periods within those fiscal years.  Early adoption is permitted in interim or annual periods with any adjustments reflected as of the beginning of the annual period that includes that interim period.  Additionally, entities that elect early adoption must adopt all the amendments in the same period.  Amendments are to be applied prospectively, except for certain amendments that are to be applied either retrospectively or with a modified retrospective approach through a cumulative effect adjustment recorded to retained earnings.  We believe the adoption will <em style="font: inherit;">not</em> significantly impact our results of operations and financial position.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">In <em style="font: inherit;"> March 2020, </em>FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">04,</em> "Reference Rate Reform (Topic <em style="font: inherit;">848</em>): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of <em style="font: inherit;"> March 12, 2020 </em>through <em style="font: inherit;"> December 31, 2022. </em>We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Principles of Consolidation</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Use of Estimates</b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Translation of Foreign Currencies</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our Canadian subsidiary uses Canadian dollars as its functional currency. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the consolidated statements of income.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Revenue Recognition</b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">On <em style="font: inherit;"> January 1, 2018, </em>we adopted Accounting Standards Update (“ASU”) <em style="font: inherit;">2014</em>-<em style="font: inherit;">09,</em> <i>Revenue from Contracts with Customers </i>and all related amendments (“ASC <em style="font: inherit;">606”</em> or “new revenue standard”) using the modified retrospective method for all incomplete contracts as of the date of adoption. We applied the practical expedient to reflect the total of all contract modifications occurring before <em style="font: inherit;"> January 1, 2018 </em>in the transaction price and performance obligations at transition rather than accounting for each modification separately. Results for reporting periods beginning on or after <em style="font: inherit;"> January 1, 2018 </em>are presented under ASC <em style="font: inherit;">606,</em> while prior period amounts are <em style="font: inherit;">not</em> adjusted and continue to be reported under the accounting standards in effect for the prior period. As discussed in more detail below and under “Deferred Contract Costs”, the largest impact of implementing the new revenue standard was the deferral and amortization of direct and incremental costs of obtaining contracts. In addition, there were other revisions to revenue recognition primarily related to performance obligation determinations and estimating variable consideration. We recorded a transition adjustment of approximately $2.7 million, net of $814,000 of tax, to the opening balance of retained earnings.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or <em style="font: inherit;">no</em> notice without penalty. See Note <em style="font: inherit;">3</em> for further information about our contracts with customers. We account for revenue using the following steps:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Identify the contract, or contracts, with a customer;</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Identify the performance obligations in the contract;</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Determine the transaction price;</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Allocate the transaction price to the identified performance obligations; and</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 3%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recognize revenue when, or as, we satisfy the performance obligations.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our revenue arrangements with a client <em style="font: inherit;"> may </em>include combinations of more than <em style="font: inherit;">one</em> service offering which <em style="font: inherit;"> may </em>be executed at the same time, or within close proximity of <em style="font: inherit;">one</em> another. We combine contracts with the same client into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together, consideration in <em style="font: inherit;">one</em> contract depends on another contract, or services in <em style="font: inherit;">one</em> or more contracts are a single performance obligation. For contracts that contain more than <em style="font: inherit;">one</em> separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable clients, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will <em style="font: inherit;">not</em> occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do <em style="font: inherit;">not</em> contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our arrangements with customers consist principally of <em style="font: inherit;">four</em> different types of arrangements: <em style="font: inherit;">1</em>) subscription-based service agreements; <em style="font: inherit;">2</em>) <em style="font: inherit;">one</em>-time specified services performed at a single point in time; <em style="font: inherit;">3</em>) fixed, non-subscription service agreements; and <em style="font: inherit;">4</em>) unit-priced service agreements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Subscription-based services - </i>Services that are provided under subscription-based service agreements are usually for a <em style="font: inherit;">twelve</em> month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the client. These agreements are renewable at the option of the client at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the client as the client receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but <em style="font: inherit;"> may </em>also be billed on a quarterly and monthly basis.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>One-time services </i>–<i> </i>These agreements typically require us to perform a specific <em style="font: inherit;">one</em>-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the client.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Fixed, non-subscription services </i>–<i> </i>These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch up adjustment which could impact the amount and timing of revenue for any period.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Unit-price services </i>–<i> </i>These arrangements typically require us to perform certain services on a periodic basis as requested by the client for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but <em style="font: inherit;">not</em> invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2700000 814000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Deferred Contract Costs </b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable client contract. In <em style="font: inherit;">2020,</em> we began providing information technology development work for certain clients specific to their implementation, which are capitalized as deferred contract costs. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from <span style="-sec-ix-hidden:c70061795">three</span> to <span style="-sec-ix-hidden:c70061796">five</span> years. The contract term was estimated by considering factors such as historical client attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract. An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services. We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of <em style="font: inherit;">one</em> year or less. Prior to <em style="font: inherit;">2018,</em> all commissions and incentives were expensed as incurred. We recorded a transition adjustment on <em style="font: inherit;"> January 1, 2018 </em>as an increase to retained earnings of $2.6 million, net of $776,000 of tax, to reflect $3.4 million of commissions and incentives related to contracts that began prior to <em style="font: inherit;">2018,</em> net of accumulated amortization. We deferred incremental costs of obtaining a contract of $3.7 million, $3.6 million and $2.6 million in the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively. Deferred contract costs, net of accumulated amortization was $4.6 million and $4.2 million at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. Total amortization by expense classification for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Direct expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,970</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,874</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,242</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $63,000, $22,000 and $51,000 for the years <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> 2600000 776000 3400000 3700000 3600000 2600000 4600000 4200000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Direct expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,970</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,874</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,242</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 272000 34000 83000 2970000 2874000 2400000 3242000 2908000 2483000 63000 22000 51000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Trade Accounts Receivable</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Trade accounts receivable are recorded at the invoiced amount. Effective <em style="font: inherit;"> January 1, 2020, </em>we adopted Accounting Standards Update (“ASU”) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Measurement of Credit Losses on Financial Instruments.</i> This ASU requires the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The adoption of this standard did <em style="font: inherit;">not</em> have an impact on our consolidated financial statements. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The COVID-<em style="font: inherit;">19</em> pandemic has resulted in an increase in accounts receivables as some clients have delayed payments or are slower paying due to such clients’ cash-flow issues.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table provides the activity in the allowance for doubtful accounts for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Beginning</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Year</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Bad Debt</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expense</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Write-offs,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">net of</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Recoveries</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">at End</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Year</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2018</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">106</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Beginning</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Year</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Bad Debt</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expense</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Write-offs,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">net of</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Recoveries</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">at End</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Year</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2018</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">75</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">106</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year Ended December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 200000 80000 105000 175000 175000 75000 106000 144000 144000 46000 70000 120000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Property and Equipment</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Property and equipment is stated at cost. Major expenditures to purchase property or to substantially increase useful lives of property are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in income.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We capitalize certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software projects and external direct costs of materials and services. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs are expensed as incurred. We capitalized approximately $2.7 million and $4.1 million of costs incurred for the development of internal-use software for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">When a software license is included in a cloud computing arrangement and we have the legal right, ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is <em style="font: inherit;">not</em> included or we do <em style="font: inherit;">not</em> have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective <em style="font: inherit;"> January 1, 2020, </em>we prospectively adopted ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> Intangibles-Goodwill and Other-Internal Use Software (Subtopic <em style="font: inherit;">350</em>-<em style="font: inherit;">40</em>). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did <em style="font: inherit;">not</em> significantly impact our results of operations and financial position.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We provide for depreciation and amortization of property and equipment using annual rates which are sufficient to amortize the cost of depreciable assets over their estimated useful lives. We use the straight-line method of depreciation and amortization over estimated useful lives of <span style="-sec-ix-hidden:c70061835">three</span> to <span style="-sec-ix-hidden:c70061836">ten</span> years for furniture and equipment, <span style="-sec-ix-hidden:c70061837">three</span> to <span style="-sec-ix-hidden:c70061838">five</span> years for computer equipment, <span style="-sec-ix-hidden:c70061839">one</span> to <span style="-sec-ix-hidden:c70061840">five</span> years for capitalized software, and <span style="-sec-ix-hidden:c70061841">seven</span> to <span style="-sec-ix-hidden:c70061842">forty</span> years for our office building and related improvements. Software licenses are amortized over the term of the license.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> 2700000 4100000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Impairment of Long-Lived Assets and Amortizing Intangible Assets</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Long-lived assets, such as property and equipment and purchased intangible assets subject to depreciation or amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we <em style="font: inherit;">first</em> compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is <em style="font: inherit;">not</em> recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and <em style="font: inherit;">third</em>-party independent appraisals, as considered necessary. No significant impairments were recorded during the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019,</em> or <em style="font: inherit;">2018.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Among others, management believes the following circumstances are important indicators of potential impairment of such assets and as a result <em style="font: inherit;"> may </em>trigger an impairment review:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant underperformance in comparison to historical or projected operating results;</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant changes in the manner or use of acquired assets or our overall strategy;</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant negative trends in our industry or the overall economy;</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A significant decline in the market price for our common stock for a sustained period; and</p> </td></tr> <tr><td style="vertical-align: top; width: 2%;"> </td><td style="vertical-align: top; width: 5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align: top; width: 93%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our market capitalization falling below the book value of our net assets.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Goodwill and Intangible Assets</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Intangible assets include customer relationships, trade names, technology, and goodwill. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. We review intangible assets with indefinite lives for impairment annually as of <em style="font: inherit;"> October 1 </em>and whenever events or changes in circumstances indicate that the carrying value of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">When performing the impairment assessment, we will <em style="font: inherit;">first</em> assess qualitative factors to determine whether it is necessary to recalculate the fair value of the intangible assets with indefinite lives. If we believe, as a result of the qualitative assessment, that it is more likely than <em style="font: inherit;">not</em> that the fair value of the indefinite-lived intangibles is less than their carrying amount, we calculate the fair value using a market or income approach. If the carrying value of intangible assets with indefinite lives exceeds their fair value, then the intangible assets are written-down to their fair values. We did <span style="-sec-ix-hidden:c70061857"><span style="-sec-ix-hidden:c70061858"><span style="-sec-ix-hidden:c70061859">not</span></span></span> recognize any impairments related to indefinite-lived intangibles during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> or <em style="font: inherit;">2018.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are <em style="font: inherit;">not</em> individually identified and separately recognized. All of our goodwill is allocated to our reporting units, which are the same as our operating segments. Goodwill is reviewed for impairment at least annually, as of <em style="font: inherit;"> October 1, </em>and whenever events or changes in circumstances indicate that the carrying value of goodwill <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We review goodwill for impairment by <em style="font: inherit;">first</em> assessing qualitative factors to determine whether any impairment <em style="font: inherit;"> may </em>exist. If we believe, as a result of the qualitative assessment, that it is more likely than <em style="font: inherit;">not</em> that the fair value of a reporting unit is less than its carrying amount, a quantitative analysis will be performed, and the fair value of the reporting unit is compared with its carrying value (including goodwill). If the carrying value of the reporting unit exceeds the fair value, then goodwill is written down by this difference. We performed a qualitative analysis as of <em style="font: inherit;"> October 1, 2020 </em>and determined the fair value of each reporting unit likely exceeded the carrying value. No impairments were recorded during the years ended <em style="font: inherit;"> December 31, 2019 </em>or <em style="font: inherit;">2018.</em> A substantial portion of the revenue earned by our Canadian subsidiary is concentrated with <span style="-sec-ix-hidden:c70061870">one</span> customer. While the customer has exercised its option to extend its existing contract to <em style="font: inherit;"> September 2022, </em>during <em style="font: inherit;"> December 2020 </em>we chose <em style="font: inherit;">not</em> to enter into a new contract with this customer or otherwise extend the term of the contract beyond <em style="font: inherit;"> September 2022. </em>We subsequently announced that we would close the Canada office at the end of the contract.  As a result, we tested for impairment of the Canada reporting unit’s goodwill at <em style="font: inherit;"> December 31, 2020. </em>We recognized an impairment of $714,000 for the excess of the Canada reporting unit’s carrying value over the fair value, using discounted cash flows. The remaining balance of goodwill of our Canada reporting unit at <em style="font: inherit;"> December 31, 2020 </em>was $1.6 million. Changes in the actual amount or timing of cash flows or other assumptions used to discount cash flows to estimate fair value of the Canada reporting unit could result in additional impairment.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> 0 714000 1600000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Insurance Recoveries</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We record insurance recoveries when the realization of the claim is probable. In <em style="font: inherit;">2020</em> we received $3.3 million in insurance recoveries, and $447,000 was paid directly to certain vendors from the insurer related to a cyber-attack in <em style="font: inherit;"> February 2020 (</em>the <em style="font: inherit;"> “February </em>incident”). We recorded $533,000, representing reimbursement for lost revenues, as insurance recoveries, and the remainder as a reduction to operating expenses. Due to insurance recoveries, the <em style="font: inherit;"> February </em>incident did <em style="font: inherit;">not</em> have a significant impact on our consolidated financial statements. In <em style="font: inherit;">2020,</em> we also recorded a gain in other income of $260,000 from insurance recoveries for property damage due to a flooding.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> 3300000 447000 533000 260000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Income Taxes</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We use the asset and liability method of accounting for income taxes. Under that method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis using enacted tax rates. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances, if any, are established when necessary to reduce deferred tax assets to the amount that is more likely than <em style="font: inherit;">not</em> to be realized. We use the deferral method of accounting for our investment tax credits related to state tax incentives. During the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> we recorded income tax benefits relating to these tax credits of $45,000, $24,000, and $0, respectively. Interest and penalties related to income taxes are included in income taxes in the Consolidated Statements of Income.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We recognize the effect of income tax positions only if those positions are more likely than <em style="font: inherit;">not</em> of being sustained. Recognized income tax positions are measured at the largest amount that is greater than <em style="font: inherit;">50%</em> likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> 45000 24000 0 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Share-Based Compensation</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">All of our existing stock option awards and non-vested stock awards have been determined to be equity-classified awards. The compensation expense on share-based payments is recognized based on the grant-date fair value of those awards. We recognize the excess tax benefits and tax deficiencies in the income statement when options are exercised. Amounts recognized in the financial statements with respect to these plans are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amounts charged against income, before income tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">680</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,224</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,514</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amount of related income tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,764</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,566</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net (benefit) expense to net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,084</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(857</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We refer to our restricted stock awards as “non-vested” stock in these consolidated financial statements.  </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amounts charged against income, before income tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">680</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,224</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,514</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amount of related income tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,764</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,566</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net (benefit) expense to net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,084</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(857</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> 680000 1224000 1514000 6764000 2081000 3566000 -6084000 -857000 -2052000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Cash and Cash Equivalents</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We consider all highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Cash equivalents were $5.0 million and $3.7 million as of <em style="font: inherit;"> December 31, 2020, </em>and <em style="font: inherit;">2019,</em> respectively, consisting primarily of money market accounts. At certain times, cash equivalent balances <em style="font: inherit;"> may </em>exceed federally insured limits.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> 5000000.0 3700000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Leases</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We adopted Accounting Standards Update (“ASU”) <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> Leases (Topic <em style="font: inherit;">842</em>) (“Topic <em style="font: inherit;">842”</em> or the “New Leases Standard”) effective <em style="font: inherit;"> January 1, 2019 </em>using a modified retrospective transition and did <em style="font: inherit;">not</em> adjust prior periods. We elected practical expedients related to existing leases at transition to <em style="font: inherit;">not</em> reassess whether contracts are or contain leases, to <em style="font: inherit;">not</em> reassess lease classification, initial direct costs, or lease terms. Additionally, we elected the practical expedient to account for lease and non-lease components as a single lease component for all asset classifications. We have also made a policy election to <em style="font: inherit;">not</em> record short-term leases with a duration of <em style="font: inherit;">12</em> months or less on the balance sheet.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Topic <em style="font: inherit;">842</em> requires lessees to recognize a lease liability and a right-of-use (“ROU”) asset on the balance sheet for operating leases. We recorded $2.3 million of ROU assets and $2.3 million of lease liabilities related to operating leases at the date of transition. The ROU assets recorded were net of $43,000 of accrued liabilities and prepaid expenses representing previously deferred (prepaid) rent. There was <em style="font: inherit;">no</em> significant impact to the consolidated statements of income, comprehensive income, shareholders’ equity or cash flows. Accounting for finance leases is substantially unchanged.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We determine whether a lease is included in an agreement at inception. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long-term liabilities. Certain lease arrangements <em style="font: inherit;"> may </em>include options to extend or terminate the lease. We include these provisions in the ROU asset and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do <em style="font: inherit;">not</em> contain any residual value guarantees.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is <em style="font: inherit;">not</em> readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> 2300000 2300000 43000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Fair Value Measurements</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (<em style="font: inherit;">1</em>) Level <em style="font: inherit;">1</em> Inputs—quoted prices in active markets for identical assets and liabilities; (<em style="font: inherit;">2</em>) Level <em style="font: inherit;">2</em> Inputs—observable market-based inputs other than Level <em style="font: inherit;">1</em> inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are <em style="font: inherit;">not</em> active, or other inputs that are observable or can be corroborated by observable market data; (<em style="font: inherit;">3</em>) Level <em style="font: inherit;">3</em> Inputs—unobservable inputs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following details our financial assets within the fair value hierarchy at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 1</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 2</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 3</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2020</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2019</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">There were <em style="font: inherit;">no</em> transfers between levels during the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our long-term debt described in Note <em style="font: inherit;">8</em> is recorded at historical cost. The fair value of long-term debt is classified in Level <em style="font: inherit;">2</em> of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following are the carrying amount and estimated fair values of long-term debt:</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total carrying amount of long-term debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of long-term debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,943</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,205</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are <em style="font: inherit;">not</em> recognized or disclosed at fair value in the financial statements on a recurring basis, which includes property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> there was <em style="font: inherit;">no</em> indication of impairment related to these assets, other than for the Canada reporting unit’s goodwill as discussed above. We estimated the fair value of the Canada reporting unit using discounted cash flows based on management’s most recent projections which are considered level <em style="font: inherit;">3</em> inputs in the fair value hierarchy.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 1</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 2</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Level 3</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2020</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2019</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total carrying amount of long-term debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of long-term debt</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,943</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,205</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 5015000 5015000 5015000 5015000 3662000 3662000 3662000 3662000 30713000 34281000 32943000 35205000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Commitments and Contingencies</b><br/> <br/> From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. We do <em style="font: inherit;">not</em> believe the final disposition of claims at <em style="font: inherit;"> December 31, 2020 </em>will have material adverse effect on our consolidated financial position, results of operations or liquidity.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">A sales tax accrual of $775,000 was recorded in <em style="font: inherit;">2019</em> for sales taxes that should have been collected from clients in <em style="font: inherit;">2019</em> and certain previous years. We received a revenue ruling from the state of Washington noting that our services are <em style="font: inherit;">not</em> subject to retail sales tax, and therefore, reversed $268,000 of sales tax accrual for the state of Washington in the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2020.</em> We have completed voluntary disclosure agreements with certain states, remitted past due sales tax, are remitting sales tax timely, are collecting sales tax from clients and <em style="font: inherit;">no</em> accrual for past due sales tax remains as of <em style="font: inherit;"> December 31, 2020. </em>State and local jurisdictions have differing rules and regulations governing sales, use, and other taxes and these rules and regulations can be complex and subject to varying interpretations that <em style="font: inherit;"> may </em>change over time. As a result, we could face the possibility of tax assessment and audits, and our liability for these taxes and associated interest and penalties could exceed our original estimates.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We became self-insured for group medical and dental insurance on <em style="font: inherit;"> January 1, 2019.   </em>We carry excess loss coverage in the amount of $150,000 per covered person per year for group medical insurance.  We do <em style="font: inherit;">not</em> self-insure for any other types of losses, and therefore do <em style="font: inherit;">not</em> carry any additional excess loss insurance.  We record a reserve for our group medical and dental insurance for all unresolved claims and for an estimate of incurred but <em style="font: inherit;">not</em> reported (“IBNR”) claims.  On a quarterly basis, we adjust our accrual based on a review of our claims experience and a <em style="font: inherit;">third</em>-party actuarial IBNR analysis.  As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> our accrual related to self-insurance was $418,000 and $270,000, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 775000 -268000 150000 418000 270000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Earnings Per Share</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Prior to the Recapitalization, net income per share of our former class A common stock and former class B common stock was computed using the <em style="font: inherit;">two</em>-class method. Basic net income per share was computed by allocating undistributed earnings to common shares and using the weighted-average number of common shares outstanding during the period.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The liquidation rights and the rights upon the consummation of an extraordinary transaction were the same for the holders of our former class A common stock and former class B common stock. Other than share distributions and liquidation rights, the amount of any dividend or other distribution payable on each share of former class A common stock was equal to <em style="font: inherit;">one</em>-<em style="font: inherit;">sixth</em> (<em style="font: inherit;">1/6th</em>) of the amount of any such dividend or other distribution payable on each share of former class B common stock. As a result, the undistributed earnings for each period were allocated based on the participation rights of the former class A and former class B common stock under our then-effective Articles of Incorporation as if the earnings for the year had been distributed.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">As described in Note <em style="font: inherit;">2,</em> we completed a Recapitalization in <em style="font: inherit;"> April 2018, </em>resulting in the elimination of the class B common stock and settlement of all then-existing outstanding class B share-based awards and reclassification of all class A common stock to Common Stock. The Recapitalization was effective on <em style="font: inherit;"> April 17, 2018. </em>Therefore, income was allocated between the former class A and class B stock using the <em style="font: inherit;">two</em>-class method through <em style="font: inherit;"> April 16, 2018, </em>and fully allocated to the Common Stock (formerly class A) following the Recapitalization.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We had 65,127, 16,221 and 93,346 options of Common Stock (former class A shares) for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(formerly</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Class A)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Class B</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands, except per share data)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator for net income per share - basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,406</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,423</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,624</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Allocation of distributed and undistributed income to unvested restricted stock shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(57</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income attributable to common shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,341</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,606</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator for net income per share - basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Weighted average common shares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,562</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,527</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per share - basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.08</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator for net income per share - diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income attributable to common shareholders for basic computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,341</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,606</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator for net income per share - diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common <b>s</b>hares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23,562</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,527</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average effect of dilutive securities – stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">526</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">844</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">886</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Denominator for diluted earnings per share – adjusted weighted average shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,628</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per share - diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.04</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.27</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> 65127 16221 93346 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(formerly</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Class A)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Class B</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands, except per share data)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator for net income per share - basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,406</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,423</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,624</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Allocation of distributed and undistributed income to unvested restricted stock shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(57</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income attributable to common shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,341</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,606</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator for net income per share - basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Weighted average common shares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,562</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,527</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per share - basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.08</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator for net income per share - diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income attributable to common shareholders for basic computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,341</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,606</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator for net income per share - diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common <b>s</b>hares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23,562</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,527</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average effect of dilutive securities – stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">526</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">844</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">886</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Denominator for diluted earnings per share – adjusted weighted average shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,628</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per share - diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.04</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.27</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 37260000 32406000 25423000 4624000 57000 109000 82000 18000 37203000 32297000 25341000 4606000 25170000 24809000 23562000 3527000 1.48 1.30 1.08 1.31 37203000 32297000 25341000 4606000 25170000 24809000 23562000 3527000 526000 844000 886000 101000 25696000 25653000 24448000 3628000 1.45 1.26 1.04 1.27 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted </b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> Simplifying the Accounting for Income Taxes (Topic <em style="font: inherit;">740</em>). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The guidance is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2020 </em>and interim periods within those fiscal years.  Early adoption is permitted in interim or annual periods with any adjustments reflected as of the beginning of the annual period that includes that interim period.  Additionally, entities that elect early adoption must adopt all the amendments in the same period.  Amendments are to be applied prospectively, except for certain amendments that are to be applied either retrospectively or with a modified retrospective approach through a cumulative effect adjustment recorded to retained earnings.  We believe the adoption will <em style="font: inherit;">not</em> significantly impact our results of operations and financial position.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">In <em style="font: inherit;"> March 2020, </em>FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">04,</em> "Reference Rate Reform (Topic <em style="font: inherit;">848</em>): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of <em style="font: inherit;"> March 12, 2020 </em>through <em style="font: inherit;"> December 31, 2022. </em>We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tbody> <tr> <td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">2</em>) </b></p> </td> <td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Recapitalization</span></b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">On <em style="font: inherit;"> April 16, 2018, </em>our shareholders approved, among other things, an amendment to our Amended and Restated Articles of Incorporation (the “Articles”) to effect a recapitalization (the “Recapitalization”) pursuant to which each share of our then-existing class B common stock was exchanged for <span style="-sec-ix-hidden:c70062079">one</span> share of the our then-existing Class A common stock plus $19.59 in cash, without interest. On <em style="font: inherit;"> April 17, 2018, </em>we filed an amendment to our Articles effecting the Recapitalization, followed by an amendment and restatement of our Articles, which resulted in the elimination of our class B common stock and the reclassification of our class A common stock as a share of Common Stock, par value $0.001 per share (“Common Stock”). We issued 3,617,615 shares of Common Stock and paid $72.4 million in exchange for all class B shares outstanding and to settle outstanding share-based awards for class B common stock. The Common Stock continues to trade on the NASDAQ Global Market under the revised symbol “NRC.”</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">In connection with the Recapitalization, on <em style="font: inherit;"> April 18, 2018, </em>we entered into a credit agreement with First National Bank of Omaha, a national banking association (“FNB”), as described in Note <em style="font: inherit;">8.</em> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> 19.59 0.001 3617615 72400000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">3</em>) </b></p> </td><td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Contracts with Customers</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table disaggregates revenue for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> based on timing of revenue recognition (In thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 994px; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 531px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 129px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 9px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 11px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 127px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 9px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 10px;"> </td><td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 125px; border-bottom: thin solid rgb(0, 0, 0); text-align: center;">2018</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 7px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 531px;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Subscription services recognized ratably over time</p> </td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">122,499</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">114,216</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 111px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">104,777</td><td style="width: 7px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 531px;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Services recognized at a point in time</p> </td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,932</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,992</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 111px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,775</td><td style="width: 7px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 531px;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fixed, non-subscription recognized over time</p> </td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,907</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,248</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 111px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,163</td><td style="width: 7px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 531px;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unit price services recognized over time</p> </td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,939</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,526</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 111px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); text-align: right;">6,971</td><td style="width: 7px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 531px;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total revenue</p> </td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,277</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127,982</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 111px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black; text-align: right;">119,686</td><td style="width: 7px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our solutions within the digital VoC platform in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> accounted for 73.3%, 62.7% and 49.6% of total revenue, respectively. The remaining revenue consists of legacy Experience and Governance Solutions.  </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (In thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivables</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,923</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,639</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contract assets included in other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">103</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,585</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(16,354</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Significant changes in contract assets and contract liabilities during the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> are as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contract</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Asset</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deferred</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Revenue</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contract</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Asset</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deferred</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Revenue</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Increase (Decrease)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Revenue recognized that was included in deferred revenue at beginning of year due to completion of services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(16,083</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,785</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Increases due to invoicing of client, net of amounts recognized as revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,631</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Decreases due to completion of services (or portion of services) and transferred to accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(103</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Change due to cumulative catch-up adjustments arising from changes in expected contract consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">264</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Increases due to revenue recognized in the period with additional performance obligations before invoicing</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">103</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We have elected to apply the practical expedient to <em style="font: inherit;">not</em> disclose the value of unsatisfied performance obligations for contracts with an original expected length of <em style="font: inherit;">one</em> year or less. Total remaining contract revenue for contracts with original duration of greater than <em style="font: inherit;"><span style="-sec-ix-hidden:c70062098">one</span></em> year expected to be recognized in the future related to performance obligations that are unsatisfied at <em style="font: inherit;"> December 31, 2020 </em>approximated $205,000, which is expected to be recognized during <em style="font: inherit;">2021.</em></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 994px; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 531px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 129px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 9px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 11px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 127px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 9px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 10px;"> </td><td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 125px; border-bottom: thin solid rgb(0, 0, 0); text-align: center;">2018</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 7px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 531px;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Subscription services recognized ratably over time</p> </td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">122,499</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">114,216</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 111px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">104,777</td><td style="width: 7px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 531px;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Services recognized at a point in time</p> </td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,932</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,992</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 111px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,775</td><td style="width: 7px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 531px;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fixed, non-subscription recognized over time</p> </td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,907</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,248</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 111px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,163</td><td style="width: 7px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 531px;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unit price services recognized over time</p> </td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,939</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,526</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 111px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); text-align: right;">6,971</td><td style="width: 7px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 531px;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total revenue</p> </td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,277</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 11px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 115px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127,982</td><td style="width: 9px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 10px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 111px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black; text-align: right;">119,686</td><td style="width: 7px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 122499000 114216000 104777000 2932000 4992000 4775000 2907000 3248000 3163000 4939000 5526000 6971000 133277000 127982000 119686000 0.733 0.627 0.496 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivables</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,923</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,639</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contract assets included in other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">103</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,585</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(16,354</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contract</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Asset</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deferred</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Revenue</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contract</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Asset</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deferred</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Revenue</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Increase (Decrease)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Revenue recognized that was included in deferred revenue at beginning of year due to completion of services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(16,083</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,785</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Increases due to invoicing of client, net of amounts recognized as revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,631</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Decreases due to completion of services (or portion of services) and transferred to accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(103</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Change due to cumulative catch-up adjustments arising from changes in expected contract consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">264</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Increases due to revenue recognized in the period with additional performance obligations before invoicing</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">103</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 13923000 11639000 311000 103000 15585000 16354000 16083000 15785000 15338000 15631000 103000 53000 24000 -264000 311000 103000 205000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">4</em>) </b></p> </td><td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Equity Investments</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We make equity investments to promote business and strategic objectives. For investments that do <em style="font: inherit;">not</em> have a readily determinable fair value, we apply either cost or equity method of accounting depending on the nature of our investment and our ability to exercise significant influence. Investments are periodically analyzed to determine whether or <em style="font: inherit;">not</em> there are any indicators of impairment and written down to fair value if the investment has incurred an other than temporary impairment. Our investment of $1.3 million in convertible preferred stock of PracticingExcellence.com, Inc., a privately-held Delaware corporation (“PX”) is included in non-current assets. It is <em style="font: inherit;">not</em> practicable for us to estimate fair value at each reporting date due to the cost and complexity of the calculations for this non-public entity. Therefore, it is carried at cost less impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, if any. We have a seat on PX's board of directors and our investment, which is <em style="font: inherit;">not</em> considered to be in-substance common stock, represents approximately 15.7% of the issued and outstanding equity interests in PX.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> 1300000 0.157 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">5</em>)</b></p> </td><td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Property and Equipment</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">At <em style="font: inherit;"> December 31, 2020, </em>and <em style="font: inherit;">2019,</em> property and equipment consisted of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,808</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,706</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,532</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Building</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,515</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leaseholds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">232</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">425</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">425</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment at cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,705</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,078</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,979</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,548</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,726</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,530</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Depreciation and amortization expense related to property and equipment, including assets under capital lease, for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> was $6.5 million, $5.4 million, and $4.8 million, respectively. There were <span style="-sec-ix-hidden:c70062157"><span style="-sec-ix-hidden:c70062156"><span style="-sec-ix-hidden:c70062158">no</span></span></span> significant impairments in property and equipment during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018.</em> However, we did shorten the useful lives of certain assets to reflect our best estimate of when assets are expected to be disposed of or replaced.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,808</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,706</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,532</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Building</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,515</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leaseholds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">232</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">425</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">425</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment at cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,705</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,078</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,979</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,548</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,726</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,530</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 4808000 5025000 2638000 2706000 27087000 24532000 7515000 9349000 232000 41000 425000 425000 42705000 42078000 30979000 28548000 11726000 13530000 6500000 5400000 4800000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tbody> <tr> <td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">6</em>) </b></p> </td> <td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Goodwill and Intangible Assets </span></b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Goodwill and intangible assets consisted of the following at <em style="font: inherit;"> December 31, 2020:</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Impairment</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,969</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(714</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,255</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Useful Life</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amortization</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In years)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-amortizing intangible assets:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Indefinite trade name</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortizing intangible assets:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer related</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; vertical-align: middle; text-align: center;"><em style="font: inherit;">-</em></td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,344</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Technology</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">7</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,360</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,229</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">131</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortizing intangible assets</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,276</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,057</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">219</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total intangible assets other than goodwill</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,467</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,057</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,410</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Goodwill and intangible assets consisted of the following at <em style="font: inherit;"> December 31, 2019:</em></p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Impairment</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,935</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,935</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Useful Life</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amortization</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In years)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-amortizing intangible assets:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Indefinite trade name</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortizing intangible assets:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer related</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,338</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,154</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">184</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Technology</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">7</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,360</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,007</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">353</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortizing intangible assets</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,270</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,733</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">537</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total intangible assets other than goodwill</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,461</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,733</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,728</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0">The following represents a summary of changes in the carrying amount of goodwill for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> (in thousands):</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2018</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,831</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency translation</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">104</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2019</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,935</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Impairment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(714</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency translation</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2020</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,255</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">As discussed in Note <em style="font: inherit;">1,</em> we recorded an impairment of $714,000 to the Canada reporting unit’s goodwill in <em style="font: inherit;"> December 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Aggregate amortization expense for customer related intangibles, trade names, and technology for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> was $318,000, $374,000, and $662,000, respectively. Estimated future amortization expense for <em style="font: inherit;">2021,</em> <em style="font: inherit;">2022</em> and <em style="font: inherit;">2023</em> is $180,000, $40,000, and -0-, respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Impairment</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,969</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(714</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,255</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Useful Life</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amortization</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In years)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-amortizing intangible assets:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Indefinite trade name</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortizing intangible assets:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer related</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; vertical-align: middle; text-align: center;"><em style="font: inherit;">-</em></td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,344</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Technology</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">7</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,360</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,229</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">131</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortizing intangible assets</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,276</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,057</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">219</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 41%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total intangible assets other than goodwill</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,467</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,057</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,410</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Impairment</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,935</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,935</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Useful Life</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accumulated</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amortization</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Net</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In years)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-amortizing intangible assets:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Indefinite trade name</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,191</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortizing intangible assets:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer related</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,338</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,154</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">184</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Technology</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">7</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,360</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,007</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">353</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td> <td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amortizing intangible assets</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,270</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,733</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">537</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 37%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total intangible assets other than goodwill</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,461</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,733</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,728</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 57969000 714000 57255000 1191000 1191000 P5Y P15Y 9344000 9256000 88000 P7Y 1360000 1229000 131000 P5Y P10Y 1572000 1572000 12276000 12057000 219000 13467000 12057000 1410000 57935000 -0 57935000 1191000 1191000 P5Y P15Y 9338000 9154000 184000 P7Y 1360000 1007000 353000 P5Y P10Y 1572000 1572000 12270000 11733000 537000 13461000 11733000 1728000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2018</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,831</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency translation</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">104</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2019</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,935</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Impairment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(714</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency translation</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2020</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,255</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 57831000 104000 57935000 714000 34000 57255000 714000 318000 374000 662000 180000 40000 0 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">7</em>) </b></p> </td><td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Income Taxes </span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">For the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> income before income taxes consists of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. Operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,357</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,056</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign Operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">110</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">474</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income before income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,467</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,519</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,709</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Income tax expense consisted of the following components:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Federal:</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,546</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,574</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">718</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,328</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,238</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,292</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,472</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Foreign</span>:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">225</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">882</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(178</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">219</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">704</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">State</span>:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">578</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">172</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">372</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">282</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,694</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">486</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,113</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Federal Tax Reform</b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">On <em style="font: inherit;"> December 22, 2017, </em>the Tax Cut and Jobs Act (the “Tax Act”) was enacted which made broad and complex changes to the U.S. tax code, including the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:28pt;"> </td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reduction in the U.S. Federal Corporate Tax Rate: The Tax Act reduced the corporate tax rate to 21%, effective<br/> <em style="font: inherit;"> January 1, 2018</em></p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:28pt;"> </td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Availability of <em style="font: inherit;">100%</em> bonus depreciation on assets placed in service after <em style="font: inherit;"> September 27, 2017</em></p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:28pt;"> </td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain stock compensation plans potentially subject to limitations on excess tax benefits</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:28pt;"> </td><td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Global Intangible Low Taxed Income (GILTI) provision</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">As a result of the Tax Act, we determined that we would <em style="font: inherit;">no</em> longer indefinitely reinvest the earnings of our Canadian subsidiary. Our Canadian subsidiary declared a deemed dividend to the Company for $9.6 million and $3 million in <em style="font: inherit;">2020</em> and <em style="font: inherit;">2018,</em> respectively. Additionally, a withholding tax of <em style="font: inherit;">5%</em> was paid for each dividend distribution.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The Tax Act subjects a U.S. corporation to tax on its Global Intangible Low Taxed Income (“GILTI”). Due to the complexity of the new GILTI tax rules, we are continuing to evaluate this provision of the Tax Act. Under Generally Accepted Accounting Principles, we can make an accounting policy election to either treat taxes due on the GILTI inclusion as a current period expense or factor such amounts into the measurement of deferred taxes. We elected the current period expense method and have <em style="font: inherit;">not</em> reflected any corresponding deferred tax assets and liabilities associated with the GILTI tax in the table of deferred tax assets and liabilities. GILTI tax has been recorded as current period expense of $10,000, $13,000, and $40,000 in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We received notice in <em style="font: inherit;"> December 2019, </em>that we met qualification requirements for the Nebraska Advantage <em style="font: inherit;">LB312</em> Act (“NAA”) related to certain investment and full-time equivalent employee thresholds in the year ended <em style="font: inherit;">2017.</em> NAA provides direct refunds of sales tax on qualified property, as well as investment credits and employment credits that can be claimed through credits of Nebraska income tax, employment tax, and sales tax on non-qualified property. We will receive direct refunds of Nebraska sales tax on qualified property incurred from <em style="font: inherit;">2014</em> to <em style="font: inherit;">2023.</em> Investment credits started to accumulate in <em style="font: inherit;">2014</em> and can be earned through <em style="font: inherit;">2023.</em> These credits can be claimed against Nebraska income taxes or through sales tax on non-qualified property through <em style="font: inherit;">2028.</em> The employment credits are earned from <em style="font: inherit;">2017</em> through <em style="font: inherit;">2023,</em> and they can be claimed against Nebraska payroll taxes through <em style="font: inherit;">2028.</em> In <em style="font: inherit;">2019,</em> we recorded cumulative adjustments for direct refunds and credits earned through the year ending <em style="font: inherit;"> December 31, 2019, </em>which reduced operating expenses by approximately $1.9 million. For the year ended <em style="font: inherit;"> December 31, 2020, </em>adjustments for credits reduced operating expenses by approximately $435,000. In addition, income tax credits of $45,000 and $24,000 were recorded as a reduction to income tax expense for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The differences between income taxes expected at the U.S. federal statutory income tax rate of <em style="font: inherit;">21</em> percent and the reported income tax (benefit) expense are summarized as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected federal income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,509</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,285</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign tax rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">146</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal benefit and state tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">607</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,344</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,579</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,041</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensation limit for covered employees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(261</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(150</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Uncertain tax positions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">157</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">90</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nondeductible expenses (income) related to recapitalization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">151</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill Impairment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">184</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tax depreciation method change</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Withholding tax on repatriation of foreign earnings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">107</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">GILTI</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">102</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,113</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Deferred tax assets and liabilities at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> were comprised of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Allowance for doubtful accounts</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">537</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">735</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,267</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued bonuses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Employer payroll tax deferral</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">323</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Foreign tax credit from repatriation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">535</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,955</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(535</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,955</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,959</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Prepaid expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">135</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred contract costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">990</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,725</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,926</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,553</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Repatriation withholding</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">174</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">528</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Unrealized translation gain on intercompany loan</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">214</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,220</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,358</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,265</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,399</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> March 27, 2020, </em>the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The CARES Act is an emergency economic stimulus package in response to the coronavirus outbreak which, among other things, contains numerous income tax provisions. As a result of the CARES Act, we have deferred $1,323,000 of employer social security tax payments into future years. We have had <em style="font: inherit;">no</em> other impacts to our consolidated financial statements or related disclosures from the CARES Act.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">In assessing the realizability of deferred tax assets, we consider whether it is more likely than <em style="font: inherit;">not</em> that some portion, or all, of the deferred tax assets will <em style="font: inherit;">not</em> be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider projected future taxable income, carry-back opportunities, and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods which the deferred tax assets are deductible, we believe it is more likely than <em style="font: inherit;">not</em> that we will realize the benefits of these deductible differences excluding the foreign tax credit carryforward. In <em style="font: inherit;">2020,</em> we wrote off the deferred tax asset for prior year foreign tax credit carryforwards of $535,000 and the related valuation allowance. We made the assessment that due to our Canadian subsidiary’s decreased projected future income and the lower US tax rate compared to the Canadian tax rate, it was unlikely we would realize this asset.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We had an unrecognized tax benefit at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> of $768,000 and $592,000, respectively, excluding interest of $15,000 and $7,000 at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. Of these amounts, $668,000 and $515,000 at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively, represents the net unrecognized tax benefits that, if recognized, would favorably impact the effective income tax rate. The change in the unrecognized tax benefits for <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance of unrecognized tax benefits at December 31, 2018</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">554</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to lapse of applicable statute of limitations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(43</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to tax positions of prior years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to settlement with taxing authorities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(300</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">381</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance of unrecognized tax benefits at December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">592</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to lapse of applicable statute of limitations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions due to tax positions of prior years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to settlement with taxing authorities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">206</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance of unrecognized tax benefits at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">768</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We file income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and Canada federal and provincial jurisdictions. Tax years <em style="font: inherit;">2017</em> and forward remain subject to U.S. federal examination. Tax years <em style="font: inherit;">2014</em> and forward remain subject to state examination. Tax years <em style="font: inherit;">2016</em> and forward remain subject to Canadian federal and provincial examination.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. Operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,357</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32,056</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign Operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">110</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">474</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income before income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,467</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,519</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,709</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 41357000 40045000 32056000 110000 474000 2653000 41467000 40519000 34709000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Federal:</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,546</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,574</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">718</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,328</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,238</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,292</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,472</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Foreign</span>:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">225</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">882</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(178</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">219</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">704</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">State</span>:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">578</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">172</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">372</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">282</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,694</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">486</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,113</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 3546000 5574000 2144000 -308000 718000 1328000 3238000 6292000 3472000 225000 94000 882000 -6000 33000 -178000 219000 127000 704000 578000 1322000 204000 172000 372000 282000 750000 1694000 486000 4207000 8113000 4662000 0.21 9600000 3000000 10000 13000 40000 1900000 435000 45000 24000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected federal income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,509</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,285</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign tax rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">146</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal benefit and state tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">607</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,344</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,579</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,041</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensation limit for covered employees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(261</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(150</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Uncertain tax positions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">157</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">90</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nondeductible expenses (income) related to recapitalization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">151</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill Impairment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">184</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tax depreciation method change</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Withholding tax on repatriation of foreign earnings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">107</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">GILTI</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">102</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,113</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 8708000 8509000 7285000 6000 26000 146000 607000 1344000 376000 -5713000 -1579000 -3041000 463000 261000 419000 150000 157000 34000 90000 -24000 151000 184000 -308000 18000 107000 10000 13000 40000 28000 102000 73000 4207000 8113000 4662000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Allowance for doubtful accounts</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">537</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">735</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,267</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued bonuses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Employer payroll tax deferral</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">323</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Foreign tax credit from repatriation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">535</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,955</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(535</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,955</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,959</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Prepaid expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">135</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred contract costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">990</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,725</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,926</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,553</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Repatriation withholding</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">174</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">528</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Unrealized translation gain on intercompany loan</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">214</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,220</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,358</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,265</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,399</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> 29000 35000 696000 537000 735000 1267000 145000 120000 323000 535000 27000 1955000 2494000 535000 1955000 1959000 93000 135000 1111000 990000 1725000 1926000 6109000 5553000 174000 528000 214000 8000 12000 9220000 9358000 7265000 7399000 1323000 535000 768000 592000 15000 7000 668000 515000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance of unrecognized tax benefits at December 31, 2018</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">554</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to lapse of applicable statute of limitations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(43</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to tax positions of prior years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to settlement with taxing authorities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(300</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">381</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance of unrecognized tax benefits at December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">592</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to lapse of applicable statute of limitations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions due to tax positions of prior years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reductions due to settlement with taxing authorities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">206</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance of unrecognized tax benefits at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">768</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 554000 43000 300000 381000 592000 34000 4000 206000 768000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">8</em>) </b></p> </td><td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Notes Payable</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our long-term debt consists of the following:  </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Term Loans</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less: current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,061</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,378</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less: unamortized debt issuance costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(108</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Notes payable, net of current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,547</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,795</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our credit agreement (the “Credit Agreement”) with First National Bank of Omaha (“FNB”) was amended and restated on <em style="font: inherit;"> May 28, 2020 </em>and includes (i) a <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">$30,000,000</em> revolving credit facility (the “Line of Credit”), (ii) a $33,002,069 term loan (the “Term Loan”) and (iii) a $15,000,000 delayed draw-dawn term facility (the “Delayed Draw Term Loan” and, together with the Line of Credit and the Term Loan, the “Credit Facilities”). The Delayed Draw Term Loan <em style="font: inherit;"> may </em>be used to fund any permitted future business acquisitions or repurchases of our Common Stock and the Line of Credit can be used to fund ongoing working capital needs and for other general corporate purposes. The <em style="font: inherit;"> May 2020 </em>amendment increased the Line of Credit from $15,000,000 to $30,000,000.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The amended Term Loan revised the remaining payments for the existing balance outstanding of <em style="font: inherit;">$33,002,069</em> to monthly installments of $462,988 through <em style="font: inherit;"> May 2025, </em>with a balloon payment due at maturity in <em style="font: inherit;"> May 2025. </em>The Term Loan bears interest at a fixed rate per annum of 5%. Borrowings under the Line of Credit and the Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the <em style="font: inherit;">30</em>-day London Interbank Offered Rate plus 225 basis points (2.40% at <em style="font: inherit;"> December 31, 2020). </em>Interest on the Line of Credit accrues and is payable monthly. Principal amounts outstanding under the Line of Credit are due and payable in full at maturity, in <em style="font: inherit;"> May 2023. </em>There were <span style="-sec-ix-hidden:c70062497">no</span> borrowings on the Line of Credit during <em style="font: inherit;">2020.</em> There have been <em style="font: inherit;">no</em> borrowings on the Delayed Draw Term Loan since origination.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We are obligated to pay ongoing unused commitment fees quarterly in arrears pursuant to the Line of Credit and the Delayed Draw Term Loan facility at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility, respectively.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The Credit Agreement is collateralized by substantially all of our assets, subject to permitted liens and other agreed exceptions, and contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our Common Stock and acquisitions, subject in each case to certain exceptions. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of <span style="-sec-ix-hidden:c70062502">1.10x</span> for all testing periods throughout the terms of the Credit Facilities, which calculation excludes, unless our liquidity falls below a specified threshold, (i) any cash dividend in a fiscal quarter that, together with all other cash dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash dividends paid or declared, (ii) the portion of the purchase price for any permitted share repurchase of our shares paid with cash on hand, and (iii) the portion of any acquisition consideration for a permitted acquisition paid with cash on hand. We are also required to maintain a cash flow leverage ratio of <span style="-sec-ix-hidden:c70062504">3.00x</span> or less for all testing periods throughout the term(s) of the Credit Facilities. As of <em style="font: inherit;"> December 31, 2020, </em>we were in compliance with our financial covenants.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Scheduled maturities of notes payable at <em style="font: inherit;"> December 31, 2020 </em>are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 36pt; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 82%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,093</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,529</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,762</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,023</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Term Loans</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less: current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,061</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,378</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less: unamortized debt issuance costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(108</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Notes payable, net of current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,547</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,795</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 30713000 34281000 4061000 4378000 105000 108000 26547000 29795000 33002069 15000000 15000000 30000000 462988 0.05 0.0225 0.0240 0.0020 5500000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 36pt; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 82%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,093</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,529</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,762</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,023</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 4093000 4306000 4529000 4762000 13023000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">9</em>)</b></p> </td><td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Share-Based Compensation</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We measure and recognize compensation expense for all share-based payments based on the grant-date fair value of those awards. All of our existing stock option awards and unvested stock awards have been determined to be equity-classified awards. We account for forfeitures as they occur. As described in Note <em style="font: inherit;">2,</em> we completed a Recapitalization in <em style="font: inherit;"> April </em><em style="font: inherit;">2018</em> which, among other things, settled all then-existing outstanding class B share-based awards and resulted in the elimination of the class B common stock. As a result, we accelerated vesting of all outstanding class B share-based awards, resulting in accelerated share-based compensation of $331,000 in the year ended <em style="font: inherit;"> December 31, 2018. </em>All outstanding class B share-based awards were then settled for the same stock to cash proportion of the class B common stock described in Note <em style="font: inherit;">2,</em> less the exercise price, if any, which approximated the awards’ intrinsic values.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our <em style="font: inherit;">2001</em> Equity Incentive Plan provided for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of our former class A common stock and 300,000 shares of our former class B common stock. Stock options granted could have been either nonqualified or incentive stock options. Stock options vest over <span style="-sec-ix-hidden:c70062537">one</span> to <span style="-sec-ix-hidden:c70062538">five</span> years following the date of grant and option terms are generally <span style="-sec-ix-hidden:c70062539">five</span> to <span style="-sec-ix-hidden:c70062540">ten</span> years following the date of grant. Due to the expiration of the <em style="font: inherit;">2001</em> Equity Incentive Plan, at <em style="font: inherit;"> December 31, 2015, </em>there were no shares of stock available for future grants.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our <em style="font: inherit;">2004</em> Non-Employee Director Stock Plan, as amended (the <em style="font: inherit;">“2004</em> Director Plan”), is a nonqualified plan that provides for the granting of options with respect to 3,000,000 shares of our Common Stock and, prior to the Recapitalization, 500,000 shares of our former class B common stock. The <em style="font: inherit;">2004</em> Director Plan provides for grants of nonqualified stock options to each of our directors who we do <em style="font: inherit;">not</em> employ. Beginning in <em style="font: inherit;">2018,</em> on the date of each annual meeting of shareholders, options to purchase shares of Common Stock equal to an aggregate grant date fair value of $100,000 are granted to each non-employee director that is elected or retained as a director at each such meeting. Stock options vest approximately <span style="-sec-ix-hidden:c70062551">one</span> year following the date of grant and option terms are generally the earlier of <span style="-sec-ix-hidden:c70062552">ten</span> years following the date of grant, or <span style="-sec-ix-hidden:c70062553">three</span> years from the termination of the outside director’s service. At <em style="font: inherit;"> December 31, 2020, </em>there were 830,419 shares of Common Stock available for issuance pursuant to future grants under the <em style="font: inherit;">2004</em> Director Plan. We have accounted for grants of 2,169,581 shares of Common Stock under the <em style="font: inherit;">2004</em> Director Plan using the date of grant as the measurement date for financial accounting purposes.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our <em style="font: inherit;">2006</em> Equity Incentive Plan (the <em style="font: inherit;">“2006</em> Equity Incentive Plan”), as amended, provides for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of Common Stock and, prior to the Recapitalization, 300,000 shares of our former class B common stock. Stock options granted <em style="font: inherit;"> may </em>be either incentive stock options or nonqualified stock options. Vesting terms vary with each grant and option terms are generally <span style="-sec-ix-hidden:c70062562">five</span> to <span style="-sec-ix-hidden:c70062563">ten</span> years following the date of grant. At <em style="font: inherit;"> December 31, 2020, </em>there were 779,800 shares of Common Stock available for issuance pursuant to future grants under the <em style="font: inherit;">2006</em> Equity Incentive Plan. We have accounted for grants of 1,020,200 shares of Common Stock and restricted stock under the <em style="font: inherit;">2006</em> Equity Incentive Plan using the date of grant as the measurement date for financial accounting purposes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">During <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> we granted options to purchase 70,471, 100,615 and 116,276 shares of Common Stock, respectively. Options to purchase shares of common stock are typically granted with exercise prices equal to the fair value of the common stock on the date of grant. We do, in certain limited situations, grant options with exercise prices that exceed the fair value of the common shares on the date of grant. The fair value of stock options granted was estimated using a Black-Scholes valuation model with the following weighted average assumptions:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 36pt; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield at date of grant</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33.62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.35</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of our stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years we estimate that options will be outstanding. We consider groups of associates that have similar historical exercise behavior separately for valuation purposes.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table summarizes stock option activity under the <em style="font: inherit;">2001</em> and <em style="font: inherit;">2006</em> Equity Incentive Plans and the <em style="font: inherit;">2004</em> Director Plan for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number of<br/> Options</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Remaining</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contractual</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Terms</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Aggregate</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Intrinsic</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Common Stock</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,245,922</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.08</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70,471</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62.23</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(630,373</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14.20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,912</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(85,449</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">600,571</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.58</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,665</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">270,876</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,811</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table summarizes information related to stock options for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 36pt; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average grant date fair value of stock options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.67</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10.02</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intrinsic value of stock options exercised (in thousands)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,912</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,280</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,621</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intrinsic value of stock options vested (in thousands)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,965</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,891</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,719</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">As of <em style="font: inherit;"> December 31, 2020, </em>the total unrecognized compensation cost related to non-vested stock option awards was approximately $1.4 million which was expected to be recognized over a weighted average period of 2.96 years.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">There was $1.7 million in cash received from stock options exercised for the year ended <em style="font: inherit;"> December 31, 2020 </em>and <span style="-sec-ix-hidden:c70062585"><span style="-sec-ix-hidden:c70062586">no</span></span> cash received from options exercised in <em style="font: inherit;">2019</em> or <em style="font: inherit;">2018.</em> We recognized $680,000, $934,000 and $1.1 million of non-cash compensation for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively, related to options, which is included in direct and selling, general and administrative expenses. The actual tax benefit realized for the tax deduction from stock options exercised was $6.3 million, $2.0 million and $3.8 million for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">During <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> we granted 6,005 and 6,793 non-vested shares of Common Stock, respectively, under the <em style="font: inherit;">2006</em> Equity Incentive Plan. <span style="-sec-ix-hidden:c70062605">No</span> shares of non-vested Common Stock were granted during the year ended <em style="font: inherit;"> December 31, 2020. </em>As of <em style="font: inherit;"> December 31, 2020, </em>we had 6,005 non-vested shares of Common Stock outstanding under the <em style="font: inherit;">2006</em> Equity Incentive Plan. These shares vest over <span style="-sec-ix-hidden:c70062608">five</span> years following the date of grant and holders thereof are entitled to receive dividends from the date of grant, whether or <em style="font: inherit;">not</em> vested. The fair value of the awards is calculated as the fair market value of the shares on the date of grant. We recognized $23,000, $290,000 and $428,000 of non-cash compensation for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively, related to this non-vested stock, which is included in direct and selling, general and administrative expenses. The actual tax benefit realized for the tax deduction from vesting of restricted stock was $235,000 and $168,000 for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2018,</em> respectively. No restricted stock vested during the year end <em style="font: inherit;"> December 31, 2019.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table summarizes information regarding non-vested stock granted to associates under the <em style="font: inherit;">2006</em> Equity Incentive Plans for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Outstanding</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average Grant</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date Fair Value</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Per Share</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">84,176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.23</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(71,378</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13.59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,793</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,005</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">As of <em style="font: inherit;"> December 31, 2020, </em>the total unrecognized compensation cost related to non-vested stock awards was approximately $138,000 and is expected to be recognized over a weighted average period of 3.00 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 331000 1800000 300000 0 3000000 500000 100000 830419 2169581 1800000 300000 779800 1020200 70471 100615 116276 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 36pt; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield at date of grant</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33.62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.35</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 0.0184 0.0260 0.0259 0.3362 0.3401 0.3247 0.0135 0.0238 0.0251 P7Y4M20D P7Y5M15D P7Y3M10D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number of<br/> Options</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Remaining</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contractual</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Terms</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Aggregate</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Intrinsic</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Common Stock</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,245,922</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.08</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70,471</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62.23</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(630,373</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14.20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,912</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(85,449</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">32.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">600,571</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.58</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,665</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">270,876</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,811</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1245922 18.08 70471 62.23 630373 14.20 25912000 85449 32.28 600571 25.31 P5Y6M29D 11665000 270876 18.00 P4Y1M20D 6811000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 36pt; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Stock</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average grant date fair value of stock options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.67</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10.02</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intrinsic value of stock options exercised (in thousands)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,912</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,280</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,621</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intrinsic value of stock options vested (in thousands)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,965</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,891</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,719</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 18.67 11.99 10.02 25912000 8280000 10621000 1965000 1891000 2719000 1400000 P2Y11M15D 1700000 680000 934000 1100000 6300000 2000000.0 3800000 6005 6793 6005 23000 290000 428000 235000 168000 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Outstanding</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average Grant</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date Fair Value</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Per Share</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">84,176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.23</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(71,378</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13.59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,793</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,005</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 84176 17.23 71378 13.59 6793 36.80 6005 38.30 138000 P3Y <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:4.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">10</em>) </b></p> </td><td style="vertical-align:top;width:0%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Leases</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We lease printing, computer, other equipment and office space in the United States and Canada. The leases remaining terms as of <em style="font: inherit;"> December 31, 2020 </em>range from less than <span style="-sec-ix-hidden:c70062690">one</span> year to 4.7 years.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Certain equipment and office lease agreements include provisions for periodic adjustments to rates and charges. The rates and charges are adjusted based on actual usage or actual costs for internet, common area maintenance, taxes or insurance, as determined by the lessor and are considered variable lease costs.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The components of lease expense for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> included (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finance leases:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Asset amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">355</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">252</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Interest on lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Variable lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">In <em style="font: inherit;">2020,</em> we adjusted the useful life of the operating right of use assts associated with our Atlanta, Georgia and Markham, Ontario office leases based on the expectation that we will vacate the office space before the end of the lease term. We recorded rent expense in connection with our operating leases of $779,000 in <em style="font: inherit;">2018.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Supplemental balance sheet information related to leases (in thousands):     </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Operating leases:</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating ROU assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,628</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Current operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">524</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Noncurrent operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,357</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,663</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Finance leases:</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,014</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">802</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Computer Equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">511</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Computer Software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment under finance lease, gross</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,883</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,520</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Less accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment under finance lease, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">786</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current obligations of finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">227</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Noncurrent obligations of finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">778</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">559</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total finance lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">786</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Weighted average remaining lease term (in years):</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Operating leases</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.68</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Finance leases</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.69</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.56</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Weighted average discount rate:</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Operating leases</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Finance leases</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Supplemental cash flow and other information related to leases were as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">596</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">789</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating cash flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Financing cash flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">332</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">229</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ROU assets obtained in exchange for operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ROU assets obtained in exchange for finance lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">817</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">192</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Undiscounted payments under non-cancelable finance and operating leases at <em style="font: inherit;"> December 31, 2020 </em>were as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Finance Leases</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Operating Leases</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">527</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">509</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">481</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">305</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">319</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">118</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total minimum lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,326</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,471</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Less: Amount representing interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(55</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(114</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Present value of minimum lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,357</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease obligations, net of current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">778</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">In addition to the above, we have an operating lease for office space commencing <em style="font: inherit;"> February 2021 </em>which requires monthly base rent payments of $14,288 through <em style="font: inherit;"> January 2024. </em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> P4Y8M12D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finance leases:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Asset amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">355</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">252</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Interest on lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Variable lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net lease cost</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 600000 781000 355000 252000 37000 39000 62000 86000 42000 42000 1096000 1200000 779000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Operating leases:</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating ROU assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,308</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,628</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Current operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">524</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Noncurrent operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,357</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,663</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Finance leases:</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,014</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">802</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Computer Equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">511</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Computer Software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment under finance lease, gross</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,883</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,520</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Less accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(605</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment under finance lease, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">786</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current obligations of finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">227</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Noncurrent obligations of finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">778</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">559</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total finance lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">786</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Weighted average remaining lease term (in years):</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Operating leases</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.68</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Finance leases</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.69</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.56</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Weighted average discount rate:</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Operating leases</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Finance leases</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> 1308000 1628000 461000 524000 896000 1139000 1357000 1663000 1014000 802000 662000 511000 207000 207000 1883000 1520000 605000 734000 1278000 786000 493000 227000 778000 559000 1271000 786000 P3Y8M4D P4Y2M1D P2Y8M8D P3Y6M21D 0.0440 0.0481 0.0338 0.0460 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">596</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">789</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating cash flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Financing cash flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">332</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">229</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ROU assets obtained in exchange for operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ROU assets obtained in exchange for finance lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">817</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">192</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 596000 789000 36000 38000 332000 229000 276000 16000 817000 192000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Finance Leases</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Operating Leases</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">527</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">509</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">481</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">305</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">319</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">118</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">--</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total minimum lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,326</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,471</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Less: Amount representing interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(55</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(114</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Present value of minimum lease payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,357</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease obligations, net of current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">778</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 527000 509000 481000 322000 305000 319000 13000 203000 118000 1326000 1471000 55000 114000 1271000 1357000 493000 461000 778000 896000 14288 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tbody> <tr> <td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">11</em>) </b></p> </td> <td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Related Party</span></b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Until <em style="font: inherit;"> January 2020, </em><em style="font: inherit;">one</em> of our directors served as an officer and director of Ameritas Life Insurance Corp. (“Ameritas”) and continues to service on the board of directors of Ameritas. In connection with our regular assessment of our insurance-based associate benefits, which is conducted by an independent insurance broker, and the costs associated therewith, we purchase dental and vision insurance for certain of our associates from Ameritas. The total value of these purchases was $248,000, $242,000 and $200,000 in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> respectively.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">A director, who served on our board through <em style="font: inherit;"> May 2020, </em>also served as a board member of IMA Financial Group. In connection with our regular assessment of our liability coverage, during <em style="font: inherit;">2020</em> we began purchasing directors and officers and employment practices liability insurance through IMA Financial Group. Total payments for these services totaled $1.1 million with $478,000 recorded as expense in <em style="font: inherit;">2020.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">During <em style="font: inherit;">2017,</em> we acquired a cost method investment in convertible preferred stock of PX (see Note <em style="font: inherit;">4</em>). Also in <em style="font: inherit;">2017,</em> we paid $250,000 to acquire certain perpetual content licenses from PX for content we include in certain of our subscription services. We also have an agreement with PX which commenced in <em style="font: inherit;">2016</em> under which we act as a reseller of PX services and receive a portion of the revenues. The total revenue earned from the PX reseller agreement in the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> was $294,000, $578,000 and $439,000, respectively. We will <em style="font: inherit;">no</em> longer earn revenue under this agreement after <em style="font: inherit;"> September 30, 2021 </em>due to termination of the reseller agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 248000 242000 200000 1100000 478000 250000 294000 578000 439000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tbody> <tr> <td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">12</em>) </b></p> </td> <td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Associate Benefits</span></b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">We sponsor a qualified <em style="font: inherit;">401</em>(k) plan covering substantially all associates with <em style="font: inherit;">no</em> eligibility service requirement. Under the <em style="font: inherit;">401</em>(k) plan, we match 25.0% of the <em style="font: inherit;">first</em> 6.0% of compensation contributed by each associate. Employer contributions, which are discretionary, vest to participants at a rate of 20% per year. We contributed $521,000, $447,000 and $396,000 in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively, as a matching percentage of associate <em style="font: inherit;">401</em>(k) contributions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.250 0.060 0.20 521000 447000 396000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tbody> <tr> <td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">13</em>) </b></p> </td> <td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Segment Information</span></b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our <span style="-sec-ix-hidden:c70062823">six</span> operating segments are aggregated into <span style="-sec-ix-hidden:c70062824">one</span> reporting segment because they have similar economic characteristics and meet the other aggregation criteria from the FASB guidance on segment disclosure. The <em style="font: inherit;">six</em> operating segments are Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Transitions, which offer a portfolio of solutions that address specific needs around market insight, experience, transparency and governance for healthcare providers, payers and other healthcare organizations.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The table below presents entity-wide information regarding our revenue and assets by geographic area (in thousands):</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 18pt; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Revenue:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130,305</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">124,369</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,451</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,972</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,613</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,235</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,277</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127,982</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">119,686</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Long-lived assets:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,448</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">78,906</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,330</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,863</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,622</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,291</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,311</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,528</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,621</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">128,319</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">95,668</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">91,080</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,104</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,017</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,952</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,423</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">110,685</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">108,032</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 18pt; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2019</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2018</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Revenue:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130,305</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">124,369</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,451</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,972</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,613</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,235</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,277</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127,982</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">119,686</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Long-lived assets:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,448</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">78,906</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,330</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,863</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,622</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,291</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,311</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,528</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,621</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">128,319</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">95,668</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">91,080</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,104</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,017</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,952</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,423</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">110,685</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">108,032</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 130305000 124369000 115451000 2972000 3613000 4235000 133277000 127982000 119686000 77448000 78906000 77330000 1863000 2622000 2291000 79311000 81528000 79621000 128319000 95668000 91080000 5104000 15017000 16952000 133423000 110685000 108032000 <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tbody> <tr> <td style="vertical-align: top; width: 4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">14</em>) </b></p> </td> <td style="vertical-align: top; width: 96%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Subsequent Event</span></b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> January 4, 2021, </em>we acquired substantially all assets and assumed certain liabilities of PatientWisdom, Inc., a company with a health engagement solution that will further our purpose of operationalizing human understanding through tangible and actionable insights. $3.0 million of the total $5.0 million all-cash consideration was paid at closing. We are required to pay the remaining $2.0 million <em style="font: inherit;">no</em> later than <em style="font: inherit;"> February 1, 2022, </em>subject to offset for indemnification claims as provided in the purchase agreement. The closing payment was funded, and we expect to fund the deferred portion of the purchase price, with cash on hand.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> 3000000.0 5000000.0 2000000.0 XML 15 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2020
Feb. 26, 2021
Jun. 30, 2020
Document Information [Line Items]      
Entity Central Index Key 0000070487    
Entity Registrant Name National Research Corporation    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2020    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2020    
Document Transition Report false    
Entity File Number 001-35929    
Entity Incorporation, State or Country Code WI    
Entity Tax Identification Number 47-0634000    
Entity Address, Address Line One 1245 Q Street    
Entity Address, City or Town Lincoln    
Entity Address, State or Province NE    
Entity Address, Postal Zip Code 68508    
City Area Code 402    
Local Phone Number 475-2525    
Title of 12(b) Security Common Stock, $.001 par value    
Trading Symbol NRC    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 653,540,609
Entity Common Stock, Shares Outstanding   25,420,408  

XML 16 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 34,690 $ 13,517
Trade accounts receivable, less allowance for doubtful accounts of $120 and $144, respectively 13,923 11,639
Prepaid expenses 2,645 2,038
Income taxes receivable 1,235 69
Other current assets 1,619 1,894
Total current assets 54,112 29,157
Net property and equipment 11,726 13,530
Intangible assets, net 1,410 1,728
Goodwill 57,255 57,935
Operating lease right-of-use assets 1,308 1,628
Deferred contract costs, net 4,555 4,204
Other 3,057 2,503
Total assets 133,423 110,685
Current liabilities:    
Current portion of notes payable, net of unamortized debt issuance costs 4,061 4,378
Accounts payable 1,095 1,279
Accrued wages and bonuses 6,460 6,086
Accrued expenses 3,184 3,408
Income taxes payable   366
Dividends payable   5,239
Deferred revenue 15,585 16,354
Other current liabilities 1,296 1,045
Total current liabilities 31,681 38,155
Notes payable, net of current portion and unamortized debt issuance costs 26,547 29,795
Deferred income taxes 7,265 7,399
Other long-term liabilities 3,615 2,444
Total liabilities 69,108 77,793
Shareholders’ equity:    
Common stock, $0.001 par value; authorized 60,000,000 shares, issued 30,775,154 in 2020 and 30,151,574 in 2019, outstanding 25,390,968 in 2020 and 24,947,500 in 2019 31 30
Additional paid-in capital 171,785 162,154
Retained earnings (accumulated deficit) (61,375) (93,357)
Accumulated other comprehensive loss, foreign currency translation adjustment (2,399) (2,209)
Treasury stock, at cost; 5,384,186 Common shares in 2020 and 5,204,074 Common shares in 2019 (43,727) (33,726)
Total shareholders’ equity 64,315 32,892
Total liabilities and shareholders’ equity $ 133,423 $ 110,685
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Allowance for doubtful accounts $ 120 $ 144
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 2,000,000 2,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 60,000,000 60,000,000
Common stock, shares issued (in shares) 30,775,154 30,151,574
Common stock, shares outstanding (in shares) 25,390,968 24,947,500
Treasury stock, shares (in shares) 5,384,186 5,204,074
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenue $ 133,277 $ 127,982 $ 119,686
Insurance recoveries 533    
Operating expenses:      
Direct 49,187 46,435 47,577
Selling, general and administrative 34,441 32,973 31,371
Depreciation, amortization and impairment 7,505 5,539 5,463
Total operating expenses 91,133 84,947 84,411
Operating income 42,677 43,035 35,275
Other income (expense):      
Interest income 18 37 62
Interest expense (1,813) (2,091) (1,513)
Other, net 585 (462) 885
Total other income (expense) (1,210) (2,516) (566)
Income before income taxes 41,467 40,519 34,709
Provision for income taxes 4,207 8,113 4,662
Net income $ 37,260 $ 32,406 30,047
Common Class A [Member]      
Other income (expense):      
Net income     $ 25,423
Basic earnings per share:      
Basic earnings per share (in dollars per share) $ 1.48 $ 1.30 $ 1.08
Diluted earnings per share:      
Diluted earnings per share (in dollars per share) $ 1.45 $ 1.26 $ 1.04
Weighted average shares and share equivalents outstanding      
Weighted average shares and share equivalents outstanding, basic (in shares) 25,170 24,809 23,562
Weighted average shares and share equivalents outstanding, diluted (in shares) 25,696 25,653 24,448
Common Class B [Member]      
Other income (expense):      
Net income     $ 4,624
Basic earnings per share:      
Basic earnings per share (in dollars per share)     $ 1.31
Diluted earnings per share:      
Diluted earnings per share (in dollars per share)     $ 1.27
Weighted average shares and share equivalents outstanding      
Weighted average shares and share equivalents outstanding, basic (in shares)     3,527
Weighted average shares and share equivalents outstanding, diluted (in shares)     3,628
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Net income $ 37,260 $ 32,406 $ 30,047
Other comprehensive income (loss):      
Cumulative translation adjustment (190) 707 (1,281)
Other comprehensive income (loss) (190) 707 (1,281)
Comprehensive income $ 37,070 $ 33,113 $ 28,766
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Cumulative Effect, Period of Adoption, Adjustment [Member]
Retained Earnings [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Common Stock [Member]
Common Class A [Member]
Common Stock [Member]
Common Class B [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock [Member]
Common Class A [Member]
Common Class B [Member]
Total
Balances at Dec. 31, 2017     $ 26 $ 4 $ 51,025 $ 77,574 $ (1,635) $ (36,953)     $ 90,041
Purchase of shares of treasury stock               (7,950)     (7,950)
Issuance of common shares for the exercise of stock options         6,098           6,098
Non-cash stock compensation expense         1,514           1,514
Settlement of class B restricted common shares and stock options in connection with Recapitalization for cash of $3,271 and 90,369 class A common shares         (2,548)     (723)     (3,271)
Settlement of class B common shares in connection with Recapitalization (3,527,246 class B common shares exchanged for $69,099 cash and 3,527,246 class A common shares)     4   118,335     (187,438)     (69,099)
Retirement of 4,328,552 class B common shares in connection with Recapitalization       $ (4) (17,112) (186,944)   204,060      
Dividends declared           (29,751)         (29,751)
Other comprehensive income, foreign currency translation adjustment             (1,281)       (1,281)
Net income           30,047     $ 25,423 $ 4,624 30,047
Balances at Dec. 31, 2018 $ 2,735 $ 2,735 30   157,312 (106,339) (2,916) (29,004)     19,083
Purchase of shares of treasury stock               (4,722)     (4,722)
Issuance of common shares for the exercise of stock options         3,618           3,618
Non-cash stock compensation expense         1,224           1,224
Dividends declared           (19,424)         (19,424)
Other comprehensive income, foreign currency translation adjustment             707       707
Net income           32,406         32,406
Balances at Dec. 31, 2019     30   162,154 (93,357) (2,209) (33,726)     32,892
Purchase of shares of treasury stock               (10,001)     (10,001)
Issuance of common shares for the exercise of stock options     1   8,951           8,952
Non-cash stock compensation expense         680           680
Dividends declared           (5,278)         (5,278)
Other comprehensive income, foreign currency translation adjustment             (190)       (190)
Net income           37,260         37,260
Balances at Dec. 31, 2020     $ 31   $ 171,785 $ (61,375) $ (2,399) $ (43,727)     $ 64,315
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Shareholders' Equity (Parentheticals) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Common Class A [Member]      
Shares of treasury stock purchased (in shares) 180,112 87,203 218,344
Shares of common stock issued for the exercise of stock option (in shares) 630,373 227,902 468,318
Issuance of restricted common shares, net of forfeitures (in shares)   6,005 3,496
Settlement of restricted common shares and stock options in connection with recapitalization (in shares)     90,369
Settlement of class B common shares in connection with recapitalization, shares issued (in shares)     3,527,246
Dividends declared per common share (in dollars per share) $ 0.21 $ 0.78 $ 1.13
Forfeitures of restricted common shares (in shares) 6,793    
Common Class B [Member]      
Shares of treasury stock purchased (in shares)     3,677
Shares of common stock issued for the exercise of stock option (in shares)     9,296
Cash paid settlement of restricted common shares and stock options in connection with recapitalization     $ 3,271
Settlement of class B common shares in connection with recapitalization, shares exchanged (in shares)     3,527,246
Settlement of class B common shares in connection with Recapitalization, cash exchanged     $ 69,099
Retirement of class B common shares in connection with recapitalization, shares retired (in shares)     4,328,552
Dividends declared per common share (in dollars per share)     $ 0.60
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities:      
Net income $ 37,260 $ 32,406 $ 30,047
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation, amortization and impairment 7,505 5,539 5,463
Deferred income taxes (134) 1,099 1,476
Reserve for uncertain tax positions 185 39 (288)
Gain on insurance recoveries for damaged property (260)    
Loss on disposal of property and equipment 12 (6) 186
Non-cash share-based compensation expense 680 1,224 1,514
Change in assets and liabilities:      
Trade accounts receivable (2,271) 311 2,767
Prepaid expenses and other current assets (827) (529) (833)
Operating lease assets and liability, net 16 (8)  
Deferred contract costs, net (351) (719) (113)
Accounts payable (247) 647 (39)
Accrued expenses, wages and bonuses 1,370 806 (566)
Income taxes receivable and payable (1,529) 11 686
Deferred revenue (773) 97 (452)
Net cash provided by operating activities 40,636 40,917 39,848
Cash flows from investing activities:      
Purchases of property and equipment (3,984) (4,656) (5,971)
Insurance proceeds for damaged property 260    
Net cash used in investing activities (3,724) (4,656) (5,971)
Cash flows from financing activities:      
Payments related to Recapitalization     (72,370)
Proceeds from issuance of note payable     40,000
Borrowings on line of credit   21,000 2,500
Payments on line of credit   (21,000) (2,500)
Payments on notes payable (3,568) (3,715) (3,071)
Payment of debt issuance costs (36)   (187)
Payments on finance lease obligations (332) (229) (157)
Proceeds from the exercise of stock options 1,734 0 0
Payment of employee payroll tax withholdings on share-based awards exercised (2,784) (1,103) (1,853)
Payment of dividends on common stock (10,517) (31,299) (16,859)
Net cash used in financing activities (15,503) (36,346) (54,497)
Effect of exchange rate changes on cash (236) 611 (1,122)
Net increase (decrease) in cash and cash equivalents 21,173 526 (21,742)
Cash and cash equivalents at beginning of period 13,517 12,991 34,733
Cash and cash equivalents at end of period 34,690 13,517 12,991
Supplemental disclosure of cash paid for:      
Interest expense, net of capitalized amounts 1,735 2,014 1,282
Income taxes 5,217 6,946 2,635
Supplemental disclosure of non-cash investing and financing activities:      
Common stock (formerly class A) issued in the Recapitalization in exchange for then-existing class B shares and options.     121,371
Finance lease obligations originated for property and equipment 817 192 879
Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans $ 7,217 $ 3,618 $ 6,098
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.20.4
Note 1 - Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

(1)

Summary of Significant Accounting Policies

 

Description of Business and Basis of Presentation

 

National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), is a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States and Canada. Our purpose is to establish human understanding. Our solutions enable health care organizations to understand what matters most to each person they serve. Our portfolio of solutions represents a unique set of capabilities that individually and collectively provide value to our clients. The solutions are offered at an enterprise level through the Voice of the Customer ("VoC") platform, The Governance Institute, and legacy Experience solutions. 

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Translation of Foreign Currencies

 

Our Canadian subsidiary uses Canadian dollars as its functional currency. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the consolidated statements of income.

 

Revenue Recognition

 

On January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers and all related amendments (“ASC 606” or “new revenue standard”) using the modified retrospective method for all incomplete contracts as of the date of adoption. We applied the practical expedient to reflect the total of all contract modifications occurring before January 1, 2018 in the transaction price and performance obligations at transition rather than accounting for each modification separately. Results for reporting periods beginning on or after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. As discussed in more detail below and under “Deferred Contract Costs”, the largest impact of implementing the new revenue standard was the deferral and amortization of direct and incremental costs of obtaining contracts. In addition, there were other revisions to revenue recognition primarily related to performance obligation determinations and estimating variable consideration. We recorded a transition adjustment of approximately $2.7 million, net of $814,000 of tax, to the opening balance of retained earnings.

 

We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or no notice without penalty. See Note 3 for further information about our contracts with customers. We account for revenue using the following steps:

 

 

●

Identify the contract, or contracts, with a customer;

 

●

Identify the performance obligations in the contract;

 

●

Determine the transaction price;

 

●

Allocate the transaction price to the identified performance obligations; and

 

●

Recognize revenue when, or as, we satisfy the performance obligations.

 

Our revenue arrangements with a client may include combinations of more than one service offering which may be executed at the same time, or within close proximity of one another. We combine contracts with the same client into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together, consideration in one contract depends on another contract, or services in one or more contracts are a single performance obligation. For contracts that contain more than one separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable clients, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do not contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.

 

Our arrangements with customers consist principally of four different types of arrangements: 1) subscription-based service agreements; 2) one-time specified services performed at a single point in time; 3) fixed, non-subscription service agreements; and 4) unit-priced service agreements.

 

Subscription-based services - Services that are provided under subscription-based service agreements are usually for a twelve month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the client. These agreements are renewable at the option of the client at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the client as the client receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but may also be billed on a quarterly and monthly basis.

 

One-time services – These agreements typically require us to perform a specific one-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the client.

 

Fixed, non-subscription services – These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch up adjustment which could impact the amount and timing of revenue for any period.

 

Unit-price services – These arrangements typically require us to perform certain services on a periodic basis as requested by the client for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.

 

Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but not invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.

 

Deferred Contract Costs

 

Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable client contract. In 2020, we began providing information technology development work for certain clients specific to their implementation, which are capitalized as deferred contract costs. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. The contract term was estimated by considering factors such as historical client attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract. An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services. We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of one year or less. Prior to 2018, all commissions and incentives were expensed as incurred. We recorded a transition adjustment on January 1, 2018 as an increase to retained earnings of $2.6 million, net of $776,000 of tax, to reflect $3.4 million of commissions and incentives related to contracts that began prior to 2018, net of accumulated amortization. We deferred incremental costs of obtaining a contract of $3.7 million, $3.6 million and $2.6 million in the years ended December 31, 2020, 2019 and 2018, respectively. Deferred contract costs, net of accumulated amortization was $4.6 million and $4.2 million at December 31, 2020 and 2019, respectively. Total amortization by expense classification for the years ended December 31, 2020, 2019 and 2018 was as follows:

 

  

2020

  

2019

  

2018

 
  

(In thousands)

 

Direct expenses

 $272  $34  $83 

Selling, general and administrative expenses

 $2,970  $2,874  $2,400 

Total amortization

 $3,242  $2,908  $2,483 

 

Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $63,000, $22,000 and $51,000 for the years December 31, 2020, 2019 and 2018, respectively.

 

Trade Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount. Effective January 1, 2020, we adopted Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments. This ASU requires the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The adoption of this standard did not have an impact on our consolidated financial statements. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The COVID-19 pandemic has resulted in an increase in accounts receivables as some clients have delayed payments or are slower paying due to such clients’ cash-flow issues.

 

The following table provides the activity in the allowance for doubtful accounts for the years ended December 31, 2020, 2019 and 2018 (in thousands):

 

  

Balance at

Beginning

of Year

  

Bad Debt

Expense

  

Write-offs,

net of

Recoveries

  

Balance

at End

of Year

 
                 

Year Ended December 31, 2018

 $200  $80  $105  $175 

Year Ended December 31, 2019

 $175  $75  $106  $144 

Year Ended December 31, 2020

 $144  $46  $70  $120 

 

Property and Equipment

 

Property and equipment is stated at cost. Major expenditures to purchase property or to substantially increase useful lives of property are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in income.

 

We capitalize certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software projects and external direct costs of materials and services. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs are expensed as incurred. We capitalized approximately $2.7 million and $4.1 million of costs incurred for the development of internal-use software for the years ended December 31, 2020 and 2019, respectively.

 

When a software license is included in a cloud computing arrangement and we have the legal right, ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is not included or we do not have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective January 1, 2020, we prospectively adopted ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did not significantly impact our results of operations and financial position.

 

We provide for depreciation and amortization of property and equipment using annual rates which are sufficient to amortize the cost of depreciable assets over their estimated useful lives. We use the straight-line method of depreciation and amortization over estimated useful lives of three to ten years for furniture and equipment, three to five years for computer equipment, one to five years for capitalized software, and seven to forty years for our office building and related improvements. Software licenses are amortized over the term of the license.

 

Impairment of Long-Lived Assets and Amortizing Intangible Assets

 

Long-lived assets, such as property and equipment and purchased intangible assets subject to depreciation or amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we first compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. No significant impairments were recorded during the years ended December 31, 2020, 2019, or 2018.

 

Among others, management believes the following circumstances are important indicators of potential impairment of such assets and as a result may trigger an impairment review:

 

 

●

Significant underperformance in comparison to historical or projected operating results;

 

●

Significant changes in the manner or use of acquired assets or our overall strategy;

 

●

Significant negative trends in our industry or the overall economy;

 

●

A significant decline in the market price for our common stock for a sustained period; and

 

●

Our market capitalization falling below the book value of our net assets.

 

Goodwill and Intangible Assets

 

Intangible assets include customer relationships, trade names, technology, and goodwill. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review intangible assets with indefinite lives for impairment annually as of October 1 and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.

 

When performing the impairment assessment, we will first assess qualitative factors to determine whether it is necessary to recalculate the fair value of the intangible assets with indefinite lives. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of the indefinite-lived intangibles is less than their carrying amount, we calculate the fair value using a market or income approach. If the carrying value of intangible assets with indefinite lives exceeds their fair value, then the intangible assets are written-down to their fair values. We did not recognize any impairments related to indefinite-lived intangibles during 2020, 2019 or 2018.

 

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. All of our goodwill is allocated to our reporting units, which are the same as our operating segments. Goodwill is reviewed for impairment at least annually, as of October 1, and whenever events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable.

 

We review goodwill for impairment by first assessing qualitative factors to determine whether any impairment may exist. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative analysis will be performed, and the fair value of the reporting unit is compared with its carrying value (including goodwill). If the carrying value of the reporting unit exceeds the fair value, then goodwill is written down by this difference. We performed a qualitative analysis as of October 1, 2020 and determined the fair value of each reporting unit likely exceeded the carrying value. No impairments were recorded during the years ended December 31, 2019 or 2018. A substantial portion of the revenue earned by our Canadian subsidiary is concentrated with one customer. While the customer has exercised its option to extend its existing contract to September 2022, during December 2020 we chose not to enter into a new contract with this customer or otherwise extend the term of the contract beyond September 2022. We subsequently announced that we would close the Canada office at the end of the contract.  As a result, we tested for impairment of the Canada reporting unit’s goodwill at December 31, 2020. We recognized an impairment of $714,000 for the excess of the Canada reporting unit’s carrying value over the fair value, using discounted cash flows. The remaining balance of goodwill of our Canada reporting unit at December 31, 2020 was $1.6 million. Changes in the actual amount or timing of cash flows or other assumptions used to discount cash flows to estimate fair value of the Canada reporting unit could result in additional impairment.

 

Insurance Recoveries

 

We record insurance recoveries when the realization of the claim is probable. In 2020 we received $3.3 million in insurance recoveries, and $447,000 was paid directly to certain vendors from the insurer related to a cyber-attack in February 2020 (the “February incident”). We recorded $533,000, representing reimbursement for lost revenues, as insurance recoveries, and the remainder as a reduction to operating expenses. Due to insurance recoveries, the February incident did not have a significant impact on our consolidated financial statements. In 2020, we also recorded a gain in other income of $260,000 from insurance recoveries for property damage due to a flooding.

 

Income Taxes

 

We use the asset and liability method of accounting for income taxes. Under that method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis using enacted tax rates. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances, if any, are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. We use the deferral method of accounting for our investment tax credits related to state tax incentives. During the years ended December 31, 2020, 2019 and 2018, we recorded income tax benefits relating to these tax credits of $45,000, $24,000, and $0, respectively. Interest and penalties related to income taxes are included in income taxes in the Consolidated Statements of Income.

 

We recognize the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

 

Share-Based Compensation

 

All of our existing stock option awards and non-vested stock awards have been determined to be equity-classified awards. The compensation expense on share-based payments is recognized based on the grant-date fair value of those awards. We recognize the excess tax benefits and tax deficiencies in the income statement when options are exercised. Amounts recognized in the financial statements with respect to these plans are as follows:

 

  

2020

  

2019

  

2018

 
  

(In thousands)

 

Amounts charged against income, before income tax benefit

 $680  $1,224  $1,514 

Amount of related income tax benefit

  (6,764

)

  (2,081

)

  (3,566

)

Net (benefit) expense to net income

 $(6,084

)

 $(857

)

 $(2,052

)

 

We refer to our restricted stock awards as “non-vested” stock in these consolidated financial statements.  

 

Cash and Cash Equivalents

 

We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents were $5.0 million and $3.7 million as of December 31, 2020, and 2019, respectively, consisting primarily of money market accounts. At certain times, cash equivalent balances may exceed federally insured limits.

 

Leases

 

We adopted Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) (“Topic 842” or the “New Leases Standard”) effective January 1, 2019 using a modified retrospective transition and did not adjust prior periods. We elected practical expedients related to existing leases at transition to not reassess whether contracts are or contain leases, to not reassess lease classification, initial direct costs, or lease terms. Additionally, we elected the practical expedient to account for lease and non-lease components as a single lease component for all asset classifications. We have also made a policy election to not record short-term leases with a duration of 12 months or less on the balance sheet.

 

Topic 842 requires lessees to recognize a lease liability and a right-of-use (“ROU”) asset on the balance sheet for operating leases. We recorded $2.3 million of ROU assets and $2.3 million of lease liabilities related to operating leases at the date of transition. The ROU assets recorded were net of $43,000 of accrued liabilities and prepaid expenses representing previously deferred (prepaid) rent. There was no significant impact to the consolidated statements of income, comprehensive income, shareholders’ equity or cash flows. Accounting for finance leases is substantially unchanged.

 

We determine whether a lease is included in an agreement at inception. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long-term liabilities. Certain lease arrangements may include options to extend or terminate the lease. We include these provisions in the ROU asset and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do not contain any residual value guarantees.

 

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is not readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.

 

Fair Value Measurements

 

Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (1) Level 1 Inputs—quoted prices in active markets for identical assets and liabilities; (2) Level 2 Inputs—observable market-based inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; (3) Level 3 Inputs—unobservable inputs.

 

The following details our financial assets within the fair value hierarchy at December 31, 2020 and 2019:

 

  

Level 1

  

Level 2

  

Level 3

  

Total

 
  

(In thousands)

 

As of December 31, 2020

                

Money Market Funds

 $5,015  $--  $--  $5,015 

Total Cash Equivalents

 $5,015  $--  $--  $5,015 
                 

As of December 31, 2019

                

Money Market Funds

 $3,662  $--  $--  $3,662 

Total Cash Equivalents

 $3,662  $--  $--  $3,662 

 

There were no transfers between levels during the years ended December 31, 2020 and 2019.

 

Our long-term debt described in Note 8 is recorded at historical cost. The fair value of long-term debt is classified in Level 2 of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit.

 

The following are the carrying amount and estimated fair values of long-term debt:

 

  

December 31,

2020

  

December 31,

2019

 
  

(In thousands)

 

Total carrying amount of long-term debt

 $30,713  $34,281 

Estimated fair value of long-term debt

 $32,943  $35,205 

 

The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are not recognized or disclosed at fair value in the financial statements on a recurring basis, which includes property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). As of December 31, 2020 and 2019, there was no indication of impairment related to these assets, other than for the Canada reporting unit’s goodwill as discussed above. We estimated the fair value of the Canada reporting unit using discounted cash flows based on management’s most recent projections which are considered level 3 inputs in the fair value hierarchy.

 

Commitments and Contingencies

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. We do not believe the final disposition of claims at December 31, 2020 will have material adverse effect on our consolidated financial position, results of operations or liquidity.

 

A sales tax accrual of $775,000 was recorded in 2019 for sales taxes that should have been collected from clients in 2019 and certain previous years. We received a revenue ruling from the state of Washington noting that our services are not subject to retail sales tax, and therefore, reversed $268,000 of sales tax accrual for the state of Washington in the third quarter of 2020. We have completed voluntary disclosure agreements with certain states, remitted past due sales tax, are remitting sales tax timely, are collecting sales tax from clients and no accrual for past due sales tax remains as of December 31, 2020. State and local jurisdictions have differing rules and regulations governing sales, use, and other taxes and these rules and regulations can be complex and subject to varying interpretations that may change over time. As a result, we could face the possibility of tax assessment and audits, and our liability for these taxes and associated interest and penalties could exceed our original estimates.

 

We became self-insured for group medical and dental insurance on January 1, 2019.   We carry excess loss coverage in the amount of $150,000 per covered person per year for group medical insurance.  We do not self-insure for any other types of losses, and therefore do not carry any additional excess loss insurance.  We record a reserve for our group medical and dental insurance for all unresolved claims and for an estimate of incurred but not reported (“IBNR”) claims.  On a quarterly basis, we adjust our accrual based on a review of our claims experience and a third-party actuarial IBNR analysis.  As of December 31, 2020 and 2019, our accrual related to self-insurance was $418,000 and $270,000, respectively.

 

Earnings Per Share

 

Prior to the Recapitalization, net income per share of our former class A common stock and former class B common stock was computed using the two-class method. Basic net income per share was computed by allocating undistributed earnings to common shares and using the weighted-average number of common shares outstanding during the period.

 

Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.

 

The liquidation rights and the rights upon the consummation of an extraordinary transaction were the same for the holders of our former class A common stock and former class B common stock. Other than share distributions and liquidation rights, the amount of any dividend or other distribution payable on each share of former class A common stock was equal to one-sixth (1/6th) of the amount of any such dividend or other distribution payable on each share of former class B common stock. As a result, the undistributed earnings for each period were allocated based on the participation rights of the former class A and former class B common stock under our then-effective Articles of Incorporation as if the earnings for the year had been distributed.

 

As described in Note 2, we completed a Recapitalization in April 2018, resulting in the elimination of the class B common stock and settlement of all then-existing outstanding class B share-based awards and reclassification of all class A common stock to Common Stock. The Recapitalization was effective on April 17, 2018. Therefore, income was allocated between the former class A and class B stock using the two-class method through April 16, 2018, and fully allocated to the Common Stock (formerly class A) following the Recapitalization.

 

We had 65,127, 16,221 and 93,346 options of Common Stock (former class A shares) for the years ended December 31, 2020, 2019 and 2018, respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.

 

  

2020

  

2019

  

2018

 
  

Common

Stock

  

Common

Stock

  

Common

Stock

(formerly

Class A)

  

Class B

Common

Stock

 
  

(In thousands, except per share data)

 

Numerator for net income per share - basic:

                

Net income

 $37,260  $32,406  $25,423  $4,624 

Allocation of distributed and undistributed income to unvested restricted stock shareholders

  (57

)

  (109

)

  (82

)

  (18

)

Net income attributable to common shareholders

 $37,203  $32,297  $25,341  $4,606 

Denominator for net income per share - basic:

                

Weighted average common shares outstanding – basic

  25,170   24,809   23,562   3,527 

Net income per share - basic

 $1.48  $1.30  $1.08  $1.31 

Numerator for net income per share - diluted:

                

Net income attributable to common shareholders for basic computation

 $37,203  $32,297  $25,341  $4,606 

Denominator for net income per share - diluted:

                

Weighted average common shares outstanding – basic

  25,170   24,809   23,562   3,527 

Weighted average effect of dilutive securities – stock options

  526   844   886   101 

Denominator for diluted earnings per share – adjusted weighted average shares

  25,696   25,653   24,448   3,628 

Net income per share - diluted

 $1.45  $1.26  $1.04  $1.27 

 

Recent Accounting Pronouncements Not Yet Adopted

 

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years.  Early adoption is permitted in interim or annual periods with any adjustments reflected as of the beginning of the annual period that includes that interim period.  Additionally, entities that elect early adoption must adopt all the amendments in the same period.  Amendments are to be applied prospectively, except for certain amendments that are to be applied either retrospectively or with a modified retrospective approach through a cumulative effect adjustment recorded to retained earnings.  We believe the adoption will not significantly impact our results of operations and financial position.

 

In March 2020, FASB issued ASU No. 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022. We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate.

 
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.20.4
Note 2 - Recapitalization
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Recapitalization [Text Block]

(2)

Recapitalization

 

On April 16, 2018, our shareholders approved, among other things, an amendment to our Amended and Restated Articles of Incorporation (the “Articles”) to effect a recapitalization (the “Recapitalization”) pursuant to which each share of our then-existing class B common stock was exchanged for one share of the our then-existing Class A common stock plus $19.59 in cash, without interest. On April 17, 2018, we filed an amendment to our Articles effecting the Recapitalization, followed by an amendment and restatement of our Articles, which resulted in the elimination of our class B common stock and the reclassification of our class A common stock as a share of Common Stock, par value $0.001 per share (“Common Stock”). We issued 3,617,615 shares of Common Stock and paid $72.4 million in exchange for all class B shares outstanding and to settle outstanding share-based awards for class B common stock. The Common Stock continues to trade on the NASDAQ Global Market under the revised symbol “NRC.”

 

In connection with the Recapitalization, on April 18, 2018, we entered into a credit agreement with First National Bank of Omaha, a national banking association (“FNB”), as described in Note 8. 

 
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.20.4
Note 3 - Contracts With Customers
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

(3)

Contracts with Customers

 

The following table disaggregates revenue for the years ended December 31, 2020 and 2019 based on timing of revenue recognition (In thousands):

 

  

2020

  

2019

  2018 

Subscription services recognized ratably over time

 $122,499  $114,216  $104,777 

Services recognized at a point in time

  2,932   4,992   4,775 

Fixed, non-subscription recognized over time

  2,907   3,248   3,163 

Unit price services recognized over time

  4,939   5,526   6,971 

Total revenue

 $133,277  $127,982  $119,686 

 

Our solutions within the digital VoC platform in 2020, 2019 and 2018 accounted for 73.3%, 62.7% and 49.6% of total revenue, respectively. The remaining revenue consists of legacy Experience and Governance Solutions.  

 

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (In thousands):

 

  

December 31,

2020

  

December 31,

2019

 

Accounts receivables

 $13,923  $11,639 

Contract assets included in other current assets

 $311  $103 

Deferred revenue

 $(15,585

)

 $(16,354

)

 

Significant changes in contract assets and contract liabilities during the years ended December 31, 2020 and 2019 are as follows (in thousands):

 

  

2020

  

2019

 
  

Contract

Asset

  

Deferred

Revenue

  

Contract

Asset

  

Deferred

Revenue

 
  

Increase (Decrease)

 

Revenue recognized that was included in deferred revenue at beginning of year due to completion of services

 $-  $(16,083

)

 $-  $(15,785

)

Increases due to invoicing of client, net of amounts recognized as revenue

  -   15,338   -   15,631 

Decreases due to completion of services (or portion of services) and transferred to accounts receivable

  (103

)

  -   (53

)

  - 

Change due to cumulative catch-up adjustments arising from changes in expected contract consideration

  -   (24

)

  -   264 

Increases due to revenue recognized in the period with additional performance obligations before invoicing

  311   -   103   - 

 

We have elected to apply the practical expedient to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Total remaining contract revenue for contracts with original duration of greater than one year expected to be recognized in the future related to performance obligations that are unsatisfied at December 31, 2020 approximated $205,000, which is expected to be recognized during 2021.

 
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.20.4
Note 4 - Equity Investments
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Cost and Equity Method Investments Disclosure [Text Block]

(4)

Equity Investments

 

We make equity investments to promote business and strategic objectives. For investments that do not have a readily determinable fair value, we apply either cost or equity method of accounting depending on the nature of our investment and our ability to exercise significant influence. Investments are periodically analyzed to determine whether or not there are any indicators of impairment and written down to fair value if the investment has incurred an other than temporary impairment. Our investment of $1.3 million in convertible preferred stock of PracticingExcellence.com, Inc., a privately-held Delaware corporation (“PX”) is included in non-current assets. It is not practicable for us to estimate fair value at each reporting date due to the cost and complexity of the calculations for this non-public entity. Therefore, it is carried at cost less impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer, if any. We have a seat on PX's board of directors and our investment, which is not considered to be in-substance common stock, represents approximately 15.7% of the issued and outstanding equity interests in PX.

 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.20.4
Note 5 - Property and Equipment
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

(5)

Property and Equipment

 

At December 31, 2020, and 2019, property and equipment consisted of the following:

 

  

2020

  

2019

 
  

(In thousands)

 

Furniture and equipment

 $4,808  $5,025 

Computer equipment

  2,638   2,706 

Computer software

  27,087   24,532 

Building

  7,515   9,349 

Leaseholds

  232   41 

Land

  425   425 

Property and equipment at cost

  42,705   42,078 

Less accumulated depreciation and amortization

  30,979   28,548 

Net property and equipment

 $11,726  $13,530 

 

Depreciation and amortization expense related to property and equipment, including assets under capital lease, for the years ended December 31, 2020, 2019, and 2018 was $6.5 million, $5.4 million, and $4.8 million, respectively. There were no significant impairments in property and equipment during 2020, 2019, and 2018. However, we did shorten the useful lives of certain assets to reflect our best estimate of when assets are expected to be disposed of or replaced.

 
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.20.4
Note 6 - Goodwill and Intangible Assets
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]

(6)

Goodwill and Intangible Assets

 

Goodwill and intangible assets consisted of the following at December 31, 2020:

 

   

Gross

    

Accumulated

Impairment

    

Net

  
   

(In thousands)

  

Goodwill

   $ 57,969     $ (714 )   $ 57,255  

 

 

 

   

Useful Life

    

Gross

    

Accumulated

Amortization

    

Net

  
   

(In years)

            

(In thousands)

          

Non-amortizing intangible assets:

                                  

Indefinite trade name

               1,191               1,191  

Amortizing intangible assets:

                                  

Customer related

   5 - 15       9,344       9,256       88  

Technology

     7         1,360       1,229       131  

Trade names

   5 - 10       1,572       1,572       --  

Total amortizing intangible assets

               12,276       12,057       219  

Total intangible assets other than goodwill

             $ 13,467     $ 12,057     $ 1,410  

 

Goodwill and intangible assets consisted of the following at December 31, 2019:

 

   

Gross

    

Accumulated

Impairment

    

Net

  
   

(In thousands)

  

Goodwill

   $ 57,935     $ -     $ 57,935  

 

 

 

   

Useful Life

    

Gross

    

Accumulated

Amortization

    

Net

  
   

(In years)

            

(In thousands)

          

Non-amortizing intangible assets:

                                  

Indefinite trade name

               1,191               1,191  

Amortizing intangible assets:

                                  

Customer related

   5 - 15       9,338       9,154       184  

Technology

     7         1,360       1,007       353  

Trade names

   5 - 10       1,572       1,572       --  

Total amortizing intangible assets

               12,270       11,733       537  

Total intangible assets other than goodwill

             $ 13,461     $ 11,733     $ 1,728  

 

The following represents a summary of changes in the carrying amount of goodwill for the years ended December 31, 2020 and 2019 (in thousands):

 

Balance as of December 31, 2018

   $ 57,831  

Foreign currency translation

     104  

Balance as of December 31, 2019

   $ 57,935  

Impairment

     (714

)

Foreign currency translation

     34  

Balance as of December 31, 2020

   $ 57,255  

 

As discussed in Note 1, we recorded an impairment of $714,000 to the Canada reporting unit’s goodwill in December 2020.

 

Aggregate amortization expense for customer related intangibles, trade names, and technology for the years ended December 31, 2020, 2019 and 2018 was $318,000, $374,000, and $662,000, respectively. Estimated future amortization expense for 2021, 2022 and 2023 is $180,000, $40,000, and -0-, respectively.

 
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

(7)

Income Taxes

 

For the years ended December 31, 2020, 2019, and 2018, income before income taxes consists of the following:

 

  

2020

  

2019

  

2018

 
  

(In thousands)

 

U.S. Operations

 $41,357  $40,045  $32,056 

Foreign Operations

  110   474   2,653 

Income before income taxes

 $41,467  $40,519  $34,709 

 

Income tax expense consisted of the following components:

 

  

2020

  

2019

  

2018

 
  

(In thousands)

 

Federal:

            

Current

 $3,546  $5,574  $2,144 

Deferred

  (308

)

  718   1,328 

Total

 $3,238  $6,292  $3,472 
             

Foreign:

            

Current

 $225  $94  $882 

Deferred

  (6

)

  33   (178

)

Total

 $219  $127  $704 
             

State:

            

Current

 $578  $1,322  $204 

Deferred

  172   372   282 

Total

 $750  $1,694  $486 
             

Total

 $4,207  $8,113  $4,662 

 

Federal Tax Reform

 

On December 22, 2017, the Tax Cut and Jobs Act (the “Tax Act”) was enacted which made broad and complex changes to the U.S. tax code, including the following:

 

 

●

Reduction in the U.S. Federal Corporate Tax Rate: The Tax Act reduced the corporate tax rate to 21%, effective
January 1, 2018

 

●

Availability of 100% bonus depreciation on assets placed in service after September 27, 2017

 

●

Certain stock compensation plans potentially subject to limitations on excess tax benefits

 

●

The Global Intangible Low Taxed Income (GILTI) provision

 

As a result of the Tax Act, we determined that we would no longer indefinitely reinvest the earnings of our Canadian subsidiary. Our Canadian subsidiary declared a deemed dividend to the Company for $9.6 million and $3 million in 2020 and 2018, respectively. Additionally, a withholding tax of 5% was paid for each dividend distribution.

 

The Tax Act subjects a U.S. corporation to tax on its Global Intangible Low Taxed Income (“GILTI”). Due to the complexity of the new GILTI tax rules, we are continuing to evaluate this provision of the Tax Act. Under Generally Accepted Accounting Principles, we can make an accounting policy election to either treat taxes due on the GILTI inclusion as a current period expense or factor such amounts into the measurement of deferred taxes. We elected the current period expense method and have not reflected any corresponding deferred tax assets and liabilities associated with the GILTI tax in the table of deferred tax assets and liabilities. GILTI tax has been recorded as current period expense of $10,000, $13,000, and $40,000 in 2020, 2019, and 2018, respectively.

 

We received notice in December 2019, that we met qualification requirements for the Nebraska Advantage LB312 Act (“NAA”) related to certain investment and full-time equivalent employee thresholds in the year ended 2017. NAA provides direct refunds of sales tax on qualified property, as well as investment credits and employment credits that can be claimed through credits of Nebraska income tax, employment tax, and sales tax on non-qualified property. We will receive direct refunds of Nebraska sales tax on qualified property incurred from 2014 to 2023. Investment credits started to accumulate in 2014 and can be earned through 2023. These credits can be claimed against Nebraska income taxes or through sales tax on non-qualified property through 2028. The employment credits are earned from 2017 through 2023, and they can be claimed against Nebraska payroll taxes through 2028. In 2019, we recorded cumulative adjustments for direct refunds and credits earned through the year ending December 31, 2019, which reduced operating expenses by approximately $1.9 million. For the year ended December 31, 2020, adjustments for credits reduced operating expenses by approximately $435,000. In addition, income tax credits of $45,000 and $24,000 were recorded as a reduction to income tax expense for the years ended December 31, 2020 and 2019, respectively.

 

The differences between income taxes expected at the U.S. federal statutory income tax rate of 21 percent and the reported income tax (benefit) expense are summarized as follows:

 

  

2020

  

2019

  

2018

 
  

(In thousands)

 

Expected federal income taxes

 $8,708  $8,509  $7,285 

Foreign tax rate differential

  6   26   146 

State income taxes, net of federal benefit and state tax credits

  607   1,344   376 

Share-based compensation

  (5,713

)

  (1,579

)

  (3,041

)

Compensation limit for covered employees

  463   --   -- 

Federal tax credits

  (261

)

  (419

)

  (150

)

Uncertain tax positions

  157   34   90 

Nondeductible expenses (income) related to recapitalization

  --   (24

)

  151 

Goodwill Impairment

  184   --   -- 

Tax depreciation method change

  --   --   (308)

Withholding tax on repatriation of foreign earnings

  18   107   -- 

GILTI

  10   13   40 

Other

  28   102   73 
  $4,207  $8,113  $4,662 

 

Deferred tax assets and liabilities at December 31, 2020 and 2019, were comprised of the following:

 

  

2020

  

2019

 
  

(In thousands)

 

Deferred tax assets:

        

Allowance for doubtful accounts

 $29  $35 

Accrued expenses

  696   537 

Share-based compensation

  735   1,267 

Accrued bonuses

  145   120 

Employer payroll tax deferral

  323   -- 

Foreign tax credit from repatriation

  --   535 

Other

  27   -- 

Gross deferred tax assets

  1,955   2,494 

Less valuation allowance

  --   (535

)

Deferred tax assets

  1,955   1,959 

Deferred tax liabilities:

        

Prepaid expenses

  93   135 

Deferred contract costs

  1,111   990 

Property and equipment

  1,725   1,926 

Intangible assets

  6,109   5,553 

Repatriation withholding

  174   528 

Unrealized translation gain on intercompany loan

  --   214 

Other

  8   12 

Deferred tax liabilities

  9,220   9,358 

Net deferred tax liabilities

 $(7,265

)

 $(7,399

)

 

In March 27, 2020, the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The CARES Act is an emergency economic stimulus package in response to the coronavirus outbreak which, among other things, contains numerous income tax provisions. As a result of the CARES Act, we have deferred $1,323,000 of employer social security tax payments into future years. We have had no other impacts to our consolidated financial statements or related disclosures from the CARES Act.

 

In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider projected future taxable income, carry-back opportunities, and tax planning strategies in making this assessment. Based upon the level of historical taxable income and projections for future taxable income over the periods which the deferred tax assets are deductible, we believe it is more likely than not that we will realize the benefits of these deductible differences excluding the foreign tax credit carryforward. In 2020, we wrote off the deferred tax asset for prior year foreign tax credit carryforwards of $535,000 and the related valuation allowance. We made the assessment that due to our Canadian subsidiary’s decreased projected future income and the lower US tax rate compared to the Canadian tax rate, it was unlikely we would realize this asset.

 

We had an unrecognized tax benefit at December 31, 2020 and 2019, of $768,000 and $592,000, respectively, excluding interest of $15,000 and $7,000 at December 31, 2020 and 2019, respectively. Of these amounts, $668,000 and $515,000 at December 31, 2020 and 2019, respectively, represents the net unrecognized tax benefits that, if recognized, would favorably impact the effective income tax rate. The change in the unrecognized tax benefits for 2020 and 2019 is as follows:

 

  

(In thousands)

 

Balance of unrecognized tax benefits at December 31, 2018

 $554 

Reductions due to lapse of applicable statute of limitations

  (43

)

Reductions due to tax positions of prior years

  -- 

Reductions due to settlement with taxing authorities

  (300

)

Additions based on tax positions related to the current year

  381 

Balance of unrecognized tax benefits at December 31, 2019

 $592 

Reductions due to lapse of applicable statute of limitations

  (34

)

Additions due to tax positions of prior years

  4 

Reductions due to settlement with taxing authorities

  -- 

Additions based on tax positions related to the current year

  206 

Balance of unrecognized tax benefits at December 31, 2020

 $768 

 

We file income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and Canada federal and provincial jurisdictions. Tax years 2017 and forward remain subject to U.S. federal examination. Tax years 2014 and forward remain subject to state examination. Tax years 2016 and forward remain subject to Canadian federal and provincial examination.

 
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.20.4
Note 8 - Notes Payable
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Debt Disclosure [Text Block]

(8)

Notes Payable

 

Our long-term debt consists of the following:  

 

  

2020

  

2019

 
  

(In thousands)

 

Term Loans

 $30,713  $34,281 

Less: current portion

  (4,061

)

  (4,378

)

Less: unamortized debt issuance costs

  (105

)

  (108

)

Notes payable, net of current portion

 $26,547  $29,795 

 

Our credit agreement (the “Credit Agreement”) with First National Bank of Omaha (“FNB”) was amended and restated on May 28, 2020 and includes (i) a $30,000,000 revolving credit facility (the “Line of Credit”), (ii) a $33,002,069 term loan (the “Term Loan”) and (iii) a $15,000,000 delayed draw-dawn term facility (the “Delayed Draw Term Loan” and, together with the Line of Credit and the Term Loan, the “Credit Facilities”). The Delayed Draw Term Loan may be used to fund any permitted future business acquisitions or repurchases of our Common Stock and the Line of Credit can be used to fund ongoing working capital needs and for other general corporate purposes. The May 2020 amendment increased the Line of Credit from $15,000,000 to $30,000,000.

 

The amended Term Loan revised the remaining payments for the existing balance outstanding of $33,002,069 to monthly installments of $462,988 through May 2025, with a balloon payment due at maturity in May 2025. The Term Loan bears interest at a fixed rate per annum of 5%. Borrowings under the Line of Credit and the Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the 30-day London Interbank Offered Rate plus 225 basis points (2.40% at December 31, 2020). Interest on the Line of Credit accrues and is payable monthly. Principal amounts outstanding under the Line of Credit are due and payable in full at maturity, in May 2023. There were no borrowings on the Line of Credit during 2020. There have been no borrowings on the Delayed Draw Term Loan since origination.

 

We are obligated to pay ongoing unused commitment fees quarterly in arrears pursuant to the Line of Credit and the Delayed Draw Term Loan facility at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility, respectively.

 

The Credit Agreement is collateralized by substantially all of our assets, subject to permitted liens and other agreed exceptions, and contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our Common Stock and acquisitions, subject in each case to certain exceptions. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of 1.10x for all testing periods throughout the terms of the Credit Facilities, which calculation excludes, unless our liquidity falls below a specified threshold, (i) any cash dividend in a fiscal quarter that, together with all other cash dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash dividends paid or declared, (ii) the portion of the purchase price for any permitted share repurchase of our shares paid with cash on hand, and (iii) the portion of any acquisition consideration for a permitted acquisition paid with cash on hand. We are also required to maintain a cash flow leverage ratio of 3.00x or less for all testing periods throughout the term(s) of the Credit Facilities. As of December 31, 2020, we were in compliance with our financial covenants.

 

Scheduled maturities of notes payable at December 31, 2020 are as follows:

 

2021

 $4,093 

2022

  4,306 

2023

  4,529 

2024

  4,762 

2025

  13,023 

 
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Share-based Compensation
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

(9)

Share-Based Compensation

 

We measure and recognize compensation expense for all share-based payments based on the grant-date fair value of those awards. All of our existing stock option awards and unvested stock awards have been determined to be equity-classified awards. We account for forfeitures as they occur. As described in Note 2, we completed a Recapitalization in April 2018 which, among other things, settled all then-existing outstanding class B share-based awards and resulted in the elimination of the class B common stock. As a result, we accelerated vesting of all outstanding class B share-based awards, resulting in accelerated share-based compensation of $331,000 in the year ended December 31, 2018. All outstanding class B share-based awards were then settled for the same stock to cash proportion of the class B common stock described in Note 2, less the exercise price, if any, which approximated the awards’ intrinsic values.

 

Our 2001 Equity Incentive Plan provided for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of our former class A common stock and 300,000 shares of our former class B common stock. Stock options granted could have been either nonqualified or incentive stock options. Stock options vest over one to five years following the date of grant and option terms are generally five to ten years following the date of grant. Due to the expiration of the 2001 Equity Incentive Plan, at December 31, 2015, there were no shares of stock available for future grants.

 

Our 2004 Non-Employee Director Stock Plan, as amended (the “2004 Director Plan”), is a nonqualified plan that provides for the granting of options with respect to 3,000,000 shares of our Common Stock and, prior to the Recapitalization, 500,000 shares of our former class B common stock. The 2004 Director Plan provides for grants of nonqualified stock options to each of our directors who we do not employ. Beginning in 2018, on the date of each annual meeting of shareholders, options to purchase shares of Common Stock equal to an aggregate grant date fair value of $100,000 are granted to each non-employee director that is elected or retained as a director at each such meeting. Stock options vest approximately one year following the date of grant and option terms are generally the earlier of ten years following the date of grant, or three years from the termination of the outside director’s service. At December 31, 2020, there were 830,419 shares of Common Stock available for issuance pursuant to future grants under the 2004 Director Plan. We have accounted for grants of 2,169,581 shares of Common Stock under the 2004 Director Plan using the date of grant as the measurement date for financial accounting purposes.

 

Our 2006 Equity Incentive Plan (the “2006 Equity Incentive Plan”), as amended, provides for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of Common Stock and, prior to the Recapitalization, 300,000 shares of our former class B common stock. Stock options granted may be either incentive stock options or nonqualified stock options. Vesting terms vary with each grant and option terms are generally five to ten years following the date of grant. At December 31, 2020, there were 779,800 shares of Common Stock available for issuance pursuant to future grants under the 2006 Equity Incentive Plan. We have accounted for grants of 1,020,200 shares of Common Stock and restricted stock under the 2006 Equity Incentive Plan using the date of grant as the measurement date for financial accounting purposes.

 

During 2020, 2019 and 2018, we granted options to purchase 70,471, 100,615 and 116,276 shares of Common Stock, respectively. Options to purchase shares of common stock are typically granted with exercise prices equal to the fair value of the common stock on the date of grant. We do, in certain limited situations, grant options with exercise prices that exceed the fair value of the common shares on the date of grant. The fair value of stock options granted was estimated using a Black-Scholes valuation model with the following weighted average assumptions:

 

  

2020

  

2019

  

2018

 
  

Common

Stock

  

Common

Stock

  

Common

Stock

 

Expected dividend yield at date of grant

  1.84

%

  2.60

%

  2.59

%

Expected stock price volatility

  33.62

%

  34.01

%

  32.47

%

Risk-free interest rate

  1.35

%

  2.38

%

  2.51

%

Expected life of options (in years)

  7.39   7.46   7.28 

 

The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of our stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years we estimate that options will be outstanding. We consider groups of associates that have similar historical exercise behavior separately for valuation purposes.

 

The following table summarizes stock option activity under the 2001 and 2006 Equity Incentive Plans and the 2004 Director Plan for the year ended December 31, 2020:

 

  

Number of
Options

  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Contractual

Terms

(Years)

  

Aggregate

Intrinsic

Value

(In

thousands)

 

Common Stock

                

Outstanding at December 31, 2019

  1,245,922  $18.08         

Granted

  70,471  $62.23         

Exercised

  (630,373

)

 $14.20      $25,912 

Forfeited

  (85,449) $32.28         

Outstanding at December 31, 2020

  600,571  $25.31   5.58  $11,665 

Exercisable at December 31, 2020

  270,876  $18.00   4.14  $6,811 

 

The following table summarizes information related to stock options for the years ended December 31, 2020, 2019 and 2018:

 

  

2020

  

2019

  

2018

 
  

Common

Stock

  

Common

Stock

  

Common

Stock

 

Weighted average grant date fair value of stock options granted

 $18.67  $11.99  $10.02 

Intrinsic value of stock options exercised (in thousands)

 $25,912  $8,280  $10,621 

Intrinsic value of stock options vested (in thousands)

 $1,965  $1,891  $2,719 

 

As of December 31, 2020, the total unrecognized compensation cost related to non-vested stock option awards was approximately $1.4 million which was expected to be recognized over a weighted average period of 2.96 years.

 

There was $1.7 million in cash received from stock options exercised for the year ended December 31, 2020 and no cash received from options exercised in 2019 or 2018. We recognized $680,000, $934,000 and $1.1 million of non-cash compensation for the years ended December 31, 2020, 2019, and 2018, respectively, related to options, which is included in direct and selling, general and administrative expenses. The actual tax benefit realized for the tax deduction from stock options exercised was $6.3 million, $2.0 million and $3.8 million for the years ended December 31, 2020, 2019 and 2018, respectively.

 

During 2019 and 2018, we granted 6,005 and 6,793 non-vested shares of Common Stock, respectively, under the 2006 Equity Incentive Plan. No shares of non-vested Common Stock were granted during the year ended December 31, 2020. As of December 31, 2020, we had 6,005 non-vested shares of Common Stock outstanding under the 2006 Equity Incentive Plan. These shares vest over five years following the date of grant and holders thereof are entitled to receive dividends from the date of grant, whether or not vested. The fair value of the awards is calculated as the fair market value of the shares on the date of grant. We recognized $23,000, $290,000 and $428,000 of non-cash compensation for the years ended December 31, 2020, 2019, and 2018, respectively, related to this non-vested stock, which is included in direct and selling, general and administrative expenses. The actual tax benefit realized for the tax deduction from vesting of restricted stock was $235,000 and $168,000 for the years ended December 31, 2020 and 2018, respectively. No restricted stock vested during the year end December 31, 2019.

 

The following table summarizes information regarding non-vested stock granted to associates under the 2006 Equity Incentive Plans for the year ended December 31, 2020:

 

  

Common Stock

Outstanding

  

Common Stock

Weighted

Average Grant

Date Fair Value

Per Share

 

Outstanding at December 31, 2019

  84,176  $17.23 

Granted

  --  $-- 

Vested

  (71,378) $13.59 

Forfeited

  (6,793) $36.80 

Outstanding at December 31, 2020

  6,005  $38.30 

 

As of December 31, 2020, the total unrecognized compensation cost related to non-vested stock awards was approximately $138,000 and is expected to be recognized over a weighted average period of 3.00 years.

 
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.20.4
Note 10 - Leases
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Leases of Lessee Disclosure [Text Block]

(10)

Leases

 

We lease printing, computer, other equipment and office space in the United States and Canada. The leases remaining terms as of December 31, 2020 range from less than one year to 4.7 years.

 

Certain equipment and office lease agreements include provisions for periodic adjustments to rates and charges. The rates and charges are adjusted based on actual usage or actual costs for internet, common area maintenance, taxes or insurance, as determined by the lessor and are considered variable lease costs.

 

The components of lease expense for the years ended December 31, 2020 and 2019 included (in thousands):

 

  

2020

  

2019

 

Operating leases

 $600  $781 

Finance leases:

        

Asset amortization

  355   252 

Interest on lease liabilities

  37   39 

Variable lease cost

  62   86 

Short-term lease cost

  42   42 

Total net lease cost

 $1,096  $1,200 

 

In 2020, we adjusted the useful life of the operating right of use assts associated with our Atlanta, Georgia and Markham, Ontario office leases based on the expectation that we will vacate the office space before the end of the lease term. We recorded rent expense in connection with our operating leases of $779,000 in 2018.

 

Supplemental balance sheet information related to leases (in thousands):     

 

  

December 31,

2020

  

December 31,

2019

 

Operating leases:

        

Operating ROU assets

 $1,308  $1,628 
         

Current operating lease liabilities

  461   524 

Noncurrent operating lease liabilities

  896   1,139 

Total operating lease liabilities

 $1,357  $1,663 

 

  

December 31,

2020

  

December 31,

2019

 

Finance leases:

        

Furniture and equipment

 $1,014  $802 

Computer Equipment

  662   511 

Computer Software

  207   207 

Property and equipment under finance lease, gross

  1,883   1,520 

Less accumulated amortization

  (605

)

  (734

)

Property and equipment under finance lease, net

 $1,278  $786 
         

Current obligations of finance leases

 $493  $227 

Noncurrent obligations of finance leases

  778   559 

Total finance lease liabilities

 $1,271  $786 
         
Weighted average remaining lease term (in years):        
Operating leases  3.68   4.17 
Finance leases  2.69   3.56 
         
Weighted average discount rate:        
Operating leases  4.40%  4.81%
Finance leases  3.38%  4.60%

 

Supplemental cash flow and other information related to leases were as follows (in thousands):

 

  

2020

  

2019

 

Cash paid for amounts included in the measurement of lease liabilities:

        

Operating cash flows from operating leases

 $596  $789 

Operating cash flows from finance leases

  36   38 

Financing cash flows from finance leases

  332   229 
         

ROU assets obtained in exchange for operating lease liabilities

  276   16 

ROU assets obtained in exchange for finance lease liabilities

  817   192 

 

Undiscounted payments under non-cancelable finance and operating leases at December 31, 2020 were as follows (in thousands):

 

  

Finance Leases

  

Operating Leases

 

2021

 $527  $509 

2022

  481   322 

2023

  305   319 

2024

  13   203 

2025

  --   118 

Thereafter

  --   -- 

Total minimum lease payments

  1,326   1,471 

Less: Amount representing interest

  (55

)

  (114

)

Present value of minimum lease payments

  1,271   1,357 

Current portion

  (493

)

  (461

)

Lease obligations, net of current portion

 $778  $896 

 

In addition to the above, we have an operating lease for office space commencing February 2021 which requires monthly base rent payments of $14,288 through January 2024. 

 
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.20.4
Note 11 - Related Party
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

(11)

Related Party

 

Until January 2020, one of our directors served as an officer and director of Ameritas Life Insurance Corp. (“Ameritas”) and continues to service on the board of directors of Ameritas. In connection with our regular assessment of our insurance-based associate benefits, which is conducted by an independent insurance broker, and the costs associated therewith, we purchase dental and vision insurance for certain of our associates from Ameritas. The total value of these purchases was $248,000, $242,000 and $200,000 in 2020, 2019 and 2018 respectively.

 

A director, who served on our board through May 2020, also served as a board member of IMA Financial Group. In connection with our regular assessment of our liability coverage, during 2020 we began purchasing directors and officers and employment practices liability insurance through IMA Financial Group. Total payments for these services totaled $1.1 million with $478,000 recorded as expense in 2020.

 

During 2017, we acquired a cost method investment in convertible preferred stock of PX (see Note 4). Also in 2017, we paid $250,000 to acquire certain perpetual content licenses from PX for content we include in certain of our subscription services. We also have an agreement with PX which commenced in 2016 under which we act as a reseller of PX services and receive a portion of the revenues. The total revenue earned from the PX reseller agreement in the years ended December 31, 2020, 2019 and 2018 was $294,000, $578,000 and $439,000, respectively. We will no longer earn revenue under this agreement after September 30, 2021 due to termination of the reseller agreement.

 
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.20.4
Note 12 - Associate Benefits
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Compensation and Employee Benefit Plans [Text Block]

(12)

Associate Benefits

 

We sponsor a qualified 401(k) plan covering substantially all associates with no eligibility service requirement. Under the 401(k) plan, we match 25.0% of the first 6.0% of compensation contributed by each associate. Employer contributions, which are discretionary, vest to participants at a rate of 20% per year. We contributed $521,000, $447,000 and $396,000 in 2020, 2019 and 2018, respectively, as a matching percentage of associate 401(k) contributions.

 
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Note 13 - Segment Information
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

(13)

Segment Information

 

Our six operating segments are aggregated into one reporting segment because they have similar economic characteristics and meet the other aggregation criteria from the FASB guidance on segment disclosure. The six operating segments are Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Transitions, which offer a portfolio of solutions that address specific needs around market insight, experience, transparency and governance for healthcare providers, payers and other healthcare organizations.

 

The table below presents entity-wide information regarding our revenue and assets by geographic area (in thousands):

 

   

2020

    

2019

    

2018

  

Revenue:

                        

United States

   $ 130,305     $ 124,369     $ 115,451  

Canada

     2,972       3,613       4,235  

Total

   $ 133,277     $ 127,982     $ 119,686  

Long-lived assets:

                        

United States

   $ 77,448     $ 78,906     $ 77,330  

Canada

     1,863       2,622       2,291  

Total

   $ 79,311     $ 81,528     $ 79,621  

Total assets:

                        

United States

   $ 128,319     $ 95,668     $ 91,080  

Canada

     5,104       15,017       16,952  

Total

   $ 133,423     $ 110,685     $ 108,032  

 
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.20.4
Note 14 - Subsequent Event
 12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Subsequent Events [Text Block]

(14)

Subsequent Event

 

On January 4, 2021, we acquired substantially all assets and assumed certain liabilities of PatientWisdom, Inc., a company with a health engagement solution that will further our purpose of operationalizing human understanding through tangible and actionable insights. $3.0 million of the total $5.0 million all-cash consideration was paid at closing. We are required to pay the remaining $2.0 million no later than February 1, 2022, subject to offset for indemnification claims as provided in the purchase agreement. The closing payment was funded, and we expect to fund the deferred portion of the purchase price, with cash on hand.

 
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.20.4
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block]

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.

 
Use of Estimates, Policy [Policy Text Block]

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 
Foreign Currency Transactions and Translations Policy [Policy Text Block]

Translation of Foreign Currencies

 

Our Canadian subsidiary uses Canadian dollars as its functional currency. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the consolidated statements of income.

 
Revenue [Policy Text Block]

Revenue Recognition

 

On January 1, 2018, we adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers and all related amendments (“ASC 606” or “new revenue standard”) using the modified retrospective method for all incomplete contracts as of the date of adoption. We applied the practical expedient to reflect the total of all contract modifications occurring before January 1, 2018 in the transaction price and performance obligations at transition rather than accounting for each modification separately. Results for reporting periods beginning on or after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. As discussed in more detail below and under “Deferred Contract Costs”, the largest impact of implementing the new revenue standard was the deferral and amortization of direct and incremental costs of obtaining contracts. In addition, there were other revisions to revenue recognition primarily related to performance obligation determinations and estimating variable consideration. We recorded a transition adjustment of approximately $2.7 million, net of $814,000 of tax, to the opening balance of retained earnings.

 

We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or no notice without penalty. See Note 3 for further information about our contracts with customers. We account for revenue using the following steps:

 

 

●

Identify the contract, or contracts, with a customer;

 

●

Identify the performance obligations in the contract;

 

●

Determine the transaction price;

 

●

Allocate the transaction price to the identified performance obligations; and

 

●

Recognize revenue when, or as, we satisfy the performance obligations.

 

Our revenue arrangements with a client may include combinations of more than one service offering which may be executed at the same time, or within close proximity of one another. We combine contracts with the same client into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together, consideration in one contract depends on another contract, or services in one or more contracts are a single performance obligation. For contracts that contain more than one separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable clients, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do not contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.

 

Our arrangements with customers consist principally of four different types of arrangements: 1) subscription-based service agreements; 2) one-time specified services performed at a single point in time; 3) fixed, non-subscription service agreements; and 4) unit-priced service agreements.

 

Subscription-based services - Services that are provided under subscription-based service agreements are usually for a twelve month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the client. These agreements are renewable at the option of the client at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the client as the client receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but may also be billed on a quarterly and monthly basis.

 

One-time services – These agreements typically require us to perform a specific one-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the client.

 

Fixed, non-subscription services – These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch up adjustment which could impact the amount and timing of revenue for any period.

 

Unit-price services – These arrangements typically require us to perform certain services on a periodic basis as requested by the client for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.

 

Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but not invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.

 
Deferred Charges, Policy [Policy Text Block]

Deferred Contract Costs

 

Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable client contract. In 2020, we began providing information technology development work for certain clients specific to their implementation, which are capitalized as deferred contract costs. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. The contract term was estimated by considering factors such as historical client attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract. An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services. We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of one year or less. Prior to 2018, all commissions and incentives were expensed as incurred. We recorded a transition adjustment on January 1, 2018 as an increase to retained earnings of $2.6 million, net of $776,000 of tax, to reflect $3.4 million of commissions and incentives related to contracts that began prior to 2018, net of accumulated amortization. We deferred incremental costs of obtaining a contract of $3.7 million, $3.6 million and $2.6 million in the years ended December 31, 2020, 2019 and 2018, respectively. Deferred contract costs, net of accumulated amortization was $4.6 million and $4.2 million at December 31, 2020 and 2019, respectively. Total amortization by expense classification for the years ended December 31, 2020, 2019 and 2018 was as follows:

 

  

2020

  

2019

  

2018

 
  

(In thousands)

 

Direct expenses

 $272  $34  $83 

Selling, general and administrative expenses

 $2,970  $2,874  $2,400 

Total amortization

 $3,242  $2,908  $2,483 

 

Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $63,000, $22,000 and $51,000 for the years December 31, 2020, 2019 and 2018, respectively.

 
Accounts Receivable [Policy Text Block]

Trade Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount. Effective January 1, 2020, we adopted Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments. This ASU requires the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The adoption of this standard did not have an impact on our consolidated financial statements. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The COVID-19 pandemic has resulted in an increase in accounts receivables as some clients have delayed payments or are slower paying due to such clients’ cash-flow issues.

 

The following table provides the activity in the allowance for doubtful accounts for the years ended December 31, 2020, 2019 and 2018 (in thousands):

 

  

Balance at

Beginning

of Year

  

Bad Debt

Expense

  

Write-offs,

net of

Recoveries

  

Balance

at End

of Year

 
                 

Year Ended December 31, 2018

 $200  $80  $105  $175 

Year Ended December 31, 2019

 $175  $75  $106  $144 

Year Ended December 31, 2020

 $144  $46  $70  $120 

 
Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

 

Property and equipment is stated at cost. Major expenditures to purchase property or to substantially increase useful lives of property are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accounts and resulting gains or losses are included in income.

 

We capitalize certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software projects and external direct costs of materials and services. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs are expensed as incurred. We capitalized approximately $2.7 million and $4.1 million of costs incurred for the development of internal-use software for the years ended December 31, 2020 and 2019, respectively.

 

When a software license is included in a cloud computing arrangement and we have the legal right, ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is not included or we do not have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective January 1, 2020, we prospectively adopted ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did not significantly impact our results of operations and financial position.

 

We provide for depreciation and amortization of property and equipment using annual rates which are sufficient to amortize the cost of depreciable assets over their estimated useful lives. We use the straight-line method of depreciation and amortization over estimated useful lives of three to ten years for furniture and equipment, three to five years for computer equipment, one to five years for capitalized software, and seven to forty years for our office building and related improvements. Software licenses are amortized over the term of the license.

 
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets and Amortizing Intangible Assets

 

Long-lived assets, such as property and equipment and purchased intangible assets subject to depreciation or amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we first compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. No significant impairments were recorded during the years ended December 31, 2020, 2019, or 2018.

 

Among others, management believes the following circumstances are important indicators of potential impairment of such assets and as a result may trigger an impairment review:

 

 

●

Significant underperformance in comparison to historical or projected operating results;

 

●

Significant changes in the manner or use of acquired assets or our overall strategy;

 

●

Significant negative trends in our industry or the overall economy;

 

●

A significant decline in the market price for our common stock for a sustained period; and

 

●

Our market capitalization falling below the book value of our net assets.

 
Goodwill and Intangible Assets, Policy [Policy Text Block]

Goodwill and Intangible Assets

 

Intangible assets include customer relationships, trade names, technology, and goodwill. Intangible assets with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review intangible assets with indefinite lives for impairment annually as of October 1 and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.

 

When performing the impairment assessment, we will first assess qualitative factors to determine whether it is necessary to recalculate the fair value of the intangible assets with indefinite lives. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of the indefinite-lived intangibles is less than their carrying amount, we calculate the fair value using a market or income approach. If the carrying value of intangible assets with indefinite lives exceeds their fair value, then the intangible assets are written-down to their fair values. We did not recognize any impairments related to indefinite-lived intangibles during 2020, 2019 or 2018.

 

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. All of our goodwill is allocated to our reporting units, which are the same as our operating segments. Goodwill is reviewed for impairment at least annually, as of October 1, and whenever events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable.

 

We review goodwill for impairment by first assessing qualitative factors to determine whether any impairment may exist. If we believe, as a result of the qualitative assessment, that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative analysis will be performed, and the fair value of the reporting unit is compared with its carrying value (including goodwill). If the carrying value of the reporting unit exceeds the fair value, then goodwill is written down by this difference. We performed a qualitative analysis as of October 1, 2020 and determined the fair value of each reporting unit likely exceeded the carrying value. No impairments were recorded during the years ended December 31, 2019 or 2018. A substantial portion of the revenue earned by our Canadian subsidiary is concentrated with one customer. While the customer has exercised its option to extend its existing contract to September 2022, during December 2020 we chose not to enter into a new contract with this customer or otherwise extend the term of the contract beyond September 2022. We subsequently announced that we would close the Canada office at the end of the contract.  As a result, we tested for impairment of the Canada reporting unit’s goodwill at December 31, 2020. We recognized an impairment of $714,000 for the excess of the Canada reporting unit’s carrying value over the fair value, using discounted cash flows. The remaining balance of goodwill of our Canada reporting unit at December 31, 2020 was $1.6 million. Changes in the actual amount or timing of cash flows or other assumptions used to discount cash flows to estimate fair value of the Canada reporting unit could result in additional impairment.

 
Insurance Recoveries [Policy Text Block]

Insurance Recoveries

 

We record insurance recoveries when the realization of the claim is probable. In 2020 we received $3.3 million in insurance recoveries, and $447,000 was paid directly to certain vendors from the insurer related to a cyber-attack in February 2020 (the “February incident”). We recorded $533,000, representing reimbursement for lost revenues, as insurance recoveries, and the remainder as a reduction to operating expenses. Due to insurance recoveries, the February incident did not have a significant impact on our consolidated financial statements. In 2020, we also recorded a gain in other income of $260,000 from insurance recoveries for property damage due to a flooding.

 
Income Tax, Policy [Policy Text Block]

Income Taxes

 

We use the asset and liability method of accounting for income taxes. Under that method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis using enacted tax rates. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances, if any, are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. We use the deferral method of accounting for our investment tax credits related to state tax incentives. During the years ended December 31, 2020, 2019 and 2018, we recorded income tax benefits relating to these tax credits of $45,000, $24,000, and $0, respectively. Interest and penalties related to income taxes are included in income taxes in the Consolidated Statements of Income.

 

We recognize the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

 
Share-based Payment Arrangement [Policy Text Block]

Share-Based Compensation

 

All of our existing stock option awards and non-vested stock awards have been determined to be equity-classified awards. The compensation expense on share-based payments is recognized based on the grant-date fair value of those awards. We recognize the excess tax benefits and tax deficiencies in the income statement when options are exercised. Amounts recognized in the financial statements with respect to these plans are as follows:

 

  

2020

  

2019

  

2018

 
  

(In thousands)

 

Amounts charged against income, before income tax benefit

 $680  $1,224  $1,514 

Amount of related income tax benefit

  (6,764

)

  (2,081

)

  (3,566

)

Net (benefit) expense to net income

 $(6,084

)

 $(857

)

 $(2,052

)

 

We refer to our restricted stock awards as “non-vested” stock in these consolidated financial statements.  

 
Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

 

We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents were $5.0 million and $3.7 million as of December 31, 2020, and 2019, respectively, consisting primarily of money market accounts. At certain times, cash equivalent balances may exceed federally insured limits.

 
Lessee, Leases [Policy Text Block]

Leases

 

We adopted Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) (“Topic 842” or the “New Leases Standard”) effective January 1, 2019 using a modified retrospective transition and did not adjust prior periods. We elected practical expedients related to existing leases at transition to not reassess whether contracts are or contain leases, to not reassess lease classification, initial direct costs, or lease terms. Additionally, we elected the practical expedient to account for lease and non-lease components as a single lease component for all asset classifications. We have also made a policy election to not record short-term leases with a duration of 12 months or less on the balance sheet.

 

Topic 842 requires lessees to recognize a lease liability and a right-of-use (“ROU”) asset on the balance sheet for operating leases. We recorded $2.3 million of ROU assets and $2.3 million of lease liabilities related to operating leases at the date of transition. The ROU assets recorded were net of $43,000 of accrued liabilities and prepaid expenses representing previously deferred (prepaid) rent. There was no significant impact to the consolidated statements of income, comprehensive income, shareholders’ equity or cash flows. Accounting for finance leases is substantially unchanged.

 

We determine whether a lease is included in an agreement at inception. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long-term liabilities. Certain lease arrangements may include options to extend or terminate the lease. We include these provisions in the ROU asset and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do not contain any residual value guarantees.

 

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is not readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.

 
Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

 

Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (1) Level 1 Inputs—quoted prices in active markets for identical assets and liabilities; (2) Level 2 Inputs—observable market-based inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; (3) Level 3 Inputs—unobservable inputs.

 

The following details our financial assets within the fair value hierarchy at December 31, 2020 and 2019:

 

  

Level 1

  

Level 2

  

Level 3

  

Total

 
  

(In thousands)

 

As of December 31, 2020

                

Money Market Funds

 $5,015  $--  $--  $5,015 

Total Cash Equivalents

 $5,015  $--  $--  $5,015 
                 

As of December 31, 2019

                

Money Market Funds

 $3,662  $--  $--  $3,662 

Total Cash Equivalents

 $3,662  $--  $--  $3,662 

 

There were no transfers between levels during the years ended December 31, 2020 and 2019.

 

Our long-term debt described in Note 8 is recorded at historical cost. The fair value of long-term debt is classified in Level 2 of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit.

 

The following are the carrying amount and estimated fair values of long-term debt:

 

  

December 31,

2020

  

December 31,

2019

 
  

(In thousands)

 

Total carrying amount of long-term debt

 $30,713  $34,281 

Estimated fair value of long-term debt

 $32,943  $35,205 

 

The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are not recognized or disclosed at fair value in the financial statements on a recurring basis, which includes property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). As of December 31, 2020 and 2019, there was no indication of impairment related to these assets, other than for the Canada reporting unit’s goodwill as discussed above. We estimated the fair value of the Canada reporting unit using discounted cash flows based on management’s most recent projections which are considered level 3 inputs in the fair value hierarchy.

 
Commitments and Contingencies, Policy [Policy Text Block]

Commitments and Contingencies

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. We do not believe the final disposition of claims at December 31, 2020 will have material adverse effect on our consolidated financial position, results of operations or liquidity.

 

A sales tax accrual of $775,000 was recorded in 2019 for sales taxes that should have been collected from clients in 2019 and certain previous years. We received a revenue ruling from the state of Washington noting that our services are not subject to retail sales tax, and therefore, reversed $268,000 of sales tax accrual for the state of Washington in the third quarter of 2020. We have completed voluntary disclosure agreements with certain states, remitted past due sales tax, are remitting sales tax timely, are collecting sales tax from clients and no accrual for past due sales tax remains as of December 31, 2020. State and local jurisdictions have differing rules and regulations governing sales, use, and other taxes and these rules and regulations can be complex and subject to varying interpretations that may change over time. As a result, we could face the possibility of tax assessment and audits, and our liability for these taxes and associated interest and penalties could exceed our original estimates.

 

We became self-insured for group medical and dental insurance on January 1, 2019.   We carry excess loss coverage in the amount of $150,000 per covered person per year for group medical insurance.  We do not self-insure for any other types of losses, and therefore do not carry any additional excess loss insurance.  We record a reserve for our group medical and dental insurance for all unresolved claims and for an estimate of incurred but not reported (“IBNR”) claims.  On a quarterly basis, we adjust our accrual based on a review of our claims experience and a third-party actuarial IBNR analysis.  As of December 31, 2020 and 2019, our accrual related to self-insurance was $418,000 and $270,000, respectively.

 
Earnings Per Share, Policy [Policy Text Block]

Earnings Per Share

 

Prior to the Recapitalization, net income per share of our former class A common stock and former class B common stock was computed using the two-class method. Basic net income per share was computed by allocating undistributed earnings to common shares and using the weighted-average number of common shares outstanding during the period.

 

Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.

 

The liquidation rights and the rights upon the consummation of an extraordinary transaction were the same for the holders of our former class A common stock and former class B common stock. Other than share distributions and liquidation rights, the amount of any dividend or other distribution payable on each share of former class A common stock was equal to one-sixth (1/6th) of the amount of any such dividend or other distribution payable on each share of former class B common stock. As a result, the undistributed earnings for each period were allocated based on the participation rights of the former class A and former class B common stock under our then-effective Articles of Incorporation as if the earnings for the year had been distributed.

 

As described in Note 2, we completed a Recapitalization in April 2018, resulting in the elimination of the class B common stock and settlement of all then-existing outstanding class B share-based awards and reclassification of all class A common stock to Common Stock. The Recapitalization was effective on April 17, 2018. Therefore, income was allocated between the former class A and class B stock using the two-class method through April 16, 2018, and fully allocated to the Common Stock (formerly class A) following the Recapitalization.

 

We had 65,127, 16,221 and 93,346 options of Common Stock (former class A shares) for the years ended December 31, 2020, 2019 and 2018, respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.

 

  

2020

  

2019

  

2018

 
  

Common

Stock

  

Common

Stock

  

Common

Stock

(formerly

Class A)

  

Class B

Common

Stock

 
  

(In thousands, except per share data)

 

Numerator for net income per share - basic:

                

Net income

 $37,260  $32,406  $25,423  $4,624 

Allocation of distributed and undistributed income to unvested restricted stock shareholders

  (57

)

  (109

)

  (82

)

  (18

)

Net income attributable to common shareholders

 $37,203  $32,297  $25,341  $4,606 

Denominator for net income per share - basic:

                

Weighted average common shares outstanding – basic

  25,170   24,809   23,562   3,527 

Net income per share - basic

 $1.48  $1.30  $1.08  $1.31 

Numerator for net income per share - diluted:

                

Net income attributable to common shareholders for basic computation

 $37,203  $32,297  $25,341  $4,606 

Denominator for net income per share - diluted:

                

Weighted average common shares outstanding – basic

  25,170   24,809   23,562   3,527 

Weighted average effect of dilutive securities – stock options

  526   844   886   101 

Denominator for diluted earnings per share – adjusted weighted average shares

  25,696   25,653   24,448   3,628 

Net income per share - diluted

 $1.45  $1.26  $1.04  $1.27 
New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements Not Yet Adopted

 

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years.  Early adoption is permitted in interim or annual periods with any adjustments reflected as of the beginning of the annual period that includes that interim period.  Additionally, entities that elect early adoption must adopt all the amendments in the same period.  Amendments are to be applied prospectively, except for certain amendments that are to be applied either retrospectively or with a modified retrospective approach through a cumulative effect adjustment recorded to retained earnings.  We believe the adoption will not significantly impact our results of operations and financial position.

 

In March 2020, FASB issued ASU No. 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022. We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate.

 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.20.4
Note 1 - Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2020
Notes Tables  
Amortization of Capitalized Contract Cost [Table Text Block]
  

2020

  

2019

  

2018

 
  

(In thousands)

 

Direct expenses

 $272  $34  $83 

Selling, general and administrative expenses

 $2,970  $2,874  $2,400 

Total amortization

 $3,242  $2,908  $2,483 
Financing Receivable, Allowance for Credit Loss [Table Text Block]
  

Balance at

Beginning

of Year

  

Bad Debt

Expense

  

Write-offs,

net of

Recoveries

  

Balance

at End

of Year

 
                 

Year Ended December 31, 2018

 $200  $80  $105  $175 

Year Ended December 31, 2019

 $175  $75  $106  $144 

Year Ended December 31, 2020

 $144  $46  $70  $120 
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
  

2020

  

2019

  

2018

 
  

(In thousands)

 

Amounts charged against income, before income tax benefit

 $680  $1,224  $1,514 

Amount of related income tax benefit

  (6,764

)

  (2,081

)

  (3,566

)

Net (benefit) expense to net income

 $(6,084

)

 $(857

)

 $(2,052

)
Fair Value, by Balance Sheet Grouping [Table Text Block]
  

Level 1

  

Level 2

  

Level 3

  

Total

 
  

(In thousands)

 

As of December 31, 2020

                

Money Market Funds

 $5,015  $--  $--  $5,015 

Total Cash Equivalents

 $5,015  $--  $--  $5,015 
                 

As of December 31, 2019

                

Money Market Funds

 $3,662  $--  $--  $3,662 

Total Cash Equivalents

 $3,662  $--  $--  $3,662 
  

December 31,

2020

  

December 31,

2019

 
  

(In thousands)

 

Total carrying amount of long-term debt

 $30,713  $34,281 

Estimated fair value of long-term debt

 $32,943  $35,205 
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

2020

  

2019

  

2018

 
  

Common

Stock

  

Common

Stock

  

Common

Stock

(formerly

Class A)

  

Class B

Common

Stock

 
  

(In thousands, except per share data)

 

Numerator for net income per share - basic:

                

Net income

 $37,260  $32,406  $25,423  $4,624 

Allocation of distributed and undistributed income to unvested restricted stock shareholders

  (57

)

  (109

)

  (82

)

  (18

)

Net income attributable to common shareholders

 $37,203  $32,297  $25,341  $4,606 

Denominator for net income per share - basic:

                

Weighted average common shares outstanding – basic

  25,170   24,809   23,562   3,527 

Net income per share - basic

 $1.48  $1.30  $1.08  $1.31 

Numerator for net income per share - diluted:

                

Net income attributable to common shareholders for basic computation

 $37,203  $32,297  $25,341  $4,606 

Denominator for net income per share - diluted:

                

Weighted average common shares outstanding – basic

  25,170   24,809   23,562   3,527 

Weighted average effect of dilutive securities – stock options

  526   844   886   101 

Denominator for diluted earnings per share – adjusted weighted average shares

  25,696   25,653   24,448   3,628 

Net income per share - diluted

 $1.45  $1.26  $1.04  $1.27 
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.20.4
Note 3 - Contracts With Customers (Tables)
 12 Months Ended
Dec. 31, 2020
Notes Tables  
Disaggregation of Revenue [Table Text Block]
  

2020

  

2019

  2018 

Subscription services recognized ratably over time

 $122,499  $114,216  $104,777 

Services recognized at a point in time

  2,932   4,992   4,775 

Fixed, non-subscription recognized over time

  2,907   3,248   3,163 

Unit price services recognized over time

  4,939   5,526   6,971 

Total revenue

 $133,277  $127,982  $119,686 
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
  

December 31,

2020

  

December 31,

2019

 

Accounts receivables

 $13,923  $11,639 

Contract assets included in other current assets

 $311  $103 

Deferred revenue

 $(15,585

)

 $(16,354

)

  

2020

  

2019

 
  

Contract

Asset

  

Deferred

Revenue

  

Contract

Asset

  

Deferred

Revenue

 
  

Increase (Decrease)

 

Revenue recognized that was included in deferred revenue at beginning of year due to completion of services

 $-  $(16,083

)

 $-  $(15,785

)

Increases due to invoicing of client, net of amounts recognized as revenue

  -   15,338   -   15,631 

Decreases due to completion of services (or portion of services) and transferred to accounts receivable

  (103

)

  -   (53

)

  - 

Change due to cumulative catch-up adjustments arising from changes in expected contract consideration

  -   (24

)

  -   264 

Increases due to revenue recognized in the period with additional performance obligations before invoicing

  311   -   103   - 
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.20.4
Note 5 - Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2020
Notes Tables  
Property, Plant and Equipment [Table Text Block]
  

2020

  

2019

 
  

(In thousands)

 

Furniture and equipment

 $4,808  $5,025 

Computer equipment

  2,638   2,706 

Computer software

  27,087   24,532 

Building

  7,515   9,349 

Leaseholds

  232   41 

Land

  425   425 

Property and equipment at cost

  42,705   42,078 

Less accumulated depreciation and amortization

  30,979   28,548 

Net property and equipment

 $11,726  $13,530 
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Note 6 - Goodwill and Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Intangible Assets and Goodwill [Table Text Block]
   

Gross

    

Accumulated

Impairment

    

Net

  
   

(In thousands)

  

Goodwill

   $ 57,969     $ (714 )   $ 57,255  
   

Useful Life

    

Gross

    

Accumulated

Amortization

    

Net

  
   

(In years)

            

(In thousands)

          

Non-amortizing intangible assets:

                                  

Indefinite trade name

               1,191               1,191  

Amortizing intangible assets:

                                  

Customer related

   5 - 15       9,344       9,256       88  

Technology

     7         1,360       1,229       131  

Trade names

   5 - 10       1,572       1,572       --  

Total amortizing intangible assets

               12,276       12,057       219  

Total intangible assets other than goodwill

             $ 13,467     $ 12,057     $ 1,410  
   

Gross

    

Accumulated

Impairment

    

Net

  
   

(In thousands)

  

Goodwill

   $ 57,935     $ -     $ 57,935  
   

Useful Life

    

Gross

    

Accumulated

Amortization

    

Net

  
   

(In years)

            

(In thousands)

          

Non-amortizing intangible assets:

                                  

Indefinite trade name

               1,191               1,191  

Amortizing intangible assets:

                                  

Customer related

   5 - 15       9,338       9,154       184  

Technology

     7         1,360       1,007       353  

Trade names

   5 - 10       1,572       1,572       --  

Total amortizing intangible assets

               12,270       11,733       537  

Total intangible assets other than goodwill

             $ 13,461     $ 11,733     $ 1,728  
Schedule of Goodwill [Table Text Block]

Balance as of December 31, 2018

   $ 57,831  

Foreign currency translation

     104  

Balance as of December 31, 2019

   $ 57,935  

Impairment

     (714

)

Foreign currency translation

     34  

Balance as of December 31, 2020

   $ 57,255  
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
  

2020

  

2019

  

2018

 
  

(In thousands)

 

U.S. Operations

 $41,357  $40,045  $32,056 

Foreign Operations

  110   474   2,653 

Income before income taxes

 $41,467  $40,519  $34,709 
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

2020

  

2019

  

2018

 
  

(In thousands)

 

Federal:

            

Current

 $3,546  $5,574  $2,144 

Deferred

  (308

)

  718   1,328 

Total

 $3,238  $6,292  $3,472 
             

Foreign:

            

Current

 $225  $94  $882 

Deferred

  (6

)

  33   (178

)

Total

 $219  $127  $704 
             

State:

            

Current

 $578  $1,322  $204 

Deferred

  172   372   282 

Total

 $750  $1,694  $486 
             

Total

 $4,207  $8,113  $4,662 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

2020

  

2019

  

2018

 
  

(In thousands)

 

Expected federal income taxes

 $8,708  $8,509  $7,285 

Foreign tax rate differential

  6   26   146 

State income taxes, net of federal benefit and state tax credits

  607   1,344   376 

Share-based compensation

  (5,713

)

  (1,579

)

  (3,041

)

Compensation limit for covered employees

  463   --   -- 

Federal tax credits

  (261

)

  (419

)

  (150

)

Uncertain tax positions

  157   34   90 

Nondeductible expenses (income) related to recapitalization

  --   (24

)

  151 

Goodwill Impairment

  184   --   -- 

Tax depreciation method change

  --   --   (308)

Withholding tax on repatriation of foreign earnings

  18   107   -- 

GILTI

  10   13   40 

Other

  28   102   73 
  $4,207  $8,113  $4,662 
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

2020

  

2019

 
  

(In thousands)

 

Deferred tax assets:

        

Allowance for doubtful accounts

 $29  $35 

Accrued expenses

  696   537 

Share-based compensation

  735   1,267 

Accrued bonuses

  145   120 

Employer payroll tax deferral

  323   -- 

Foreign tax credit from repatriation

  --   535 

Other

  27   -- 

Gross deferred tax assets

  1,955   2,494 

Less valuation allowance

  --   (535

)

Deferred tax assets

  1,955   1,959 

Deferred tax liabilities:

        

Prepaid expenses

  93   135 

Deferred contract costs

  1,111   990 

Property and equipment

  1,725   1,926 

Intangible assets

  6,109   5,553 

Repatriation withholding

  174   528 

Unrealized translation gain on intercompany loan

  --   214 

Other

  8   12 

Deferred tax liabilities

  9,220   9,358 

Net deferred tax liabilities

 $(7,265

)

 $(7,399

)
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
  

(In thousands)

 

Balance of unrecognized tax benefits at December 31, 2018

 $554 

Reductions due to lapse of applicable statute of limitations

  (43

)

Reductions due to tax positions of prior years

  -- 

Reductions due to settlement with taxing authorities

  (300

)

Additions based on tax positions related to the current year

  381 

Balance of unrecognized tax benefits at December 31, 2019

 $592 

Reductions due to lapse of applicable statute of limitations

  (34

)

Additions due to tax positions of prior years

  4 

Reductions due to settlement with taxing authorities

  -- 

Additions based on tax positions related to the current year

  206 

Balance of unrecognized tax benefits at December 31, 2020

 $768 
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.20.4
Note 8 - Notes Payable (Tables)
 12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Debt [Table Text Block]
  

2020

  

2019

 
  

(In thousands)

 

Term Loans

 $30,713  $34,281 

Less: current portion

  (4,061

)

  (4,378

)

Less: unamortized debt issuance costs

  (105

)

  (108

)

Notes payable, net of current portion

 $26,547  $29,795 
Schedule of Maturities of Long-term Debt [Table Text Block]

2021

 $4,093 

2022

  4,306 

2023

  4,529 

2024

  4,762 

2025

  13,023 
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Share-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
  

2020

  

2019

  

2018

 
  

Common

Stock

  

Common

Stock

  

Common

Stock

 

Expected dividend yield at date of grant

  1.84

%

  2.60

%

  2.59

%

Expected stock price volatility

  33.62

%

  34.01

%

  32.47

%

Risk-free interest rate

  1.35

%

  2.38

%

  2.51

%

Expected life of options (in years)

  7.39   7.46   7.28 
Share-based Payment Arrangement, Activity [Table Text Block]
  

Number of
Options

  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Contractual

Terms

(Years)

  

Aggregate

Intrinsic

Value

(In

thousands)

 

Common Stock

                

Outstanding at December 31, 2019

  1,245,922  $18.08         

Granted

  70,471  $62.23         

Exercised

  (630,373

)

 $14.20      $25,912 

Forfeited

  (85,449) $32.28         

Outstanding at December 31, 2020

  600,571  $25.31   5.58  $11,665 

Exercisable at December 31, 2020

  270,876  $18.00   4.14  $6,811 
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value, Intrinsic Value of Exercised and Vested in Period, and Fair Value of Vested in Period [Table Text Block]
  

2020

  

2019

  

2018

 
  

Common

Stock

  

Common

Stock

  

Common

Stock

 

Weighted average grant date fair value of stock options granted

 $18.67  $11.99  $10.02 

Intrinsic value of stock options exercised (in thousands)

 $25,912  $8,280  $10,621 

Intrinsic value of stock options vested (in thousands)

 $1,965  $1,891  $2,719 
Schedule of Nonvested Share Activity [Table Text Block]
  

Common Stock

Outstanding

  

Common Stock

Weighted

Average Grant

Date Fair Value

Per Share

 

Outstanding at December 31, 2019

  84,176  $17.23 

Granted

  --  $-- 

Vested

  (71,378) $13.59 

Forfeited

  (6,793) $36.80 

Outstanding at December 31, 2020

  6,005  $38.30 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.20.4
Note 10 - Leases (Tables)
 12 Months Ended
Dec. 31, 2020
Notes Tables  
Lease, Cost [Table Text Block]
  

2020

  

2019

 

Operating leases

 $600  $781 

Finance leases:

        

Asset amortization

  355   252 

Interest on lease liabilities

  37   39 

Variable lease cost

  62   86 

Short-term lease cost

  42   42 

Total net lease cost

 $1,096  $1,200 
Lessee, Lease, Balance Sheet Information [Table Text Block]
  

December 31,

2020

  

December 31,

2019

 

Operating leases:

        

Operating ROU assets

 $1,308  $1,628 
         

Current operating lease liabilities

  461   524 

Noncurrent operating lease liabilities

  896   1,139 

Total operating lease liabilities

 $1,357  $1,663 
  

December 31,

2020

  

December 31,

2019

 

Finance leases:

        

Furniture and equipment

 $1,014  $802 

Computer Equipment

  662   511 

Computer Software

  207   207 

Property and equipment under finance lease, gross

  1,883   1,520 

Less accumulated amortization

  (605

)

  (734

)

Property and equipment under finance lease, net

 $1,278  $786 
         

Current obligations of finance leases

 $493  $227 

Noncurrent obligations of finance leases

  778   559 

Total finance lease liabilities

 $1,271  $786 
         
Weighted average remaining lease term (in years):        
Operating leases  3.68   4.17 
Finance leases  2.69   3.56 
         
Weighted average discount rate:        
Operating leases  4.40%  4.81%
Finance leases  3.38%  4.60%
Lease, Cash flow [Table Text Block]
  

2020

  

2019

 

Cash paid for amounts included in the measurement of lease liabilities:

        

Operating cash flows from operating leases

 $596  $789 

Operating cash flows from finance leases

  36   38 

Financing cash flows from finance leases

  332   229 
         

ROU assets obtained in exchange for operating lease liabilities

  276   16 

ROU assets obtained in exchange for finance lease liabilities

  817   192 
Lessee, Operating and Finance Lease, Liability, Maturity [Table Text Block]
  

Finance Leases

  

Operating Leases

 

2021

 $527  $509 

2022

  481   322 

2023

  305   319 

2024

  13   203 

2025

  --   118 

Thereafter

  --   -- 

Total minimum lease payments

  1,326   1,471 

Less: Amount representing interest

  (55

)

  (114

)

Present value of minimum lease payments

  1,271   1,357 

Current portion

  (493

)

  (461

)

Lease obligations, net of current portion

 $778  $896 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Note 13 - Segment Information (Tables)
 12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
   

2020

    

2019

    

2018

  

Revenue:

                        

United States

   $ 130,305     $ 124,369     $ 115,451  

Canada

     2,972       3,613       4,235  

Total

   $ 133,277     $ 127,982     $ 119,686  

Long-lived assets:

                        

United States

   $ 77,448     $ 78,906     $ 77,330  

Canada

     1,863       2,622       2,291  

Total

   $ 79,311     $ 81,528     $ 79,621  

Total assets:

                        

United States

   $ 128,319     $ 95,668     $ 91,080  

Canada

     5,104       15,017       16,952  

Total

   $ 133,423     $ 110,685     $ 108,032  
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.20.4
Note 1 - Summary of Significant Accounting Policies (Details Textual)
 12 Months Ended
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
Dec. 31, 2018
USD ($)
shares
Sep. 30, 2020
USD ($)
Jan. 01, 2019
USD ($)
Jan. 01, 2018
USD ($)
Incremental Costs of Obtaining a Contract, Deferred During Period $ 3,700,000 $ 3,600,000 $ 2,600,000      
Capitalized Contract Cost, Net, Noncurrent 4,555,000 4,204,000        
Capitalized Computer Software, Additions 2,700,000 4,100,000        
Asset Impairment Charges, Total 0 0 0      
Impairment of Intangible Assets (Excluding Goodwill), Total 0 0 0      
Goodwill, Impairment Loss 714,000 0 0      
Goodwill, Ending Balance 57,255,000 57,935,000 57,831,000      
Proceeds from Insurance Settlement, Investing Activities 260,000          
Income Tax Credits and Adjustments 45,000 24,000 $ 0      
Cash Equivalents, at Carrying Value, Total 5,000,000.0 3,700,000        
Operating Lease, Right-of-Use Asset 1,308,000 1,628,000     $ 2,300,000  
Accrued Liabilities and Prepaid Expenses, Net         43,000  
Sales and Excise Tax Payable   775,000        
Excess Loss Coverage Per Person 150,000          
Self Insurance Reserve, Current $ 418,000 $ 270,000        
Common Class A [Member]            
Stock Options Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 65,127 16,221 93,346      
WASHINGTON            
Sales and Excise Tax Payable (Reversal of Liability)       $ (268,000)    
Other Current Liabilities and Other Noncurrent Liabilities [Member]            
Operating Lease, Liability, Total $ 1,357,000 $ 1,663,000     $ 2,300,000  
Cyber Attack [Member] | Recoveries Received Direct by the Company [Member]            
Proceeds from Insurance Settlement, Operating Activities 3,300,000          
Cyber Attack [Member] | Recoveries Paid Directly by Insurer to Outside Vendor [Member]            
Proceeds from Insurance Settlement, Operating Activities 447,000          
Cyber Attack [Member] | Reimbursement for Lost Revenue [Member]            
Insurance Recoveries 533,000          
Canadian Subsidiary [Member]            
Goodwill, Impairment Loss $ 714,000          
Number of Customers 1          
Goodwill, Ending Balance $ 1,600,000          
Selling, General and Administrative Expenses [Member]            
Capitalized Contract Cost, Impairment Loss 63,000 $ 22,000 $ 51,000      
Other Income [Member] | Property Damage Excluding Cyber Attack [Member]            
Proceeds from Insurance Settlement, Investing Activities $ 260,000          
Minimum [Member]            
Capitalized Contract Cost, Amortization Period (Year) 3 years          
Minimum [Member] | Furniture and Fixtures [Member]            
Property, Plant and Equipment, Useful Life (Year) 3 years          
Minimum [Member] | Computer Equipment [Member]            
Property, Plant and Equipment, Useful Life (Year) 3 years          
Minimum [Member] | Software and Software Development Costs [Member]            
Property, Plant and Equipment, Useful Life (Year) 1 year          
Minimum [Member] | Building and Building Improvements [Member]            
Property, Plant and Equipment, Useful Life (Year) 7 years          
Maximum [Member]            
Capitalized Contract Cost, Amortization Period (Year) 5 years          
Maximum [Member] | Furniture and Fixtures [Member]            
Property, Plant and Equipment, Useful Life (Year) 10 years          
Maximum [Member] | Computer Equipment [Member]            
Property, Plant and Equipment, Useful Life (Year) 5 years          
Maximum [Member] | Software and Software Development Costs [Member]            
Property, Plant and Equipment, Useful Life (Year) 5 years          
Maximum [Member] | Building and Building Improvements [Member]            
Property, Plant and Equipment, Useful Life (Year) 40 years          
Accounting Standards Update 2014-09 [Member] | Changes Related to Contract Costs [Member]            
Capitalized Contract Cost, Gross           $ 3,400,000
Accounting Standards Update 2014-09 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Revenue Recognition [Member]            
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance           2,700,000
Accounting Standards Update 2014-09 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Income Tax Related to Revenue Adjustment [Member]            
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance           814,000
Accounting Standards Update 2014-09 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Changes Related to Contract Costs [Member]            
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance           2,600,000
Accounting Standards Update 2014-09 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Changes Related to Contract Costs, Income Tax Effect [Member]            
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance           $ 776,000
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.20.4
Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Capitalized contract cost $ 3,242 $ 2,908 $ 2,483
Direct Expenses [Member]      
Capitalized contract cost 272 34 83
Selling, General and Administrative Expenses [Member]      
Capitalized contract cost $ 2,970 $ 2,874 $ 2,400
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.20.4
Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Balance $ 144 $ 175 $ 200
Bad Debt Expense (Benefit) 46 75 80
Write-offs 70 106 105
Balance $ 120 $ 144 $ 175
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.20.4
Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Non-cash share-based compensation expense $ 680 $ 1,224 $ 1,514
Amount of related income tax benefit (6,764) (2,081) (3,566)
Net (benefit) expense to net income $ (6,084) $ (857) $ (2,052)
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.20.4
Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Total carrying amount of long-term debt $ 30,713 $ 34,281
Estimated fair value of long-term debt 32,943 35,205
Fair Value, Recurring [Member]    
Assets, fair value 5,015 3,662
Money Market Funds [Member] | Fair Value, Recurring [Member]    
Assets, fair value 5,015 3,662
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]    
Assets, fair value 5,015 3,662
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] | Fair Value, Recurring [Member]    
Assets, fair value $ 5,015 $ 3,662
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.20.4
Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Numerator for net income per share - basic:      
Net income $ 37,260 $ 32,406 $ 30,047
Common Stock [Member]      
Numerator for net income per share - basic:      
Net income 37,260 32,406  
Allocation of distributed and undistributed income to unvested restricted stock shareholders (57) (109)  
Net income attributable to common shareholders $ 37,203 $ 32,297  
Basic earnings per share:      
Weighted average common shares outstanding – basic (in shares) 25,170 24,809  
Net income per share - basic (in dollars per share) $ 1.48 $ 1.30  
Diluted earnings per share:      
Net income attributable to common shareholders $ 37,203 $ 32,297  
Weighted average common shares outstanding – basic (in shares) 25,170 24,809  
Weighted average effect of dilutive securities – stock options (in shares) 526 844  
Denominator for diluted earnings per share – adjusted weighted average shares (in shares) 25,696 25,653  
Net income per share - diluted (in dollars per share) $ 1.45 $ 1.26  
Common Class A [Member]      
Numerator for net income per share - basic:      
Net income     25,423
Allocation of distributed and undistributed income to unvested restricted stock shareholders     (82)
Net income attributable to common shareholders     $ 25,341
Basic earnings per share:      
Weighted average common shares outstanding – basic (in shares) 25,170 24,809 23,562
Net income per share - basic (in dollars per share) $ 1.48 $ 1.30 $ 1.08
Diluted earnings per share:      
Net income attributable to common shareholders     $ 25,341
Weighted average common shares outstanding – basic (in shares) 25,170 24,809 23,562
Weighted average effect of dilutive securities – stock options (in shares)     886
Denominator for diluted earnings per share – adjusted weighted average shares (in shares) 25,696 25,653 24,448
Net income per share - diluted (in dollars per share) $ 1.45 $ 1.26 $ 1.04
Common Class B [Member]      
Numerator for net income per share - basic:      
Net income     $ 4,624
Allocation of distributed and undistributed income to unvested restricted stock shareholders     (18)
Net income attributable to common shareholders     $ 4,606
Basic earnings per share:      
Weighted average common shares outstanding – basic (in shares)     3,527
Net income per share - basic (in dollars per share)     $ 1.31
Diluted earnings per share:      
Net income attributable to common shareholders     $ 4,606
Weighted average common shares outstanding – basic (in shares)     3,527
Weighted average effect of dilutive securities – stock options (in shares)     101
Denominator for diluted earnings per share – adjusted weighted average shares (in shares)     3,628
Net income per share - diluted (in dollars per share)     $ 1.27
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.20.4
Note 2 - Recapitalization (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Apr. 17, 2018
Apr. 16, 2018
Dec. 31, 2018
Dec. 31, 2020
Dec. 31, 2019
Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001     $ 0.001 $ 0.001
Payments Related to Recapitalization     $ 72,370    
Conversion of Class B Common Stock Into Class A Common Stock [Member]          
Conversion of Stock, Number of Shares Exchanged for Each Share (in shares)   1      
Conversion of Stock, Cash Paid Per Share Converted (in dollars per share)   $ 19.59      
Conversion of Stock, Shares Issued (in shares) 3,617,615        
Payments Related to Recapitalization $ 72,400        
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.20.4
Note 3 - Contracts With Customers 1 (Details Textual)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
VoC Platform [Member]      
Revenue from Contract with Customer, Percent of Total Revenue 73.30% 62.70% 49.60%
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.20.4
Note 3 - Contracts With Customers 2 (Details Textual) - Long-term Contract with Customer [Member] - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Dec. 31, 2020
USD ($)
Revenue, Remaining Performance Obligation, Amount $ 205,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) 1 year
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.20.4
Note 3 - Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenue $ 133,277 $ 127,982 $ 119,686
Transferred over Time [Member] | Subscription Services [Member]      
Revenue 122,499 114,216 104,777
Transferred over Time [Member] | Fixed, Non-subscription Services [Member]      
Revenue 2,907 3,248 3,163
Transferred over Time [Member] | Unit Price Services [Member]      
Revenue 4,939 5,526 6,971
Transferred at Point in Time [Member] | Service [Member]      
Revenue $ 2,932 $ 4,992 $ 4,775
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.20.4
Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Accounts receivables $ 13,923 $ 11,639
Deferred revenue (15,585) (16,354)
Revenue recognized that was included in deferred revenue at beginning of year due to completion of services (16,083) (15,785)
Increases due to invoicing of client, net of amounts recognized as revenue 15,338 15,631
Decreases due to completion of services (or portion of services) and transferred to accounts receivable (103) (53)
Change due to cumulative catch-up adjustments arising from changes in expected contract consideration (24) 264
Increases due to revenue recognized in the period with additional performance obligations before invoicing 311 103
Other Current Assets [Member]    
Contract assets included in other current assets $ 311 $ 103
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.20.4
Note 4 - Equity Investments (Details Textual) - PracticingExcellence.com [Member]
$ in Millions
Dec. 31, 2020
USD ($)
Cost Method Investments $ 1.3
Cost Method Investment, Ownership Percentage 15.70%
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.20.4
Note 5 - Property and Equipment (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Depreciation, Amortization and Impairment $ 7,505 $ 5,539 $ 5,463
Impairment of Long-Lived Assets Held-for-use 0 0 0
Including Assets Held under Capital Lease [Member]      
Depreciation, Amortization and Impairment $ 6,500 $ 5,400 $ 4,800
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.20.4
Note 5 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Property and equipment at cost $ 42,705 $ 42,078
Less accumulated depreciation and amortization 30,979 28,548
Net property and equipment 11,726 13,530
Furniture and Fixtures [Member]    
Property and equipment at cost 4,808 5,025
Computer Equipment [Member]    
Property and equipment at cost 2,638 2,706
Software and Software Development Costs [Member]    
Property and equipment at cost 27,087 24,532
Building and Building Improvements [Member]    
Property and equipment at cost 7,515 9,349
Leasehold Improvements [Member]    
Property and equipment at cost 232 41
Land [Member]    
Property and equipment at cost $ 425 $ 425
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.20.4
Note 6 - Goodwill and Intangible Assets (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Goodwill, Impairment Loss $ 714,000 $ 0 $ 0
Amortization of Intangible Assets, Total 318,000 $ 374,000 $ 662,000
Finite-Lived Intangible Asset, Expected Amortization, Year One 180,000    
Finite-Lived Intangible Asset, Expected Amortization, Year Two 40,000    
Finite-Lived Intangible Asset, Expected Amortization, Year Three 0    
Canadian Subsidiary [Member]      
Goodwill, Impairment Loss $ 714,000    
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.20.4
Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Goodwill, gross $ 57,969 $ 57,935  
Goodwill, accumulated impairment (714) 0  
Goodwill, Ending Balance 57,255 57,935 $ 57,831
Finite-lived intangible assets, gross 12,276 12,270  
Finite-lived intangible assets, accumulated amortization 12,057 11,733  
Finite-lived intangible assets, net 219 537  
Total intangible assets other than goodwill 13,467 13,461  
Total intangible assets other than goodwill 1,410 1,728  
Customer Relationships [Member]      
Finite-lived intangible assets, gross 9,344 9,338  
Finite-lived intangible assets, accumulated amortization 9,256 9,154  
Finite-lived intangible assets, net $ 88 $ 184  
Customer Relationships [Member] | Minimum [Member]      
Finite-lived intangible assets, useful life (Year) 5 years 5 years  
Customer Relationships [Member] | Maximum [Member]      
Finite-lived intangible assets, useful life (Year) 15 years 15 years  
Technology-Based Intangible Assets [Member]      
Finite-lived intangible assets, useful life (Year) 7 years 7 years  
Finite-lived intangible assets, gross $ 1,360 $ 1,360  
Finite-lived intangible assets, accumulated amortization 1,229 1,007  
Finite-lived intangible assets, net 131 353  
Trade Names [Member]      
Finite-lived intangible assets, gross 1,572 1,572  
Finite-lived intangible assets, accumulated amortization $ 1,572 $ 1,572  
Trade Names [Member] | Minimum [Member]      
Finite-lived intangible assets, useful life (Year) 5 years 5 years  
Trade Names [Member] | Maximum [Member]      
Finite-lived intangible assets, useful life (Year) 10 years 10 years  
Trade Names 1 [Member]      
Indefinite trade name $ 1,191 $ 1,191  
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Balance $ 57,935 $ 57,831  
Foreign currency translation 34 104  
Impairment (714) 0 $ 0
Balance $ 57,255 $ 57,935 $ 57,831
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 21.00% 21.00% 21.00%
Deemed Dividend Paid by Foreign Subsidiary $ 9,600,000   $ 3,000,000
Provisional Tax Expense (Benefit) for Global Intangible Low Taxed Income 10,000 $ 13,000 40,000
Cumulative Tax Incentives 435,000 1,900,000  
Income Tax Credits and Adjustments 45,000 24,000 0
Change in Tax Law, Deferral of Social Security Tax Payments 1,323,000    
Deferred Tax Asset, Prior Year Foreign Tax Credit Carryforwards, Write Off 535,000    
Unrecognized Tax Benefits, Ending Balance 768,000 592,000 $ 554,000
Unrecognized Tax Benefits, Interest on Income Taxes Accrued 15,000 7,000  
Unrecognized Tax Benefits that Would Impact Effective Tax Rate $ 668,000 $ 515,000  
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes - Income Before Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
U.S. Operations $ 41,357 $ 40,045 $ 32,056
Foreign Operations 110 474 2,653
Income before income taxes $ 41,467 $ 40,519 $ 34,709
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes - Income Tax Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Current $ 3,546 $ 5,574 $ 2,144
Deferred (308) 718 1,328
Total 3,238 6,292 3,472
Current 225 94 882
Deferred (6) 33 (178)
Total 219 127 704
Current 578 1,322 204
Deferred 172 372 282
Total 750 1,694 486
Income Tax Expense (Benefit), Total $ 4,207 $ 8,113 $ 4,662
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes - Income Tax Reconciliation (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Expected federal income taxes $ 8,708,000 $ 8,509,000 $ 7,285,000
Foreign tax rate differential 6,000 26,000 146,000
State income taxes, net of federal benefit and state tax credits 607,000 1,344,000 376,000
Share-based compensation (5,713,000) (1,579,000) (3,041,000)
Compensation limit for covered employees 463,000    
Federal tax credits (261,000) (419,000) (150,000)
Uncertain tax positions 157,000 34,000 90,000
Nondeductible expenses (income) related to recapitalization   (24,000) 151,000
Goodwill Impairment 184,000    
Tax depreciation method change     (308,000)
Withholding tax on repatriation of foreign earnings 18,000 107,000  
GILTI 10,000 13,000 40,000
Other 28,000 102,000 73,000
Income Tax Expense (Benefit), Total $ 4,207,000 $ 8,113,000 $ 4,662,000
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred tax assets:    
Allowance for doubtful accounts $ 29 $ 35
Accrued expenses 696 537
Share-based compensation 735 1,267
Accrued bonuses 145 120
Employer payroll tax deferral 323  
Foreign tax credit from repatriation   535
Other 27  
Gross deferred tax assets 1,955 2,494
Less valuation allowance   (535)
Deferred tax assets 1,955 1,959
Deferred tax liabilities:    
Prepaid expenses 93 135
Deferred contract costs 1,111 990
Property and equipment 1,725 1,926
Intangible assets 6,109 5,553
Repatriation withholding 174 528
Unrealized translation gain on intercompany loan   214
Other 8 12
Deferred tax liabilities 9,220 9,358
Net deferred tax liabilities $ (7,265) $ (7,399)
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Balance of unrecognized tax benefits $ 592,000 $ 554,000
Reductions due to lapse of applicable statute of limitations (34,000) (43,000)
Reductions due to settlement with taxing authorities   (300,000)
Additions based on tax positions related to the current year 206,000 381,000
Additions due to tax positions of prior years 4,000  
Balance of unrecognized tax benefits $ 768,000 $ 592,000
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.20.4
Note 8 - Notes Payable (Details Textual) - Credit Agreement [Member] - First National Bank of Omaha [Member]
 12 Months Ended
Dec. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
May 28, 2020
USD ($)
Debt Instrument, Covenant, Minimum Fixed Charge Coverage Ratio 1.10    
Debt Instrument, Covenant, Exception, Fixed Charge Coverage Ratio, Dividend Threshold $ 5,500,000    
Debt Instrument, Covenant, Maximum Cash Flow Leverage Ratio 3.00    
London Interbank Offered Rate (LIBOR) [Member]      
Debt Instrument, Basis Spread on Variable Rate 2.25%    
Revolving Credit Facility [Member]      
Line of Credit Facility, Maximum Borrowing Capacity $ 30,000,000 $ 15,000,000  
Debt Instrument, Percentage Bearing Variable Interest, Percentage Rate 2.40%    
Long-term Line of Credit, Total $ 0    
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.20%    
Term Loan [Member]      
Debt Instrument, Face Amount     $ 33,002,069
Debt Instrument, Periodic Payment, Total $ 462,988    
Debt Instrument, Interest Rate, Stated Percentage 5.00%    
Delayed Draw Term Loan [Member]      
Line of Credit Facility, Maximum Borrowing Capacity     $ 15,000,000
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.20.4
Note 8 - Notes Payable - Summary of Notes Payable (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Less: current portion $ (4,061) $ (4,378)
Less: unamortized debt issuance costs (105) (108)
Notes payable, net of current portion 26,547 29,795
Term Loan [Member]    
Term Loans $ 30,713 $ 34,281
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.20.4
Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details)
$ in Thousands
Dec. 31, 2020
USD ($)
2021 $ 4,093
2022 4,306
2023 4,529
2024 4,762
2025 $ 13,023
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Share-based Compensation (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2015
Proceeds from Stock Options Exercised $ 1,734,000 $ 0 $ 0  
Share-based Payment Arrangement, Exercise of Option, Tax Benefit 6,300,000 2,000,000.0 3,800,000  
Share-based Payment Arrangement, Option [Member]        
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total $ 1,400,000      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) 2 years 11 months 15 days      
Share-based Payment Arrangement, Option [Member] | Direct, Selling, General and Administrative Expenses [Member]        
Share-based Payment Arrangement, Expense $ 680,000 $ 934,000 $ 1,100,000  
Common Stock Options [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) 70,471 100,615 116,276  
Nonvested [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 5 years      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total $ 138,000      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) 3 years      
Nonvested [Member] | Direct, Selling, General and Administrative Expenses [Member]        
Share-based Payment Arrangement, Expense $ 23,000 $ 290,000 $ 428,000  
Restricted Stock [Member]        
Tax Benefit Realized Restricted Stock Vested $ 235,000 0 168,000  
The 2001 Equity Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)       0
The 2001 Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | Minimum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 1 year      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 5 years      
The 2001 Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 5 years      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 10 years      
Director Plan 2004 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) 830,419      
Share-based Compensation Arrangement by Share-based Payment Award, Options Grants Cumulative (in shares) 2,169,581      
Director Plan 2004 [Member] | Nonqualified Stock Options [Member] | Director [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 1 year      
Share Based Compensation Arrangement By Share Based Payment Award, Award Annual Options Grant Amount $ 100,000 $ 100,000 $ 100,000  
Director Plan 2004 [Member] | Nonqualified Stock Options [Member] | Minimum [Member] | Director [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 3 years      
Director Plan 2004 [Member] | Nonqualified Stock Options [Member] | Maximum [Member] | Director [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 10 years      
The 2006 Equity Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) 779,800      
Share-based Compensation Arrangement by Share-based Payment Award, Options Grants Cumulative (in shares) 1,020,200      
The 2006 Equity Incentive Plan [Member] | Minimum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 5 years      
The 2006 Equity Incentive Plan [Member] | Maximum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 10 years      
The 2006 Equity Incentive Plan [Member] | Nonvested [Member]        
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) 0 6,005 6,793  
Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Restricted Stock, Outstanding Number (in shares) 6,005      
Common Class B [Member]        
Share-based Payment Arrangement, Accelerated Cost     $ 331,000  
Common Class B [Member] | The 2001 Equity Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 300,000      
Common Class B [Member] | Director Plan 2004 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 500,000      
Common Class B [Member] | The 2006 Equity Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 300,000      
Common Stock [Member] | The 2001 Equity Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 1,800,000      
Common Stock [Member] | Director Plan 2004 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 3,000,000      
Common Stock [Member] | The 2006 Equity Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 1,800,000      
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details) - Common Stock [Member]
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Expected dividend yield at date of grant 1.84% 2.60% 2.59%
Expected stock price volatility 33.62% 34.01% 32.47%
Risk-free interest rate 1.35% 2.38% 2.51%
Expected life of options (in years) (Year) 7 years 4 months 20 days 7 years 5 months 15 days 7 years 3 months 10 days
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Common Stock [Member]      
Exercised, aggregate intrinsic value $ 25,912 $ 8,280 $ 10,621
Common Stock Options [Member]      
Outstanding, number of options (in shares) 1,245,922    
Outstanding, weighted average exercise price (in dollars per share) $ 18.08    
Granted, number of options (in shares) 70,471 100,615 116,276
Granted, weighted average exercise price (in dollars per share) $ 62.23    
Exercised, number of options (in shares) (630,373)    
Exercised, weighted average exercise price (in dollars per share) $ 14.20    
Forfeited, number of options (in shares) (85,449)    
Forfeited, weighted average exercise price (in dollars per share) $ 32.28    
Outstanding, number of options (in shares) 600,571 1,245,922  
Outstanding, weighted average exercise price (in dollars per share) $ 25.31 $ 18.08  
Outstanding, weighted average remaining contractual term (Year) 5 years 6 months 29 days    
Exercisable, number of options (in shares) 270,876    
Weighted average exercise price (in dollars per share) $ 18.00    
Exercisable, weighted average remaining contractual term (Year) 4 years 1 month 20 days    
Common Stock Options [Member] | Common Stock [Member]      
Exercised, aggregate intrinsic value $ 25,912    
Outstanding, aggregate intrinsic value 11,665    
Exercisable, aggregate intrinsic value $ 6,811    
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Share-based compensation - Stock Option Activity (Details) - Common Stock [Member] - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Weighted average grant date fair value of stock options granted (in dollars per share) $ 18.67 $ 11.99 $ 10.02
Exercised, aggregate intrinsic value $ 25,912 $ 8,280 $ 10,621
Intrinsic value of stock options vested (in thousands) $ 1,965 $ 1,891 $ 2,719
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Share-based Compensation - Non-vested Stock (Details) - Common Stock [Member]
 12 Months Ended
Dec. 31, 2020
$ / shares
shares
Outstanding (in shares) | shares 84,176
Outstanding (in dollars per share) | $ / shares $ 17.23
Vested (in shares) | shares (71,378)
Vested (in dollars per share) | $ / shares $ 13.59
Forfeited (in shares) | shares (6,793)
Forfeited (in dollars per share) | $ / shares $ 36.80
Outstanding (in shares) | shares 6,005
Outstanding (in dollars per share) | $ / shares $ 38.30
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.20.4
Note 10 - Leases (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
Feb. 28, 2021
Dec. 31, 2018
Dec. 31, 2020
Operating Leases, Rent Expense, Net, Total   $ 779,000  
Subsequent Event [Member]      
Lessee, Operating Lease, Monthly Base Rent Payments $ 14,288    
Minimum [Member]      
Lessee, Operating Lease, Remaining Lease Term (Year)     1 year
Maximum [Member]      
Lessee, Operating Lease, Remaining Lease Term (Year)     4 years 8 months 12 days
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.20.4
Note 10 - Leases - Lease Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Operating leases $ 600 $ 781
Asset amortization 355 252
Interest on lease liabilities 37 39
Variable lease cost 62 86
Short-term lease cost 42 42
Total net lease cost $ 1,096 $ 1,200
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.20.4
Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Jan. 01, 2019
Operating lease right-of-use assets $ 1,308 $ 1,628 $ 2,300
Property and equipment at cost 42,705 42,078  
Less accumulated amortization (30,979) (28,548)  
Property and equipment under finance lease, net 11,726 13,530  
Current obligations of finance leases 493 227  
Noncurrent obligations of finance leases 778 559  
Total finance lease liabilities $ 1,271 $ 786  
Operating leases (Year) 3 years 8 months 4 days 4 years 2 months 1 day  
Finance leases (Year) 2 years 8 months 8 days 3 years 6 months 21 days  
Operating leases 4.40% 4.81%  
Finance leases 3.38% 4.60%  
Other Current Liabilities [Member]      
Current operating lease liabilities $ 461 $ 524  
Other Noncurrent Liabilities [Member]      
Operating lease obligations, net of current portion 896 1,139  
Other Current Liabilities and Other Noncurrent Liabilities [Member]      
Total operating lease liabilities 1,357 1,663 $ 2,300
Furniture and Equipment Held under Finance Leases [Member]      
Property and equipment at cost 1,014 802  
Computer Equipment Held under Finance Leases [Member]      
Property and equipment at cost 662 511  
Computer Software Held under Finance Leases [Member]      
Property and equipment at cost 207 207  
Assets Held under Finance Leases [Member]      
Property and equipment at cost 1,883 1,520  
Less accumulated amortization (605) (734)  
Property and equipment under finance lease, net $ 1,278 $ 786  
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.20.4
Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Operating cash flows from operating leases $ 596 $ 789  
Operating cash flows from finance leases 36 38  
Financing cash flows from finance leases 332 229 $ 157
ROU assets obtained in exchange for operating lease liabilities 276 16  
ROU assets obtained in exchange for finance lease liabilities $ 817 $ 192  
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.20.4
Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Jan. 01, 2019
Finance leases, 2021 $ 527    
Operating leases, 2021 509    
Finance leases, 2022 481    
Operating leases, 2022 322    
Finance leases, 2023 305    
Operating leases, 2023 319    
Finance leases, 2024 13    
Operating leases, 2024 203    
Operating leases, 2025 118    
Finance leases, total minimum lease payments 1,326    
Operating leases, total minimum lease payments 1,471    
Finance leases, less: Amount representing interest (55)    
Operating leases, less: Amount representing interest (114)    
Present value of minimum finance lease payments 1,271 $ 786  
Current portion, finance leases (493) (227)  
Finance leases obligations, net of current portion 778 559  
Other Current Liabilities and Other Noncurrent Liabilities [Member]      
Operating Lease, Liability, Total 1,357 1,663 $ 2,300
Other Current Liabilities [Member]      
Current portion, operating leases (461) (524)  
Other Noncurrent Liabilities [Member]      
Operating lease obligations, net of current portion $ 896 $ 1,139  
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.20.4
Note 11 - Related Party (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Ameritas Life Insurance Corp [Member]        
Related Party Transaction, Amounts of Transaction $ 248,000 $ 242,000 $ 200,000  
IMA Financial Group [Member] | Purchasing Directors and Officers and Employment Practices Liability Insurance [Member]        
Related Party Transaction, Amounts of Transaction 1,100,000      
Related Party Transaction, Expenses from Transactions with Related Party 478,000      
PracticingExcellence.com [Member]        
Payments to Acquire Intangible Assets       $ 250,000
Revenue from Related Parties $ 294,000 $ 578,000 $ 439,000  
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.20.4
Note 12 - Associate Benefits (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay 25.00%    
Defined Contribution Plan, Maximum Percentage of Annual Contribution Employee Subject to Match 6.00%    
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage 20.00%    
Defined Contribution Plan, Employer Discretionary Contribution Amount $ 521,000 $ 447,000 $ 396,000
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.20.4
Note 13 - Segment Information (Details Textual)
 12 Months Ended
Dec. 31, 2020
Number of Operating Segments 6
Number of Reportable Segments 1
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.20.4
Note 13 - Segment Information - Assets by Geographic Area (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenue $ 133,277 $ 127,982 $ 119,686
Long-lived assets 79,311 81,528 79,621
Total assets 133,423 110,685 108,032
UNITED STATES      
Revenue 130,305 124,369 115,451
Long-lived assets 77,448 78,906 77,330
Total assets 128,319 95,668 91,080
CANADA      
Revenue 2,972 3,613 4,235
Long-lived assets 1,863 2,622 2,291
Total assets $ 5,104 $ 15,017 $ 16,952
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.20.4
Note 14 - Subsequent Event (Details Textual) - Subsequent Event [Member] - PatientWisdom, Inc. [Member]
$ in Millions
Jan. 04, 2021
USD ($)
Payments to Acquire Businesses, Gross $ 3
Business Combination, Consideration Transferred, Total 5
Business Combination, Consideration Transferred, Liabilities Incurred $ 2
EXCEL 88 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
)(:X8Q/ M \+7(87FK$K#:2H?U*.]3::.;/!8IL$&8J:*IAT\\VWFTW"=AH(4J]G#!L[8?[CUD5! MNUP3KW3J/C55AMF((LV=5.8O/RPP)2?>_TG#]-4>W&)%_V$DO%3[;SZ>,LSV M?YR@S:F_MHH- U07S*6M:^AT-KAT5 M0O@7CM3.)H 'HI927%=4RVH46#6H*%@'3]2$JB[7?$YT= F6%!=5.97%KJIU MTIY\CHN"6Y<(?PDQCG+VSH*0W]%SE:E5D:*F#:N 0L>!F+MB1DU4 ' 4HA MX8+9J460%_2U%373J>A2ZJ7(RRO16D77&V^V5Z;2[/[;/[:; M;;@;APGLQOOU05_7ICRPL/I[L\QJ^4JKZ*XD\ !%&&[Y;2SS1+K%38HP8RC/$D$8EUC-4XXU:B$\O3\0H-W1FEIA?8B<; M6(2Y)Y0I#7-E ,9#L;BI*6#C:WL[+U%D&]SKR<4WL.R*6Y[V6HZ2+B;6%U_X MK6%TOH6:?'?4!B414P/Y0VW"WRY9LXS3,[)>DY3_>@7W$2E4.B\YJA%=SW6<0.=0KE_BB%BR:GL#CZLD400K']4AW]6/8LK M0K" //[E@'A.GZ1Z1]U[O*&_8BBV!R$,Z7:]P!F+;2BI7)*,GW:CLAM#1;X. MH@<3:'_@2 R)>T9P8FSPF4"0Q39M50 $U5WVVC!A;&A L6AL*&#CR]C@T48@ MMEB,)*3V T;QI86!'7'0 694=%83\"5*% MY4&MO=;A:\Z MPI!4?;AF\-8/,BH#C,H)5.%!38P11%4E!/I \1I=X*2%_DH9;IKGLNBA'&\" MUG.)PL8HIASJWNO:RU-$EN ^MZ=Y &UMXV(WWZ;TL,<*0] /<0I=F^)G/-_0 M%>075U%,%XW*!_O*WOYE"B/W&]Q8S*>V Z*3KU;I#'>,[.'FF4H_T%5>]4PRJEI!T_)#V8P2&H8J/6+X:X J*:R MR*P1V@F'.BFLW4!(D^J"3&.O=;!Y3F@W]+F]A3+;VU>P7]G>@":PH[ Z@B#O M&5Y1;.G^QV^++TF&XZ>4EQ4,=^RJ(F#!!2=IQ#XE7#U$_]CF!9#@!A>WR\?@ MRQWO*7M2%%F\V!9,;9"[8*BBI&L$^VZZW@!:U.HL&1134..I< M4DZ<0AIWFF61T/:4$ \4F,')&F95EA -=UJ$M%E.U+E<'18I]<,*KDV2E*3/ M."_HUUS5&S5&!@9W8X8(D)C"^?J&HL=Q*VV15V5[#*VNOM4AM62OI,5T%:Y5NPF5ZE/&3R5ZI@5O3SR3/.@B?\D8Y?G%.RU<4@18?BJ>'G MNE^OZ7G8U@\<'1: '9$D";(<;>ANS43"8UG4*9"^\[@_%>2/@_ M8XIE2 YEM U;/T@W#=7>TNV5%0G*JS^F7 Y#=I4&FYRID/YKV4"I5;[$<;&E M/#&]W5,'N)2[_7;9.+?YQLF_J,X7M3;-=]XX>O!*X;Z=G#X(VQB;PM8';MOQ:SX:9R,DS/:%!';7(F@_P47*4]36&N.O<24\!;?8TV M/ &X"+)"\=)B6U!%ED901U['POOZB'B1*A:J&TO"5VF\I_[)+!"$T^#Z*DRAT?P@;_R8661+XOC]/,=/[/->RWM>7G&QFS]A M\I0%FU4SA\'T=0VYO[6 M*,[Z:L@SVK']=9ZL1"K)K"N$2-8I88XV1!^30(#_/OU%XRRBC5X%X9!OU6 MH>$VB5N1[H,\U$U,7Y4):LW'-*=F10*50497(I !YK(=2XT/SWF:U?31?_W%M?S[3.HYHTWK,'4\K?^OK/(8(!,U# M3I9!6_,RSO+BAN$9)*=!^OOM\G8=K()/N,/[)/^"AHW9/[#U+ J CBKP".## M#LXP0+]Q' 8V:?M3TNWH4H>U0$<7^CZ8('T3=E\J4)*KB#I=1TG'8>\5D=TK M]:R&3 C'M"T.AX"IQ2IKJUJ=A7YE3-! MNG,O"<-L1)2H.HTJ1-5*U M;'374*)*S:B%>26GU-).O/B"LS#.85H'(=;E+_@NBT/C"3QZT%V?4=6PM"V? M%6P4<. (E]#1!L!_%8D*FGQAXD@U9K$]R/QB>(H+Y2G>XW40IW'Z=$92IMJV M0?*(L_5A ?@)8#)&%[C%V+9>:*$T0R^'2B*KT((^FQ5>J*"(H3=_PT'F44%X M8IQ#9>&3&]PJ#G:15';"X27X1(9SSY.:@MW0R&R1:B/#O=5S=TJ< L)0E%Y8G. U-N$IF"9@?7%4LC2#@+(C""K5:( M@".%WE,&L T#N6M MI!%)+]=[2Z?U$9AX.L9K8&S]GK=!Z;^-OW@,XQCT"(SFAM>U9;>FZ\0_, C/ MTQ8NQ,NIJ']=OH#AM3:XG4LNX.N23E9#+_?6-F4<%IXD61%;YR$A3X "BD#( MEQ0)+M]@O;,V0+4-SQ[[2@K C^0C@UIB%'.,"CL^(WGQ"1+=OM FR(@[C#0_>IOH/@K=CGHJ( M41!6-:Z6]!56I*F,[J9D77.RTK'+QZ@YX#[>6U5BR8C%HF3Y&-& M\L.2!KW/:!H#>V.YNAO8 ZKCXA^)M89.J2#.J-TPB+0E\Z![W8D46?QP\=5Z M0W=ZNO^'(6^VBR/^%4C>]3"'2[\_DOL'X;B6C$&$QDB-R=GN)[\^CA&LH$$' MQ34^7B5-GO\ZI%"1S(X/SCC<4MS.\:+HCX(4/ZA[_#P:T-F5]!%DK>OE,?B/ M%I=KG.<_E_VVZZA./X=5,6,0>6J]+G>1V'?M(E-($;I_1Z_/3"''TW%:R\(V MI4W4'>RX5C.0J_4J"3FF0J$=,D[4?ZFJX.S<;DPUY:VZ%?TU+E9GV[P@:YQ= MQ\$B3N)BUV_$J;RJN6W(@+"M\\_Q$E- $XD6">5>#\[J\SE"14+U!1KI'Y8#9EK\*&]:(KL&G:@S1 M8*10=\FR_U!QE3J4^Z$ MX]H6D1(P%0=89^PG;FF8JD295&[YZ&*]2<@.X[(JM#0_2;^GR5>#X[OBKQ$G6Q^"+I (3/S].@1V/:YO!.$14 ,BJ9IE/ M)=9#V6,E-D0NM[QT'C_'$4XCN>IW T]K\I%@5.L7@Q58KRPT1%*B2"?GJ@CB M_>6XI_]A?274,:B#+8Y!]:U]^NA)U(CDEG'N\3-)GB&M.\-17%P&(;O^[6R6 MHO2.)AOUCFV_1T0)'''HJ (OV2_%$G_)T9MH$7%B3B'Y0""K)7:$YT46AP7#=TU2AAS$>;#:;R52<*Q*4QS"!X@LJYKZE#U]#A2V"U Z*>&6 M4+)>4)SB34WA.$)YC3GO"57A7F<=,^R94VB_\@(5O&8*Z(7.X:BCE'):]F2H MJ=MN;D-_!=<[2[4.UF##LPSNFMS1-@.SL> 9WU0A4J+M]:BSN1X>4KQMBRQQ MR3FORP8>#+'S%;HZ]?#4UV(S#T[$AZ5HDKIC>O*VXGR_/JM17L1:A)Y$OEDE7,"Y2JEF&7_42/L MPH=TSC <[!18YH"F0J;I(I1;MKDC21SNZAC:@7ZM T]K,H]@5%<&BP"\CIEA M;"8:58!.ZII7B*$1>PIT&.(1HD@NM_+PF 41O@G6..^] Q(]IBD!A\/99GT& M#S& ?N]VA'0DLL1Y):=7[J&\79;']><@3N *E%J?+)[9]*%5$ISKL^H 6I,_ MH@[@[_1D:IR6.CUB /:<55-';?11"W^TV*'V<^4<$)O$#-W4QU@^$53/A)5X M9'-YO2=;63DT<:!58HA7HC:I48,3G 7%_IM0+-.TRI0 Y5I=]J T>579@[M3 M-6F4AB-59*WZ&K1GJ(4@&J;.U!2'ZR%$M([9YF>G(=D5%G#'6>)QG/KOYP@NS5U$FZANY>PJ MC? R3N,"7\?/^*CLP.GN4_ /DITE09[W>,DU1]&4045H]K,5*G3F">#34:;" MH\M==VF((7I/BIT;1,'MT>O+'S&2';;N@NB?M6>(X8488LSQY?>Z8,RRR;/\ M\%IXMI;N,K+!6;&[H\M9P/4K_7:S%J=NJ ]@RGX2 O)F2 DQ,F)1F9COF$"' M._K]BAX"8TO]VD<1/54 $ M*^TM"K"2?$OW@KE_=.OU]>(4FE:C!. CTB" 2!8_T1^KEC038E79!2&:5'9M M,H49\Q $R5[@XUY7[6/?0:MPA-"",C6PMD$U%@%7>]!X3'7V)A_TT7 ''/7Z MP\LE#EF\VY MFV#"X8U-J?"9_TRI"W&7S),2J3UW8=.+N-)S%!,S\ZCOV# M2MRG8L29%B$CP29#:^Q6FQU4,-U7N*TJ" /)&[K#:&HE57"V-<^1?X9OZ3SG M'/YD[MKG(&$Q':1!T(ML:"\6,;4"SMV[53E"R'B_P2(N%C^H[WX]&-!EW4A? M7CX1#8D\8=PRR''MTP%U-_R")L.(![:>\5BVUDT:#'[VPD 2M"7J!'-<,[(O M/M-($*;;2$O]<$KMF$D"=X5*R#["*RAPCZJZP2V/JJVZFL)03?_QF-4F@KJEJWR&10LHV*&O_ ,=S=CPZ3,6\(<7?<'&/0_*4]L0,6(5U_TI4)+]? MO"19^14\)XHY\(/$U)1I)[*O7L-VSFI2:M<0W?WJXC+J 5)U6M/P&07A2:A= M*&P)CG&KQ6]PP6\UKTG>5$AZ)&56 J1BK$@240ZE\X]#@1K6'$53CRI""6-L+I7Q;9I3,GA,RE*20=B:$62'6C;LFPHWN&WDB-'39/"E M\I=-UVY1$@Q5DT1]_1Q[B+=Y075HQKHW S*K>--_DR7QAJ[_5SRR_:@E#AKM MP?9[4R5#:*)!OU?+K[ GZ*P#;.#N]OU.I"8\);7@:VC_6XA/$ M64<5)N7W-%H/2HUO6Y[;2,R@X5V-!KNNC&M$5%L!6IJ=ALFY/\63PRE>36V* M>JT+'Z%?X=-3QK04PER*H(%@Z:""]H+0GC L ZO+YH7%*BA0D##&Q;SK80@. M1:JQZGB;H*PK%Z='7Y$,17B38)9FQ;\$_P ?/.>CEVH.@0)"6V[9L^Z*_'%8 M _C(0FQ10D_A;:R/VRVR8>!SPYLPXA,AT4OL]LY)74L0;&^GGG,46@.-U1M@'M&Z3=C>#U7M90AO) [+>&KS!!%2J(XP(YA\!X)3J2 M9KW;N>KV/:U;F&;-]+-J^M'>]$..H?M>I!J,2,91?*30Q>O%EFY7L!Z7)+NF M>O4>/^-TBWMD3?(=+1$;&-N^9+408/=2@ (J<1@A3L;G94"*#J>:P%0SCI8/ MT9'E*Z)%5$.[$R3?<[JS3?9CA[))# &4?X%YQ&))/8I]2'&;5CR8-S MN'+>($C=$(251GAFV/G"T!A!D_,5(#DH8@PE\J\%W1^HYF\7R?>8M*:S.L0 MR2?#Q0H-(#1',<_-/AH_]'/TU)H^Z"Z5'&M/K=G#0[C"T3:ANXO4Y<<)=[?2 MOVZ7AQ&$;"\:,G"LP].MSF8++\]&$:L("_[TB'FKR]+Q[8P':C:QV#C?QI-] MSB#.EWOLDA79L!=/\Q_M5HA*DN0529Y:) GV25)>Q^7N MO0IC.)<86HY1 ERUC3D/UL$3!1,F6RCD=K:C8$Z*(@A_%TJMZJL:HBH+PGI2 M>]6+A2.":DP00P5Q7+0ETMXT1XMAW84FXC/']=>\)29CXPA]4C_ M._/KMS)7>GSL_8]J^=&[A[3O*^?73NW<*'U/N*DY&/!V'TW+AR][@$V("MU& M,7==VK&DT2,I@9Y$_]CF!=!:R.W*[VJPOS0,1Z4Z(=:^Q4Z5E#38: N)Q9F. MEII65&9V+$M!C:![45+G03**W*.$[6P%1^:\AGA&4E;\DAWO:H0N6+6_E^4>*+#U+2M4&@% M^[TBL+J<*JT11J^1XV+.-5;B.]_.9W1+.[?'4NFJ568C(2+^XD(O>2>4EVT&%$#@O#$JHU+PO2F [-S+W@"3JL MJ!#3=3N>(W1JK_M'GE26",1*Y57MECW#(.Q[!M49S^5LM#M>'$D4(L4*HL'I M$;Q**/13Q5*)L\@8 D^Z*ME WZ.1H[FI4N:J8]+-=HTSF E+-TJ;XET;RM&\ MZ]L<+0 C/XV4QBZ6?LVN*;1@NLM(B'&40[D#EHT14((]X*)(F _BBE4_-_!O,X%*@Q TUR/GI;*#/H<3<2DSF5/8QHTI*_5RV]YKYDQD;?@)G,X:' MX=.9YMPLG,^>AF?G_H2VSUER9[0.DHZ[*&YVZK)ZG?@Z>.!1G4M?P9 .NH% MV50&N"QNJ!\E:VX2HR]HJW*P;%Z$(^/AZG6(48@*X=SN'_=T,\OBD-*3X=5; M.;'W6PG*U&BU2C=R"XC%\.]W!>']Y4E-W^D#T*D M ,^L..B,S7X\IX);=T2$FD,IG5!*3TKLB]ME55\THK_]PBJA5Z/1+^H7;Y?[ MO[$,&%'JTMR*4])HA3C&H?<9G,D,5 MU5!)-OX( L(A( !B%(#C5$DY_@6$&]7$8RD>G$3MH>';9@AXX_ 9Y32Q_Y^' M1E;%"Q;;),A05%< J*K/O90SGP9/ CO,;<*]Q?1U\-*A??=US&H2Q98;&[G7(AU\?FQ) MY,-QO><#[9G.^.GXVCD99O#;&4]=UX$1 M$5Z*78+R01)ZPV@'3*B!J#PO[6@"DU. M)*9([#A2O(E>;!>;34=M?%O#Z\:G&T+# ME2(PA:^.@O!'*PW%<8WS?"_>.&JAS*MLC(S!]D"._68BCP:HXCT*V[@>(+97 MR'GH3S=2XGAMF5?TPWF$0UL/4<-%4Z\#!!B/469F9\+:3ZB)XJ2GHQ5DU#$5 MM*463X:HS<,BCA((F*:>VBPM! %3JZE:5KDC[155F?XT4QD!7?]ZBFW'0- M:5M: .8<@"* .O.>+=]+5J)"*[^'O)? MCH-JQF5<]-Q1'C^@OT>7 ZESR#/.%D1UY[JI<\@TMUYM=-7="G[PU# '/"*K MY^&00=:>G7(H.F28%H[EGY[BXC#>!)",](##;<:2DRIA@#[6%((9QB>6UFP2 MRH4WY*,F<>L[-472-X)9I=$%R;."Z$+)H#(P,V.S@E_B!,="Z4F[E?!>CAR6 MYF&BJTAN7HENCL,_/Y%G.B\Z>K;CDEM^.!3:\NN_GYT7]31HCF-6_79#L5ST1**)\4MXHG;49UD3#!'>= MXU:5D01+!UJMQ.DV3I]N-U!+$Q ^Q4N2X;KO"LX_Q2G)XF)WE=)=".<%R_]N MCW+!B@)\PL6*1-Q]P;I,"&3 P;:F77.,'67E.=L2GKY?!.FN,9UQB)/_\#3HU37T:BVU0QS9N=PVPKU M:>7YW?(D]"67=9SCT-&;$OZW,\2JJ7L483&['(G; /F_KBTC^^P_VY'Q%-.3(].PU_1 43;61F8D]\)!F):-// MK4B=0W8^5'Y*>60&)(52NI?E;[+\4U"$*^BGW7K@)$VW0?(+OV>\PW2]TB)X M$@F?!0B:8FH0$U<";1!E'='W2C$-)5'BB]KX(,!XAFJ<487TWE,SQ/%&)>)( MEG"6-(T-J2$.%G92V@N<)QG+>P^RW=Y4F(-73V%)#FI'1PT GXA:&L#2@B8R M3A<[R@?MX;G_I QM_"@;68Z7UR]*RS4IE=*E&$M=J*=.) :THTIZ $]$C?1@ M:$&%&*6')?4A,%U*-%G-Y;)N9?YOB*6:0CG.*>H4&;:7UR?2:^=6ET" )G@8 MGX,$O(HGQ5F093N*)ZMG*] 7EX:\LL"CELXS"!E MO4*CJI+NS_,GR59$CZ;NY>HDC;3%2_K=$5(V",-) #RD*87P!V[P\,9^\F0G MHVCIN&HDSQ'#$2N"?7I81[WTGM_@XG;Y&'P1<*7>(+H5()6 .:OSJ(255OE" MR_/63!A^LR@OAA NKXH*TNI'ZJ=&H1X_$C/$GJ( CQ)<)P([+4&U)Z!.K+G! MC@92T_0JG?I2:; Y5^?E5[;%414Q_VOPA/-3DF[IWW2?YT4* #NZMQ_(G+'Q M-%I1C8)K6S)+5*K]@QX]7@ ;9OTM.$JJ;9,S6]$*LXTR7(%T#W5 MBT=VYC@3HZ#E-3,Y(XW3SQY\G\<=&:8A&G2SJA7/XF)W0O7V&8D.3R>BGS5T M8GL8ZRXK: X(P!! ^:&(?E<59X M72WQCO:-=,_8[BZ=>Y#0NU:/_GK1N5X$*F;7'!FOC3<1@91CP%X1 M5:"M<__VFJ2M/?EV6^1%P)IMB1W<@Z_H>[B%0UOW_3'8W,J:E885(@U\[_:6 M%-V)#C'=A[N\0*NQ2Y*=46GG+0$H>NDEZUE(T;NO]^?\$?X[=*(U,>2(T!A= MT+99NL8 -2C,4(TQ*W+ <4: -/J-H>?]R&MD-8F-);)[G0)7_&EQ&>=AD/P- M!]E%&IT'1>?5RL"C.MO'5H: MY \;:GY$M^DO018#5]]3%-])N=V'7S?B@1>#\>.,%^,SWB]OV;? M7K:=!+L>^R;O,@RAY)7SM0R]/DFCVV*%LQ-Z4NZKA3MB,&,^>QF@_ESW,MB9 M\> ;IL/H[H4E/OL)#@1P06%Y[ \DIN_,T:_$O+W^?O65<*L%RI*UZ1/32;_B M^&D%/1*?Z;=/K"D=!(N ,=9?6D9W&$W)5P5G6^9K?/BVXX>-M=> F"*L5:_H M>9F8Q7UM/!CODGYWN"5)/:OA%Q6.:9NY*L"59Y2#1@RV<\?H,&6)$KE\:KL> M6UW\H!&-Y=)Z/X:L8V.8P%_# 3)!Q2HRZHG*T8JQ'=*T6 MV871%)3B,4T[5:* 4*ZC/M*<)''$LHOE@L9E7M&.^A /;3_JHP5[ <1O$H9"DT>/I]L+3Q>N;8Z]O_U<.O 0*9&".B>X1(O%ERTY M8J4N3$K4O'7H'KV$Q/BZ.#DA\).X.**L][D1IX.]\9R=#4I?B;G-H(14UI]3J3.C6Y!ZOZ22J'\&@ M%H5:Z@YCX]:D YPZ_].A%F2LCP^] =?(0&J%KQF:\,$.XS4!-Z<"-\K>'PTN M@%4#Z"(MJ-:XC!-\LUTO<-9A^X@>T3![#H>RS6D<'@* B$-T;NL(J4=D2.)@ M[2_6.'NB[/FAP2+YM#9'=([JB#DJV(@#1R5T3XS23U^B2#2? M =R708@'^GCU/VXD.+L9UD\H=@-_?.#UF+F8"+,&^'[;8 TPC#!^6D0Y)[Z% M1PJDQZ70_GF$)P&&<>9 &#>O 9[!"-#5'",,T#E;!=F3L$Y* M_\.Z";>=@SJK/=\)7:O6O*%YZ+0R!M"H@8U*X#ZKM WP"E$CG .S\F$=),GI M-H]3G'=%7/0\I6U&[HWFR'QD,%$%U)/5V$U&(DD;%]RPPDDR=+;H>DB?%UJ# MN6(% .GY_-!)0R)'&,>GA?@YCG :Y:U"'-!%2G1:&'A<][0@&-;9:4$ 7^NT M,'XN^SD-BN>%"CR*<)@$&8[\G!*&&(6H4LS)*>$J79)LS2*3KJF.OBKPNB]0 ML>_Q$:>(KF&=G2I:P-%O !XQ^&YC.Z2)3%0IYYJ-6*2)' OM/6J&?=B0?EB' M@9X$U^S357"0D.W;6]SVB;YZVQ'%GG'")B(#T9YUT$)%)4<70'F)U1 ML^^)9.(S6N=3HVX"Z]$<7@9FJ +J\3[PF(Q'5X("VOB\UCGY$HO\F>('C5SE MP(#6#8K].P_T&P#ULV'T4%-XSW%,(@>*HZSV=E^U](,"-9U)5C*/:ZN2[F$= MZ92J2E\-'7'PGK3+ (F)*MU\ZIN;8(W/"83(2&F=X\>-Z)YF6,<::(8 -/J- M Y^")NJ@L% ?B.AC/D0*JH7+SQI?B$1&3 M2%/( 6?\BI/D?Z?D)7W 04X@KC;/MSV1;P//:W.*8%Q'' /0Y[\#>%3!1QP! M3[PS1&:B3#O'J7DDC4C**O4M@O3WV^429SB"JB#75Z>W][VN%:5W==/V9&!8 M3^)C2* :"U2BP2HWHC<,DV_].FK4UH*,(K#CM/9@$Q=!$O^3-Y7?4D0?R+)X M"3)\$D4Q.")%1SN55W73W"5 N+J5D\%%JZ&OE3EJA+BT$$$5)JA"988D)VDK MK5^%V<@8ZOJIE@HJH?=((WYP9+W49D!G!5.98O=Z?.FA9D?15!&)/*IJWAL' MDL<_9N0HF$KE%1.J^6!H+RKY (?1JGCTG$:K8(X!JVXP0Q*3[ M]Z5TT2_^7G=3O,*H_#%7V(V7-#IC80MH__+#AM2N@5#)\A-%" M_EX?A)"?!R*TV*%@LTEV<$?#4*8OY44'^@_+9KCUB1K'(Z530 M)L/PN?P)1)@.#7VCMS!@69: +@ *BB*+%]N"V<#;;@[XLU--HRU]9"S_N=WZ M/Q(2O<1)TBC&:['1W/^PYN;>/:BKW;P;NL[V;6H>&OMU!7K63L/Q-H\Q4=$- M4"]VQ0"#$S4J^?.7](2=B!XSX"MQ$7)RX"GQ%W BI*/ 2S(NV,2:C^1D#8$, M_]PS9.3._EUOFO68M"%8+]W:\B^$E7_!6[%-%9(/^Q?$=)P$"TJ9'DKOFF5# M/X:)%#(&77D>S)8>GYZ2'>-6"(=M PT*._;W';68.0E95XZ\:5TLWLCC-V;9]C__8QGE#I]>;!E*2S@8?212WN.G M&+90GC!BC+;_.D=P24)++DF836Z8TDEGK'K.9Q$U_< MHWM\QAK+T7M8_WA*FNSD)='/VAK'#8>4FL8+.PA)1H;H, F5TKY>XUX+_8O4 M_??M7:=R.)[OLHX1,GB?96*V9N^TVAA53:5DVI3XNV,^X$:UF^8NHEM5RM?X M*4BXKN@X6_0\H:&:#T:RG@@*X%"EH]T?%_J(1R0HXF S/HDB2L"\_.W9)>E4K6]OQF2)&B3*)!>OY>OEF(KH4=2M M5#W"3?PVV[%JP>P.[R3\8QMG8#CDQ2=R8O812%\ M'LLN M>X.ZYA@.'%'H",#[99IN\G;Q30_-',?%;#>;A$4\! FT [A,R,L%_R(?"H91 M>%4W D8"A/6PEQ8.*(KS,"%TTV"[( L5%9!#*&LNY4&@O" MNUG6O M20%QYF:3PD;+W69IGKRX!%756:$FGZ=!$@QN1S[F:]@SN*NJ4;T(/?"?C6* 6&KZ" M4&7(3O1H:975(-,-"O?OU@N2='!5Y^\:#+0WCFU>*8$A#LTY2W33C P28E1I M+<9)K)!U=+[-* 0><,!YZP$715)F8=QC>A:-H>Q1R8+LB9,T8B/<;E@-GJOT MC*0I#N'#KW&QHFJP"G'HJHW@#P&-\EYN$;7N3*D1!O])5J,,B79Z0 M1SC>8,"'->;HA:(.>:Y[N*,W<37 0%#.ZZ.R7LVR>[RAOX)+AQ4 "]9@)+2N M;V(V812Q&;=+CF4X@8,;E &#;W.+J^:^,I@GT2?^.6V4RJ;XX.P9K$[9 HB2 M;V@HQ8&1;6NQ$CPKU"*>J@(S/2+_*85AV>"IU055B,*3\]T1E/GBBN.4% MPD&64O9EM0*S88*XEW-9]B,:*V##^&%.'X^VCUWXYDP?.WBZM7S"),AS=#IR M+SV< Y,_=BE%0?S+][/W?WG'!OKP=O;]3Q]*H"?[D Q92E-9%".&TC-,QJ81 M%$S7#+*L!?JM(!=<-$IUWP4[=D5ZSWGCD4BH6^EW-%3DX-BVU9H4$JHZQL*L M-*),*RS0?:,(IC2S4;%\U=RR:<[-SK%WPS%$:ZB7U7OJ]:^>Y;4&T2+_> OV M'A<0*WFDOV4M4-7W=2U(63@N5*420EJFF879CE$T')W*:OIA]OW[O\Y^_/%] M;0"'A]?T0S;N5(ABWMXL.PMD>Q3C=%H,TVDR)J6R6)/1"^7F*N(,EN*T;8?: MO'?0AV;SDD$=*S_GZD%Q.126V8%/W,5=@@MB3NGB0'MQ)G,X-BJFJA<"8]G% M;OXV53?)W8JD6%B13O2(3@;WP5#64[@!'F( ?56:$U*/R)#$B;_:Y@9I$)A% M3_17LST>>9;??#_[\?U?9N]_^$DP"/X2KBA@S'(AT+_\]&'V]L,'[HP&E^CA MZP=>:%.;K)<5,7@&H,B2,&9;*%N'XTWT3'8))W,@L"O,B@YEEYNHB:K%?;9! MRP5^\05G89QC43:V_D#:M8M5 5K7A'7*N;6RCIK\RXQMP#CKHUXZCR%>AY3K4PE">ZP M;I?+.,3LSXOU)B',?WL'F7?TZ_PZ#A9Q$A>[JS3?9A#P_0EW6-:VAM>YC#*( MAFUMT."*:F29H5*ARSXT"*,:8U2CC&J*@F\T,3U#%?#ZVG![B'*-#3RC4]-WI'W-/W#V#PHKX;D/WX M[N,KV#%W2OQ*=_REDD4"&?%A-6?'@XE//-9&D\T'+JYEEL:M9?:1*DIH7WF; MGL=Y%9E_N^1U!@\KKJJ]I&FY]0_NRI+KQT*K#[NI>8V)O0$$$%5.$4.![H<0 M I<1V#%W_!CVQS;>^.O7+L=81(^J$W+4-D',[+&3ER"+Z(8O;)<\;C ;#ELA M4%<2JH>=<4>M03IHG-T83,1Q0QRYLA1]55M@AAH,>=4!Q'"<(8;EM%VYPYPM MZ\Z57*:)JXA+DBUQ7.C=Z4@-Z$I5U(!MJXL2T+:\Z!$FZ;PZ.3A>NC&R(%B/ M46?-QQ6F5'AW04T*\$:&U*J(G_$=71ZAET7V%8WSY-#0UFMZT),.(( X!JA& M 0$.VBX8\],R;]>G),O("YW/6;"AOQ2'/7#'#*$I&2J@7)V]5'#2.7'9 MG;/&.0L08J%V#"54X31#)5:H1@O)S=N2L&OQ)3%!^%&68G6[#7LLG?(/0ONP M_T$-J[![0-MR5$'EIA_ U;;_3$W E-7W0QWDX6VOX9?RBBTT_X@_Z"#1MDLJO@WP#[G&XI5M7> M'8<0'ZZ!)C M.A4X@P5/HNK2H\:2R16VU15J^X@U#/QR;2,S_=M7_I:!&K/X"F/I '9#]'8[FHU8\1@XC>Z>O#\6AK*L#X:4657U"V.:5:,"/;)XA_V49BFA0U+%+%"=TS*>/.,59D)RDT4FTCM-2+3WC"UZ& M7.0'57I9U_DI!<1^10^&Q0P]<3Q8)&^PAXD?SZ;:$I!Q='7+FZR594Z%OJ/G MEH C95[1Y,.^H6USWVD0H7.\*%"Y*NC-*5VV95SXB7>0HC+1(=VXQ"NX@E@$ M.2M;#71B.\9)ED&%'-B 3G?-(V7A5A8Y43KN/]('B_QLN]XF3 0Z+ E;('22 MMPRCXJ00JV&MO@WVS0N\F_1$Z!9UJH!+Q4V=RU7*[WA[\X;L0=*UF,UC9'MS^,B%;%0AI D3PZO6 MGU5JGQ*R2ER:2&*21=$A#EG ?VC'-4XCG/6Z_65?,QBHT1[>>K%84? !1\+O M)8$T[0<""<0$'75PNB'I,\ZI_A5Z4 5/:!Q;#D:RS18U.&UWZ&B$]:S4*V&U ME;2>$M?=[@U1$3<0"8JYU94M)0^UO"AF0?--.]RAD_-'CJ*I216AV9:@,Y+0 M%PCW"NY9'^ ";7^^A?LH5*SH&6G_):^Z5W?QB*$5\>/2JF7P(%.HU4&^LV2\ M6Z NW5[2R$W:$28]"V?>'(MT]7-L:DR&P[(.]$C53*IL2>#%@V:1YGK6RDU] M;&^LDU8*9YD<0!KT7I'W3%VKC?6G:2ZO_V-H3X3PT.,&CYTNHG_+4R6$N/B, M_1VDZL"!4C^NUQ03\4JZ<=->=D422MF76Y)/QYZ*22F MYU:0(DC4=NE'>*4N/1U7#9Q!&9;(_.N?_OK^W5_^O:QOX4FV))F,Z%+7K:S5 MD4?W."3/.(N%E2IZGM24J(X170E1!V@=N3$R PV#M@GJD\7?DCCT,051H-.H MAF@L9B3;<:8O/QSR>_GUWRGU]I?R^ =%;FX&L,V\GV^N'B_.T/%@]/E M[B 2$<]\$FEJZGEI]A+1W&>>M8!/, M-,>W,MSTJ0$LZGT;XCEDN\Y%EL\=G M4\FX$=-[F->,7Z,Q<^^1'0PAVS=?)3BOJP'<+MLU KJ\KNIOZY9\EX-B/:2: ME84H2ERJYK7@*@G2'0NW"DO\Q-4DN@K"=Y;$4[+YK!-*S\GVV&Y:GG=2+[1$ M/4_5X17%@8Q<.M=[#5SJXN@BR.!J-S\)0QXZAZ-SO(S#N!!N.+(O:N\Z0P < M]()@&"!! T2*.)8^(E:4B _T:>I6U[\1%*\^Q1DO^/BY.0U<]!M 1@RT'SX:HBY1))EK3V6!X?:P/_M0\)2VAW)O-'?>R3VP M>IY)7,CH3#3\[AX]8]YX* PB71Q.8CMYQ\60-3ELX M]&$^MP3F%E9SV]"YL0^01L\0:[<'RW&RG#<=89]8#\,UCN*PS'V. )^D:1KK M_H0H(U%$<37&A5&SF(S;Y=F6GK+7=/0.-2!\1B>4^G L%R)_!%0YGGH\UCH= M6.L )9^(CPVN"BO0*.#ITQ"'!KZ> .7;!<0&%="!+* <@FA MR%&C/H"V\2H+R'JT^ J"VU@'<=8?CNT5K4"/GSW9BV$R3E#CVIL+:(AK;-/"1 46U-=4S+O?(=9!.B M0C>OE3I^8=&Q]&B74?LS#ED)[JXK-8M@/%3LZ$+'>J7W"MKAS5-UA50&>T,4 M?+$BVYSJ>_>E),Q09NPQ*XJ72WJ<@O/2 AO9RN,TH+D6R*U]Z M11'W,N)GJ&;%,.V('C$R)-W2=Z>*17;E'>U#0<94:G9'.*9045."I M07 9IU3*X:SV0-4-SRSTD ;HDD)Z1\[!G\Q6KH$ AV29@B128.9VHG1'%R;:@MD\ MYF(=N %^9EY0Z\W%W<.W4,UX[S?P2<%/G[]%S(;$:+F%_H41#2PHB9B;;F$0#,4O,4ZS12 M0Q'#O#2NV1RFAG"&H\?@2RLCYG.:X2")_TF_ARC,A&'S,8C3VY3=TI7!:]ZQ)PJT@Z#V&BYK0"L;*(+A29 +2R_]?4##243JO"*@6.)C )$SHC;&:5P[&5Z8XZ4KRT"ZGL;$/6 MY0**JI;W)%64D <-,20:1('0CFN8;AUNZ)RY8UC 2-+O:3+5X/BV&:Q& M "6 2*+)'X*RDJI*2X5'4.E\K-[83WYA2#:U)T$2ZHQHAWVL][!BA6\( >L MUS*[=;S9QN:B8> T4L2 SU -?H;89*I\ MUP? /M/9AZ@KWOJ[238)37NFL_.?V=SVS]SL^2481PI8?5)C$C'.]FV5V>$D M_=PK2C+3L$+N)*9WO=Q;$&+P>7.ZV4TA"(%V]ED$8IC&_1IZ3/$'8]'%9 W. M!EZ1+V<=V/ZQS5EG>'%E+IF7]*.(>P9WEQ'7AX5>@IS9>6E5\0(4F"^P1()7 MSY:=F+VX:!EV(GJT="M//*0&JU@\,J]HRE+?T,ZLG<:S 4Z-)4=)RBJP.JE] M:^=1Q[M^8/*H3,V2*$GQ$M&AY03$:-!K*/F626%RYS%L(#D2J3%3T]B<+O=F M,5F'J"R/#0G9-)RA5VE!UR!>)/B$)4JQME(\8@>Z\A(2O<1)(A WM9?U*R)( M '%8*$$"&\WZ"5;FJ2&)W$T_465/B.C".RUU-^/E3 M9O!Y,Z?\W%D1F\-3?NZ_C,TPC<6G?!'A?'IB[^.G57&[_)QS*9!RQ K>,>*' M/1C;]=5K!N#G9#F',%VNZL:[84?/R<1MV'TU,XH&8GA,P LKXB2A$[:7E&[E MZ!I3#+# 1USF=>7G1UF@NJ]K2I!$F%FX3;0/B. :?!T=BV!;#, M[Z/\"%5XT3(A+SG/*#+K,A@SL3&7CA4X" /?FU';>^#=2R!F*8&/8("<$]KR M/J=1G+,20#CBU:TZ\Q^-C&5C,Q3!G,3.*$+.^#9I@ ICI/AXUX1*V3]7*8T9 MWD!M EYE*B[K*$YO[QQD7]F-5&XU)N".5W'"VW"]NQ+23N#&O.Q.3H9W7(*: M&B"51;J_:\I9IG8GI]O&;7\FTB%5+F\)I.\&_-;/YIEG]15[6;+V%*=X*6P& M(/F6=CWMWM&=E0'I1T.K%(CIF6DHAPH'R*&"\) B^.)):F2YB&@2<$*6<^NX M_#<<9(\4\%BOT=$XEMU'-;Q)6,M=B-ET*(V8_2C7;F4C4Z;[?GI6<"\[:KB2 M!%2>KB!?TA4T(,?M81R(,8";HA0#7K:%6&_NIF3XA\G+\!XK:HKP,8TG+,'Q MLXF=N#V,"PFFX"8IP10OZQ*L-7=3$OSC]"6XS8JZ$GQ$8\<>J"#.6%G,3Q3+ M;<9J%=Z1) YW_+]#<3+*[^MZJF3A6+_[@8)B#!/40F6&.!KHM_)?W[$UZNM" M1A/;N>\T+JA[S-#@%$(E;3::,X08(@&:6'/.SJ"C8G159F\ M,NCQ#(TI.DV2-H/7JPW"=EA_+!=_(.NTR/Y%!3A MZD -V 6B5Z#4,#*.*I8:QEJC>*=WNNE='+'NV&UT$" ^0R7JJ,$=;ITY]OO/ M5_BC<@)0\?/5$E&OO&%%K,T>L7!%F"=(4H&[^1E:[%A!0[I6Z[QJY;%A!&=% M#UF-:?X:%)/>H6"S2>A_VR.O868H;"\!I7C FIG#8N[] F-[J:9J2Z<1-[PR M3>_F#3T./[[@Y!E_HO-9B<)AQPYGV=MY"'9J7L]#_&QZ/\?3PI07]-VDO:!" M5M7PAO;3?)J2W^]5TAS%17B!.T^2(EK60PL<>8\ZA?G]I(6YQQ\TBL+CBJ2# MA1"$Q:]QL:K:QM:03^,D@4X7'>_3%)4&@C4R3J@*4 M81T.EM1\APQ[Z"$#7?F@60S]K>J[7%%Q4>*_]QL=L6RT3N%(4N7%^6]S@L[3MVO5CA(_R[M^EK\.[*V.PFU\GX]L_PJ+:^ M>ZZ)[^M-C;X1Q8 <\R[D<<1L%M+5<\K\X(8,"3TDG%L;Y2[8MBC*]FW44(SI M-OM"YX2"J,(6OEZ2;,WR2=JUMA:8?HT;Z\6$->**AB9-%E8Q@UD=;9Q*TV,% M/6]9%^$C$Z:T;3+>UZDV61CY^9AA-5_Z"!T1^NCF2TJQLK\>KT D6!X/35W, M"V:/+62"4]P:3"=AV:L'1[>PYK1A6L]%K,4F0HS MU$:-E6!N(S>Y$,W1RTF,KY%; 3D+-G'!&R]6&_,9R4%V!TO2JKRJR?8R(&QS M>)U#&I88T#_R@E=NU3F VYF33@O%!A%488( E1FZ@7-V@XX7V51B+S*&OH[+ M8$)#Z%-JYT:PM]*-M>ML+/>P;@',SD$=%'F>LUI-K%?Y? 'PF156(5"UL/13 M"+.?T$2->HY+8(*AQEU#P]T'^Y[5+7G9-:;U4I< U$_-QUX2$B6Z^+A39U>' MDO:NQ!NC[LH[1[;-.ASTC)<2S2=CC,K0^NA"6(* X[R_NP7EX:((PM\[V^/V M/J/CBST28.>I?-B;LLO&H,< ,;1DZ**'X MH#=PQ_CMQ"X8.]A.ZAI11&>WDG@19"D$/]SAC!G6__PDGT.8UP5CH&F,4DM&747]8P;S8YG$*,6D%09N,T*\QNQWFSN_R M?IA_2$G!JKS2Z4?L%IDB&214NN-Z%0 AQ/^ZMPTU9(J,8QY/+4C* M8)S\9)$SOZ/(!S/T_-C6(X?CNFL[4KKP\I_]=N,0$K:K$T<_M5PW+2MK//@3_[K MT3O1)9_L>[HW?$/C6_?_D/4:PK$ -GH#P5;YO]_QZ' MU?52=V 8?2B=XR^EB<%'.>57'MP((!L/$5WJJTFTE\@S7[/#17[%5DV:J3M? M,L71>X.[\MOT8Z%U;VUX7CHWUC4*8'DS)&;\A)PCC@=Z0P622YL?/XTD:_6) M5P]=/YS&O^QQ>;4K3US*4WP1J?DW40BX(J)-XPQ8O-R/;MF [=".#1;QR!B7!? M!ZW[&$Y$0,?1WLS]<-8;6='YC&Z$=7LL5R;#'E ="V$DUMK]4:K>Z3(-3FU% M9WN SWQUDD;PS\4?V_@Y2.#VN"XW>A[G84*@XJA(>:J^KQWZ*0G' M>NI >1&XA*JSK,N0IW!(5;J3T<2<0F#D+3OB;8_IR+_+NC!!RFH)UJ]#MY.H7=Y<,:46'V MD9#H)4X2$4OIC*'+:BJP7!F[2DCI&,.69ZWA/6LP@A/B85V%'+VIT4(57M_. M$#.Q_4BH%H\2(TO@5J(?,U;D?]=R_PGDMN=)3>GL&-&V#%8@^:7+K+H=\>VZ M[:,M42"8:_<7W%\Q9)@M+_1Y=3^F[>C:'\[E+=T,_SMZ^9?\ON6E6W>%]_W;VE[_\.'OWXP]P;0?T9#=R].MW/[Z; M_?B7\NMW'V:(;(N<*@RF#-__./O^P]O9AY_^NO?:^Q]F'W[XR^Q'"J=\S9.# M3;"P1':U'+O2ZOSP_)% C88XC')WN/N<0O%K' M:YR$U(YG_6\'XFQL@M)U[%E R;H#I,&9EYPIL695[:K&JH1]8OE]FQ)U"$PC M=6104./M)S;(*C,0EROLJ3O5Z:[5BN@RPW]L(LEIG\^ M!+?0-LNHYN[,*M!YU2 G'H)PUYQOAFK0DMD##EE12/D!7NPGI[>C'S^'GM2G MH.%3H.B-\0?"PY'=G@VK4,OF0.C;KR!#].[#6C\E/3,;#U"39;3]ITTQ&1_5 M"X/%4XDW["=T'V-U4<\;4]T%V6WV4$#A.:9SJSS!808;>G,\LXD@N&6\VMW% MF"XB21)D.50,Y0PXP'\.)ZD5V8XB=@L4=UR80R,TSME%50Y:9F2=Y4^(N,(.DH>!W*&==L/SIMC/"BPM"1$$R0!9/6<,LB[GJX"-0K/T/ MC\T7WAO47;(PNRU84@',$2QFN!.(>\ME7)&5C1Z$JZ?Q= M0YGLC6/=GUFV#?7B-A)3C0R2PGTL]R65'Z@N2/^\2I\QRSL]2:/+.*7;VMYM M4A/E.W!O:FK8$9'?8\!;W^NVFTW"MC>ZV44U> BJ2JL:IW&%- L56%9H>[\% M-;:TQ-9ZN7= Q/RV%N+C20J(8XJR;(%,]0%&N"/D +GP2I28,.[>PV5RA1LT M%HB,I[J#?3].^_?]KM]U]OWV.-;W?0[,X[[?234R2 K[ZWW':DL5M]D#+RG5 M$7@Q])C&ZG<-9YL)2IA,MY1@?014#%*3R)+(6S7P_H15\8/CZX [2EV]Y:U\ M_.=_]M"RNR"X^4Q0%2T"FUG)KGEG](S4L_KZY'A,+TK%EW-JF+)$B5R>KP=N ML$C%]#UJZ@* #NG-XW^CUP+&S!PT\N7K7C9%\,6GNNSEBS['_1&A''GJ!=;6 MT6^Z7GHW!6H$/GH_MM4Q[4@O04;5!'X($@Q:].)+&.>L-%^P@SQ.Z#69Y4%R MNZS;<1\LL^;;&E6!%:#89A5%=%1K EN=J4;T <.'F08<(ZA B4JW8YPVBXCJ0<<2U;P!!Q9AB]PD7 M*Q)QYS[&PAIK\B]HF$K] ]NO7@$083%\%E93(#!1IYJ?D^39*LB>9&];KL'MPVA]7'LQ+\Y"Y3)&G?<8*3(>@H"_^&I']L@R1>QCABD96\]$\N[/0A M]X*&'=\_L&T>:D/G\;2HA*_=PL/TA$:W.DO;<^25N[V4U59@(Z).2I_A:/D] M)739&$'LWI-ZQTAPVL'8KAQ^O4CH>/X,STKCK-N8SAP%R-*CA\ 2B[+UL[^B M/W(L)8S"ZZ6H\[K$++SEU[A8G6VIEEJ7=S\4K_Z+.84W]>L4#T%P4*^8=QPO M6QGQ'DB\TP*9RK6>RDJ0$>1URYEW66F4R6;S#;^@R8?B@>W?!U:V]B33^B0H M3M3)Z+K$9>7!B".Q#2%X2KNLY=YH]ET"'%S5]VK&JN"0):J[Q%!>"IB;U8\" M$U&72)+,OG?I(5SA:)O@V^6QGP(."2+OA>!&SL1P&IZI,6#=^ZW\7/@961IB MFM[.M]X-E;/20NTW WN?U=]PC\=TL-<"T+HYH*\=M8>:1(E$WNK]9N=QOB'\ MOHK0(P\T"N6!$9+] D<,-;[ZKS1(ZQJQ50DW0Q56['X7&L(RQ%!5]W]B+MA1 M2]A='%=S73Q'G;%@2MFXL[V'346>L4&]Q9XQZ$:BSS3GH>-\&L;95<39/D?T MQ9QUD,:^KIN)^W19";F MR)+'P9D/ZIW UO,1DZT)AK3-H^WX7D[A@T2E"A1R?4! M"JH$%#MHXU) 0!<]Z&T R2:O=,@(UAE"^[@E#\I!!@3#A5JT@ T/=ZSP00U" MZ#??)J[6 A$35'?+RU7K"=:>:+\]A=QQ3GT 33Z6!V1=@Y:8,/8]ZF$RN=.: MQ@J1\61WL(/CI\.=01@../BLS@XN&M/M#NXK '"8I$2)3A/9P[5W;NO[]41V MZ=\>642^;ZVFL XRV_(D-N.C8__'C.2BHW;_PZ;\2VQ0;_XE!MV(?TES'AKY MC0P2BJ::Y;C/)7T^IPZ2^8\1&2PO+O>2P5@1=T7&1?$B$ZHS+DG]@;B1:50; MKP2B;KY99;_$PM9X,J^,U,Q=0[O6SUTXC-'29N8T-A<]D9V,957=RSP="GN8 M>F[EIHF+@,S&=(OS2SK/BR\%SM(@J6(1(1/RX*;O=+?GY8,>A\S6'#+)[0/4 ME%E[B%G/TR\QA_OH$G>>VU@ACVKLV?&@X\YZL4-[!U4VBZF<'ARP#''/!S[- M,\7>"6HO&S'7?'50.#+;QC51<&*YJ702T*'RJ#0[NN&!).!SS/]M]2UD"1A< M=D":X%-K5SR. #8UG$:*WABP+FIOC,%/-;O/$2WV&Q$HAHWL%P:O4D9@\ZOK M4;#0ZXG.W5"5CKC$%KV)2GR_9=DR NHLZ1:'(@P%Q*!S QW@\,F6U>T^<=*( MZ!/3Z^C<$QYB'#&3Y"K-MQF4?WC 1<'K2W>TA!5[QC4'TO>4*P)T=5!6QTSG M^.QB_AHQ2!5:_,!0(X8:S&:HT::R)+!WC:#+M,3<2CBN\-/54[+^\K]BBFP6 MKM1;V@Z.H5OO1P66;1%O>HNB&C*S FY.?IE>M]OA)1GJ-2I'9T\,?)5NMD5^ M30_5R3NYQK?B-\8RY_'([EAQACCT&6+PT;N)-+OMH787WPV1T!.7G>Z.A8 A M*==X7N+EL;S7"\2O1IQ$%WJ9)>AN1"]-UU$>#7J^RHKXG^Q0=KL\:Q)WJRS^ M,Y(7O;[PD:-H^"\TH-GFQ#9*<-9L(87J6@^ EK(;VM/T]4[K%.HV";*#OD!! MFSAE&B1:DHR?U5&&0_*4,E(QNST$,L4\1C]"!4%D401PTL_0G^#%\3PRMIN= (?I']5V9-'J/57(:%*[3YH.BB O,@(1'!?/D/_5YU4=?F%$(G7W MP YJP;8A(P;:KZ-4@LI$G73^=V=!]K+*:Q9V9A65[X2-@35'<(&6QZ F@2+SE"#EK\&I-JK),N\O:2?2![@YQPOM\EU MO!1',$J_:3H3L('@,*!A"!7-" ;S,]0+61!G/,X0QP8!.NC-WW"0^0K1E.604?KI M7!-5"+!KZJA$@6YE,I28UJV1C&R,OS^27C"WBJM,>KOG$09P I0K+27]GJ9: M&1S?MI:H,BNG4BE*GN!$FXJ.;XZJ^H'7<8JOZ)^B/4_\H.Y=T-& UB]]*HCH M-X")&%!/5SMB:A)Y$HT*J;O&5''R-J:G0<+B\5<8%U,SX_VY9JC$"3&D4 LK X%T]J=N,HIN45(B9Y2(6Y3(< )9A2AA M\_FWO,QOXT!I# M8A C%':<7K#-J+FT92$,E_$7^*L_BF7X!=TT N' UE,'*LC,XU[!]IR\,DQF MHDX[QY['+6!PNZP=HV4-3J'K<>AY7=^C:%QGA?Q%"&A5]#D(FUEJZ 6I'Q+#DTDDPW)$ MAW)^-J5[O"%9 7A)[DKB%T9N2\<#N]Z7CC$8LS&9F,^HG:E!8!I;4P_G=.Q- M0^2;W'7?&5G#O^Q,3NW/4YSB95SDK-[6*3V^1^T'("9:_\)/&Y2]*S]EE"9T MZ:>,NZ5K/P*YCW8H>"TCF.BE5&MD\K^L6RI$-9-B[+Z$CL3LB]WUR+1E=S6W?2D8M@6W@LQ.L_6'-AY^ M/91J"T%&45>%/?.*/W,<_OF)/'^7%YN,SN[=7]E?<_BKG5-"O_O[KR<'W';P MK6KF!W_;-H?\>O+P7U)&2'\2E)M_F84C%JXSOW M%QS@,7TGP0'";CT#HZDUHES,0F;"D_,"B/CY*!" M(%@#KZKFMOL44%5 _Y4,.Q\YGG8,NB9<5P'I3>P3CQALR>\,73>-6"HLC06H M.Z.+R6AUJN7H9X@&@9NT)CF<_E2'J9,]BNZ+?=W9QE<4^U@I(,:7T'F$&B^F M@J/;8H4S. 9D>$5/ E3'\\:/O3Y[Y??U8]?DX%C?XV_/KM!)463Q8LL#40J" M[H+,6T$=_94@H\GKF%>CB*7_!*Z)BGK#2=B4ND7=;ES$(!U MMJPQ0!N*PCQ.J3IF2/AA1GF*$WTRND[UI BL2$+MO1Q.6\5NH%[,\ O:J9^B M@:VG@$(D2 GY7__TU_?O_O+OS.@O=GZJODB0F*C3S2U?75.SJ'>//7Y DV^: M@:Q;TV#J>=T..XA&ABGA>.7!. 1^E Z1D'A#ES?$(]L_>I6@)Q0"(4-HHD&] MB10?E*N/H?JZZ3*$CJME#!3I*VMH3*66AO+BR%3LFU!EC::(9WY)LK,5N >O MTC+WA)ZQ[[(X#>--@GLJGFF-H7T&4(!E/5R$@8?&N0T"J,9@AA[I #Y+I>DM M##%";;=LS([3-R2MO6#\-%W>N@KX5NXE34;M']PV9S+H$GVL+3&>)&6)'KG< MLE8/U_<:D=+O:3+8X/C3T'X^.P3(+P'1INM$3,W3'9"[9Y-6>-.T@=E L'[& M(>G3_)K=FS[2[V-P'+-+1)^[L KE9:Q'$3F=5\55VFQM[;/>MMA!!+12@,W- MIB!%D%PK3>D17D$$MF+H&4FAHS=ER91B"]5L7C@*J M<4 -$N@WWXXHE24@(^CJ/Z_AC'Z.B[,@RW9+DKT$603.!QP_B32EWB &,Q3$ MP'RF(8BQ,I5K8'+>&@D%)2Q4!%]0R%#A[3(RO F*+)Y6K0$)AAQ()9"EMF,' M,D.OK$LT<%7?^ZRN0[AK3/M=P!BX,O[6SZ5\/S&)$H4*H53>UVN]@_XBKC*W\!A^J,XTW=1(MY"#89C\%5)3S+6S-<$1R8@L9 M=C-=HH,J?&9H2A/5"S*GAP'Z*XO^*%88+HE0L 9?-P24!R4AD@-";$I"E/X@ M^B6[&Z1/QM0"RX(T9T&%$*>;XI15&B;;B#L;-B0/$K:%TS? ^4#@2HV*6)G%05+1A94/%'2O M8AVBZLJCX')..OZ(:=-\PWHE/Q1!5JC9(:SU)^RW+,T+-RBCH$ +_!2G*9C[ M=*/F(+Y6TEVDD4'"X322)9FM4 0?VHQ,8!G3_98T1;5%NX_N.+I;B"H\9_N *F):&LGB[#_PV:?X"?+NU)3* M.0XS7E,@VK(41"ACFV!VT*'Z!%HWQB']]0W)$+M@V?_^6Z:0V.&HLE%)5W5^ M/QI)F\.)L85SJQNNTF?,HUEY>,!56F"Z^*(ST]#CFI(N&M:V0%=PRL@.+SPW M2%*B2J=7="RZ8]8'G0Q3*95JJ??6BR\ABSR\IVKJ8KG$PK.\'R1\'(V4D7T5 MAR/E63FW\1W072,Z[89U:N2XH#=1B=6WB"5A"XS_UV?KZPNH*6M_Y.H[#D/% M!:!_EY'G.,+1Z>YSCBGNO"X(U B!WD7,D2N*2U4>0#=051J0L\A5:8RT0EDM MSE=3>S#ML,WYG<6R0H1:Y'+SM!7DJLZ!9#R9'>=@-Q$(WQ[H9R94D MM4#JB,HHC+7CO!-9I&TE?W>L.)$@BG^'4EUIZHR7\XF?\5E0A*O/FR9A$@Z] MSSC=XBJ?Z"(OXC7=,V^7C^ 0 *5#TCNZ ZNXH"Q!-NBT,HRA3S>7X:F8K++&*+V;9T5+Y])/A_J6?O7W\SBCJTNRSKQ:\0.J MS46.!K(>HE!"\U-LI8=P9)@:CO/X]Q.XKDDNLA=[GM3-V#\>T=7NTP%:9[

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end

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 90 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 91 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 244 499 1 false 84 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://nrchealth.com/20201231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Income Sheet http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income Consolidated Statements of Income Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Comprehensive Income Sheet http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity Consolidated Statements of Shareholders' Equity Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals) Sheet http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals Consolidated Statements of Shareholders' Equity (Parentheticals) Statements 7 false false R8.htm 007 - Statement - Consolidated Statements of Cash Flows Sheet http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 008 - Disclosure - Note 1 - Summary of Significant Accounting Policies Sheet http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies Note 1 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 2 - Recapitalization Sheet http://nrchealth.com/20201231/role/statement-note-2-recapitalization Note 2 - Recapitalization Notes 10 false false R11.htm 010 - Disclosure - Note 3 - Contracts With Customers Sheet http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers Note 3 - Contracts With Customers Notes 11 false false R12.htm 011 - Disclosure - Note 4 - Equity Investments Sheet http://nrchealth.com/20201231/role/statement-note-4-equity-investments Note 4 - Equity Investments Notes 12 false false R13.htm 012 - Disclosure - Note 5 - Property and Equipment Sheet http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment Note 5 - Property and Equipment Notes 13 false false R14.htm 013 - Disclosure - Note 6 - Goodwill and Intangible Assets Sheet http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets Note 6 - Goodwill and Intangible Assets Notes 14 false false R15.htm 014 - Disclosure - Note 7 - Income Taxes Sheet http://nrchealth.com/20201231/role/statement-note-7-income-taxes Note 7 - Income Taxes Notes 15 false false R16.htm 015 - Disclosure - Note 8 - Notes Payable Notes http://nrchealth.com/20201231/role/statement-note-8-notes-payable Note 8 - Notes Payable Notes 16 false false R17.htm 016 - Disclosure - Note 9 - Share-based Compensation Sheet http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation Note 9 - Share-based Compensation Notes 17 false false R18.htm 017 - Disclosure - Note 10 - Leases Sheet http://nrchealth.com/20201231/role/statement-note-10-leases Note 10 - Leases Notes 18 false false R19.htm 018 - Disclosure - Note 11 - Related Party Sheet http://nrchealth.com/20201231/role/statement-note-11-related-party Note 11 - Related Party Notes 19 false false R20.htm 019 - Disclosure - Note 12 - Associate Benefits Sheet http://nrchealth.com/20201231/role/statement-note-12-associate-benefits Note 12 - Associate Benefits Notes 20 false false R21.htm 020 - Disclosure - Note 13 - Segment Information Sheet http://nrchealth.com/20201231/role/statement-note-13-segment-information Note 13 - Segment Information Notes 21 false false R22.htm 021 - Disclosure - Note 14 - Subsequent Event Sheet http://nrchealth.com/20201231/role/statement-note-14-subsequent-event Note 14 - Subsequent Event Notes 22 false false R23.htm 022 - Disclosure - Significant Accounting Policies (Policies) Sheet http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies 23 false false R24.htm 023 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables) Sheet http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables Note 1 - Summary of Significant Accounting Policies (Tables) Tables http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies 24 false false R25.htm 024 - Disclosure - Note 3 - Contracts With Customers (Tables) Sheet http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-tables Note 3 - Contracts With Customers (Tables) Tables http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers 25 false false R26.htm 025 - Disclosure - Note 5 - Property and Equipment (Tables) Sheet http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-tables Note 5 - Property and Equipment (Tables) Tables http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment 26 false false R27.htm 026 - Disclosure - Note 6 - Goodwill and Intangible Assets (Tables) Sheet http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-tables Note 6 - Goodwill and Intangible Assets (Tables) Tables http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets 27 false false R28.htm 027 - Disclosure - Note 7 - Income Taxes (Tables) Sheet http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables Note 7 - Income Taxes (Tables) Tables http://nrchealth.com/20201231/role/statement-note-7-income-taxes 28 false false R29.htm 028 - Disclosure - Note 8 - Notes Payable (Tables) Notes http://nrchealth.com/20201231/role/statement-note-8-notes-payable-tables Note 8 - Notes Payable (Tables) Tables http://nrchealth.com/20201231/role/statement-note-8-notes-payable 29 false false R30.htm 029 - Disclosure - Note 9 - Share-based Compensation (Tables) Sheet http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-tables Note 9 - Share-based Compensation (Tables) Tables http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation 30 false false R31.htm 030 - Disclosure - Note 10 - Leases (Tables) Sheet http://nrchealth.com/20201231/role/statement-note-10-leases-tables Note 10 - Leases (Tables) Tables http://nrchealth.com/20201231/role/statement-note-10-leases 31 false false R32.htm 031 - Disclosure - Note 13 - Segment Information (Tables) Sheet http://nrchealth.com/20201231/role/statement-note-13-segment-information-tables Note 13 - Segment Information (Tables) Tables http://nrchealth.com/20201231/role/statement-note-13-segment-information 32 false false R33.htm 032 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual Note 1 - Summary of Significant Accounting Policies (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables 33 false false R34.htm 033 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) Sheet http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) Details 34 false false R35.htm 034 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) Sheet http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) Details 35 false false R36.htm 035 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details) Sheet http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details) Details 36 false false R37.htm 036 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) Sheet http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) Details 37 false false R38.htm 037 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details) Sheet http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details) Details 38 false false R39.htm 038 - Disclosure - Note 2 - Recapitalization (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual Note 2 - Recapitalization (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-2-recapitalization 39 false false R40.htm 039 - Disclosure - Note 3 - Contracts With Customers 1 (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-1-details-textual Note 3 - Contracts With Customers 1 (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-tables 40 false false R41.htm 040 - Disclosure - Note 3 - Contracts With Customers 2 (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-2-details-textual Note 3 - Contracts With Customers 2 (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-tables 41 false false R42.htm 041 - Disclosure - Note 3 - Contracts With Customers - Disaggregation of Revenue (Details) Sheet http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details Note 3 - Contracts With Customers - Disaggregation of Revenue (Details) Details 42 false false R43.htm 042 - Disclosure - Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) Sheet http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) Details 43 false false R44.htm 043 - Disclosure - Note 4 - Equity Investments (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-4-equity-investments-details-textual Note 4 - Equity Investments (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-4-equity-investments 44 false false R45.htm 044 - Disclosure - Note 5 - Property and Equipment (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-details-textual Note 5 - Property and Equipment (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-tables 45 false false R46.htm 045 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details Note 5 - Property and Equipment - Summary of Property and Equipment (Details) Details 46 false false R47.htm 046 - Disclosure - Note 6 - Goodwill and Intangible Assets (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual Note 6 - Goodwill and Intangible Assets (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-tables 47 false false R48.htm 047 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Sheet http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Details 48 false false R49.htm 048 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) Sheet http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) Details 49 false false R50.htm 049 - Disclosure - Note 7 - Income Taxes (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual Note 7 - Income Taxes (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables 50 false false R51.htm 050 - Disclosure - Note 7 - Income Taxes - Income Before Income Taxes (Details) Sheet http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-before-income-taxes-details Note 7 - Income Taxes - Income Before Income Taxes (Details) Details 51 false false R52.htm 051 - Disclosure - Note 7 - Income Taxes - Income Tax Expense (Details) Sheet http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details Note 7 - Income Taxes - Income Tax Expense (Details) Details 52 false false R53.htm 052 - Disclosure - Note 7 - Income Taxes - Income Tax Reconciliation (Details) Sheet http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details Note 7 - Income Taxes - Income Tax Reconciliation (Details) Details 53 false false R54.htm 053 - Disclosure - Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 54 false false R55.htm 054 - Disclosure - Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details) Sheet http://nrchealth.com/20201231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details) Details 55 false false R56.htm 055 - Disclosure - Note 8 - Notes Payable (Details Textual) Notes http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual Note 8 - Notes Payable (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-8-notes-payable-tables 56 false false R57.htm 056 - Disclosure - Note 8 - Notes Payable - Summary of Notes Payable (Details) Notes http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details Note 8 - Notes Payable - Summary of Notes Payable (Details) Details 57 false false R58.htm 057 - Disclosure - Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details) Notes http://nrchealth.com/20201231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details) Details 58 false false R59.htm 058 - Disclosure - Note 9 - Share-based Compensation (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual Note 9 - Share-based Compensation (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-tables 59 false false R60.htm 059 - Disclosure - Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details) Sheet http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details) Details 60 false false R61.htm 060 - Disclosure - Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) Sheet http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) Details 61 false false R62.htm 061 - Disclosure - Note 9 - Share-based compensation - Stock Option Activity (Details) Sheet http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-details Note 9 - Share-based compensation - Stock Option Activity (Details) Details 62 false false R63.htm 062 - Disclosure - Note 9 - Share-based Compensation - Non-vested Stock (Details) Sheet http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details Note 9 - Share-based Compensation - Non-vested Stock (Details) Details 63 false false R64.htm 063 - Disclosure - Note 10 - Leases (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual Note 10 - Leases (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-10-leases-tables 64 false false R65.htm 064 - Disclosure - Note 10 - Leases - Lease Expense (Details) Sheet http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details Note 10 - Leases - Lease Expense (Details) Details 65 false false R66.htm 065 - Disclosure - Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details) Sheet http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details) Details 66 false false R67.htm 066 - Disclosure - Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) Sheet http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) Details 67 false false R68.htm 067 - Disclosure - Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details) Sheet http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details) Details 68 false false R69.htm 068 - Disclosure - Note 11 - Related Party (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual Note 11 - Related Party (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-11-related-party 69 false false R70.htm 069 - Disclosure - Note 12 - Associate Benefits (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-12-associate-benefits-details-textual Note 12 - Associate Benefits (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-12-associate-benefits 70 false false R71.htm 070 - Disclosure - Note 13 - Segment Information (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-13-segment-information-details-textual Note 13 - Segment Information (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-13-segment-information-tables 71 false false R72.htm 071 - Disclosure - Note 13 - Segment Information - Assets by Geographic Area (Details) Sheet http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details Note 13 - Segment Information - Assets by Geographic Area (Details) Details 72 false false R73.htm 072 - Disclosure - Note 14 - Subsequent Event (Details Textual) Sheet http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual Note 14 - Subsequent Event (Details Textual) Details http://nrchealth.com/20201231/role/statement-note-14-subsequent-event 73 false false All Reports Book All Reports nrc20201231_10k.htm ex_228150.htm ex_228151.htm ex_228152.htm ex_228153.htm ex_228154.htm nrc-20201231.xsd nrc-20201231_cal.xml nrc-20201231_def.xml nrc-20201231_lab.xml nrc-20201231_pre.xml picture1copy2.gif picture2copy6.jpg http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 94 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nrc20201231_10k.htm": { "axisCustom": 0, "axisStandard": 37, "contextCount": 244, "dts": { "calculationLink": { "local": [ "nrc-20201231_cal.xml" ] }, "definitionLink": { "local": [ "nrc-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "nrc20201231_10k.htm" ] }, "labelLink": { "local": [ "nrc-20201231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "nrc-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "nrc-20201231.xsd" ], "remote": [ "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 661, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 72, "http://nrchealth.com/20201231": 12, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 90 }, "keyCustom": 61, "keyStandard": 438, "memberCustom": 39, "memberStandard": 42, "nsprefix": "nrc", "nsuri": "http://nrchealth.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://nrchealth.com/20201231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nrc:RecapitalizationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 2 - Recapitalization", "role": "http://nrchealth.com/20201231/role/statement-note-2-recapitalization", "shortName": "Note 2 - Recapitalization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nrc:RecapitalizationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 3 - Contracts With Customers", "role": "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers", "shortName": "Note 3 - Contracts With Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CostAndEquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 4 - Equity Investments", "role": "http://nrchealth.com/20201231/role/statement-note-4-equity-investments", "shortName": "Note 4 - Equity Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CostAndEquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 5 - Property and Equipment", "role": "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment", "shortName": "Note 5 - Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 6 - Goodwill and Intangible Assets", "role": "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets", "shortName": "Note 6 - Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 7 - Income Taxes", "role": "http://nrchealth.com/20201231/role/statement-note-7-income-taxes", "shortName": "Note 7 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 8 - Notes Payable", "role": "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "shortName": "Note 8 - Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 9 - Share-based Compensation", "role": "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "shortName": "Note 9 - Share-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 10 - Leases", "role": "http://nrchealth.com/20201231/role/statement-note-10-leases", "shortName": "Note 10 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 11 - Related Party", "role": "http://nrchealth.com/20201231/role/statement-note-11-related-party", "shortName": "Note 11 - Related Party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "role": "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 12 - Associate Benefits", "role": "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits", "shortName": "Note 12 - Associate Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 13 - Segment Information", "role": "http://nrchealth.com/20201231/role/statement-note-13-segment-information", "shortName": "Note 13 - Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 14 - Subsequent Event", "role": "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event", "shortName": "Note 14 - Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables)", "role": "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables", "shortName": "Note 1 - Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 3 - Contracts With Customers (Tables)", "role": "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-tables", "shortName": "Note 3 - Contracts With Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 5 - Property and Equipment (Tables)", "role": "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-tables", "shortName": "Note 5 - Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 6 - Goodwill and Intangible Assets (Tables)", "role": "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-tables", "shortName": "Note 6 - Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 7 - Income Taxes (Tables)", "role": "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables", "shortName": "Note 7 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 8 - Notes Payable (Tables)", "role": "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-tables", "shortName": "Note 8 - Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 9 - Share-based Compensation (Tables)", "role": "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-tables", "shortName": "Note 9 - Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 10 - Leases (Tables)", "role": "http://nrchealth.com/20201231/role/statement-note-10-leases-tables", "shortName": "Note 10 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 13 - Segment Information (Tables)", "role": "http://nrchealth.com/20201231/role/statement-note-13-segment-information-tables", "shortName": "Note 13 - Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-5", "first": true, "lang": null, "name": "nrc:IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 1 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-5", "first": true, "lang": null, "name": "nrc:IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalizedContractCostAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalizedContractCostAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2019-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2017-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "-4", "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "nrc:RecapitalizationTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2018-04-17", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 2 - Recapitalization (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual", "shortName": "Note 2 - Recapitalization (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nrc:RecapitalizationTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2018-04-17", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Income", "role": "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "shortName": "Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "lang": null, "name": "nrc:InsuranceRecoveries1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_ProductOrServiceAxis-VoCPlatformMember", "decimals": "3", "first": true, "lang": null, "name": "nrc:RevenueFromContractWithCustomerPercentOfTotalRevenue", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 3 - Contracts With Customers 1 (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-1-details-textual", "shortName": "Note 3 - Contracts With Customers 1 (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_ProductOrServiceAxis-VoCPlatformMember", "decimals": "3", "first": true, "lang": null, "name": "nrc:RevenueFromContractWithCustomerPercentOfTotalRevenue", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31_ContractWithCustomerDurationAxis-LongTermContractWithCustomerMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2021-01-01", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 3 - Contracts With Customers 2 (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-2-details-textual", "shortName": "Note 3 - Contracts With Customers 2 (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31_ContractWithCustomerDurationAxis-LongTermContractWithCustomerMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2021-01-01", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 3 - Contracts With Customers - Disaggregation of Revenue (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details", "shortName": "Note 3 - Contracts With Customers - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_ProductOrServiceAxis-SubscriptionServicesMember_TimingOfTransferOfGoodOrServiceAxis-TransferredOverTimeMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "shortName": "Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CostAndEquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PracticingExcellencecomMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CostMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 4 - Equity Investments (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-4-equity-investments-details-textual", "shortName": "Note 4 - Equity Investments (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CostAndEquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-PracticingExcellencecomMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CostMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nrc:DepreciationAmortizationAndImpairment", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 5 - Property and Equipment (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-details-textual", "shortName": "Note 5 - Property and Equipment (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-IncludingAssetsHeldUnderCapitalLeaseMember", "decimals": "-5", "lang": null, "name": "nrc:DepreciationAmortizationAndImpairment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 5 - Property and Equipment - Summary of Property and Equipment (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details", "shortName": "Note 5 - Property and Equipment - Summary of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 6 - Goodwill and Intangible Assets (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual", "shortName": "Note 6 - Goodwill and Intangible Assets (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "shortName": "Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2019-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "shortName": "Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-4", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 7 - Income Taxes (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual", "shortName": "Note 7 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 7 - Income Taxes - Income Before Income Taxes (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-before-income-taxes-details", "shortName": "Note 7 - Income Taxes - Income Before Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 7 - Income Taxes - Income Tax Expense (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details", "shortName": "Note 7 - Income Taxes - Income Tax Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 7 - Income Taxes - Income Tax Reconciliation (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details", "shortName": "Note 7 - Income Taxes - Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details", "shortName": "Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2019-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "shortName": "Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-FirstNationalBankOfOmahaMember", "decimals": "INF", "first": true, "lang": null, "name": "nrc:DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 8 - Notes Payable (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual", "shortName": "Note 8 - Notes Payable (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-FirstNationalBankOfOmahaMember", "decimals": "INF", "first": true, "lang": null, "name": "nrc:DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SecuredDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 8 - Notes Payable - Summary of Notes Payable (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details", "shortName": "Note 8 - Notes Payable - Summary of Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SecuredDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details", "shortName": "Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromStockOptionsExercised", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note 9 - Share-based Compensation (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual", "shortName": "Note 9 - Share-based Compensation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2017-12-31_StatementClassOfStockAxis-CommonClassAMember_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Shareholders' Equity", "role": "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "shortName": "Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2017-12-31_StatementClassOfStockAxis-CommonClassAMember_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details", "shortName": "Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAndIntrinsicValueOfExercisedAndVestedInPeriodAndFairValueOfVestedInPeriodTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "shortName": "Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_AwardTypeAxis-CommonStockOptionsMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAndIntrinsicValueOfExercisedAndVestedInPeriodAndFairValueOfVestedInPeriodTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note 9 - Share-based compensation - Stock Option Activity (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "shortName": "Note 9 - Share-based compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAndIntrinsicValueOfExercisedAndVestedInPeriodAndFairValueOfVestedInPeriodTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2019-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note 9 - Share-based Compensation - Non-vested Stock (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "shortName": "Note 9 - Share-based Compensation - Non-vested Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2019-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2018-01-01_2018-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Note 10 - Leases (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual", "shortName": "Note 10 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2018-01-01_2018-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Note 10 - Leases - Lease Expense (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details", "shortName": "Note 10 - Leases - Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "shortName": "Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:LeaseCashFlowTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details", "shortName": "Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:LeaseCashFlowTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "shortName": "Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_RelatedPartyTransactionsByRelatedPartyAxis-AmeritasLifeInsuranceCorpMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Note 11 - Related Party (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual", "shortName": "Note 11 - Related Party (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_RelatedPartyTransactionsByRelatedPartyAxis-AmeritasLifeInsuranceCorpMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)", "role": "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "shortName": "Consolidated Statements of Shareholders' Equity (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R70": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Note 12 - Associate Benefits (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits-details-textual", "shortName": "Note 12 - Associate Benefits (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R71": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Note 13 - Segment Information (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-13-segment-information-details-textual", "shortName": "Note 13 - Segment Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Note 13 - Segment Information - Assets by Geographic Area (Details)", "role": "http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details", "shortName": "Note 13 - Segment Information - Assets by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2021-01-04_2021-01-04_BusinessAcquisitionAxis-PatientWisdomIncMember_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Note 14 - Subsequent Event (Details Textual)", "role": "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual", "shortName": "Note 14 - Subsequent Event (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2021-01-04_2021-01-04_BusinessAcquisitionAxis-PatientWisdomIncMember_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "007 - Statement - Consolidated Statements of Cash Flows", "role": "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 1 - Summary of Significant Accounting Policies", "role": "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "shortName": "Note 1 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 84, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-document-and-entity-information", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20201231/role/statement-note-10-leases", "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-tables", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual", "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits", "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits-details-textual", "http://nrchealth.com/20201231/role/statement-note-13-segment-information", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-details-textual", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-tables", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-2-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-tables", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-tables", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-tables", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-before-income-taxes-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-tables", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-tables", "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-document-and-entity-information", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20201231/role/statement-note-10-leases", "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-tables", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual", "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits", "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits-details-textual", "http://nrchealth.com/20201231/role/statement-note-13-segment-information", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-details-textual", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-tables", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-2-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-tables", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-tables", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-tables", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-before-income-taxes-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-tables", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-tables", "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "nrc_AccruedLiabilitiesAndPrepaidExpensesNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the net amount of accrued liabilities and prepaid expenses adjusted in transition to new lease standard.", "label": "nrc_AccruedLiabilitiesAndPrepaidExpensesNet", "terseLabel": "Accrued Liabilities and Prepaid Expenses, Net" } } }, "localname": "AccruedLiabilitiesAndPrepaidExpensesNet", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_AmeritasLifeInsuranceCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about related party.", "label": "Ameritas Life Insurance Corp [Member]" } } }, "localname": "AmeritasLifeInsuranceCorpMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "domainItemType" }, "nrc_AmortizationOfCapitalizedContractCostTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Amortization of Capitalized Contract Cost [Table Text Block]" } } }, "localname": "AmortizationOfCapitalizedContractCostTableTextBlock", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "nrc_AssetsHeldUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived property, plant or equipment assets held by a lessee through a finance lease arrangement.", "label": "Assets Held under Finance Leases [Member]" } } }, "localname": "AssetsHeldUnderFinanceLeasesMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "domainItemType" }, "nrc_CanadianSubsidiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Canadian Subsidiary.", "label": "Canadian Subsidiary [Member]" } } }, "localname": "CanadianSubsidiaryMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "nrc_CashPaidSettlementOfRestrictedCommonSharesAndStockOptionsInconnectionWithRecapitaization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of cash paid during the period related to the settlement of restricted common shares and stock options in connection with recapitalization.", "label": "Cash paid settlement of restricted common shares and stock options in connection with recapitalization" } } }, "localname": "CashPaidSettlementOfRestrictedCommonSharesAndStockOptionsInconnectionWithRecapitaization", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "monetaryItemType" }, "nrc_ChangeInTaxLawDeferralOfSocialSecurityTaxPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of deferral of social security tax payments due to a change in tax law.", "label": "nrc_ChangeInTaxLawDeferralOfSocialSecurityTaxPayments", "terseLabel": "Change in Tax Law, Deferral of Social Security Tax Payments" } } }, "localname": "ChangeInTaxLawDeferralOfSocialSecurityTaxPayments", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_ChangesRelatedToContractCostsIncomeTaxEffectMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the income tax effect of changes related to contract costs.", "label": "Changes Related to Contract Costs, Income Tax Effect [Member]" } } }, "localname": "ChangesRelatedToContractCostsIncomeTaxEffectMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_ChangesRelatedToContractCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to changes related to contract costs.", "label": "Changes Related to Contract Costs [Member]" } } }, "localname": "ChangesRelatedToContractCostsMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_CommonStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to common stock options.", "label": "Common Stock Options [Member]" } } }, "localname": "CommonStockOptionsMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "domainItemType" }, "nrc_ComputerEquipmentHeldUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer equipment held by a lessee through a finance lease arrangement.", "label": "Computer Equipment Held under Finance Leases [Member]" } } }, "localname": "ComputerEquipmentHeldUnderFinanceLeasesMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "domainItemType" }, "nrc_ComputerSoftwareHeldUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer software held by a lessee through a finance lease arrangement.", "label": "Computer Software Held under Finance Leases [Member]" } } }, "localname": "ComputerSoftwareHeldUnderFinanceLeasesMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "domainItemType" }, "nrc_ContractWithCustomerAssetIncreaseRevenueRecognizedConditionalConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right to consideration in exchange for good or service transferred to customer with right conditioned on satisfaction of other performance obligations.", "label": "Increases due to revenue recognized in the period with additional performance obligations before invoicing" } } }, "localname": "ContractWithCustomerAssetIncreaseRevenueRecognizedConditionalConsideration", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "nrc_ContractWithCustomerLiabilityBillings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in obligation to transfer good or service to customer due to billings to customer in excess of revenue", "label": "Increases due to invoicing of client, net of amounts recognized as revenue" } } }, "localname": "ContractWithCustomerLiabilityBillings", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "nrc_ConversionOfClassBCommonStockIntoClassACommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the conversion of class B common stock into class A common stock.", "label": "Conversion of Class B Common Stock Into Class A Common Stock [Member]" } } }, "localname": "ConversionOfClassBCommonStockIntoClassACommonStockMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-2-recapitalization", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual" ], "xbrltype": "domainItemType" }, "nrc_ConversionOfStockCashPaidPerShareConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the amount of cash paid to shareholders per share of stock converted in a stock conversion transaction.", "label": "nrc_ConversionOfStockCashPaidPerShareConverted", "terseLabel": "Conversion of Stock, Cash Paid Per Share Converted (in dollars per share)" } } }, "localname": "ConversionOfStockCashPaidPerShareConverted", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual" ], "xbrltype": "perShareItemType" }, "nrc_ConversionOfStockNumberOfSharesExchangedForEachShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares of one class of stock exchanged for each share of another class of stock in a stock conversion transaction.", "label": "nrc_ConversionOfStockNumberOfSharesExchangedForEachShare", "terseLabel": "Conversion of Stock, Number of Shares Exchanged for Each Share (in shares)" } } }, "localname": "ConversionOfStockNumberOfSharesExchangedForEachShare", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual" ], "xbrltype": "sharesItemType" }, "nrc_CostMethodInvestmentOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the cost method of accounting.", "label": "nrc_CostMethodInvestmentOwnershipPercentage", "terseLabel": "Cost Method Investment, Ownership Percentage" } } }, "localname": "CostMethodInvestmentOwnershipPercentage", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-4-equity-investments-details-textual" ], "xbrltype": "percentItemType" }, "nrc_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a credit agreement, providing a revolving credit facility, term loan facility, and delayed draw-down term facility.", "label": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "nrc_CumulativeTaxIncentives": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cumulative state tax incentives that reduced the operating expenses.", "label": "nrc_CumulativeTaxIncentives", "terseLabel": "Cumulative Tax Incentives" } } }, "localname": "CumulativeTaxIncentives", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_CyberAttackMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents cyber attack.", "label": "Cyber Attack [Member]" } } }, "localname": "CyberAttackMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The maximum amount of quarterly dividends included in the fixed charge coverage calculation unless liquidity falls below a specified threshold.", "label": "nrc_DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold", "terseLabel": "Debt Instrument, Covenant, Exception, Fixed Charge Coverage Ratio, Dividend Threshold" } } }, "localname": "DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_DebtInstrumentCovenantMaximumCashFlowLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum cash flow leverage ratio the borrower is allowable to maintain under a debt instrument agreement.", "label": "nrc_DebtInstrumentCovenantMaximumCashFlowLeverageRatio", "terseLabel": "Debt Instrument, Covenant, Maximum Cash Flow Leverage Ratio" } } }, "localname": "DebtInstrumentCovenantMaximumCashFlowLeverageRatio", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "pureItemType" }, "nrc_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum fixed charge coverage ratio the borrower is required to maintain under a debt instrument agreement.", "label": "nrc_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio", "terseLabel": "Debt Instrument, Covenant, Minimum Fixed Charge Coverage Ratio" } } }, "localname": "DebtInstrumentCovenantMinimumFixedChargeCoverageRatio", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "pureItemType" }, "nrc_DebtInstrumentPercentageBearingVariableInterestPercentageRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of debt instrument borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.", "label": "nrc_DebtInstrumentPercentageBearingVariableInterestPercentageRate", "terseLabel": "Debt Instrument, Percentage Bearing Variable Interest, Percentage Rate" } } }, "localname": "DebtInstrumentPercentageBearingVariableInterestPercentageRate", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "nrc_DeemedDividendPaidByForeignSubsidiary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of deemed dividend paid by foreign subsidiary.", "label": "nrc_DeemedDividendPaidByForeignSubsidiary", "terseLabel": "Deemed Dividend Paid by Foreign Subsidiary" } } }, "localname": "DeemedDividendPaidByForeignSubsidiary", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_DeferredTaxAssetPriorYearForeignTaxCreditCarryforwardsWriteOff": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of prior year foreign tax credit carryforwards deferred tax assets and valuation allowance written off.", "label": "nrc_DeferredTaxAssetPriorYearForeignTaxCreditCarryforwardsWriteOff", "terseLabel": "Deferred Tax Asset, Prior Year Foreign Tax Credit Carryforwards, Write Off" } } }, "localname": "DeferredTaxAssetPriorYearForeignTaxCreditCarryforwardsWriteOff", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_DeferredTaxAssetsEmployerPayrollTaxDeferral": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to employer payroll tax deferral.", "label": "Employer payroll tax deferral" } } }, "localname": "DeferredTaxAssetsEmployerPayrollTaxDeferral", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "nrc_DeferredTaxLiabilitiesContractCosts": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to contract costs.", "label": "nrc_DeferredTaxLiabilitiesContractCosts", "terseLabel": "Deferred contract costs" } } }, "localname": "DeferredTaxLiabilitiesContractCosts", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "nrc_DeferredTaxLiabilitiesRepatriationWithholding": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences attributable to repatriation withholding.", "label": "nrc_DeferredTaxLiabilitiesRepatriationWithholding", "terseLabel": "Repatriation withholding" } } }, "localname": "DeferredTaxLiabilitiesRepatriationWithholding", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "nrc_DeferredTaxLiabilitiesUnrealizedTranslationGainOnIntercompanyLoan": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 6.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of deferred tax liabilities related to unrealized translation gain on intercompany loans.", "label": "nrc_DeferredTaxLiabilitiesUnrealizedTranslationGainOnIntercompanyLoan", "terseLabel": "Unrealized translation gain on intercompany loan" } } }, "localname": "DeferredTaxLiabilitiesUnrealizedTranslationGainOnIntercompanyLoan", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "nrc_DefinedContributionPlanMaximumPercentageOfAnnualContributionEmployeeSubjectToMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay, by the terms of the plan, that the employer may apply a percentage match contribution to a defined contribution plan.", "label": "nrc_DefinedContributionPlanMaximumPercentageOfAnnualContributionEmployeeSubjectToMatch", "terseLabel": "Defined Contribution Plan, Maximum Percentage of Annual Contribution Employee Subject to Match" } } }, "localname": "DefinedContributionPlanMaximumPercentageOfAnnualContributionEmployeeSubjectToMatch", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits-details-textual" ], "xbrltype": "percentItemType" }, "nrc_DelayedDrawTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a delayed draw term loan.", "label": "Delayed Draw Term Loan [Member]" } } }, "localname": "DelayedDrawTermLoanMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "nrc_DepreciationAmortizationAndImpairment": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets and the total loss recognized during the period from the impairment of goodwil", "label": "Depreciation, amortization and impairment", "terseLabel": "Depreciation, Amortization and Impairment" } } }, "localname": "DepreciationAmortizationAndImpairment", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_DirectExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to direct expenses.", "label": "Direct Expenses [Member]" } } }, "localname": "DirectExpensesMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "xbrltype": "domainItemType" }, "nrc_DirectSellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to direct, selling, general and administrative expenses.", "label": "Direct, Selling, General and Administrative Expenses [Member]" } } }, "localname": "DirectSellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_DirectorPlan2004Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2004 director plan.", "label": "Director Plan 2004 [Member]" } } }, "localname": "DirectorPlan2004Member", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_EffectiveIncomeTaxRateReconciliationNondeductibleRecapitalizationExpenseAmount": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 11.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to recapitalization.", "label": "Nondeductible expenses (income) related to recapitalization" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleRecapitalizationExpenseAmount", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "nrc_ExcessLossCoveragePerPerson": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess loss coverage per covered person related to self-insurance group medical and dental insurance.", "label": "nrc_ExcessLossCoveragePerPerson", "terseLabel": "Excess Loss Coverage Per Person" } } }, "localname": "ExcessLossCoveragePerPerson", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_FirstNationalBankOfOmahaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity First National Bank of Omaha.", "label": "First National Bank of Omaha [Member]" } } }, "localname": "FirstNationalBankOfOmahaMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "nrc_FixedNonSubscriptionServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to fixed, non-subscription services.", "label": "Fixed, Non-subscription Services [Member]" } } }, "localname": "FixedNonSubscriptionServicesMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "nrc_FurnitureAndEquipmentHeldUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Furniture and equipment held by a lessee through a finance lease arrangement.", "label": "Furniture and Equipment Held under Finance Leases [Member]" } } }, "localname": "FurnitureAndEquipmentHeldUnderFinanceLeasesMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "domainItemType" }, "nrc_GainOnPropertyInsuranceRecoveries": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount by which an insurance settlement exceeds net book value of property damaged from an event, such as a natural catastrophe, explosion or fire.", "label": "nrc_GainOnPropertyInsuranceRecoveries", "negatedLabel": "Gain on insurance recoveries for damaged property" } } }, "localname": "GainOnPropertyInsuranceRecoveries", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "nrc_IMAFinancialGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to IMA Financial Group.", "label": "IMA Financial Group [Member]" } } }, "localname": "IMAFinancialGroupMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "domainItemType" }, "nrc_IncludingAssetsHeldUnderCapitalLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale, including long lived property, plant or equipment assets held by a lessee through a capital lease arrangement.", "label": "Including Assets Held under Capital Lease [Member]" } } }, "localname": "IncludingAssetsHeldUnderCapitalLeaseMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-details-textual" ], "xbrltype": "domainItemType" }, "nrc_IncomeTaxReconciliationCompensationLimitForCoveredEmployees": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation limits for covered employees.", "label": "Compensation limit for covered employees" } } }, "localname": "IncomeTaxReconciliationCompensationLimitForCoveredEmployees", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "nrc_IncomeTaxReconciliationUncertainTaxPositions": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of the differences between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable uncertain tax positions.", "label": "Uncertain tax positions" } } }, "localname": "IncomeTaxReconciliationUncertainTaxPositions", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "nrc_IncomeTaxRelatedToRevenueAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to income tax related to revenue adjustment.", "label": "Income Tax Related to Revenue Adjustment [Member]" } } }, "localname": "IncomeTaxRelatedToRevenueAdjustmentMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_IncreaseDecreaseCapitalizedContractCost": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Capitalized costs incurred to obtain or fulfill contract with customer net of amortization recorded during the period.", "label": "nrc_IncreaseDecreaseCapitalizedContractCost", "negatedTerseLabel": "Deferred contract costs, net" } } }, "localname": "IncreaseDecreaseCapitalizedContractCost", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "nrc_IncreaseDecreaseInAccruedExpensesWagesBonusesAndProfitSharing": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net change during the reporting period in the aggregate amount of expenses and accrued compensation incurred but not yet paid.", "label": "Accrued expenses, wages and bonuses" } } }, "localname": "IncreaseDecreaseInAccruedExpensesWagesBonusesAndProfitSharing", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "nrc_IncreaseDecreaseInIncomeTaxExpenseFromChangingSoftwareDevelopmentTaxDepreciationMethod": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 12.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in income taxes accrued due to a tax depreciation methodology change.", "label": "Tax depreciation method change" } } }, "localname": "IncreaseDecreaseInIncomeTaxExpenseFromChangingSoftwareDevelopmentTaxDepreciationMethod", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "nrc_IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating lease assets after deduction of operating lease liabilities.", "label": "nrc_IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet", "negatedLabel": "Operating lease assets and liability, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "nrc_IncrementalCostsOfObtainingAContractDeferredDuringPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of incremental costs of obtaining a contract deferred during the period.", "label": "nrc_IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "terseLabel": "Incremental Costs of Obtaining a Contract, Deferred During Period" } } }, "localname": "IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_InsuranceRecoveries1": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount recovered from insurance for lost revenues that are reported as a separate line item.", "label": "Insurance recoveries" } } }, "localname": "InsuranceRecoveries1", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "nrc_InsuranceRecoveriesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure for accounting policies related to insurance recoveries.", "label": "Insurance Recoveries [Policy Text Block]" } } }, "localname": "InsuranceRecoveriesPolicyTextBlock", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "nrc_LeaseCashFlowTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow and other information related to leases.", "label": "Lease, Cash flow [Table Text Block]" } } }, "localname": "LeaseCashFlowTableTextBlock", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-tables" ], "xbrltype": "textBlockItemType" }, "nrc_LesseeLeaseBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of balance sheet information related lessee's lease .", "label": "Lessee, Lease, Balance Sheet Information [Table Text Block]" } } }, "localname": "LesseeLeaseBalanceSheetInformationTableTextBlock", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-tables" ], "xbrltype": "textBlockItemType" }, "nrc_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating and finance lease liability.", "label": "Lessee, Operating and Finance Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-tables" ], "xbrltype": "textBlockItemType" }, "nrc_LesseeOperatingLeaseMonthlyBaseRentPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of monthly base rent payments for the operating lease of a lessee.", "label": "nrc_LesseeOperatingLeaseMonthlyBaseRentPayments", "terseLabel": "Lessee, Operating Lease, Monthly Base Rent Payments" } } }, "localname": "LesseeOperatingLeaseMonthlyBaseRentPayments", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_NonqualifiedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents nonqualified stock options.", "label": "Nonqualified Stock Options [Member]" } } }, "localname": "NonqualifiedStockOptionsMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_NonvestedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to nonvested shares.", "label": "Nonvested [Member]" } } }, "localname": "NonvestedMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_NumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of customers accounting for a substantial portion of one reporting unit's revenue.", "label": "nrc_NumberOfCustomers", "terseLabel": "Number of Customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "nrc_OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities and other noncurrent liabilities.", "label": "Other Current Liabilities and Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesAndOtherNoncurrentLiabilitiesMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "domainItemType" }, "nrc_PatientWisdomIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to PatientWisdom, Inc.", "label": "PatientWisdom, Inc. [Member]" } } }, "localname": "PatientWisdomIncMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "domainItemType" }, "nrc_PaymentsRelatedToRecapitalization": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of payment made during the period related to recapitalization.", "label": "nrc_PaymentsRelatedToRecapitalization", "negatedLabel": "Payments related to Recapitalization", "terseLabel": "Payments Related to Recapitalization" } } }, "localname": "PaymentsRelatedToRecapitalization", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_PracticingExcellencecomMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the entity PracticingExcellence.com.", "label": "PracticingExcellence.com [Member]" } } }, "localname": "PracticingExcellencecomMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments-details-textual" ], "xbrltype": "domainItemType" }, "nrc_PropertyDamageExcludingCyberAttackMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to property damage excluding cyber attack.", "label": "Property Damage Excluding Cyber Attack [Member]" } } }, "localname": "PropertyDamageExcludingCyberAttackMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_ProvisionalTaxExpenseBenefitForGlobalIntangibleLowTaxedIncome": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) from the December 22, 2017 Tax Cut and Jobs Act related to the GILTI tax.", "label": "GILTI", "terseLabel": "Provisional Tax Expense (Benefit) for Global Intangible Low Taxed Income" } } }, "localname": "ProvisionalTaxExpenseBenefitForGlobalIntangibleLowTaxedIncome", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "nrc_PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about purchasing directors and officers and employment practices liability insurance in a related party transaction.", "label": "Purchasing Directors and Officers and Employment Practices Liability Insurance [Member]" } } }, "localname": "PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "domainItemType" }, "nrc_RecapitalizationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The complete disclosure of recapitalization of the company.", "label": "Recapitalization [Text Block]" } } }, "localname": "RecapitalizationTextBlock", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-2-recapitalization" ], "xbrltype": "textBlockItemType" }, "nrc_RecoveriesPaidDirectlyByInsurerToOutsideVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to recoveries paid directly by insurer to outside vendor.", "label": "Recoveries Paid Directly by Insurer to Outside Vendor [Member]" } } }, "localname": "RecoveriesPaidDirectlyByInsurerToOutsideVendorMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_RecoveriesReceivedDirectByTheCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to recoveries received direct by the company.", "label": "Recoveries Received Direct by the Company [Member]" } } }, "localname": "RecoveriesReceivedDirectByTheCompanyMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_ReimbursementForLostRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to reimbursement for lost revenue.", "label": "Reimbursement for Lost Revenue [Member]" } } }, "localname": "ReimbursementForLostRevenueMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_ReserveForUncertainTaxPositions": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings to reserve for uncertain tax positions.", "label": "Reserve for uncertain tax positions" } } }, "localname": "ReserveForUncertainTaxPositions", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "nrc_RevenueFromContractWithCustomerPercentOfTotalRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent of total revenue from contracts with customers.", "label": "nrc_RevenueFromContractWithCustomerPercentOfTotalRevenue", "terseLabel": "Revenue from Contract with Customer, Percent of Total Revenue" } } }, "localname": "RevenueFromContractWithCustomerPercentOfTotalRevenue", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-1-details-textual" ], "xbrltype": "percentItemType" }, "nrc_RevenueRecognitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to revenue Recognition.", "label": "Revenue Recognition [Member]" } } }, "localname": "RevenueRecognitionMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_SalesAndExciseTaxPayableReversalOfLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sales and excise tax payable (reversal of liability).", "label": "nrc_SalesAndExciseTaxPayableReversalOfLiability", "terseLabel": "Sales and Excise Tax Payable (Reversal of Liability)" } } }, "localname": "SalesAndExciseTaxPayableReversalOfLiability", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_SettlementOfClassBCommonSharesInConnectionWithRecapitalization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of cash exchanged for shares during the period related to the settlement of class B common shares in connection with recapitalization.", "label": "Settlement of class B common shares in connection with Recapitalization, cash exchanged" } } }, "localname": "SettlementOfClassBCommonSharesInConnectionWithRecapitalization", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "monetaryItemType" }, "nrc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardAnnualOptionsGrantAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the fair value granted for share based compensation arrangement to each non-employee director at the annual meeting.", "label": "nrc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardAnnualOptionsGrantAmount", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award, Award Annual Options Grant Amount" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardAnnualOptionsGrantAmount", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of nonvested restricted shares outstanding.", "label": "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Restricted Stock, Outstanding Number (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsCumulative": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted for plan to date.", "label": "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsCumulative", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options Grants Cumulative (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsCumulative", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAndIntrinsicValueOfExercisedAndVestedInPeriodAndFairValueOfVestedInPeriodTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value, aggregate intrinsic value of equity options exercised and intrinsic value and fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value, Intrinsic Value of Exercised and Vested in Period, and Fair Value of Vested in Period [Table Text Block]" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueAndIntrinsicValueOfExercisedAndVestedInPeriodAndFairValueOfVestedInPeriodTableTextBlock", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently vested.", "label": "Intrinsic value of stock options vested (in thousands)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedIntrinsicValue", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "nrc_StockExchangedDuringPeriodSharesSettlementOfClassBCommonSharesInConnectionWithRecapitalization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of Class B shares settled and exchanged in connection with a recapitalization.", "label": "Settlement of class B common shares in connection with recapitalization, shares exchanged (in shares)" } } }, "localname": "StockExchangedDuringPeriodSharesSettlementOfClassBCommonSharesInConnectionWithRecapitalization", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "sharesItemType" }, "nrc_StockIssuedDuringPeriodSharesSettlementOfClassBCommonSharesInConnectionWithRecapitalization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the amount of shares issued during the period related to the settlement of class B common shares in connection with recapitalization.", "label": "Settlement of class B common shares in connection with recapitalization, shares issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesSettlementOfClassBCommonSharesInConnectionWithRecapitalization", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "sharesItemType" }, "nrc_StockIssuedDuringPeriodSharesSettlementOfRestrictedCommonSharesAndStockOptionsInConnectionWithRecapitalization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the amount of shares issued during the period related to the settlement of restricted common shares and stock options in connection with recapitalization.", "label": "Settlement of restricted common shares and stock options in connection with recapitalization (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesSettlementOfRestrictedCommonSharesAndStockOptionsInConnectionWithRecapitalization", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "sharesItemType" }, "nrc_StockIssuedDuringPeriodValueSettlementOfClassBCommonSharesInConnectionWithRecapitalization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the value associated with the settlement of Class B common shares in connection with a recapitalization.", "label": "Settlement of class B common shares in connection with Recapitalization (3,527,246 class B common shares exchanged for $69,099 cash and 3,527,246 class A common shares)" } } }, "localname": "StockIssuedDuringPeriodValueSettlementOfClassBCommonSharesInConnectionWithRecapitalization", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "nrc_StockIssuedDuringPeriodValueSettlementOfRestrictedCommonSharesAndStockOptionsInConnectionWithRecapitalization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the value related to the settlement of restricted common shares and stock options in connection with a recapitalization.", "label": "Settlement of class B restricted common shares and stock options in connection with Recapitalization for cash of $3,271 and 90,369 class A common shares" } } }, "localname": "StockIssuedDuringPeriodValueSettlementOfRestrictedCommonSharesAndStockOptionsInConnectionWithRecapitalization", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "nrc_StockOptionsExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because the exercise price exceeds the fair market value.", "label": "nrc_StockOptionsExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Stock Options Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "StockOptionsExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "sharesItemType" }, "nrc_StockRetiredDuringPeriodSharesRecapitalization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares retired during the period related to recapitalization.", "label": "Retirement of class B common shares in connection with recapitalization, shares retired (in shares)" } } }, "localname": "StockRetiredDuringPeriodSharesRecapitalization", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "sharesItemType" }, "nrc_StockRetiredDuringPeriodValueRecapitalization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the value of the retirement of class b common shares in connection with a recapitalization.", "label": "nrc_StockRetiredDuringPeriodValueRecapitalization", "negatedLabel": "Retirement of 4,328,552 class B common shares in connection with Recapitalization" } } }, "localname": "StockRetiredDuringPeriodValueRecapitalization", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "nrc_StockTenderedCashlessExerciseOfStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of stock tendered to the company for cashless exercise of stock options in connection with equity incentive plans.", "label": "Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans" } } }, "localname": "StockTenderedCashlessExerciseOfStockOptions", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "nrc_SubscriptionServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to subscription services.", "label": "Subscription Services [Member]" } } }, "localname": "SubscriptionServicesMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "nrc_TaxBenefitRealizedRestrictedStockVested": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The tax benefit realized from the vesting of restricted stock during the period.", "label": "nrc_TaxBenefitRealizedRestrictedStockVested", "terseLabel": "Tax Benefit Realized Restricted Stock Vested" } } }, "localname": "TaxBenefitRealizedRestrictedStockVested", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a term loan.", "label": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "domainItemType" }, "nrc_The2001EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2001 equity incentive plan.", "label": "The 2001 Equity Incentive Plan [Member]" } } }, "localname": "The2001EquityIncentivePlanMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_The2006EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2006 Equity Incentive plan.", "label": "The 2006 Equity Incentive Plan [Member]" } } }, "localname": "The2006EquityIncentivePlanMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_TradeNames1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names 1 [Member]" } } }, "localname": "TradeNames1Member", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "nrc_UnitPriceServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to unit price services.", "label": "Unit Price Services [Member]" } } }, "localname": "UnitPriceServicesMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "nrc_VoCPlatformMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Voice of the Customer Platform.", "label": "VoC Platform [Member]" } } }, "localname": "VoCPlatformMember", "nsuri": "http://nrchealth.com/20201231", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-1-details-textual" ], "xbrltype": "domainItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Net Income Per Share Computation (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Share-based Compensation Amounts Recognized in Financial Statements (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-tables", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-leases-lease-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Lease Expense (Details)" } } }, "localname": "statement-statement-note-10-leases-lease-expense-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Supplemental Balance Sheet Information Related to Leases (Details)" } } }, "localname": "statement-statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)" } } }, "localname": "statement-statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases" } } }, "localname": "statement-statement-note-10-leases-tables", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Undiscounted Payments Under Non-cancelable Leases (Details)" } } }, "localname": "statement-statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-13-segment-information-assets-by-geographic-area-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Segment Information - Assets by Geographic Area (Details)" } } }, "localname": "statement-statement-note-13-segment-information-assets-by-geographic-area-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-13-segment-information-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Segment Information" } } }, "localname": "statement-statement-note-13-segment-information-tables", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-3-contracts-with-customers-disaggregation-of-revenue-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Contracts With Customers - Disaggregation of Revenue (Details)" } } }, "localname": "statement-statement-note-3-contracts-with-customers-disaggregation-of-revenue-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details)" } } }, "localname": "statement-statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-3-contracts-with-customers-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Contracts With Customers" } } }, "localname": "statement-statement-note-3-contracts-with-customers-tables", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-5-property-and-equipment-summary-of-property-and-equipment-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Property and Equipment - Summary of Property and Equipment (Details)" } } }, "localname": "statement-statement-note-5-property-and-equipment-summary-of-property-and-equipment-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-5-property-and-equipment-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Property and Equipment" } } }, "localname": "statement-statement-note-5-property-and-equipment-tables", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details)" } } }, "localname": "statement-statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)" } } }, "localname": "statement-statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-6-goodwill-and-intangible-assets-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Goodwill and Intangible Assets" } } }, "localname": "statement-statement-note-6-goodwill-and-intangible-assets-tables", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Change in Unrecognized Tax Benefits (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Deferred Tax Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-income-taxes-income-before-income-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Income Before Income Taxes (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-income-before-income-taxes-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-income-taxes-income-tax-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Income Tax Expense (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-income-tax-expense-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-income-taxes-income-tax-reconciliation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Income Tax Reconciliation (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-income-tax-reconciliation-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes" } } }, "localname": "statement-statement-note-7-income-taxes-tables", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Notes Payable - Scheduled Maturities of Notes Payable (Details)" } } }, "localname": "statement-statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-8-notes-payable-summary-of-notes-payable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Notes Payable - Summary of Notes Payable (Details)" } } }, "localname": "statement-statement-note-8-notes-payable-summary-of-notes-payable-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-8-notes-payable-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Notes Payable" } } }, "localname": "statement-statement-note-8-notes-payable-tables", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-9-sharebased-compensation-nonvested-stock-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Share-based Compensation - Non-vested Stock (Details)" } } }, "localname": "statement-statement-note-9-sharebased-compensation-nonvested-stock-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-9-sharebased-compensation-stock-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Share-based compensation - Stock Option Activity (Details)" } } }, "localname": "statement-statement-note-9-sharebased-compensation-stock-option-activity-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details)" } } }, "localname": "statement-statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Share-based Compensation - Stock Options Valuation Assumptions (Details)" } } }, "localname": "statement-statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-9-sharebased-compensation-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Share-based Compensation" } } }, "localname": "statement-statement-note-9-sharebased-compensation-tables", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "nrc_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://nrchealth.com/20201231", "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r417", "r418", "r424", "r425", "r582" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r417", "r418", "r424", "r425" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r117", "r124", "r205", "r344", "r345", "r346", "r387", "r388" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r117", "r124", "r205", "r344", "r345", "r346", "r387", "r388" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r117", "r124", "r205", "r344", "r345", "r346", "r387", "r388" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-4-equity-investments", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments-details-textual" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r301", "r303", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r549", "r552" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases", "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r301", "r303", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r549", "r552" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases", "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r182", "r278", "r282", "r499", "r548", "r550" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r182", "r278", "r282", "r499", "r548", "r550" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r290", "r301", "r303", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r549", "r552" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases", "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r290", "r301", "r303", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r549", "r552" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases", "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-4-equity-investments", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments-details-textual" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r183", "r184", "r278", "r283", "r551", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r183", "r184", "r278", "r283", "r551", "r566", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r188", "r482" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "stpr_WA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WASHINGTON" } } }, "localname": "WA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r21", "r189", "r190" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Trade accounts receivable, less allowance for doubtful accounts of $120 and $144, respectively", "terseLabel": "Accounts receivables" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r14", "r521", "r536" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r31", "r247" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedTerseLabel": "Less accumulated amortization", "terseLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r47", "r49", "r50", "r51", "r441" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated other comprehensive loss, foreign currency translation adjustment" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r48", "r51", "r52", "r114", "r115", "r116", "r423", "r555", "r556" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r22" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r114", "r115", "r116", "r344", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis": { "auth_ref": [ "r118", "r119", "r120", "r121" ], "lang": { "en-us": { "role": { "documentation": "Information by type of change in accounting principle. Excludes change from amendment to accounting standards.", "label": "Change in Accounting Principle, Type [Axis]" } } }, "localname": "AdjustmentsForChangeInAccountingPrincipleAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r118", "r119", "r120", "r121", "r202", "r203", "r204", "r205", "r206", "r207", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r385", "r386", "r387", "r388", "r501", "r502", "r503", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r305", "r307", "r350", "r351" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Non-cash stock compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r307", "r336", "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "totalLabel": "Net (benefit) expense to net income" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "auth_ref": [ "r193", "r213" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.", "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]" } } }, "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r196", "r208", "r209", "r212" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r27", "r196", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r211" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Write-offs" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r90", "r230", "r238" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "us-gaap_AmortizationOfIntangibleAssets", "terseLabel": "Amortization of Intangible Assets, Total" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r90", "r245" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "us-gaap_AssetImpairmentCharges", "terseLabel": "Asset Impairment Charges, Total" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r103", "r168", "r172", "r178", "r201", "r417", "r424", "r443", "r519", "r535" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r46", "r103", "r201", "r417", "r424", "r443" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r308", "r338" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r429", "r430" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r300", "r302" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r300", "r302", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r407", "r408", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "us-gaap_BusinessCombinationConsiderationTransferred1", "terseLabel": "Business Combination, Consideration Transferred, Total" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r406", "r407", "r408", "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "terseLabel": "Business Combination, Consideration Transferred, Liabilities Incurred" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsIncurred": { "auth_ref": [ "r95", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in lease obligation from new lease.", "label": "Finance lease obligations originated for property and equipment" } } }, "localname": "CapitalLeaseObligationsIncurred", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareAdditions": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additions made to capitalized computer software costs during the period.", "label": "us-gaap_CapitalizedComputerSoftwareAdditions", "terseLabel": "Capitalized Computer Software, Additions" } } }, "localname": "CapitalizedComputerSoftwareAdditions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized contract cost" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortizationPeriod": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_CapitalizedContractCostAmortizationPeriod", "terseLabel": "Capitalized Contract Cost, Amortization Period (Year)" } } }, "localname": "CapitalizedContractCostAmortizationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_CapitalizedContractCostAxis": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.", "label": "Capitalized Contract Cost [Axis]" } } }, "localname": "CapitalizedContractCostAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalizedContractCostDomain": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.", "label": "Capitalized Contract Cost [Domain]" } } }, "localname": "CapitalizedContractCostDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalizedContractCostGross": { "auth_ref": [ "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "us-gaap_CapitalizedContractCostGross", "terseLabel": "Capitalized Contract Cost, Gross" } } }, "localname": "CapitalizedContractCostGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostImpairmentLoss": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "us-gaap_CapitalizedContractCostImpairmentLoss", "terseLabel": "Capitalized Contract Cost, Impairment Loss" } } }, "localname": "CapitalizedContractCostImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNetNoncurrent": { "auth_ref": [ "r217" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.", "label": "Deferred contract costs, net", "terseLabel": "Capitalized Contract Cost, Net, Noncurrent" } } }, "localname": "CapitalizedContractCostNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r28", "r92" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Assets, fair value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r93", "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r86", "r92", "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r86", "r444" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r28" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "us-gaap_CashEquivalentsAtCarryingValue", "terseLabel": "Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingPrincipleMember": { "auth_ref": [ "r118", "r119", "r120", "r121" ], "lang": { "en-us": { "role": { "documentation": "Change in accounting principle. Excludes change from amendment to accounting standards.", "label": "Change in Accounting Principle, Type [Domain]" } } }, "localname": "ChangeInAccountingPrincipleMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r102", "r103", "r133", "r137", "r138", "r141", "r143", "r149", "r150", "r151", "r201", "r443" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r99", "r253", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Dividends declared per common share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r20", "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; authorized 60,000,000 shares, issued 30,775,154 in 2020 and 30,151,574 in 2019, outstanding 25,390,968 in 2020 and 24,947,500 in 2019" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r288", "r289", "r304", "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r55", "r57", "r58", "r62", "r528", "r544" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r99", "r419" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r262", "r264", "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract assets included in other current assets" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": { "auth_ref": [ "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.", "label": "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable", "negatedLabel": "Decreases due to completion of services (or portion of services) and transferred to accounts receivable" } } }, "localname": "ContractWithCustomerAssetReclassifiedToReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerDurationAxis": { "auth_ref": [ "r278", "r284" ], "lang": { "en-us": { "role": { "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract with Customer, Duration [Axis]" } } }, "localname": "ContractWithCustomerDurationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-2-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerDurationDomain": { "auth_ref": [ "r278", "r284" ], "lang": { "en-us": { "role": { "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract with Customer, Duration [Domain]" } } }, "localname": "ContractWithCustomerDurationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-2-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "auth_ref": [ "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.", "label": "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "negatedLabel": "Change due to cumulative catch-up adjustments arising from changes in expected contract consideration" } } }, "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r262", "r263", "r279" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue", "negatedTerseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "negatedLabel": "Revenue recognized that was included in deferred revenue at beginning of year due to completion of services" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r95", "r96", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Common stock (formerly class A) issued in the Recapitalization in exchange for then-existing class B shares and options." } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "auth_ref": [ "r95", "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "Information by description of stock conversions.", "label": "Stock Conversion Description [Axis]" } } }, "localname": "ConversionOfStockByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-2-recapitalization", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockNameDomain": { "auth_ref": [ "r95", "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "The unique name of a noncash or part noncash stock conversion.", "label": "Conversion of Stock, Name [Domain]" } } }, "localname": "ConversionOfStockNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-2-recapitalization", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r95", "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_ConversionOfStockSharesIssued1", "terseLabel": "Conversion of Stock, Shares Issued (in shares)" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cost method and equity method investments included basis, impairment losses, recognized or unrecognized gains (losses).", "label": "Cost and Equity Method Investments Disclosure [Text Block]" } } }, "localname": "CostAndEquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-4-equity-investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostMethodInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after adjustment, of cost-method investment. Adjustments include, but are not limited to, dividends received in excess of earnings after date of investment that are considered a return of investment and other than temporary impairments.", "label": "us-gaap_CostMethodInvestments", "terseLabel": "Cost Method Investments" } } }, "localname": "CostMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-4-equity-investments-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r65" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r106", "r381", "r391" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 0.0, "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_CurrentFederalTaxExpenseBenefit", "terseLabel": "Current" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r111", "r381" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 1.0, "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_CurrentForeignTaxExpenseBenefit", "terseLabel": "Current" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r106", "r381", "r391" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 0.0, "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_CurrentStateAndLocalTaxExpenseBenefit", "terseLabel": "Current" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r14", "r15", "r520", "r523", "r534" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r454", "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r40", "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "us-gaap_DebtInstrumentPeriodicPayment", "terseLabel": "Debt Instrument, Periodic Payment, Total" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r32", "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r382", "r391" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 1.0, "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Deferred" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r32", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "us-gaap_DeferredFinanceCostsNet", "negatedLabel": "Less: unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r382", "r391" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 0.0, "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "terseLabel": "Deferred" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r90", "r106", "r382", "r391", "r392", "r393" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r16", "r17", "r372", "r522", "r533" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "totalLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r357", "r358" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r382", "r391" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 1.0, "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "terseLabel": "Deferred" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r373" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r375" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r379", "r380" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "us-gaap_DeferredTaxAssetsOther", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": { "auth_ref": [ "r378", "r379", "r380" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.", "label": "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign", "terseLabel": "Foreign tax credit from repatriation" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses": { "auth_ref": [ "r379", "r380" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses", "terseLabel": "Accrued bonuses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r379", "r380" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "terseLabel": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r379", "r380" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r379", "r380" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r374" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedTerseLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r358", "r375" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "us-gaap_DeferredTaxLiabilities", "negatedTotalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r379", "r380" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r379", "r380" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "us-gaap_DeferredTaxLiabilitiesOther", "terseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses", "terseLabel": "Prepaid expenses" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r379", "r380" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "terseLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.", "label": "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "terseLabel": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DirectOperatingCosts": { "auth_ref": [ "r68" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate direct operating costs incurred during the reporting period.", "label": "Direct" } } }, "localname": "DirectOperatingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-10-leases", "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits", "http://nrchealth.com/20201231/role/statement-note-13-segment-information", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "us-gaap_DividendsCommonStockCash", "negatedLabel": "Dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r9", "r37" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r63", "r122", "r123", "r124", "r125", "r126", "r130", "r133", "r141", "r142", "r143", "r146", "r147", "r529", "r545" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic earnings per share (in dollars per share)", "terseLabel": "Net income per share - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r63", "r122", "r123", "r124", "r125", "r126", "r133", "r141", "r142", "r143", "r146", "r147", "r529", "r545" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted earnings per share (in dollars per share)", "terseLabel": "Net income per share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r99", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r444" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r360", "r395" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r352", "r360" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Share-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued wages and bonuses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r336" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details": { "order": 0.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "negatedLabel": "Amount of related income tax benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "auth_ref": [ "r339" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "terseLabel": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r114", "r115", "r116", "r119", "r127", "r129", "r148", "r205", "r258", "r259", "r344", "r345", "r346", "r387", "r388", "r445", "r446", "r447", "r448", "r449", "r450", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r433", "r439" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r433", "r442" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r434", "r489", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r433", "r434", "r435", "r436", "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r291", "r292", "r297", "r299", "r434", "r489" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r489", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r438", "r440" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r105", "r359" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "totalLabel": "Total" } } }, "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r461", "r467", "r477" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r463", "r471" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r460", "r476" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "us-gaap_FinanceLeaseLiability", "terseLabel": "Present value of minimum finance lease payments", "totalLabel": "Total finance lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r460" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details": { "order": 0.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Current obligations of finance leases", "negatedTerseLabel": "Current portion, finance leases" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r460" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Noncurrent obligations of finance leases", "terseLabel": "Finance leases obligations, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r476" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "totalLabel": "Finance leases, total minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r476" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "Finance leases, 2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r476" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour", "terseLabel": "Finance leases, 2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r476" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 0.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree", "terseLabel": "Finance leases, 2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r476" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "Finance leases, 2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Finance leases, less: Amount representing interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r462", "r471" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Financing cash flows from finance leases", "negatedLabel": "Payments on finance lease obligations" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r461", "r467", "r477" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Asset amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r474", "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r473", "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1", "verboseLabel": "Finance leases (Year)" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-lived intangible assets, useful life (Year)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r237" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "terseLabel": "Finite-lived intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r231", "r233", "r237", "r241", "r500", "r504" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r237", "r504" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsGross", "terseLabel": "Finite-lived intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r231", "r236" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r237", "r500" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsNet", "terseLabel": "Finite-lived intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r99", "r452" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r110" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations", "totalLabel": "Total" } } }, "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r90" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "us-gaap_GainLossOnDispositionOfAssets1", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r219", "r221", "r518" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Goodwill, Ending Balance" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r99", "r226", "r234" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillForeignCurrencyTranslationGainLoss", "terseLabel": "Foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r222", "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillGross", "terseLabel": "Goodwill, gross" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r222", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss", "negatedTerseLabel": "Goodwill, accumulated impairment" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r90", "r220", "r223", "r227" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillImpairmentLoss", "negatedLabel": "Impairment", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r90", "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill", "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill), Total" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r90", "r245", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse", "terseLabel": "Impairment of Long-Lived Assets Held-for-use" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r99", "r244", "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r109", "r394" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-before-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "terseLabel": "U.S. Operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-before-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r61", "r168", "r171", "r174", "r177", "r180", "r517", "r527", "r531", "r546" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r109", "r394" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-before-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "terseLabel": "Foreign Operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-before-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r109", "r168", "r171", "r174", "r177", "r180" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-before-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-before-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxCreditsAndAdjustments": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.", "label": "us-gaap_IncomeTaxCreditsAndAdjustments", "terseLabel": "Income Tax Credits and Adjustments" } } }, "localname": "IncomeTaxCreditsAndAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r361", "r370", "r377", "r389", "r396", "r398", "r399", "r400" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r128", "r129", "r167", "r359", "r390", "r397", "r547" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r59", "r99", "r355", "r356", "r370", "r371", "r376", "r383", "r569" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r360" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Foreign tax rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r360" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Expected federal income taxes" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r360" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.", "label": "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "verboseLabel": "Goodwill Impairment" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r360" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "us-gaap_IncomeTaxReconciliationOtherReconcilingItems", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r360" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.", "label": "Withholding tax on repatriation of foreign earnings" } } }, "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r360" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State income taxes, net of federal benefit and state tax credits" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "auth_ref": [ "r360" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "us-gaap_IncomeTaxReconciliationTaxCredits", "negatedLabel": "Federal tax credits" } } }, "localname": "IncomeTaxReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r44", "r525", "r543" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income taxes receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r89" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r89" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedTerseLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r89" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxes": { "auth_ref": [ "r89" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.", "label": "us-gaap_IncreaseDecreaseInIncomeTaxes", "terseLabel": "Income taxes receivable and payable" } } }, "localname": "IncreaseDecreaseInIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r89" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r134", "r135", "r136", "r143" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "terseLabel": "Weighted average effect of dilutive securities \u2013 stock options (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r232", "r240" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill", "terseLabel": "Indefinite trade name" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r232", "r240" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_InsuranceRecoveries": { "auth_ref": [ "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.", "label": "us-gaap_InsuranceRecoveries", "terseLabel": "Insurance Recoveries" } } }, "localname": "InsuranceRecoveries", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "terseLabel": "Total intangible assets other than goodwill" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r229", "r235" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net", "terseLabel": "Total intangible assets other than goodwill" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r60", "r166", "r453", "r455", "r530" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r83", "r87", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest expense, net of capitalized amounts" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r71", "r165" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r475", "r477" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "us-gaap_LeaseCost", "totalLabel": "Total net lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r476" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Operating leases, total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r476" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "Operating leases, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r476" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "terseLabel": "Operating leases, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r476" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "Operating leases, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r476" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "Operating leases, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r476" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "Operating leases, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Operating leases, less: Amount representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm", "terseLabel": "Lessee, Operating Lease, Remaining Lease Term (Year)" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r36", "r103", "r173", "r201", "r418", "r424", "r425", "r443" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r103", "r201", "r443", "r524", "r540" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r38", "r103", "r201", "r418", "r424", "r425", "r443" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r15", "r523", "r534" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "us-gaap_LineOfCredit", "terseLabel": "Long-term Line of Credit, Total" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r34", "r107" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermContractWithCustomerMember": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which duration is classified as long-term.", "label": "Long-term Contract with Customer [Member]" } } }, "localname": "LongTermContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-2-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r15", "r256", "r523", "r538" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Total carrying amount of long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Estimated fair value of long-term debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r112", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r112", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r112", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r112", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r112", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "us-gaap_LongTermDebtNoncurrent", "terseLabel": "Notes payable, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r40" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes payable, net of current portion and unamortized debt issuance costs" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r40", "r255" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r86", "r88", "r91" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r122", "r123", "r124", "r125", "r130", "r131", "r140", "r143", "r168", "r171", "r174", "r177", "r180" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "terseLabel": "Net income attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator for net income per share - basic:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncatastrophicEventAxis": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Information by type of noncatastrophic event causing change in the insurer's provision.", "label": "Noncatastrophic Event [Axis]" } } }, "localname": "NoncatastrophicEventAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_NoncatastrophicEventDomain": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Noncatastrophic event causing change in the insurer's provision.", "label": "Noncatastrophic Event [Domain]" } } }, "localname": "NoncatastrophicEventDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "us-gaap_NoncurrentAssets", "terseLabel": "Long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r72" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Current portion of notes payable, net of unamortized debt issuance costs" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-13-segment-information-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-13-segment-information-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r168", "r171", "r174", "r177", "r180" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r468", "r477" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "us-gaap_OperatingLeaseCost", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r460" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total operating lease liabilities", "terseLabel": "Operating Lease, Liability, Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r460" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current operating lease liabilities", "negatedLabel": "Current portion, operating leases" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r460" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease obligations, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r464", "r471" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r459" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r474", "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r473", "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "verboseLabel": "Operating leases (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r457" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "us-gaap_OperatingLeasesRentExpenseNet", "terseLabel": "Operating Leases, Rent Expense, Net, Total" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r415", "r416", "r422" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Cumulative translation adjustment", "terseLabel": "Other comprehensive income, foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r54", "r57", "r415", "r416", "r422" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r429", "r432" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeMember": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other revenue.", "label": "Other Income [Member]" } } }, "localname": "OtherIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r37" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": { "auth_ref": [ "r139", "r140" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "negatedTerseLabel": "Allocation of distributed and undistributed income to unvested restricted stock shareholders" } } }, "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r81" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r79" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "us-gaap_PaymentsOfDividendsCommonStock", "negatedLabel": "Payment of dividends on common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r79" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Payment of employee payroll tax withholdings on share-based awards exercised" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r75", "r410" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "us-gaap_PaymentsToAcquireBusinessesGross", "terseLabel": "Payments to Acquire Businesses, Gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "us-gaap_PaymentsToAcquireIntangibleAssets", "terseLabel": "Payments to Acquire Intangible Assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r76" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r308", "r338" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r3", "r5", "r214", "r215" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": { "auth_ref": [ "r74", "r85" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities.", "label": "Insurance proceeds for damaged property", "terseLabel": "Proceeds from Insurance Settlement, Investing Activities" } } }, "localname": "ProceedsFromInsuranceSettlementInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": { "auth_ref": [ "r82", "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.", "label": "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities", "terseLabel": "Proceeds from Insurance Settlement, Operating Activities" } } }, "localname": "ProceedsFromInsuranceSettlementOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r78", "r108" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Borrowings on line of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r78" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from issuance of note payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r77", "r339" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from the exercise of stock options", "terseLabel": "Proceeds from Stock Options Exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r53", "r56", "r84", "r103", "r118", "r128", "r129", "r168", "r171", "r174", "r177", "r180", "r201", "r415", "r420", "r421", "r427", "r428", "r443", "r531" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r31", "r248" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r252", "r570", "r571", "r572" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r30", "r246" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentGross", "terseLabel": "Property and equipment at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r248", "r541" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Net property and equipment", "terseLabel": "Property and equipment under finance lease, net", "totalLabel": "Net property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r29", "r99", "r248", "r570", "r571" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r11", "r248" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r11", "r246" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r64", "r210" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad Debt Expense (Benefit)" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r298", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r480", "r483" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r298", "r480", "r481", "r483" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r480" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r298", "r480", "r483", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r478", "r479", "r481", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r80", "r108" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "us-gaap_RepaymentsOfLinesOfCredit", "negatedLabel": "Payments on line of credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r80" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "us-gaap_RepaymentsOfNotesPayable", "negatedLabel": "Payments on notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r259", "r347", "r539", "r559", "r564" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r114", "r115", "r116", "r119", "r127", "r129", "r205", "r344", "r345", "r346", "r387", "r388", "r555", "r557" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r163", "r164", "r170", "r175", "r176", "r182", "r183", "r186", "r277", "r278", "r499" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r267", "r268", "r269", "r270", "r271", "r272", "r275", "r276", "r281", "r287" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r66", "r565" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "us-gaap_RevenueFromRelatedParties", "terseLabel": "Revenue from Related Parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "us-gaap_RevenueRemainingPerformanceObligation", "terseLabel": "Revenue, Remaining Performance Obligation, Amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-2-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-2-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-2-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r472", "r477" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "ROU assets obtained in exchange for finance lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r472", "r477" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "ROU assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent": { "auth_ref": [ "r526", "r542" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax.", "label": "us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent", "terseLabel": "Sales and Excise Tax Payable" } } }, "localname": "SalesAndExciseTaxPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r307", "r335", "r349" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r226", "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r67", "r185" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-13-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r320", "r324", "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r369", "r384" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r15", "r523", "r538" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "us-gaap_SecuredDebt", "terseLabel": "Term Loans" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r13", "r520", "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "us-gaap_SecuredDebtCurrent", "negatedTerseLabel": "Less: current portion" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r159", "r161", "r162", "r168", "r169", "r174", "r178", "r179", "r180", "r181", "r182", "r185", "r186", "r187" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-13-segment-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_SelfInsuranceReserveCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).", "label": "us-gaap_SelfInsuranceReserveCurrent", "terseLabel": "Self Insurance Reserve, Current" } } }, "localname": "SelfInsuranceReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r70" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Non-cash share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "terseLabel": "Share-based Payment Arrangement, Accelerated Cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Outstanding (in shares)", "periodStartLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Outstanding (in dollars per share)", "periodStartLabel": "Outstanding (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield at date of grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Exercised, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "negatedLabel": "Forfeited, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, number of options (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted average grant date fair value of stock options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r315", "r338" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding, number of options (in shares)", "periodStartLabel": "Outstanding, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r306", "r312" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r99", "r308", "r313" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r330", "r348" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life of options (in years) (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r469", "r477" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r104", "r359", "r390" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.", "label": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "totalLabel": "Total" } } }, "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r18", "r19", "r20", "r102", "r103", "r133", "r137", "r138", "r141", "r143", "r149", "r150", "r151", "r201", "r258", "r443" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r43", "r114", "r115", "r116", "r119", "r127", "r129", "r148", "r205", "r258", "r259", "r344", "r345", "r346", "r387", "r388", "r445", "r446", "r447", "r448", "r449", "r450", "r555", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20201231/role/statement-note-10-leases", "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-tables", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual", "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits", "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits-details-textual", "http://nrchealth.com/20201231/role/statement-note-13-segment-information", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-details-textual", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-tables", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-2-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-tables", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-tables", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-tables", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-before-income-taxes-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-tables", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-tables", "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r114", "r115", "r116", "r148", "r499" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-comprehensive-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-sharebased-compensation-amounts-recognized-in-financial-statements-details", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20201231/role/statement-note-10-leases", "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-balance-sheet-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-supplemental-cash-flow-and-other-information-related-to-leases-details", "http://nrchealth.com/20201231/role/statement-note-10-leases-tables", "http://nrchealth.com/20201231/role/statement-note-10-leases-undiscounted-payments-under-noncancelable-leases-details", "http://nrchealth.com/20201231/role/statement-note-11-related-party", "http://nrchealth.com/20201231/role/statement-note-11-related-party-details-textual", "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits", "http://nrchealth.com/20201231/role/statement-note-12-associate-benefits-details-textual", "http://nrchealth.com/20201231/role/statement-note-13-segment-information", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-details-textual", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-tables", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization", "http://nrchealth.com/20201231/role/statement-note-2-recapitalization-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-1-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-2-details-textual", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-tables", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments", "http://nrchealth.com/20201231/role/statement-note-4-equity-investments-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-details-textual", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-summary-of-property-and-equipment-details", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-tables", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-details-textual", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-tables", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-deferred-tax-assets-and-liabilities-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-before-income-taxes-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-expense-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-income-tax-reconciliation-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-scheduled-maturities-of-notes-payable-details", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-tables", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-tables", "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r19", "r20", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Forfeitures of restricted common shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r19", "r20", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Issuance of restricted common shares, net of forfeitures (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r19", "r20", "r258", "r259", "r317" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Shares of common stock issued for the exercise of stock option (in shares)", "negatedTerseLabel": "Exercised, number of options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r43", "r258", "r259" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Issuance of common shares for the exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r24", "r25", "r103", "r198", "r201", "r443" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets", "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r103", "r114", "r115", "r116", "r119", "r127", "r201", "r205", "r259", "r344", "r345", "r346", "r387", "r388", "r413", "r414", "r426", "r443", "r445", "r446", "r450", "r556", "r557" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "terseLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r451", "r487" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases", "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r451", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases", "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r451", "r487" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases", "http://nrchealth.com/20201231/role/statement-note-10-leases-details-textual", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event", "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r486", "r488" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-14-subsequent-event" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash paid for:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20201231/role/statement-note-10-leases-tables", "http://nrchealth.com/20201231/role/statement-note-13-segment-information-tables", "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-tables", "http://nrchealth.com/20201231/role/statement-note-5-property-and-equipment-tables", "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-tables", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-tables", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-tables", "http://nrchealth.com/20201231/role/statement-note-9-sharebased-compensation-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r278", "r285" ], "lang": { "en-us": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing of Transfer of Good or Service [Axis]" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [ "r278", "r285" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.", "label": "Timing of Transfer of Good or Service [Domain]" } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r191", "r192", "r194", "r195", "r197", "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-6-goodwill-and-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredAtPointInTimeMember": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred at point in time.", "label": "Transferred at Point in Time [Member]" } } }, "localname": "TransferredAtPointInTimeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredOverTimeMember": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred over time.", "label": "Transferred over Time [Member]" } } }, "localname": "TransferredOverTimeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-3-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r42", "r260" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r42", "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r20", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Shares of treasury stock purchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r42", "r260", "r261" ], "calculation": { "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, at cost; 5,384,186 Common shares in 2020 and 5,204,074 Common shares in 2019" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r258", "r259", "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "us-gaap_TreasuryStockValueAcquiredCostMethod", "negatedLabel": "Purchase of shares of treasury stock" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r118", "r119", "r120", "r121", "r202", "r203", "r204", "r205", "r206", "r207", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r385", "r386", "r387", "r388", "r501", "r502", "r503", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r354", "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "periodEndLabel": "Balance of unrecognized tax benefits", "periodStartLabel": "Balance of unrecognized tax benefits", "terseLabel": "Unrecognized Tax Benefits, Ending Balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details", "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "negatedTerseLabel": "Reductions due to settlement with taxing authorities" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "terseLabel": "Additions based on tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Additions due to tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "auth_ref": [ "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense accrued for an underpayment of income taxes.", "label": "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "terseLabel": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued" } } }, "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "negatedTerseLabel": "Reductions due to lapse of applicable statute of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-change-in-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r368" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r152", "r153", "r154", "r155", "r156", "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r470", "r477" ], "calculation": { "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-10-leases-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-note-8-notes-payable", "http://nrchealth.com/20201231/role/statement-note-8-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r132", "r143" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average shares and share equivalents outstanding, diluted (in shares)", "terseLabel": "Denominator for diluted earnings per share \u2013 adjusted weighted average shares (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares and share equivalents outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r130", "r143" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares and share equivalents outstanding, basic (in shares)", "terseLabel": "Weighted average common shares outstanding \u2013 basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20201231/role/statement-consolidated-statements-of-income", "http://nrchealth.com/20201231/role/statement-note-1-summary-of-significant-accounting-policies-net-income-per-share-computation-details" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2740-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131251-203054" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r257": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r287": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624186-113959" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r452": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717" }, "r458": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r485": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r488": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r583": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r584": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r585": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r586": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r587": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r588": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3337-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "21B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080549-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" } }, "version": "2.1" } ZIP 95 0001437749-21-005096-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-005096-xbrl.zip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